

REFINITIV

DELTA REPORT

10-K

PG - PROCTER & GAMBLE CO
10-K - JUNE 30, 2024 COMPARED TO 10-K - JUNE 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	3443
CHANGES	367
DELETIONS	946
ADDITIONS	2130

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark one)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended **June 30, 2023** **June 30, 2024**

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 1-434

Cincinnati**One Procter & Gamble Plaza****513****THE PROCTER & GAMBLE COMPANY**

One Procter & Gamble Plaza, Cincinnati, Ohio 45202

Telephone (513) 983-1100

IRS Employer Identification No. 31-0411980

State of Incorporation: Ohio

OH**45202****983-1100****31-0411980****OH**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, without Par Value	PG	New York Stock Exchange
1.125% Notes due 2023	PG23A	New York Stock Exchange
0.500% Notes due 2024	PG24A	New York Stock Exchange
0.625% Notes due 2024	PG24B	New York Stock Exchange
1.375% Notes due 2025	PG25	New York Stock Exchange
0.110% Notes due 2026	PG26D	New York Stock Exchange
3.250% EUR Notes due 2026	PG26E PG26F	New York Stock Exchange
4.875% EUR Notes due May 2027	PG27A	New York Stock Exchange
1.200% Notes due 2028	PG28	New York Stock Exchange
3.150% EUR Notes due 2028	PG28B	New York Stock Exchange
1.250% Notes due 2029	PG29B	New York Stock Exchange
1.800% Notes due 2029	PG29A	New York Stock Exchange
6.250% GBP Notes due January 2030	PG30	New York Stock Exchange
0.350% Notes due 2030	PG30C	New York Stock Exchange
0.230% Notes due 2031	PG31A	New York Stock Exchange
3.250% EUR Notes due 2031	PG31B	New York Stock Exchange
5.250% GBP Notes due January 2033	PG33	New York Stock Exchange
3.200% EUR Notes due 2034	PG34C	New York Stock Exchange
1.875% Notes due 2038	PG38	New York Stock Exchange
0.900% Notes due 2041	PG41	New York Stock Exchange

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☐Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☐Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☐Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated **filed, filer,**" "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>	Emerging growth company	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. --

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). --

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No p

The aggregate market value of the voting stock held by non-affiliates amounted to \$357 billion| \$345 billion on December 31, 2022| December 31, 2023.

There were 2,357,306,187| 2,354,050,987 shares of Common Stock outstanding as of July 31, 2023| July 31, 2024.

Documents Incorporated by Reference

Portions of the Proxy Statement for the 2023 2024 Annual Meeting of Shareholders, which will be filed within one hundred and twenty days of the fiscal year ended June 30, 2023 (2023 June 30, 2024 (2024 Proxy Statement), are incorporated by reference into Part III of this report to the extent described herein.

FORM 10-K TABLE OF CONTENTS			Page
PART I	Item 1.	Business	1
	Item 1A.	Risk Factors	3
	Item 1B.	Unresolved Staff Comments	9
	Item 1C.	Cybersecurity	9
	Item 2.	Properties	9 10
	Item 3.	Legal Proceedings	9 10
	Item 4.	Mine Safety Disclosure	9 10
		Information about our Executive Officers	10 11
PART II	Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	11 12
	Item 6.	Intentionally Omitted	12 13
	Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12 13
	Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	30 31
	Item 8.	Financial Statements and Supplementary Data	31 32
		Management's Report and Reports of Independent Registered Public Accounting Firm	31 32
		Consolidated Statements of Earnings	35 36
		Consolidated Statements of Comprehensive Income	35 36
		Consolidated Balance Sheets	36 37
		Consolidated Statements of Shareholders' Equity	37 38
		Consolidated Statements of Cash Flows	38 39
		Notes to Consolidated Financial Statements	39 40
		Note 1: Summary of Significant Accounting Policies	39 40
		Note 2: Segment Information	41 42
		Note 3: Supplemental Financial Information	44 45
		Note 4: Goodwill and Intangible Assets	45 46
		Note 5: Income Taxes	46 48
		Note 6: Earnings Per Share	48 50
		Note 7: Share-based Share-based Compensation	49 51
		Note 8: Postretirement Benefits and Employee Stock Ownership Plan	51 53
		Note 9: Risk Management Activities and Fair Value Measurements	56 58
		Note 10: Short-term and Long-term Debt	59 60
		Note 11: Accumulated Other Comprehensive Income/(Loss)	60 62
		Note 12: Leases	60 62
		Note 13: Commitments and Contingencies	61 63
		Note 14: Supplier Finance Programs	64
		Note 15: Subsequent Event	64
	Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	62 64
	Item 9A.	Controls and Procedures	62 65
	Item 9B.	Other Information	62 65
	Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	62 65
PART III	Item 10.	Directors, Executive Officers and Corporate Governance	63 65
	Item 11.	Executive Compensation	63 65
	Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	63 65
	Item 13.	Certain Relationships and Related Transactions and Director Independence	63 66
	Item 14.	Principal Accountant Fees and Services	63 66
PART IV	Item 15.	Exhibits and Financial Statement Schedules	64 66
	Item 16.	Form 10-K Summary	66 69
		Signatures	67 70

PART I

Item 1. Business.

The Procter & Gamble Company (the Company) is a world-leading multinational consumer goods company focused on providing trusted, branded products of superior quality, performance and value to improve the lives of consumers around the world's consumers, world - now and for generations to come. Our products are sold in about 180 countries and territories throughout the world. The Company was incorporated in Ohio in 1905, having first been established as a New Jersey corporation in 1890, and was built from a business founded in Cincinnati in 1837 by William Procter and James Gamble.

Additional information required by this item is incorporated herein by reference to Management's Discussion and Analysis (MD&A); and Notes 1 and 2 to our Consolidated Financial Statements. Unless the context indicates otherwise, the terms "Company," "P&G," "we," "our" or "us" as used herein refer to The Procter & Gamble Company (the registrant) and its subsidiaries. Throughout this Form 10-K, we incorporate by reference information from other documents filed with the Securities and Exchange Commission (SEC).

The Company's Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and amendments thereto, are filed electronically with the SEC. The SEC maintains an internet site that contains these reports at: www.sec.gov. Reports can also be accessed and downloaded through links from our website at: www.pginvestor.com. P&G includes the website link solely as a textual reference and the information on our website is not incorporated by reference into this report.

Copies of these reports are also available, without charge, by contacting EQ Shareowner Services, 1100 Centre Pointe Curve, Suite 101, Mendota, MN 55120-4100.

Financial Information about Segments

Information about our reportable segments can be found in the MD&A and Note 2 to our Consolidated Financial Statements.

Narrative Description of Business

Business Model. Our business model is built to deliver focused on delivering sustainable value creation by driving balanced top- and bottom-line growth growth. We create, manufacture, market and value creation. We rely on the continued growth and success distribute a diversified portfolio of existing brands and daily-use products as well as the creation of new innovative products and brands. We offer products in markets and industry segments that are highly competitive. Our products are sold in approximately 180 countries and territories through numerous channels as well as direct-to-consumer. Our growth strategy is to deliver meaningful and noticeable delight consumers with irresistible superiority across five key vectors of our consumer proposition - product performance, packaging, brand communication, retail execution and consumer and customer value. We use our invest in research and development (R&D) and consumer insights to provide superior invent new categories or products and packaging. innovate our existing products, ensuring they meet evolving consumer needs and preferences. We utilize leverage marketing strategies including advertising, promotions and endorsements to drive brand awareness and loyalty among consumers. The Company utilizes various distribution channels, including retail stores, e-commerce platforms and direct-to-consumer platforms to deliver our products. Our business model relies on continued productivity improvements to fuel investments in R&D and marketing and online presence deliver value creation. Our objective is to deliver superior brand messaging to our consumers. We partner with our customers to deliver superior retail execution, both in-store sustainable and online. In conjunction with the above vectors, we provide superior value to consumers and our retail customers in each price tier in which we compete. Productivity improvement is also critical to delivering our objectives of balanced top- and bottom-line growth while serving the needs of all stakeholders — consumers, customers, employees, society and value creation. shareowners.

Key Product Categories. Information on key product categories can be found in the MD&A and Note 2 to our Consolidated Financial Statements.

Key Customers. Our customers include mass merchandisers, e-commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to consumers. Sales to Walmart Inc. and its affiliates represent approximately 15% 16% of our total sales in 2024 and 15% in 2023 2022 and 2021, 2022. No other customer represents more than 10% of our total sales. Our top ten customers accounted for 40% 42% of our total net sales in 2024, 40% in 2023 and 39% in 2022 and 2021, 2022.

Sources and Availability of Materials. Almost all of the raw and packaging materials used by the Company are purchased from third parties, some of whom are single-source suppliers. We produce certain raw materials, primarily chemicals, for further use in the manufacturing process. In addition, fuel, natural gas and derivative products are important commodities consumed in our manufacturing processes and in the transportation of input materials and finished products. The prices we pay for materials and other commodities are subject to fluctuation. When prices for these items change, we may or may not pass the change to our customers. The Company purchases a substantial variety of other raw and packaging materials, none of which are material to our business taken as a whole.

Trademarks and Patents. We own or have licenses under rights to patents and registered trademarks, which are used in connection with our activity in all businesses. Some Our patents cover a range of these patents or licenses cover product features, including significant product formulation and processes used to manufacture our products. The trademarks are important to the overall marketing and branding of our products. All major trademarks in each business are registered. In part, our success can be attributed to the existence and continued protection of these trademarks patents and licenses. patents.

Competitive Condition. The markets in which our products are sold are highly competitive. Our products compete against similar products from many a broad range of companies, both large and small, companies, both established and new, including well-known global competitors. In many of the markets and industry segments, in which we sell our products, we compete against other branded products as well as retailers' private-label brands. We In this highly competitive setting, we are well positioned in the industry segments and markets in which we operate, often holding a leadership or significant market share position. We support Our integrated strategy and our products with advertising, promotions focus on driving superiority across product, packaging, brand communication, retail execution and other marketing vehicles to build awareness and trial of our brands and products value are key differentiators in conjunction with our sales force. We believe this combination provides the marketplace.

most efficient method of marketing for these types of products. Product quality, performance, value and packaging are also important differentiating factors.

Government Regulation. Our Company is subject to a wide variety of laws and regulations across the countries in which we do business. In the United States, many of our products and manufacturing operations are subject to one or more federal or state regulatory agencies, including the U.S. Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA), the Federal Trade Commission (FTC) and the Consumer Product Safety Commission (CPSC). We are also subject to anti-corruption laws and regulations, such as the U.S. Foreign Corrupt Practices Act, and antitrust and competition laws and regulations that govern our dealings with suppliers, customers, competitors and government officials.

In addition, many foreign jurisdictions in which we do business have regulations and regulatory bodies that govern similar aspects of our operations and products, in some cases to an even more significant degree. We are also subject to expanding laws and regulations related to environmental protection and other sustainability-related matters, non-financial reporting and diligence, labor and employment, trade, taxation and data privacy and data protection, including the European Union's General Data Protection Regulation (GDPR) and similar regulations in states within the United States and in countries around the world.

The Company has in place compliance programs and internal and external experts to help guide our business in complying with these and other existing laws and regulations that apply to us around the globe; and we have made, and plan to continue making, necessary expenditures for compliance with these laws and regulations. We also expect that our many suppliers, consultants and other third parties working on our behalf share our commitment to compliance, and we have policies and procedures in place to manage these relationships, though they inherently involve a lesser degree of control over operations and governance. We do not expect that the Company's expenditures for compliance with current government regulations, including current environmental regulations, will have a material effect on our total capital expenditures, earnings or competitive position in fiscal year 2024 2025 as compared to prior periods.

Human Capital. Our employees are a key source of competitive advantage. Their actions, guided by our Purpose, Values and Principles (PVPs), are critical to the long-term success of our business. We aim to retain our talented employees by offering competitive compensation and benefits, strong career development and a respectful and inclusive culture that provides equal opportunity for all.

Our Board of Directors, through the Compensation and Leadership Development Committee (C&LD Committee), provides oversight of the Company's policies and strategy relating to talent, including diversity, equality and inclusion, as well as the Company's compensation principles and practices. The C&LD Committee also evaluates and approves the Company's compensation plans, policies and programs applicable to our senior executives.

Employees

As of June 30, 2023 June 30, 2024, the Company had approximately 107,000 108,000 employees, an increase of 1% unchanged versus the prior year due primarily to business growth. year. The total number of employees is an estimate of total Company employees excluding interns, co-ops, contractors and employees of joint ventures. 49% 48% of our employees are in manufacturing roles and 27% 28% of our employees are located in the United States. 41% 42% of our global employees are women and 30% 32% of our U.S. employees identify as multicultural.

Training and Development

We focus on attracting, developing and retaining skilled and diverse the widest pool of talent available, both from universities and the broader market. We recruit from among the best universities across markets in which we compete and are generally able to select from the top talent. We focus on developing our employees by providing a variety of job experiences, training programs and skill development opportunities. Given our develop-from-within model for staffing most of our senior leadership positions, it is particularly important for us to ensure holistic growth and full engagement of our employees.

Diversity, Equality and Inclusion

As a consumer products company, we believe that it is important for our workforce to reflect the diversity of our consumers worldwide. We also seek to foster an inclusive work environment where each individual can bring their authentic self, which helps drive innovation and enables us to better serve our consumers. We aspire to achieve equal gender representation globally and at key management and leadership levels. Within the U.S. workforce, our aspiration is to achieve 40% multicultural representation overall as well as at management and leadership levels.

Compensation and Benefits

Market-competitive compensation and reward programs are critical elements of our employee value equation to attract and retain the best talent. Our total rewards programs are based on the principles of paying for performance, paying competitively versus peer companies that we compete with for talent in the marketplace and focusing on long-term success through a combination of short-term and long-term incentive programs. We also offer competitive benefit programs, including retirement plans and health insurance, in line with local country practices, with flexibility to accommodate the needs of a diverse workforce.

Sustainability. Environmental sustainability is integrated into our business strategy to offer consumers strategy. We are focused on designing and manufacturing irresistibly superior products that are more sustainable. Our We aim is to deliver balanced top-reduce our own environmental footprint and bottom-line growth, value creation enable our consumers to reduce their footprint without compromising on the performance of the products they use. We develop and key license technologies that can be used across industries to improve environmental sustainability objectives. In 2021, the Company announced at a 2040 net zero ambition and published a Climate Transition Action broader scale.

The Procter & Gamble Company 3

Combined, this approach intends to positively impact the total environmental impact of the Company while driving market growth and value creation.

In 2021, the Company announced a 2040 net zero ambition. Our Climate Transition Action Plan which describes outlines the Company's ongoing efforts toward reducing greenhouse gas emissions across scopes 1 and 2 and elements of scope 3. This includes a long-term objective of net zero emissions for scopes 1 and 2, elements of scope 3 and interim goals to help us pace our progress. The Company has also declared goals objectives towards using purchasing renewable electricity for our operations, reducing use of virgin petroleum-based plastic in packaging, increasing the recyclability or reusability of packaging, responsible sourcing of key forest-based commodities, improving efficiency of water usage in our operations and driving a global portfolio of water restoration projects to that help address water scarcity, scarcity in key water basins. Our progress towards these objectives may be influenced and impacted by various stakeholders and developments beyond our control.

We use the standards and guidelines of the Global Reporting Initiative, Sustainability Accounting Standards Board (SASB) industry specific standards and the Task Force on Climate-related Financial Disclosures (TCFD) to inform our sustainability and related disclosures included in this Annual Report, our Proxy Statement and our sustainability

reports. reports are informed by standards and guidelines such as the Global Reporting Initiative (GRI) and the Task Force on Climate-related Financial Disclosures (TCFD). The “materiality” thresholds in those standards and guidelines may differ from the concept of “materiality” for purposes of the federal securities laws and disclosures required by the Commission’s rules in this Annual Report. References to our sustainability reports and website are for informational purposes only and neither the sustainability reports nor the other information on our website is incorporated by reference into this Annual Report on Form 10-K. Additional detailed information on our sustainability efforts can be found on our website at <https://pginvestor.com/esg>.

Item 1A. Risk Factors.

We discuss our expectations regarding future performance, events and outcomes, such as our business outlook and objectives in this Form 10-K, as well as in our quarterly and annual reports, current reports on Form 8-K, press releases and other written and oral communications. All statements, except for historical and present factual information, are “forward-looking statements” and are based on financial data and business plans available only as of the time the statements are made, which may become outdated or incomplete. We assume no obligation to update any forward-looking statements as a result of new information, future events or other factors, except to the extent required by law. Forward-looking statements are inherently uncertain, and investors must recognize that events could significantly differ from our expectations.

The following discussion of “risk factors” identifies significant factors that may adversely affect our business, operations, financial position or future financial performance. This information should be read in conjunction with Management’s Discussion and Analysis and the Consolidated Financial Statements and related Notes incorporated in this report. The following discussion of risks is not all inclusive but is designed to highlight what we believe are important factors to consider when evaluating our expectations. These and other factors could cause our future results to differ from those in the forward-looking statements and from historical trends, perhaps materially.

MACROECONOMIC CONDITIONS AND RELATED FINANCIAL RISKS

Our business is subject to numerous risks as a result of having significant operations and sales in international markets, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility, controls.

We are a global company, with operations in approximately about 70 countries and products sold in approximately about 180 countries and territories around the world. We hold assets, incur liabilities, generate sales and pay expenses in a variety of currencies other than the U.S. dollar, and our operations outside the U.S. generate more than 50% of our annual net sales. Fluctuations in exchange rates for foreign currencies have and could continue to reduce the U.S. dollar value of sales, earnings and cash flows we receive from non-U.S. markets, increase our supply costs (as measured in U.S. dollars) in those markets, negatively impact our competitiveness in those markets or otherwise adversely impact our business results or financial condition.

Further, we have a significant amount of foreign currency debt and derivatives as part of our capital markets activities. The maturity cash outflows of these instruments could be adversely impacted by significant appreciation of foreign currency exchange rates (particularly the Euro), which could adversely impact our overall cash flows. Moreover, discriminatory or conflicting fiscal or trade policies in different countries, including changes to tariffs and existing trade policies and agreements, could adversely affect our results. See also the Results of Operations and Cash Flow, Financial Condition and Liquidity sections of the MD&A and the Consolidated Financial Statements and related Notes.

We also have businesses and maintain local currency cash balances in a number of countries with currency exchange, import authorization, pricing or other controls or restrictions, such as Egypt, Argentina and Pakistan. restrictions. Our results of operations, financial condition and cash flows could be adversely impacted if we are unable to successfully manage such controls and restrictions, continue existing business operations and repatriate earnings from overseas, or if new or increased tariffs, quotas, exchange or price controls, trade barriers or similar restrictions are imposed on our business.

Additionally, our business, operations or employees have been and could continue to be adversely affected (including by the need to de-consolidate or even exit certain businesses in particular countries) by geopolitical conflicts, political volatility, trade controls, labor market disruptions or other crises or vulnerabilities in individual countries or regions. This could include political instability, upheaval or acts of war (such as the Russia-Ukraine War) and the related government and other entity responses, broad economic instability or sovereign risk related to a default by or deterioration in the creditworthiness of local governments, particularly in emerging markets.

Uncertain economic or social conditions may adversely impact demand for our products or cause our customers and other business partners to suffer financial hardship, which could adversely impact our business.

Our business could be negatively impacted by reduced demand for our products related to one or more significant local, regional or global economic or social disruptions. These disruptions have included and may in the future include: a slow-down,

4 The Procter & Gamble Company

recession or inflationary pressures in the general economy; reduced market growth rates; tighter credit markets for our suppliers, vendors or customers; a significant shift in government policies; significant social unrest; the deterioration of economic relations between countries or regions; potential negative consumer sentiment toward non-local products or sources;

4 The Procter & Gamble Company

or the inability to conduct day-to-day transactions through our financial intermediaries to pay funds to or collect funds from our customers, vendors and suppliers. Additionally, these and other economic conditions may cause our suppliers, distributors, contractors or other third-party partners to suffer financial or operational difficulties that they cannot overcome, resulting in their inability to provide us with the materials and services we need, in which case our business and results of operations could be adversely affected. Customers may also suffer financial hardships due to economic conditions such that their accounts become uncollectible or are subject to longer collection cycles. In addition, if we are unable to generate sufficient sales, income and cash flow, it could affect the Company’s ability to achieve expected share repurchase and dividend payments.

Disruptions in credit markets or to our banking partners or changes to our credit ratings may reduce our access to credit or overall liquidity.

A disruption in the credit markets or a downgrade of our current credit rating could increase our future borrowing costs and impair our ability to access capital and credit markets on terms commercially acceptable to us, which could adversely affect our liquidity and capital resources or significantly increase our cost of capital. In addition, we rely on top-tier banking partners in key markets around the world, who themselves face economic, societal, political and other risks, for access to credit and to facilitate collection, payment and supply chain finance programs. A disruption to one or more of these top-tier partners could impact our ability to draw on existing credit facilities or otherwise adversely affect our cash flows or the cash flows of our customers and vendors.

Changing political and geopolitical conditions could adversely impact our business and financial results.

Changes in the political conditions in markets in which we manufacture, sell or distribute our products, as well as changing geopolitical conditions, may be difficult to predict and may adversely affect our business and financial results. Results of elections, referendums, sanctions or other political processes and pressures in certain markets in which our products are manufactured, sold or distributed could create uncertainty regarding how existing governmental policies, laws and regulations may change, including with respect to sanctions, taxes, tariffs, import and export controls and the general movement of goods, materials, services, capital, data and people between countries. The potential implications of such uncertainty, which include, among others, exchange rate fluctuations, new or increased tariffs, trade barriers and market contraction, could adversely affect the Company's results of operations and cash flows.

The Company operates a global business with sales, manufacturing, distribution and research and development organizations globally that contribute to our overall growth. If geopolitical tensions and trade controls were to increase or disrupt our business in markets where we have significant sales or operations, including disruptions due to governmental responses to such conflicts (such as the imposition of sanctions, export controls, retaliatory tariffs, increased business licensing requirements or limitations on profits), such disruptions could adversely impact our business, financial condition, results of operations and cash flows.

The war between Russia and Ukraine has adversely impacted Our business, operations or employees have been and could continue to be adversely impact our business affected (including by the need to de-consolidate or even exit certain businesses in particular countries) by geopolitical conflicts, political volatility, trade controls, labor market disruptions or other crises or vulnerabilities in individual countries or regions. This could include political instability, upheaval or acts of war and financial results, the related responses of governments or other entities (including, but not limited to, boycotts in certain regions), broad economic instability or sovereign risk related to a default by or deterioration in the creditworthiness of local governments, particularly in emerging markets.

The For example, the ongoing war between Russia and Ukraine has negatively impacted, and the situation it generates may continue to negatively impact, our operations. Beginning in March 2022, the Company reduced its product portfolio, discontinued new capital investments and suspended media, advertising and promotional activity in Russia. Future impacts to the Company are difficult to predict due to the high level of uncertainty as to how the overall situation will evolve. Within Ukraine, there is a possibility of physical damage and destruction of our two manufacturing facilities, our distribution centers or those of our customers. We may not be able to operate our manufacturing sites and source raw materials from our suppliers or ship finished products to our customers. Within Russia, we may reduce further or discontinue our operations in Russia due to sanctions and export controls and counter-sanctions, monetary, currency or payment controls, restrictions on access to financial institutions, supply and transportation challenges or other circumstances and considerations. Ultimately, these could result in loss of assets or impairments of our manufacturing plants and fixed assets or write-downs of other operating assets and working capital.

The More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation worsen, including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures, energy and supply chain cost increases or the geographic proximity of the war between Russia and Ukraine relative to the rest of Europe.

Changes in geopolitical conditions could also amplify or affect the other risk factors set forth in this Part I, Item 1A, including, but not limited to, foreign exchange volatility, disruptions to the financial and credit markets, energy supply and supply chain disruptions, increased risks of an information security or operational technology incident, cost fluctuations and commodity cost increases and increased costs to ensure compliance with global and local laws and regulations. The occurrence

Disruptions in credit markets or to our banking partners or changes to our credit ratings may reduce our access to credit or overall liquidity.

A disruption in the credit markets or a downgrade of any of these risks, combined with the increased impact from the war between Russia our current credit rating could increase our future borrowing costs and Ukraine, impair our ability to access capital and credit markets on terms commercially acceptable to us, which could adversely impact affect our business liquidity and financial results.

More broadly, there could be additional negative impacts capital resources or significantly increase our cost of capital. In addition, we rely on top-tier banking partners in key markets around the world, who themselves face economic, societal, political and other risks, for access to our net sales, earnings credit and cash flows should the situation worsen, including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures, energy facilitate collection, payment and supply chain cost increases finance programs. A disruption to one or more of these top-tier partners could impact our ability to draw on existing credit facilities or otherwise adversely affect our cash flows or the geographic proximity cash flows of the war relative to the rest of Europe. our customers and vendors.

BUSINESS OPERATIONS RISKS

Our business results depend on our ability to manage disruptions in our global supply chain.

Our ability to meet our customers' needs and achieve cost targets depends on our ability to maintain key manufacturing and supply arrangements, including execution of supply chain optimizations and certain sole supplier or sole manufacturing plant

The Procter & Gamble Company 5

arrangements. The loss or disruption of such manufacturing and supply arrangements, including for issues such as labor disputes or controversies, loss or impairment of key manufacturing sites, discontinuity or disruptions in our internal information

The Procter & Gamble Company 5

and data systems or those of our suppliers, cybersecurity incidents including but not limited to ransomware attacks, misuse of artificial intelligence and machine learning technologies, inability to procure sufficient raw or input materials (including water, recycled materials and materials that meet our labor standards), significant changes in trade policy, natural disasters, increasing severity or frequency of extreme weather events due to climate change or otherwise, acts of war or terrorism, disease outbreaks or other external factors over which we have no control, have at times interrupted and could, in the future, interrupt product supply and, if not effectively managed and remedied, could have an adverse impact on our business, financial condition, results of operations or cash flows.

Our businesses face cost fluctuations and pressures that could affect our business results.

Our costs are subject to fluctuations, particularly due to changes in the prices of commodities (including certain petroleum-derived materials like resins and paper-based materials like pulp) and raw and packaging materials and the costs of labor, transportation (including trucks and containers), energy, pension and healthcare. Inflation pressures could also sometimes result in increases in these input costs. Therefore, our business results depend, in part, on our continued ability to manage these fluctuations through pricing actions, cost saving projects and sourcing decisions, while maintaining and improving margins and market share. Failure to manage these fluctuations and to anticipate consumer reaction to our management of these fluctuations could adversely impact our results of operations or cash flows.

The ability to achieve our business objectives depends on how well we can compete with our local and global competitors in new and existing markets and channels.

The consumer products industry is highly competitive. Across all of our categories, we compete against a wide variety of global and local competitors. As a result, we experience ongoing competitive pressures in the environments in which we operate, which may result in challenges in maintaining sales and profit margins. To address these challenges, we must be able to successfully respond to competitive factors and emerging retail trends, including pricing, promotional incentives, product delivery windows and trade terms. In addition, evolving sales channels and business models may affect customer and consumer preferences as well as market dynamics, which, for example, may be seen in the growing consumer preference for shopping online, ease of competitive entry into certain categories and growth in hard discounter channels. Failure to successfully respond to competitive factors and emerging retail trends and effectively compete in growing sales channels and business models, particularly e-commerce and mobile or social commerce applications, could negatively impact our results of operations or cash flows.

A significant change in customer relationships or in customer demand for our products could have a significant impact on our business.

We sell most of our products via retail customers, which include mass merchandisers, e-commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. Our success depends on our ability to successfully manage relationships with our retail trade customers, which includes our ability to offer trade terms that are mutually acceptable and are aligned with our pricing and profitability targets. Continued concentration among our retail customers could create significant cost and margin pressure on our business, and our business performance could suffer if we cannot reach agreement with a key customer on trade terms and principles. Our business could also be negatively impacted if a key customer were to significantly reduce the inventory level of or shelf space allocated to our products as a result of increased offerings of other branded manufacturers, private label brands and generic non-branded products or for other reasons, significantly tighten product delivery windows or experience a significant business disruption.

If the reputation of the Company or one or more of our brands erodes significantly, it could have a material impact on our financial results.

The Company's reputation, and the reputation of our brands, form the foundation of our relationships with key stakeholders and other constituencies, including consumers, customers and suppliers. The quality and safety of our products are critical to our business. Many of our brands have worldwide recognition and our financial success directly depends on the success of our brands. The success of our brands can suffer if our marketing plans or product initiatives do not have the desired impact on a brand's image or its ability to attract consumers. Our results of operations or cash flows could also be negatively impacted if the Company or one of our brands suffers substantial harm to its reputation due to a significant product recall, product-related litigation, defects or impurities in our products, product misuse, changing consumer perceptions of certain ingredients, negative perceptions of packaging (such as plastic and other petroleum-based materials), lack of recyclability or other environmental impacts, attributes, concerns about actual or alleged labor or equality and inclusion practices, privacy lapses failures or data breaches, allegations of product tampering or the distribution and sale of counterfeit products. Additionally, negative or inaccurate postings or comments on social media or networking websites about the Company or one of its brands could generate adverse publicity that could damage the reputation of our brands or the Company. If we are unable to effectively manage real or perceived issues, including concerns about safety, quality, ingredients, efficacy, environmental or social impacts or similar matters, sentiments toward the Company or our products could be negatively impacted, and our results of operations or cash flows could suffer. Our Company also devotes time and resources to citizenship efforts that are consistent with our corporate values and are designed to strengthen our business and protect and preserve our reputation, including programs driving ethics and corporate responsibility, strong communities, equality and inclusion and environmental sustainability. While the Company has many programs and

6 The Procter & Gamble Company

has many programs and initiatives to further these goals, our ability to achieve these goals is citizenship efforts, we are impacted in part by the actions and efforts of third parties including local and other governmental authorities, suppliers, vendors and customers. Consumer or broader stakeholder perceptions of these programs and initiatives widely vary and could adversely affect our business. If these programs are not executed as planned or suffer negative publicity, the Company's reputation and results of operations or cash flows could be adversely impacted.

We rely on third parties in many aspects of our business, which creates additional risk.

Due to the scale and scope of our business, we must rely on relationships with third parties, including our suppliers, contract manufacturers, distributors, contractors, commercial banks, joint venture partners and external business partners, for certain functions. If we are unable to effectively manage our third-party relationships and the agreements under which our third-party partners operate, our results of operations and cash flows could be adversely impacted. Further, failure of these third parties to meet their obligations to the Company, including the transparency and accuracy of the disclosures of ingredients in materials or processes, and the proper security of Company data and personal data, or substantial disruptions in the relationships between the Company and these third parties could adversely impact our operations and financial results. Additionally, while we have policies and procedures for managing these relationships, they inherently involve a lesser degree of control over business operations, governance and compliance, thereby potentially increasing our financial, legal, reputational and operational risk.

A significant information security or operational technology incident, including a cybersecurity breach, or the failure of one or more key information or operations technology systems, networks, hardware, processes and/or associated sites owned or operated by involving the Company or one of its service providers could have a material adverse impact on our business or reputation.

We rely extensively on information and operational technology (IT/OT) systems, networks and services, including internet and intranet sites, data hosting and processing facilities and technologies, physical security systems and other hardware, software and technical applications and platforms, many platforms. Many of which these are managed, hosted, provided and/or used by third parties or their vendors, to assist in conducting our business, vendors. The various uses of these IT/OT systems, networks and services include, but are not limited to:

- to, ordering and managing materials from suppliers;
- converting materials to finished products;
- shipping, products to customers;
- marketing and selling products to consumers;
- products; collecting, transferring, storing and/or processing customer, consumer, employee, vendor, investor and other stakeholder information and personal data, including such data from persons covered by an expanding landscape of privacy and data regulations, such as citizens of the European Union who are covered by the General Data Protection Regulation (GDPR), residents of California covered by the California Consumer Privacy Act (CCPA), citizens of China covered by the Personal Information Protection Law (PIPL) and citizens of Brazil covered by the General Personal Data Protection Law (LGPD);
- summarizing and reporting results of operations, including financial reporting;
- managing our banking and other cash liquidity systems and platforms;
- hosting, processing and sharing, as appropriate, confidential and proprietary research, business plans and financial information;
- collaborating via an online and efficient means of global business communications;
- complying with regulatory, legal and tax requirements;
- providing data security; and
- handling other processes necessary to manage our business.

Numerous and evolving information security threats, including advanced persistent cybersecurity threats, pose a risk to the security of our services, systems, networks and supply chain, as well as to the confidentiality, availability and integrity of our data and of our critical business operations. In addition, because the techniques, tools and tactics used in cyber-attacks frequently change and may be difficult to detect for periods of time, we may face difficulties in anticipating and implementing adequate preventative measures or fully mitigating harms after such an attack, attack, including acquired and divested businesses.

Our IT/OT databases and systems and our third-party providers' databases and systems have been, and will likely continue to be, subject to advanced computer viruses or other malicious codes, ransomware, unauthorized access attempts, denial of service attacks, phishing, social engineering, hacking and other cyber-attacks. Such attacks may originate from outside parties, hackers, criminal organizations or other threat actors, including nation states. In addition, insider actors - malicious or otherwise - could cause technical disruptions and/or confidential data leakage. We cannot guarantee that our security efforts or the security efforts of our third-party providers will prevent material breaches, operational incidents or other breakdowns to our or our third-party providers' IT/OT databases or systems.

A breach of our data security systems or failure of our IT/OT databases and systems and those of our third-parties may have a material adverse impact on our business operations and financial results. If the IT/OT systems, networks or service providers we rely upon fail to function properly or cause operational outages or aberrations, or if we or one of our third-party providers suffer significant unavailability of key operations, or inadvertent disclosure of, lack of integrity of, or loss of our sensitive business or stakeholder information,

The Procter & Gamble Company 7

including personal information, due to any number of causes, including catastrophic events, natural disasters, power outages, computer and telecommunications failures, improper data handling, viruses, phishing attempts, cyber-attacks, malware and ransomware attacks, security breaches, misuse or malicious use of artificial intelligence, security incidents or employee error or malfeasance, and our business continuity plans do not effectively address these failures on a timely basis, we may suffer interruptions in our ability to manage operations and be exposed to reputational, competitive, operational, financial and business harm as well as litigation and regulatory action. If our critical IT systems or back-up systems or those of our third-party vendors are damaged or cease to function properly, we may have to make a significant investment to repair or replace them.

In addition, if a ransomware attack or other cybersecurity incident occurs, either internally or at our third-party technology service providers, we could be prevented from accessing our data or systems, which may cause interruptions or delays in our business operations, cause us to incur remediation costs, subject us to demands to pay a ransom or damage our reputation. In addition, such events could result in unauthorized disclosure or loss of confidential information or stakeholder information, including personal information, data

The Procter & Gamble Company 7

from customers, consumers, employees, vendors, investors and other stakeholders, and we may suffer financial and reputational damage because of lost or misappropriated information belonging to us or to our partners, our employees, customers and suppliers, as a result. Additionally, we could be exposed to potential liability, litigation, governmental inquiries, reporting requirements, investigations or regulatory enforcement actions; and we could be subject to payment of fines or other penalties, legal claims by our suppliers, customers or employees and significant remediation costs.

Periodically, we and/or our suppliers also upgrade our IT/OT systems or adopt new technologies, technologies, including those enabled by machine learning or artificial intelligence. If such a new system or technology does not function properly, provides flawed or otherwise inaccurate outputs or exposes us to increased cybersecurity breaches and failures, it could affect our ability to order materials, make and ship orders and process payments in addition to other operational and information integrity and loss issues. The costs and

operational consequences of responding to the above items and implementing remediation measures could be significant and could adversely impact our results of operations and cash flows, flows and generate negative publicity affecting Company reputation and relationships among consumers, customers and other business partners.

We must successfully manage the demand, supply and operational challenges associated with the effects of any future disease outbreak, including epidemics, pandemics or similar widespread public health concerns.

Our business may be negatively impacted by the fear of exposure to or actual effects of a disease outbreak, epidemic, pandemic or similar widespread public health concern. These impacts may include, but are not limited to:

- Significant reductions in demand or significant volatility in demand for one or more of our products, which may be caused by, among other things: the temporary inability of consumers to purchase our products due to illness, quarantine or other travel restrictions or financial hardship, shifts in demand away from one or more of our more discretionary or higher priced products to lower priced products or stockpiling or similar pantry-loading activity. If prolonged, such impacts can further increase the difficulty of business or operations planning and may adversely impact our results of operations and cash flows; or
- Significant changes in the political conditions in markets in which we manufacture, sell or distribute our products, including quarantines, import/export restrictions, price controls, or governmental or regulatory actions, closures or other restrictions that limit or close our operating and manufacturing facilities, restrict our employees' ability to travel or perform necessary business functions or otherwise prevent our third-party partners, suppliers or customers from sufficiently staffing operations.

Despite efforts to manage and remedy these impacts, their ultimate impact also depends on factors beyond our knowledge or control, including the duration and severity of any such outbreak as well as third-party actions taken to contain its spread and mitigate its public health effects.

BUSINESS STRATEGY & ORGANIZATIONAL RISKS

Our ability to meet our growth targets depends on successful product, marketing and operations innovation and successful responses to competitive innovation, evolving digital marketing and selling platforms and changing consumer habits.habits.

We are a consumer products company that relies on continued global demand for our brands and products. Achieving our business results depends, in part, on successfully developing, introducing and marketing new products and on making significant improvements to our equipment and manufacturing processes. The success of such innovation depends on our ability to correctly anticipate customer and consumer acceptance and trends, to obtain, maintain and enforce necessary intellectual property protections and to avoid infringing upon the intellectual property rights of others and to continue to deliver efficient and effective marketing across evolving media and mobile platforms with dynamic and increasingly more restrictive privacy requirements. We must also successfully respond to technological advances made by, and intellectual property rights granted to, competitors, customers and vendors. Failure to continually innovate, improve and respond to competitive moves, platform evolution and changing consumer habits and platform evolution, including the timely and effective adoption of emerging technologies, could compromise our competitive position and adversely impact our financial condition, results of operations or cash flows.

We must successfully manage ongoing acquisition, joint venture and divestiture activities.

As a company that manages a portfolio of consumer brands, our ongoing business model includes a certain level of acquisition, joint venture and divestiture activities. We must be able to successfully manage the impacts of these activities, while at the same time delivering against our business objectives. Specifically, our financial results have been, and in the future could be, adversely impacted by the dilutive impacts from the loss of earnings associated with divested brands or dissolution of joint ventures. Our results of operations and cash flows have been, and in the future could also be, impacted by acquisitions or joint

8 The Procter & Gamble Company

venture activities, if: 1) changes in the cash flows or other market-based assumptions cause the value of acquired assets to fall below book value, or 2) we are not able to deliver the expected cost and growth synergies associated with such acquisitions and joint ventures, including as a result of integration and collaboration challenges, which could also result in an impairment of goodwill and intangible assets.

Our business results depend on our ability to successfully manage productivity improvements and ongoing organizational change, including attracting and retaining key talent as part of our overall succession planning.

Our financial projections assume certain ongoing productivity improvements and cost savings, including staffing adjustments and employee departures. Failure to deliver these planned productivity improvements and cost savings, while continuing to

8 The Procter & Gamble Company

invest in business growth, could adversely impact our results of operations and cash flows. Additionally, successfully executing organizational change, management transitions at leadership levels of the Company and motivation and retention of key employees is critical to our business success. Factors that may affect our ability to attract and retain sufficient numbers of qualified employees include employee morale, our reputation, competition from other employers and availability of qualified individuals. Our success depends on identifying, developing and retaining key employees to provide uninterrupted leadership and direction for our business. This includes developing and retaining organizational capabilities in key growth markets where the depth of skilled or experienced employees may be limited and competition for these resources is intense as well as continuing the development and execution of robust leadership succession plans.

LEGAL & REGULATORY RISKS

We must successfully manage compliance with current and expanding laws and regulations, as well as manage new and pending legal and regulatory matters in the U.S. and abroad.

Our business is subject to a wide variety of laws and regulations across the countries in which we do business, including those laws and regulations involving intellectual property, product liability, product composition or formulation, manufacturing processes, packaging content or corporate responsibility for packaging and product disposal, marketing, antitrust and competition, privacy, cybersecurity and data protection, artificial intelligence, environmental (including increasing focus on the climate, nature, water and waste impacts of consumer packaged goods companies' operations and products), employment, healthcare, anti-bribery and anti-corruption (including interactions with health care professionals and government officials as well as corresponding internal controls and record-keeping requirements), trade (including tariffs, sanctions and export controls), tax, accounting and financial reporting or other matters. In addition, increasing governmental and societal attention to environmental, social and governance (ESG) matters, including expanding mandatory and voluntary reporting, diligence and disclosure on topics such as climate change, waste production, water usage, nature impacts, human capital, labor and risk oversight, could expand the nature, scope and complexity of matters that we are required to control, assess and report. These and other rapidly changing laws, regulations, policies and related interpretations as well as increased enforcement actions by various governmental and regulatory agencies, create challenges for the Company, may alter the environment in which we do business, may increase the ongoing costs and complexities of compliance including by requiring investments in technology or other compliance systems and may ultimately result in the need to cease manufacturing, sales or other business activities in certain jurisdictions, which could adversely impact our results of operations and cash flows. If we are unable to continue to meet these challenges and comply with all laws, regulations, policies and related interpretations, it could negatively impact our reputation and our business results. Additionally, we are currently, and in the future may be, subject to a number of inquiries, investigations, claims, proceedings and requests for information from governmental agencies or private parties, the adverse outcomes of which could harm our business. Failure to successfully manage these new or pending regulatory and legal matters and resolve such matters without significant liability or damage to our reputation may materially adversely impact our financial condition, results of operations and cash flows. Furthermore, if new or pending legal or regulatory matters result in fines or costs in excess of the amounts accrued to date, that may also materially impact our results of operations and financial position.

Changes in applicable tax laws and regulations and resolutions of tax disputes could negatively affect our financial results.

The Company is subject to taxation in the U.S. and numerous foreign jurisdictions. Changes in the various tax laws can and do occur. For example, in December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the U.S. Tax Act). The changes included in the U.S. Tax Act were broad and complex. Under the current U.S. presidential administration, comprehensive federal income tax reform has been proposed, including an increase in the U.S. Federal corporate income tax rate, elimination of certain investment incentives and an increase in U.S. taxation of non-U.S. earnings. While these proposals are controversial, likely to change during the legislative process and may prove difficult to enact as proposed in the current closely divided U.S. Congress, their impact could nonetheless be significant.

Additionally, longstanding international tax norms that determine each country's jurisdiction to tax cross-border international trade are subject to potential evolution. An outgrowth of the original Base Erosion and Profit Shifting (BEPS) project is a project undertaken by the approximately 140 member countries of the expanded Organisation for Economic Co-operation and Development (OECD) Inclusive Framework focused on "Addressing the Challenges of the Digitalization of the Economy." The breadth of this project extends beyond pure digital businesses and, as proposed, would likely impact a large portion of multinational businesses by potentially redefining jurisdictional taxation rights in market countries and establishing a global minimum tax. In December 2022, the European Union (EU) approved a directive requiring member states to incorporate a 15% global minimum tax into their respective domestic laws effective for fiscal years beginning on or after December 31, 2023. Most member states complied with the directive while some were permitted a delayed implementation. In

The Procter & Gamble Company 9

addition, several non-EU countries have recently proposed and/or adopted legislation consistent with the global minimum tax framework. Important details of these minimum tax developments are still to be determined and, in some cases, enactment and timing remain uncertain.

While it is too early Based on current legislation and available guidance, we do not anticipate the Pillar Two global minimum tax to have a material impact to our financial condition, results of operations, cash flows or effective tax rate in the fiscal year ending June 30, 2025. The Company continues to assess the overall impact of these potential changes as these developments occur, consistent with our practice to monitor all changes in tax laws. As the Pillar Two global minimum tax and other tax laws and related regulations are revised,

The Procter & Gamble Company 9

enacted and implemented, a material impact to our financial condition, results of operations, and cash flows could be materially impacted, or effective tax rate may occur.

Furthermore, we are subject to regular review and audit by both foreign and domestic tax authorities. While we believe our tax positions will be sustained, the final outcome of tax audits and related litigation, including maintaining our intended tax treatment of divestiture transactions such as the fiscal 2017 Beauty Brands transaction with Coty, may differ materially from the tax amounts recorded in our Consolidated Financial Statements, which could adversely impact our results of operations and cash flows.

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Risk Management and Strategy

The Company employs multiple tools and processes for assessing, identifying, and managing material risks from cybersecurity threats. A multi-functional enterprise security team reviews and assesses top cybersecurity risks. This assessment is shared with members of senior management, including the Chief Information Officer (CIO) and Chief Information Security Officer (CISO), and helps guide the Company's cybersecurity operational priorities and strategy. In addition, cybersecurity risks are integrated into the Company's broader Enterprise Risk Management program and, when identified, are reported to relevant business and governance leaders within the Company for appropriate action.

To support the ongoing identification and management of cybersecurity issues, the Company provides information security employee training, conducts global and targeted phishing simulation campaigns and conducts tabletop exercises. The Company also deploys a large library of security tools and experts to help prevent, detect, contain, eradicate and recover from potential cybersecurity issues and cyber-attacks. Further, the Company engages third-party consultants and services for cyber intelligence, insights and assessments of its cybersecurity risk posture and governance.

Cybersecurity reviews are embedded into the Company's Third-Party Risk Management program. Generally under this program, third parties that process personal data or high-risk business data on behalf of the Company complete privacy and cybersecurity assessments on a risk basis, which may require such third parties to sign data processing agreements, comply with particular security controls or complete an additional security and privacy assessment.

As a global company, we manage a variety of cybersecurity threats and cannot wholly eliminate the risk of adverse impacts from such incidents. However, as of the date of this Form 10-K, we have not identified any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of our operations or financial condition. For additional information on the risks from cybersecurity threats that we have faced in the past and expect to continue to face in the future, please refer to the "Risk Factors" in Part I, Item 1A of this Form 10-K.

Governance

The Company's Board of Directors oversees cybersecurity risks consistent with its general risk oversight responsibility. The Audit Committee of the Board has specific responsibility for reviewing the status of the security of the Company's electronic data processing information systems and the general security, including cybersecurity, of the Company's people, assets and information systems. In support of this general oversight, the full Board reviews at least annually the most significant enterprise risks facing the Company, including cybersecurity risks, as identified in the Company's Enterprise Risk Management program. This review, which includes key members of senior management, covers any key risks from information security that have been identified and corresponding action plans. The Audit Committee also receives regular updates from the Company's CIO and CISO about the Company's information security and systems security programs and plans, including emerging trends and progress on overall enterprise cybersecurity programs and priorities. These updates occur at least three times a year, with interim updates as needed.

The Company's management is responsible for implementing its strategic plans, including identifying, evaluating, managing and mitigating the risks inherent in them, such as cybersecurity risks. Within management, the Company's CISO has specific responsibility for cybersecurity risk management, reporting to the CIO.

The Company's CISO has over 15 years of experience in cybersecurity, information security and information risk management, including several years each in security engineering and in operations, as well as running incident response organizations. The CISO's organization includes a dedicated team of centralized information security experts and a network of security professionals embedded in each business unit and function.

The CISO also leads the design and development of the Company's cybersecurity program, relying on functional experts within the central Information Security organization as well as on information security experts within each of the Company's Organizational Units. These embedded experts are responsible for the execution of the Company's overall information security strategy and report security risks in their area of responsibility to their Organization Unit leader and to the CISO. Experts within the Company's central Information Security organization help develop the Company's cybersecurity strategies, policies and standards and similarly report security risks within the central enterprise to the CISO.

10 The Procter & Gamble Company

A central team within the Company leads enterprise-wide incident investigations and response, assisting and consulting on cyber security incidents impacting individual Organizational Units. Alerts of potential incidents can arise from security tool alerts, employee reports, threat intelligence sources, threat hunting activities or external entities, among other sources. The Company's Security Operations Center initially responds to incident alerts and notifies central experts to any potentially significant cybersecurity incidents. Members of the Security Operations Center and relevant response teams work to contain and eradicate potential and identified threats and support the system's recovery efforts, advised as needed by the Legal department and other Company experts. Incidents are communicated to the CISO and other members of management, including the Company's Ethics & Compliance Committee, as well as the Audit Committee of the Board, based on documented escalation criteria. The central enterprise team also regularly reviews incident reports to update the CISO.

As described above, both the CIO and CISO report information about the Company's identification and management of cybersecurity risks to the Audit Committee.

Item 2. Properties.

In the U.S., we own and operate 24 manufacturing sites located in 18 different states. In addition, we own and operate 80 78 manufacturing sites in 34 33 other countries. Many of the domestic and international sites manufacture products for multiple businesses. Beauty products are manufactured at 23 22 of these locations; Grooming products at 17; Health Care products at 20; Fabric & Home Care products at 37 35; and Baby, Feminine & Family Care products at 37. We own our Corporate headquarters in Cincinnati, Ohio. We own or lease our principal regional general offices in Switzerland, Panama, Singapore, China and the United Arab Emirates. We own or lease our principal regional shared service centers in Costa Rica, the United Kingdom and the Philippines. Management believes that the Company's sites are adequate to support the business and that the properties and equipment have been well maintained.

Item 3. Legal Proceedings.

The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold (\$1 million or more).

On November 22, 2023, Procter & Gamble UK ("P&G UK"), a United Kingdom based wholly owned subsidiary of the Company, received notification from the U.K. Environment Agency of its intent to assess an unspecified civil penalty for P&G UK's prior inadvertent failure to secure a required permit for its London-based manufacturing site under the European Union's and United Kingdom's Emission Trading Systems. Among other requirements, these Emissions Trading Systems require registration of the site and accounting of and payment for certain past greenhouse gas emissions. The site has been properly registered since March 2021, and P&G UK proactively notified the U.K. Environment Agency after learning of the prior issue.

There are no other relevant matters to disclose under this Item for this period. See Note 13 to our Consolidated Financial Statements for information on certain legal proceedings for which there are contingencies.

This item should be read in conjunction with the Company's Risk Factors in Part I, Item 1A for additional information.

Item 4. Mine Safety Disclosure.
Not applicable.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The names, ages and positions held by the Executive Officers of the Company on August 4, 2023 August 5, 2024, are:

Name	Name	Position	Age	First Elected to Officer Position	Name	Position	Age	First Elected to Officer Position
Jon R. Moeller	Jon R. Moeller	Chairman of the Board, President and Chief Executive Officer	59	2009 ⁽¹⁾				
Jon R. Moeller					Jon R. Moeller	Chairman of the Board, President and Chief Executive Officer	60	2009 ⁽¹⁾
Shailesh Jejurikar					Shailesh Jejurikar			
Shailesh Jejurikar	Shailesh Jejurikar	Chief Operating Officer	56	2018 ⁽²⁾	Shailesh Jejurikar	Chief Operating Officer	57	2018 ⁽²⁾
Andre Schulten	Andre Schulten	Chief Financial Officer	52	2021 ⁽³⁾				
Andre Schulten					Andre Schulten	Chief Financial Officer	53	2021 ⁽³⁾
Gary A. Coombe					Gary A. Coombe			
Gary A. Coombe	Gary A. Coombe	Chief Executive Officer - Grooming	59	2014 ⁽⁴⁾	Gary A. Coombe	Chief Executive Officer - Grooming	60	2014
Jennifer L. Davis	Jennifer L. Davis	Chief Executive Officer - Health Care	52	2022 ⁽⁵⁾				
Jennifer L. Davis					Jennifer L. Davis	Chief Executive Officer - Health Care	53	2022 ⁽⁴⁾
Ma. Fatima D. Francisco					Ma. Fatima D. Francisco			
Ma. Fatima D. Francisco	Ma. Fatima D. Francisco	Chief Executive Officer - Baby, Feminine and Family Care and Executive Sponsor for Gender Equality	55	2018 ⁽⁶⁾	Ma. Fatima D. Francisco	Chief Executive Officer - Baby, Feminine and Family Care	56	2018 ⁽⁵⁾

R. Alexandra Keith	R. Alexandra Keith	Chief Executive Officer - Beauty and Executive Sponsor for Corporate Sustainability	55	2017 ⁽⁷⁾			
R. Alexandra Keith		Chief Executive Officer - Beauty and Executive Sponsor for Corporate Sustainability	56	2017 ⁽⁶⁾			
Sundar Raman							
Sundar Raman							
Sundar Raman	Sundar Raman	Chief Executive Officer - Fabric and Home Care	48	2021 ⁽⁸⁾			
Victor Aguilar	Victor Aguilar	Chief Research, Development and Innovation Officer	56	2020 ⁽⁹⁾			
Victor Aguilar		Chief Research, Development and Innovation Officer	57	2020 ⁽⁸⁾			
Marc S. Pritchard							
Marc S. Pritchard							
Marc S. Pritchard	Marc S. Pritchard	Chief Brand Officer	63	2008 ⁽¹⁾			
Balaji Purushothaman	Balaji Purushothaman	Chief Human Resources Officer	54	2023 ⁽¹⁰⁾			
Balaji Purushothaman		Chief Human Resources Officer	55	2023 ⁽⁹⁾			
Susan Street Whaley	Susan Street Whaley	Chief Legal Officer and Secretary	49	2022 ⁽¹¹⁾			
Susan Street Whaley		Chief Legal Officer and Secretary	50	2022 ⁽¹⁰⁾			

All the Executive Officers named above have been employed by the Company for more than the past five years.

- (1) Mr. Moeller previously served as President and Chief Executive Officer (2021 - 2022), Vice Chairman, Chief Operating Officer and Chief Financial Officer (2019 - 2021), Vice Chairman and Chief Financial Officer (2017 - 2019) and as Chief Financial Officer (2009 - 2017).
- (2) Mr. Jejurikar previously served as Chief Executive Officer - Fabric and Home Care (2019 - 2021), and President - Global Fabric, Home Care and P&G Professional (2018 - 2019), and President - Global Fabric Care and Brand-Building Officer Global Fabric & Home Care (2015 - 2018).
- (3) Mr. Schulten previously served as Senior Vice President - Baby Care, North America (2018 - 2021) and Senior Vice President - Finance & Accounting, Global Baby, Feminine and Family Care (2014 - 2018).
- (4) Mr. Coombe previously served as President - Europe Selling & Market Operations (2014 - 2018).
- (5) Ms. Davis previously served as President - Feminine Care (2019 - 2022), and President - Global Feminine Care (2018 - 2019), and Vice President - Feminine Care, North America and Brand Franchise Leader, Tampax (2016 - 2018).
- (6) Ms. Francisco previously served as Chief Executive Officer - Baby and Feminine Care (2019 - 2021), and President - Global Baby Care and Baby & Feminine Care Sector (2018 - 2019), and President - Global Feminine Care (2015 - 2018).
- (7) Ms. Keith previously served as Chief Executive Officer - Beauty (2017 - 2022).
- (8) Mr. Raman previously served as President - Home Care and P&G Professional (2020 - 2021), President - Fabric Care, North America and P&G Professional (2019 - 2020), and Vice President - Fabric Care, North America (2015 - 2019).
- (9) Mr. Aguilar previously served as Senior Vice President - Research & Development, Corporate Function Research & Development (2020), Senior Vice President - Research & Development, Corporate Function Research & Development and Global Fabric Care (2019), and Senior Vice President - Research & Development Global Fabric Care; and Sector Leader, Research & Development Global Fabric and Home Care (2014 - 2019).

- (9)** Mr. Purushothaman previously served as Senior Vice President - Human Resources, Global Total Rewards, Employee and Labor Relations and Corporate Services (2020 - 2022) and as Senior Vice President - Human Resources, Beauty, Grooming, and Family Care (2015 - 2020).
- (10)** Ms. Whaley previously served as Senior Vice President and General Counsel - North America, Practice Groups and Sector Business Units (2019 - 2022), and Vice President and General Counsel - North America, Global Go-To-Market and Practice Groups, and Global Business Units (2016 - 2019).

12 The Procter & Gamble Company **11**

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

ISSUER PURCHASES OF EQUITY SECURITIES				
Period	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share ⁽²⁾	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽³⁾	Approximate Dollar Value of Shares that May Yet Be Purchased Under Our Share Repurchase Program
4/1/2023 - 4/30/2023	—	—	—	(3)
5/1/2023 - 5/31/2023	—	—	—	(3)
6/1/2023 - 6/30/2023	914,324	\$149.95	—	(3)
Total	914,324	\$149.95	—	(3)

Period	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share ⁽²⁾	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽³⁾	Approximate Dollar Value of Shares that May Yet Be Purchased Under Our Share Repurchase Program
4/1/2024 - 4/30/2024	—	—	—	(3)
5/1/2024 - 5/31/2024	4,518,335	\$165.99	4,518,335	(3)
6/1/2024 - 6/30/2024	4,491,564	166.96	4,491,564	(3)
Total	9,009,899	\$166.48	9,009,899	(3)

- ⁽¹⁾ All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to satisfy **minimum** tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third party and does not repurchase stock in connection with cashless exercises.
- ⁽²⁾ Average price paid per share for open market transactions excludes commission.
- ⁽³⁾ **On April 21, 2023** in accordance with the repurchase program announced on July 28, 2023, the Company **stated** reaffirmed in its earnings release on April 19, 2024, that in fiscal year 2023 the Company **it** expected to reduce outstanding shares through direct share repurchases at a value of **\$7.4 \$5 to \$8.0 billion, \$6 billion** in fiscal year 2024, notwithstanding any purchases under the Company's compensation and benefit plans. The share repurchases were authorized pursuant to a resolution issued by the Company's Board of Directors and were financed through a combination of operating cash flows and issuance of debt. The total value of the shares purchased under the share repurchase plan was **\$7.4 billion \$5 billion**. The share repurchase plan ended on **June 30, 2023 June 30, 2024**.

Additional information required by this item can be found in Part III, Item 12 of this Form 10-K.

SHAREHOLDER RETURN PERFORMANCE GRAPHS

Market and Dividend Information

P&G has been paying a dividend for **133 134** consecutive years since its incorporation in 1890 and has increased its dividend for **67 68** consecutive years since 1956. Over the past ten years, the dividend has increased at an annual compound average rate of 5%. Nevertheless, as in the past, further dividends will be considered after reviewing dividend yields, profitability and cash flow expectations and financing needs and will be declared at the discretion of the Company's Board of Directors.

 DividendPerShare_07.jpg

(in dollars; split-adjusted)	1956	1964	1974	1984	1994	2004	2014	2024
Dividends per share	\$ 0.01	\$ 0.03	\$ 0.06	\$ 0.15	\$ 0.31	\$ 0.93	\$ 2.45	\$ 3.83

(in dollars; split-adjusted)	1956	1963	1973	1983	1993	2003	2013	2023
Dividends per share	\$ 0.01	\$ 0.02	\$ 0.05	\$ 0.14	\$ 0.28	\$ 0.82	\$ 2.29	\$ 3.68

Common Stock Information

P&G trades on the New York Stock Exchange under the stock symbol PG. As of **June 30, 2023** **June 30, 2024**, there were approximately **five million 6 million** common stock shareowners, including shareowners of record, participants in P&G stock ownership plans and beneficial owners with accounts at banks and brokerage firms.

Shareholder Return

The following graph compares the cumulative total return of P&G's common stock for the five-year period ended **June 30, 2023** **June 30, 2024**, against the cumulative total return of the S&P 500 Stock Index (broad market comparison) and the S&P 500 Consumer Staples Index (line of business comparison). The graph and table assume \$100 was invested on **June 30, 2018** **June 30, 2019**, and that all dividends were reinvested.

TSR_07.19.24.jpg

Cumulative Value of \$100 Investment, through June 30								Cumulative Value of \$100 Investment, through June 30							
Cumulative Value of \$100 Investment, through June 30								Cumulative Value of \$100 Investment, through June 30							
Company	Company							Company	Company						
Name/Index	Name/Index	2018	2019	2020	2021	2022	2023	Name/Index	Name/Index	2019	2020	2021	2022	2023	2024
P&G	P&G	\$100	\$145	\$162	\$188	\$205	\$222								
S&P 500	S&P 500	100	110	119	167	149	179								
S&P 500	S&P 500														
Consumer	Consumer														
Staples	Staples	100	116	121	149	159	169								

Item 6. Intentionally Omitted.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may appear throughout this report, including without limitation, the following sections: "Management's Discussion and Analysis," "Risk Factors" and "Notes 4, 8 and 13 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no

obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.

Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing **controls and localized volatility; controls**; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential implications such as exchange rate fluctuations, market contraction, boycotts, sanctions or other trade controls; (4) the ability to manage disruptions in credit markets or to our banking partners or changes to our credit rating; (4) (5) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various factors, including ones outside of our control, such as natural disasters, acts of war (including the Russia-Ukraine War) or terrorism or disease outbreaks; (5) (6) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits, evolving digital marketing and selling platform requirements and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and

trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging content, supply chain practices or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third-party information and operational technology systems, networks and services and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political the demand, supply and geopolitical conditions and potential implications such operational challenges, as exchange rate fluctuations and market contraction; well as governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (13) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully manage current respond to changing consumer habits, evolving digital marketing and expanding regulatory and legal selling platform requirements and matters (including, without limitation, those laws technological advances attained by, and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, privacy and data protection, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and patents granted to, resolve new and pending matters within current estimates; competitors; (14) the ability to manage changes in applicable tax laws and regulations; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company's overall business strategy and financial objectives, without impacting the delivery of base business objectives; (16) (15) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; (17) (16) the ability to successfully manage current and expanding regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, manufacturing processes, intellectual property, labor and employment, antitrust, privacy, cybersecurity and data protection, artificial intelligence, tax, the demand, supply environment, due diligence, risk oversight, accounting and operational challenges, as well as governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (18) financial reporting) and to resolve new and pending matters within current estimates; (17) the ability to manage the uncertainties, sanctions changes in applicable tax laws and economic effects from the war between Russia regulations; and Ukraine; and (19) (18) the ability to successfully achieve our ambition of reducing our greenhouse gas emissions and delivering progress towards our environmental sustainability priorities. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from those projected herein is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part I, Item 1A) of this Form 10-K.

Purpose, Approach and Non-GAAP Measures

The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying Notes. The MD&A is organized in the following sections:

- Overview
- Summary of 2023 2024 Results
- Economic Conditions and Uncertainties
- Results of Operations
- Segment Results
- Cash Flow, Financial Condition and Liquidity
- Critical Accounting Policies and Estimates
- Other Information

Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under accounting principles generally accepted in the United States of America (U.S. GAAP), consisting of U.S. GAAP, including organic sales growth, core Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. Organic sales growth is net sales growth excluding the impacts of acquisitions and divestitures and foreign exchange from year-over-year comparisons. Core EPS is diluted EPS excluding certain items that are not judged by management to be part of the Company's sustainable results or trends. Adjusted free cash flow is operating cash flow less

14 The Procter & Gamble Company

capital spending and excluding payments for the transitional tax resulting from the U.S. Tax Act. Adjusted free cash flow productivity is the ratio of adjusted free cash flow to net earnings excluding certain one-time items. We believe these measures provide our investors with additional information about our underlying results and trends as well as insight to some of the metrics used to evaluate management. The explanation at the end of the MD&A provides more the

The Procter & Gamble Company 15

definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the most directly comparable U.S. GAAP measure.

Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite limitations on the availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the percentage of sales of our products in dollar terms on a constant

currency basis relative to all product sales in the category. The Company measures quarter and fiscal year-to-date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is used to explain changes in organic sales. In our presentation of data in tables or other charts, certain columns and rows may not add due to rounding.

OVERVIEW

Procter & Gamble P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to our consumers around the world. Our products are sold in approximately about 180 countries and territories primarily through mass merchandisers, e-commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual consumers. We have on-the-ground operations in approximately about 70 countries.

Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the industry segments and markets in which we operate, often holding a leadership or significant market share position.

Organizational Structure

Our organizational structure is comprised of Sector Business Units (SBUs), Enterprise Markets (EMs), Corporate Functions (CF) and Global Business Services (GBS).

Sector Business Units

The Company's ten product categories are organized into five SBUs and five reportable segments (under U.S. GAAP): Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The SBUs are responsible for global brand strategy, product upgrades and innovation, marketing plans and supply chain. They have direct profit responsibility for markets (referred to as Focus Markets) representing the large majority of the Company's sales and earnings and are also responsible for innovation plans, supply plans and operating frameworks to drive growth and value creation in the remaining markets (referred to as Enterprise Markets). Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific and India, Middle East and Africa (IMEA).

16 The Procter & Gamble Company 15

The following provides additional detail on our reportable segments and the ten product categories and brand composition within each segment.

Reportable Segments	% of Net Sales Earnings			Major Brands	Reportable Segments	% of Net Sales Earnings			Major Brands
	Reportable Segments	(1)	(1)			Reportable Segments	(1)	(1)	
Beauty	Beauty	18%	21%	Hair Care (Conditioners, Shampoos, Styling Aids, Treatments)	Beauty	18%			Head & Shoulders, Herbal Essences, Pantene, Rejoice
				Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin Care)					Olay, Old Spice, Safeguard, Secret, SK-II
Grooming (2)		8%	10%	Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming)					Braun, Gillette, Venus
Grooming					Grooming	8%	9%		Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming)
Health Care	Health Care	14%		Oral Care (Toothbrushes, Toothpastes, Other Oral Care)	Health Care	14%			Oral Care (Toothbrushes, Toothpastes, Other Oral Care)
				Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Other Personal Health Care)					Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Other Personal Health Care)

Fabric & Home Care	Fabric & Home Care	35%	32%	Fabric Care (<i>Fabric Enhancers, Laundry Additives, Laundry Detergents</i>)	Ariel, Downy, Gain, Tide	Fabric & Home Care	36%	34%	Fabric Care (<i>Fabric Enhancers, Laundry Additives, Laundry Detergents</i>)	Ariel, Downy, Gain, Tide
				Home Care (<i>Air Care, Dish Care, P&G Professional, Surface Care</i>)	Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer				Home Care (<i>Air Care, Dish Care, P&G Professional, Surface Care</i>)	Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer
Baby, Feminine & Family Care	Baby, Feminine & Family Care	25%	23%	Baby Care (<i>Baby Wipes, Taped Diapers and Pants</i>)	Luvs, Pampers	Baby, Feminine & Family Care	24%	25%	Baby Care (<i>Baby Wipes, Taped Diapers and Pants</i>)	Luvs, Pampers
				Feminine Care (<i>Adult Incontinence, Feminine Care</i>)	Always, Always Discreet, Tampax				Feminine Care (<i>Adult Incontinence, Menstrual Care</i>)	Always, Always Discreet, Tampax
				Family Care (<i>Paper Towels, Tissues, Toilet Paper</i>)	Bounty, Charmin, Puffs				Family Care (<i>Paper Towels, Tissues, Toilet Paper</i>)	Bounty, Charmin, Puffs

(1) Percent of Net sales and Net earnings for the fiscal year ended **June 30, 2023** **June 30, 2024** (excluding results held in Corporate).

(2) Effective July 1, 2022, the Grooming Sector Business Unit completed the full integration of its Shave Care and Appliances categories to cohesively serve consumers' grooming needs. This transition included the integration of the management team, strategic decision-making, innovation plans, financial targets, budgets and internal management reporting.

Organization Design:

Sector Business Units

Beauty: We are a global market leader amongst the beauty categories in which we compete, including hair care and skin and personal care. We are a global market leader in the retail hair care market with **nearly about** 20% global market share primarily behind our **Pantene and Head & Shoulders and Pantene** brands. In skin and personal care, we offer a wide variety of products, ranging from deodorants to personal cleansing to skin care, such as our Olay brand, which is one of the top facial skin care brands in the world with **nearly about** 5% global market share.

Grooming: We are the global market leader in the **blades and razors market, grooming market, where we hold more than 45% share**. Our global blades and razors market share is more than 60%, primarily behind our Gillette and Venus brands. Our appliances, such as electric shavers and **epilators, intense pulse light devices**, are sold primarily under the Braun brand in a number of markets around the world where we compete against both global and regional competitors, brand. We hold **nearly over** 25% of the male electric shavers market and over 50% of the female epilators market.

Health Care: We compete in oral care and personal health care. In oral care, there are several global competitors in the market, and we have the number two market share position with **nearly about** 20% global market share behind our Crest and Oral-B brands. In personal health care, we are a global market leader among the categories in which we compete, including respiratory treatments, digestive wellness, **sleep aids**, vitamins and analgesics behind our Vicks, Metamucil, Pepto-Bismol and Neurobion brands.

Fabric & Home Care: This segment is comprised of a variety of fabric care products, including laundry detergents, additives and fabric enhancers; and home care products, including dishwashing liquids and detergents, surface cleaners and air fresheners. In fabric care, we generally have the number one or number two market share position **in the markets in which we compete** and are the global market leader with over 35% **global** market share **in the markets in which we compete**, primarily behind our Tide, Ariel and Downy brands. Our global home care market share is about 25% across the categories in which we compete, primarily behind our Cascade, Dawn, Febreze and Swiffer brands.

Baby, Feminine & Family Care: In baby care, we are a global market leader and compete mainly in taped diapers, pants and baby wipes, with more than 20% global market share. We **generally** have the number one or number two market share position in the markets in which we compete, primarily behind our Pampers brand. We are a global market leader in the feminine care category with over **25% 20%** global market share, share. **We compete in the menstrual care sub-category** primarily behind our Always and Tampax brands, brands with over 25% global market share. We also compete in the adult incontinence **category in certain markets sub-category** behind Always Discreet, with **over 10% about 15%** market share in the **key** markets in which we compete. Our family care business is predominantly a North American business comprised primarily of the Bounty paper towel and Charmin toilet paper brands. North America market shares are over 40% for Bounty and over 25% for Charmin.

16 The Procter & Gamble Company 17

Enterprise Markets

Enterprise Markets are responsible for sales and profit delivery in specific countries, supported by SBU-agreed innovation and supply chain plans, along with scaled services like planning, distribution and customer management.

Corporate Functions

Corporate Functions provides company-level strategy and portfolio analysis, corporate accounting, treasury, tax, external relations, governance, human resources, information technology and legal services.

Global Business Services

Global Business Services provides scaled services in technology, process and data tools to enable the SBUs, the EMs and CF to better serve consumers and customers. The GBS organization is responsible for providing world-class services and solutions that drive value for P&G.

Strategic Focus

Procter & Gamble aspires to serve the world's consumers better than our best competitors in every category and in every country in which we compete and, as a result, deliver total shareholder return in the top one-third of our peer group. Delivering and sustaining leadership levels of shareholder value creation requires balanced top- and bottom-line growth and strong cash generation.

Our strategy is to deliver and sustain value creation through five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure.

The Company competes in daily-use product categories where performance plays a significant role in the consumer's choice of brands, and therefore, play plays to P&G's strengths. Our focused portfolio of businesses consists of ten product categories where P&G has leading market positions, strong brands and consumer-meaningful product technologies, technologies with typically leadership market positions.

Within these categories, our strategic choices are focused on delighting and winning with consumers. Our consumers are at the center of everything we do. We win with consumers by delivering irresistible superiority across five key vectors - product performance, packaging, brand communication, retail execution and value. Winning with consumers around the world and against our best competitors requires superior innovation. Innovation has always been, and continues to be, P&G's lifeblood. Superior products delivered with superior execution drive market growth, value creation for retailers and build share growth for P&G.

Ongoing productivity improvement is strategic and crucial to delivering our balanced top- and bottom-line growth, cash generation and value creation objectives. Productivity improvement enables investments to strengthen the superiority of our brands via product and packaging innovation, more efficient and effective supply chains, equity and awareness-building brand advertising and other programs and expansion of sales coverage and R&D programs. Productivity improvements also enable us to mitigate and manage through periods of challenging cost environments (including periods of increasing commodity, inflation and negative foreign exchange impacts). Our objective is to drive productivity improvements across all elements of the statement of earnings and balance sheet, including cost of goods sold, marketing and promotional spending, overhead costs and capital spending.

We act with agility and are constructively disrupting our highly competitive industry and the way we do business, including how we innovate, communicate and leverage new technologies, to create more value.

We are improving operational effectiveness and organizational culture through enhanced clarity of roles and responsibilities, accountability and incentive compensation programs.

Additionally, within this to further strengthen our integrated strategy, of superiority, productivity, constructive disruption and organization, we have declared four focus areas to strengthen our performance going forward. areas. These are 1) leveraging environmental sustainability as an additional driver of superior performing products and packaging innovations, 2) increasing digital acumen to drive consumer and customer preference, reduce cost and enable rapid and efficient decision making, 3) developing next-level supply chain capabilities to enable flexibility, agility, resilience and a new level of productivity and 4) delivering a superior employee value equation for all gender identities, employees inclusive of all genders, races, ethnicities, sexual orientations, ages and abilities - for all roles - to ensure we continue to attract, retain and develop the best talent, talent to better serve our diverse consumer base.

We believe this strategy is right for the long-term health of the Company and our objective of delivering total shareholder return in the top one-third of our peer group.

The Company expects the delivery of the following long-term growth algorithm will result in total shareholder returns in the top third of the competitive, fast-moving consumer goods peer group:

- Organic sales growth above market growth rates in the categories and geographies in which we compete;
- Core EPS growth of mid-to-high single digits; and
- Adjusted free cash flow productivity of 90% or greater.

While periods of significant macroeconomic pressures may cause short-term results to deviate from the long-term growth algorithm, we intend to maintain a disciplined approach to investing in our business.

¹⁸ The Procter & Gamble Company ¹⁷

RECENT DEVELOPMENTS

Limited Market Portfolio Restructuring

In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company announced that it expected to record incremental restructuring charges of \$1.0 to \$1.5 billion after tax, consisting primarily of foreign currency translation losses to be recognized as non-cash charges upon the substantial liquidation of operations in the affected markets.

As of June 30, 2024, the Company has substantially liquidated its operations in certain Enterprise Markets, including Nigeria, and recorded a non-cash charge of \$216 million after tax for accumulated currency translation losses previously included in Accumulated other comprehensive income/(loss). On July 1, 2024, the Company completed the divestiture of its business in Argentina. The Company expects to record a non-cash charge of approximately \$750 million for accumulated currency translation losses in the first quarter of the fiscal year ending June 30, 2025. Consistent with our historical policies for ongoing restructuring-type activities, resulting charges were funded by and included within Corporate for segment reporting. Restructuring charges above the normal ongoing level of restructuring costs were reported as non-core charges. For more details on the restructuring program, refer to Note 3 to the Consolidated Financial Statements.

Intangible Asset Impairment

During the fiscal year ended June 30, 2024, the Company recorded a \$1.3 billion before tax (\$1.0 billion after tax) non-cash impairment charge on an indefinite-lived intangible asset acquired as part of the Company's 2005 acquisition of The Gillette Company. The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived

intangible asset due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of the non-core restructuring program described above. This impairment charge adjusted the carrying value of the Gillette indefinite-lived intangible asset to fair value. For a more detailed discussion of the Gillette impairment, refer to Note 4 to the Consolidated Financial Statements.

SUMMARY OF 2023 2024 RESULTS

Amounts in millions, except per share amounts	Amounts in millions, except per share amounts	2023	2022	Change vs. Prior Year	Amounts in millions, except per share amounts	2024	2023	Change vs. Prior Year
Net sales	Net sales	\$82,006	\$80,187	2 %	Net sales	\$ 84,039	\$ 82,006	2 %
Operating income	Operating income	18,134	17,813	2 %	Operating income	18,545	18,134	2 %
Net earnings	Net earnings	14,738	14,793	— %	Net earnings	14,974	14,738	2 %
Net earnings attributable to Procter & Gamble	Net earnings attributable to Procter & Gamble	14,653	14,742	(1) %	Net earnings attributable to Procter & Gamble	14,879	14,653	2 %
Diluted net earnings per common share	Diluted net earnings per common share	5.90	5.81	2 %	Diluted net earnings per common share	6.02	5.90	2 %
Core earnings per share	Core earnings per share	5.90	5.81	2 %	Core earnings per share	6.59	5.90	12 %
Cash flow from operating activities	Cash flow from operating activities	16,848	16,723	1 %	Cash flow from operating activities	19,846	16,848	18 %

- Net sales increased 2% to \$82.0 billion \$84.0 billion versus the prior year. The net sales growth was driven by a mid-single-digit increase increases in Health Care, low single-digit increases in Fabric & Home Care and Grooming and a low single-digit increase in Beauty. Net Sales were unchanged in Baby, Feminine & Family Care and Beauty, partially offset by a low single-digit decrease in Grooming. Care. Organic sales, which excludes exclude the impact of acquisitions and divestitures and foreign exchange, increased 7% 4%. Organic sales increased high single digits in Health Care and Grooming, mid-single digits in Fabric & Home Care and mid-single Health Care and low single digits in Beauty and Baby, Feminine & Family Care, Beauty and Grooming. Care.
- Operating income increased \$321 million \$411 million, or 2%, to \$18.1 billion versus year ago \$18.5 billion due to the increase in net sales, partially offset by a modest decrease in operating margin. the non-cash impairment charge of \$1.3 billion related to the Gillette intangible asset.
- Net earnings decreased modestly by \$55 million increased \$236 million, or 2%, to \$14.7 billion versus year ago as \$15.0 billion due to the increase in operating income, was more than fully partially offset by a higher effective tax rate. Foreign exchange impacts reduced net earnings by approximately \$1.4 billion \$589 million.
- Net earnings attributable to Procter & Gamble decreased \$89 million increased \$226 million, or 1% 2%, to \$14.7 billion versus the prior year due primarily to the decrease in net earnings, \$14.9 billion.
- Diluted EPS increased 2% to \$5.90 as \$6.02 due to the decrease increase in net earnings was more than offset by a reduction in shares outstanding. earnings. Core EPS, which excludes the charge for the Gillette intangible asset impairment and incremental restructuring charges, increased 12% to \$6.59.
- Cash flow from operating activities was \$16.8 billion \$19.8 billion.
 - Adjusted free cash flow, which is operating cash flow less capital expenditures and certain other impacts, was \$14.0 billion \$16.9 billion.
 - Adjusted free cash flow productivity, which is the ratio of adjusted free cash flow to net earnings excluding the Gillette intangible asset impairment charge and a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in certain Enterprise Markets, including Nigeria, was 95% 105%.

The Procter & Gamble Company 19

ECONOMIC CONDITIONS AND UNCERTAINTIES

We discuss expectations regarding future performance, events and outcomes, such as our business outlook and objectives, in annual and quarterly reports, press releases and other written and oral communications. All such statements, except for historical and present factual information, are "forward-looking statements" and are based on financial data and our business plans available only as of the time the statements are made, which may become out-of-date or incomplete. We assume no obligation to update any forward-looking statements as a result of new information, future events or other factors, except as required by law. Forward-looking statements are inherently uncertain and investors must recognize that events could be significantly different from our expectations. For more information on risk factors that could impact our results, please refer to "Risk Factors" in Part I, Item 1A of this Form 10-K. **UNCERTAINTIES**

Global Economic Conditions. Our products are sold in numerous countries across North America, Europe, Latin America, Asia, Australia and Africa, worldwide, with more than half our sales generated outside the United States. Our largest international markets are Greater China, the United Kingdom, Canada, Japan and Germany and collectively comprise more than comprised approximately 20% of our net sales in fiscal 2023, 2024. As such, a result, we are exposed to and impacted by global macroeconomic factors, geopolitical tensions U.S. and foreign government policies and foreign exchange fluctuations. policies. We are also exposed to market risks from operating in challenging environments including unstable due to economic, political and social conditions, civil unrest, instabilities, natural disasters, debt and credit issues, and currency controls, or fluctuations, foreign exchange and interest rate changes. These risks can reduce negatively impact our net sales, net earnings and cash flows. For example, we are exposed to risks due to the ongoing war between Russia and Ukraine. Our Russia business accounted for less than 2% of consolidated net sales, net earnings and net assets as of June 30, 2024.

Foreign Exchange. We have significant exposure to exchange rate fluctuations, both due to translation and transaction exposures. Translation exposures arise from measuring income statements of foreign subsidiaries with functional currencies other than the U.S. dollar. Transaction exposures involve impacts from 1) input costs that are denominated in currencies other than the local reporting currency and 2) revaluation of working capital balances denominated in currencies other than the functional currency. We have experienced significant foreign exchange impacts in the past due to the weakening of certain foreign currencies versus the US dollar, which have negatively impacted net sales, net earnings and cash flows. In response to the devaluation of foreign currencies (including those deemed highly inflationary), any lags or erode inability (due to government restrictions) to implement price increases or the negative impacts of such actions on product consumption may lead to a decline in our operating margins and consequently reduce our net sales, net earnings and cash flows.

Changes in Costs, Commodities and Supply Chain. Our costs are subject to fluctuations particularly due to changes in commodity and input material prices, transportation costs, other broader inflationary impacts and our own productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-derived materials like resins and paper-based materials like pulp. Volatility in the market price of these commodities and input materials has a direct impact on directly affects our costs. Disruptions in our manufacturing, supply and distribution operations due can lead to energy shortages, natural disasters, labor or freight constraints have impacted our costs and could do so in the future. New or increased legal costs. Legal or regulatory requirements along with and sustainability initiatives to meet our sustainability goals, could also may result in increased costs due to higher material costs and investments in facilities and equipment costs. We strive to implement, achieve and sustain cost improvement plans, including supply chain optimization and general overhead and workforce optimization. Increased pricing in response to certain inflationary or cost increases may also offset portions of the cost impacts; however, such price increases may negatively impact product consumption. If we are unable to manage cost impacts through pricing actions and consistent productivity improvements, it may adversely negatively impact our net sales, gross margin, operating margin, net earnings and cash flows.

18 The Procter & Gamble Company

Foreign Exchange. We have significant translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. In the past three years, weakening of certain foreign currencies versus the U.S. dollar has resulted in significant foreign exchange impacts leading to lower net sales, net earnings and cash flows. Certain countries that recently had and are currently experiencing significant exchange rate fluctuations include Argentina, Brazil, the United Kingdom, Japan, Russia and Turkey. These fluctuations have significantly impacted our historical net sales, net earnings and cash flows and could do so in the future. Increased pricing in response to certain fluctuations in foreign currency exchange rates may offset portions of the currency impacts but could also have a negative impact on the consumption of our products, which would negatively affect our net sales, gross margin, operating margin, net earnings and cash flows.

Government Policies. Our net sales, gross margin, operating margin, net earnings and cash flows could be affected by We are exposed to changes in U.S. or and foreign government legislative, regulatory or enforcement policies. For example, our policies that can have a negative impact on net sales, net earnings and cash flows could be affected by any future legislative or regulatory changes in U.S. or non-U.S. flows. These include tax policy changes (both U.S. and foreign), including changes those resulting from the current work being led by the OECD/G20 Inclusive Framework focused on "Addressing the Challenges of the Digitalization of the Economy." The breadth of the OECD project extends beyond pure digital businesses Economy". Government controls such as currency exchanges, pricing and import authorizations as proposed, is likely to impact most large multinational businesses by both redefining jurisdictional taxation rights and establishing a 15% global minimum tax. Our net sales, gross margin, operating margin, net earnings and cash flows may also be impacted by changes in U.S. and foreign well as government policies related to environmental and climate change matters. Additionally, we attempt to carefully manage our debt, currency matters and other exposures in certain countries with currency exchange, import authorization and pricing controls, such as Egypt, Argentina and Pakistan. Further, our net sales, gross margin, operating margin, net earnings and cash flows could be affected by changes to international trade agreements in North America and elsewhere. Changes in government policies in the above areas might cause an increase or decrease in our net sales, gross margin, operating margin, net earnings and cash flows.

Russia-Ukraine War. The war between Russia and Ukraine has negatively impacted our operations. Our Ukraine business includes two manufacturing sites and accounted for less than 1% of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023. Net assets of our Ukraine business accounted for less than 1% of consolidated net assets as of June 30, 2023. Our Russia business includes two manufacturing sites. Beginning in March 2022, the Company reduced its product portfolio, discontinued new capital investments and suspended media, advertising and promotional activity in Russia. The Russia business accounted for approximately 2% of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023. Net assets of our Russia business accounted for less than 2% of consolidated net assets as of June 30, 2023.

Future impacts to the Company are difficult to predict due to the high level of uncertainty related to the war's duration, evolution and ultimate resolution. Within Ukraine, there is a possibility of physical damage and destruction of our two manufacturing facilities. We may not be able to operate our manufacturing sites and source raw materials from our suppliers or ship finished products to our customers.

Within Russia, we may not be able to continue our reduced operations at current levels due to sanctions and counter-sanctions, monetary, currency or payment controls, legislative restrictions or policies, restrictions on access to financial institutions and supply and transportation challenges. Our suppliers, distributors and retail customers are also impacted by the war and their ability to successfully maintain their operations could can also impact our operations or negatively impact the sales of our products.

More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope, including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures and supply chain cost increases or the geographic proximity of the war relative to the rest of Europe. financial performance.

For additional information on risk factors that could impact our business results, please refer to "Risk Factors" Risk Factors in Part I, Item 1A of this the Company's Form 10-K. 10-K for the fiscal year ended June 30, 2024.

RESULTS OF OPERATIONS

The key metrics included in the discussion of our consolidated results of operations include net sales, gross margin, selling, general and administrative costs (SG&A), operating margin, other non-operating items, income taxes and net earnings. The primary factors driving year-over-year changes in net sales include overall market growth in the categories in which we compete, product initiatives, competitive activities (the level of initiatives, pricing and other activities by competitors), marketing spending, retail executions (both in-store and online) and acquisition and divestiture activity, all of which drive changes in our underlying unit volume, as well as our pricing actions (which can also impact volume), changes in product and geographic mix and foreign exchange impacts on sales outside the U.S.

For most of our categories, our cost of products sold and SG&A are variable in nature to some extent. Accordingly, our discussion of these operating costs focuses primarily on relative margins rather than the absolute year-over-year changes in total costs. The primary drivers of changes in gross margin are input costs (energy and other commodities), pricing impacts, geographic mix (for example, gross margins in North America are generally higher than the Company average for similar products), product mix (for example, the Beauty segment has higher gross margins than the Company average), foreign

The Procter & Gamble Company 19

exchange rate fluctuations (in situations where certain input costs may be tied to a different functional currency than the underlying sales), the impacts of manufacturing savings projects and reinvestments (for example, product or package improvements) and, to a lesser extent, scale impacts (for costs that are fixed or less variable in nature). The primary components of SG&A are marketing-related costs and non-manufacturing overhead costs. Marketing-related costs are primarily variable in nature, although we may achieve some level of scale benefit over time due to overall growth and other marketing efficiencies. While overhead costs are variable to some extent, we generally experience more scale-related impacts for these costs due to our ability to leverage our organization and systems' infrastructures to support business growth. The main drivers of changes in SG&A as a percentage of net sales are overhead and marketing cost savings, reinvestments (for example, increased advertising), inflation, foreign exchange fluctuations and scale impacts.

20 The Procter & Gamble Company

For a detailed discussion of the fiscal 2022 2023 year-over-year changes, please refer to the MD&A in Part II, Item 7 of the Company's Form 10-K for the fiscal year ended June 30, 2022 June 30, 2023.

Net Sales

Net sales increased 2% to \$82.0 billion \$84.0 billion in fiscal 2023, 2024. The increase in net sales was driven by higher pricing of 9% and a favorable mix of 1% 4%, partially offset by unfavorable foreign exchange of 5% 2%. Volume and a 3% decrease in unit volume mix were unchanged versus the prior year. Favorable mix was driven by a higher proportion of sales in North America (with higher than Company-average selling prices) and decline in Europe (with lower than Company-average selling prices). Excluding the impacts of foreign exchange and acquisitions and divestitures, organic sales grew 7%.

Net sales increased mid-single digits in Health Care, Fabric & Home Care and Grooming and increased low single digits in Beauty. Net sales were unchanged in Baby, Feminine & Family Care. Organic sales, which exclude the impacts of acquisitions and divestitures and foreign exchange, increased 4%. Organic sales increased high single digits in Grooming, mid-single digits in Fabric & Home Care Baby, Feminine & Family and Health Care and Beauty and decreased low single digits in Grooming. On a regional basis, volume decreased double digits in Europe, mid-single digits in Greater China and low single digits in Asia Pacific, IMEA Beauty and North America. Volume increased low single digits in Latin America. Baby, Feminine & Family Care.

Operating Costs

Comparisons as a percentage of net sales; fiscal years ended June 30	Comparisons as a percentage of net sales; fiscal years ended June 30	Basis Point		Comparisons as a percentage of net sales; fiscal years ended June 30			Basis Point Change	
		2023	2022	Change	2024	2023		
				50				
Gross margin	Gross margin	47.9 %	47.4 %	bps	Gross margin	51.4 %	47.9 %	350 bps

Selling, general and administrative expense	Selling, general and administrative expense	25.7 %	25.2 %	50 bps	Selling, general and administrative expense	27.7 %	25.7 %	200 bps
Operating margin	Operating margin	22.1 %	22.2 %	(10) bps	Operating margin	22.1 %	22.1 %	0 bps
Earnings before income taxes	Earnings before income taxes	22.4 %	22.4 %	0 bps	Earnings before income taxes	22.3 %	22.4 %	(10) bps
Net earnings	Net earnings	18.0 %	18.4 %	(40) bps	Net earnings	17.8 %	18.0 %	(20) bps
Net earnings attributable to Procter & Gamble	Net earnings attributable to Procter & Gamble	17.9 %	18.4 %	(50) bps	Net earnings attributable to Procter & Gamble	17.7 %	17.9 %	(20) bps

Gross margin increased 50 350 basis points to 47.9% 51.4% of net sales. The increase in gross margin was due to:

- a 430 220 basis-point increase from higher pricing manufacturing productivity savings,
- 160 basis points of lower commodity costs and
- a 150 170 basis-point increase from manufacturing productivity savings. higher pricing.

These increases were partially offset by by:

- 320 basis points of increased commodity and input material costs,
- a 110 an 80 basis-point decline from unfavorable product mix due to including the launch and growth of premium products (which have lower than Company-average gross margins) and the disproportionate decline of the super-premium SK-II brand,
- a 50 60 basis-point decline from unfavorable foreign exchange impacts,
- 30 basis points due to capacity start-up costs of product and other manufacturing impacts packaging investments and
- 20 30 basis points of product and packaging investments. one-time manufacturing related costs including capacity startup costs.

Total SG&A increased 4% 10% to \$21.1 billion \$23.3 billion due primarily to an increase in increased marketing spending and overhead costs and other net operating costs. SG&A as a percentage of net sales increased 50 200 basis points to 25.7% 27.7% due primarily to an the increase in overhead and other net operating costs as a percentage of net sales, partially offset by a decrease in marketing spending as a percentage of net sales.

- Marketing spending as a percentage of net sales decreased 40 increased 170 basis points due to as the increase in marketing spending was partially offset by the positive scale impacts of the net sales increase and increased productivity savings, partially offset by increased media reinvestments. savings.
- Overhead costs as a percentage of net sales increased 40 20 basis points due to wage inflation and other cost increases, partially offset by the positive scale impacts of the net sales increase and productivity savings.
- Other net operating expenses as a percentage of net sales increased 60 basis points due primarily to higher foreign exchange transactional charges.

Productivity-driven cost savings delivered 90 60 basis points of benefit to SG&A as a percentage of net sales.

In the fiscal year ended June 30, 2024, the Company recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) on the Gillette intangible asset. The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of the limited market portfolio restructuring program. For further discussion of the Gillette impairment charge, refer to Note 4 to the Consolidated Financial Statements.

Operating margin decreased 10 basis points to was unchanged at 22.1% as the increase in gross margin was more than fully offset by the increase in SG&A as a percentage of net sales and the non-cash impairment charge, as discussed above.

Operating income increased \$411 million, or 2%, to \$18.5 billion due to the increase in net sales, as discussed above.

20 The Procter & Gamble Company

Non-Operating Items

- Interest expense was \$756 \$925 million, an increase of \$317 million \$169 million versus the prior year due primarily to higher interest rates and an increase in short-term debt in the current year. rates.
- Interest income was \$307 \$473 million, an increase of \$256 million \$166 million versus the prior year due primarily to higher interest rates.
- Other non-operating income increased \$98 million to was unchanged at \$668 million due primarily to a prior year unrealized loss on equity investments and a current year gain on divestiture as gains from the sale of minor brands. brands and an increase in net non-operating benefits on postretirement plans were fully offset by a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in certain Enterprise Markets, including Nigeria.

Income Taxes

The effective income tax rate for fiscal year ended June 30, 2024, was 20.2%, compared to 19.7% for the fiscal year ended June 30, 2023. The increase in the effective tax rate increased 190 basis points versus the prior year period was primarily driven by unfavorable geographic mix impacts, partially offset by decreases due to 19.7% due to:

- a 100 basis-point increase from lower higher excess tax benefits of share-based compensation,
- a 50 basis-point increase from discrete impacts related to uncertain tax positions and
- a 40 basis-point increase primarily from lower current year deductions for foreign-derived intangible income versus prior year compensation.

Net Earnings

Operating Earnings before income taxes increased \$321 million \$408 million, or 2%, to \$18.1 billion \$18.8 billion due to the increase in net sales, partially offset by a modest decrease in operating margin, both of which are income discussed above.

Earnings before income taxes Net earnings increased \$358 million \$236 million, or 2%, to \$18.4 billion due primarily to the increase in operating income. Net earnings declined modestly by \$55 million to \$14.7 billion \$15.0 billion due to the increase in earnings before income taxes, more than fully partially offset by the increase in the effective income tax rate discussed above.

Foreign exchange impacts reduced net earnings by approximately \$1.4 billion \$589 million due to a weakening of certain currencies against the U.S. dollar. This impact includes both transactional charges and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars.

Net earnings attributable to Procter & Gamble decreased \$89 million increased \$226 million, or 1% 2%, to \$14.7 billion \$14.9 billion.

Diluted EPS increased \$0.09, \$0.12, or 2%, to \$5.90 as \$6.02 due primarily to the decrease increase in net earnings was more than fully offset by a reduction in shares outstanding earnings.

SEGMENT RESULTS

Segment results reflect information on the same basis we use for internal management reporting and performance evaluation. The results of these reportable segments do not include certain non-business unit specific costs which are reported in our Corporate segment and are included as part of our Corporate segment discussion. Additionally, we apply blended statutory tax rates in the segments. Eliminations to adjust segment results to arrive at our consolidated effective tax rate are included in Corporate. See Note 2 to the Consolidated Financial Statements for additional information on items included in the Corporate segment.

		Net Sales Change Drivers 2023 vs. 2022 ⁽¹⁾																													
		Volume																													
		Volume with Acquisitions & Divestitures					Excluding Acquisitions & Foreign Exchange Price Mix ⁽²⁾					Net Sales Growth																			
Net Sales Change Drivers 2024 vs. 2023 ⁽¹⁾																						Net Sales Change Drivers vs. 2023 ⁽¹⁾									
		Volume with Acquisitions & Divestitures										Volume with Acquisitions & Divestitures										Volume with Acquisitions & Divestitures									
Beauty	Beauty	(1) %	(2) %	(5) %	8 %	(1) %	1 %	2 %	Beauty	— %	— %	(2) %	4 %	(1) %	— %	1 %															
Grooming	Grooming	(3) %	(3) %	(7) %	9 %	(2) %	— %	(3) %	Grooming	1 %	1 %	(5) %	8 %	— %	— %	4 %															
Health Care	Health Care	(1) %	(1) %	(4) %	5 %	4 %	— %	4 %	Health Care	(1) %	(1) %	— %	4 %	2 %	— %	5 %															
Fabric & Home Care	Fabric & Home Care	(4) %	(4) %	(5) %	11 %	1 %	— %	3 %	Fabric & Home Care	1 %	1 %	(1) %	3 %	1 %	— %	4 %															
Baby, Feminine & Family Care	Baby, Feminine & Family Care	(3) %	(3) %	(4) %	8 %	1 %	— %	2 %	Baby, Feminine & Family Care	(2) %	(2) %	(2) %	3 %	1 %	— %	— %															
TOTAL COMPANY	TOTAL COMPANY	(3) %	(3) %	(5) %	9 %	1 %	— %	2 %	TOTAL COMPANY	— %	— %	(2) %	4 %	— %	— %	2 %															

⁽¹⁾ Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.

⁽²⁾ Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.

BEAUTY

(\$ millions)	(\$ millions)	2023	2022	Change vs. 2022	(\$ millions)	2024	2023	Change vs. 2023
Volume	Volume	N/A	N/A	(1)%	Volume	N/A	N/A	—%
Net sales	Net sales	\$15,008	\$14,740	2%	Net sales	\$15,220	\$15,008	1%
Net earnings	Net earnings	\$3,178	\$3,160	1%	Net earnings	\$2,963	\$3,178	(7)%
% of net sales	% of net sales	21.2%	21.4%	(20) bps	% of net sales	19.5%	21.2%	(170) bps

Beauty net sales increased 2% 1% to \$15.0 billion \$15.2 billion as the positive impacts impact of higher pricing of 8% and benefit from acquisitions of 1% were 4% was partially offset by unfavorable foreign exchange of 5%, 2% and an unfavorable mix of 1% (due primarily to the decline of the super-premium SK-II brand, which has higher than segment-average selling prices) and a 1% decrease in unit volume.

The Procter & Gamble Company 21

. Unit volume was unchanged. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 6% 3%. Global market share of the Beauty segment increased 0.3 0.1 points.

- Hair Care net sales increased low single mid-single digits. Positive impacts of higher pricing (driven by all regions) Latin America, Europe and North America), a net benefit from acquisitions and divestitures and favorable brand mix (due to growth of the premium Native brand) were partially offset by the negative impacts of unfavorable foreign exchange and a decrease exchange. Unit volume was unchanged as growth in unit volume. Mix had a neutral impact on net sales. The volume decrease was driven primarily by declines in Europe Latin America (due to portfolio reduction market growth), North America and Asia Pacific (both due to innovation) was offset by a decline in Russia and increased pricing), Greater China (due to market contraction and pandemic-related disruptions) and Asia Pacific (due to increased pricing) distribution footprint changes). Organic sales increased high single digits driven by 20% due to an approximately 30% growth in Latin America, and double-digit growth increases in Europe and North America and Europe, partially offset by a mid-single-digit decline in Greater China. Global market share of the hair care category decreased more than half a point. 0.2 points.
- Skin and Personal Care net sales increased decreased low single digits. Positive Negative impacts of unfavorable mix (due to the decline of the super-premium SK-II brand, which has higher than category-average selling prices) and unfavorable foreign exchange

22 The Procter & Gamble Company

were partially offset by the positive impacts of higher pricing (across all regions), a and an increase in unit volume. The unit volume increase was driven by growth in North America and a benefit from acquisitions were Europe (both due to innovation in Personal Care), partially offset by a decline in Greater China (due to the decline of the super-premium SK-II brand and market contraction). Organic sales decreased low single digits due to mid-teen declines in Asia Pacific and Greater China, partially offset by a double-digit increase in North America. Global market share of the skin and personal care category increased 0.3 points.

Net earnings decreased 7% to \$3.0 billion as the increase in net sales was more than offset by a 170 basis-point decline in net earnings margin. Net earnings margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate. The gross margin improvement was driven by productivity savings and increased pricing, partially offset by negative impacts from unfavorable product mix (due primarily to the decline of the super-premium SK-II brand) and unfavorable foreign exchange. The volume increase was driven primarily by growth in North America, Latin America and Greater China (all due to innovation), partially offset by a decline in Asia Pacific (due to the decline of the super-premium SK-II brand in the travel retail channel). Organic sales increased mid-single digits as more than 20% increases in Latin America and Europe and a double-digit increase in North America were partially offset by a double-digit decrease in Asia Pacific. Global market share of the skin and personal care category increased nearly a point.

Net earnings increased 1% to \$3.2 billion due to the increase in net sales, partially offset by a 20 basis-point decrease in net earnings margin. Net earnings margin decreased due to a reduction in gross margin, partially offset by a reduction in SG&A as a percentage of net sales. The gross margin reduction was driven by negative product mix (due to the decline of the super-premium SK-II brand), increased commodity costs and unfavorable foreign exchange, partially offset by increased pricing. SG&A as a percentage of net sales decreased primarily increased due to a decrease an increase in marketing spending, and overhead spending, partially offset by the positive scale effects of the net sales increase. The higher effective tax rate was driven by unfavorable geographic mix.

GROOMING

(\$ millions)	(\$ millions)	2023	2022	Change vs. 2022	(\$ millions)	2024	2023	Change vs. 2023
Volume	Volume	N/A	N/A	(3)%	Volume	N/A	N/A	1%

Net sales	Net sales	\$6,419	\$6,587	(3)%	Net sales	\$6,654	\$6,419	4%
Net earnings	Net earnings	\$1,461	\$1,490	(2)%	Net earnings	\$1,477	\$1,461	1%
% of net sales	% of net sales	22.8%	22.6%	20 bps	% of net sales	22.2%	22.8%	(60) bps

Grooming net sales decreased 3% increased 4% to \$6.4 billion \$6.7 billion driven by higher pricing of 8% (driven primarily by Latin America and Europe) and a 1% increase in unit volume, partially offset by unfavorable foreign exchange of 7%, 5%. Mix had a 3% decrease neutral impact on net sales growth. The increase in unit volume was due to growth in IMEA and unfavorable mix of 2% (due Latin America (both due to decline of appliances, which have higher than segment-average selling prices) innovation), partially offset by higher pricing of 9% (driven by all regions). The volume decrease was primarily driven by decreases decline in Europe (due to portfolio reduction in Russia and increased pricing) and North America (due to market contraction and increased pricing). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 5% 9% driven by growth in all regions led by a more than 20% an approximately 40% growth in Latin America and a double-digit high single-digit growth in Asia Pacific, Europe, partially offset by a low single-digit decline in North America. Global market share of the Grooming segment increased 1 point. 0.5 points.

Net earnings decreased 2% increased 1% to \$1.5 billion due to the decrease increase in net sales, partially offset by a 20 60 basis-point increase decrease in net earnings margin. Net earnings margin increased declined as a decrease an increase in gross margin was more than fully offset by a decrease an increase in SG&A as a percentage of net sales. The gross margin decrease increase was driven by unfavorable product mix (due to a disproportionate decline of higher gross margin appliances such as premium shavers), commodity cost increases and unfavorable foreign exchange, partially offset by higher pricing and productivity savings, savings, partially offset by unfavorable foreign exchange and unfavorable mix due to the growth of premium innovation that has lower than segment-average gross margins. SG&A as a percentage of net sales decreased increased due primarily to a decrease an increase in marketing spending, spending, partially offset by the positive scale effects of the net sales increase.

HEALTH CARE

(\$ millions)	(\$ millions)	2023	2022	Change vs. 2022	(\$ millions)	2024	2023	Change vs. 2023
Volume	Volume	N/A	N/A	(1)%	Volume	N/A	N/A	(1)%
Net sales	Net sales	\$11,226	\$10,824	4%	Net sales	\$11,793	\$11,226	5%
Net earnings	Net earnings	\$2,125	\$2,006	6%	Net earnings	\$2,258	\$2,125	6%
% of net sales	% of net sales	18.9%	18.5%	40 bps	% of net sales	19.1%	18.9%	20 bps

Health Care net sales increased 4% 5% to \$11.2 billion \$11.8 billion driven by higher pricing of 5% 4% and favorable mix of 4% 2% (due to growth in North America and the Personal Health Care category, Europe, both of which have higher than segment-average selling prices), partially offset by unfavorable foreign exchange of 4% and a 1% decrease in unit volume. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales also increased 8% 5%. Global market share of the Health Care segment decreased 0.2 increased 0.6 points.

22 The Procter & Gamble Company

- Oral Care net sales decreased low single digits. Negative increased mid-single digits due to the positive impacts of unfavorable foreign exchange favorable product mix (due to growth of premium paste and power brushes, which have higher than category-average selling prices) and higher pricing (driven by Latin America, Europe and North America), partially offset by a decrease in unit volume. The unit volume decrease were partially offset by increased pricing (driven primarily by North America and Europe) and favorable premium product mix. Volume was due to a decline was primarily driven by Europe (due to portfolio reduction in Russia and increased pricing), North America (due to increased pricing) and Greater China (due to market contraction, especially in the power brush market). Organic sales increased low single digits driven by a more than 20% growth in Latin America and Greater China (both due to share losses) partially offset by growth in North America and Europe (both due to market growth). Organic sales also increased mid-single digits due to a double-digit increase in Europe and a mid-single-digit increase in North America partially offset by a low single-digit growth decline in North America, Greater China. Global market share of the oral care category was unchanged, increased 0.1 points.
- Personal Health Care net sales increased double digits. Positive mid-single digits due to the positive impacts of higher pricing (driven by North America, Latin America and Europe) and favorable foreign exchange, partially offset by unfavorable mix (due to the disproportionate growth decline of North America and respiratory products both of which that have higher than category-average selling prices), higher pricing (driven primarily by North America, Europe and Latin America) and a decrease in unit volume. The unit volume increase were decrease was due to declines in Latin America and IMEA (both due to market contraction including lower cough and cold incidence), partially offset by unfavorable foreign exchange. Volume increase was primarily driven by growth in North America (due to innovation innovation). Organic sales increased low single digits due to mid-single-digit growth in Europe and a stronger respiratory season) and Latin North America, partially offset by a low single-digit decline in IMEA (versus a prior year impacted by pandemic-related consumption increases in certain markets). Organic sales increased mid-teens driven by a high teens increase in North America, a mid-teens increase in Europe and a low teens increase in Latin America, Asia Pacific. Global market share of the personal health care category was unchanged, increased 0.7 points.

Net earnings increased 6% to **\$2.1 billion** **\$2.3 billion** due to the increase in net sales and a **40 basis-point** increase in net earnings margin. Net earnings margin increased as a decrease in gross margin was more than fully offset by a decrease in SG&A as a percentage of net sales. The decrease in gross margin was driven by unfavorable product mix (due to the growth of products such as manual brushes, which have lower gross margins) and increased commodity and input material costs, partially offset by increased pricing. SG&A as a percentage of net sales decreased due to the positive scale impacts of the net sales increase and lower marketing spending, partially offset by increased overhead spending.

FABRIC & HOME CARE

(\$ millions)	2023	2022	Change vs. 2022
Volume	N/A	N/A	(4)%
Net sales	\$28,371	\$27,556	3%
Net earnings	\$4,828	\$4,386	10%
% of net sales	17.0%	15.9%	110 bps

Fabric & Home Care net sales increased 3% to \$28.4 billion driven by higher pricing of 11% and favorable mix of 1% (due to a disproportionate volume decline in Europe, which has lower than segment-average selling prices), partially offset by unfavorable foreign exchange of 5% and a 4% decrease in unit volume. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 8%. Global market share of the Fabric & Home Care segment was unchanged.

- Fabric Care net sales increased low single digits. Positive impacts of higher pricing (driven by all regions) and favorable geographic mix (due to decline in Europe, which has lower than category-average selling prices) were partially offset by unfavorable foreign exchange and a decrease in unit volume. The volume decrease was primarily driven by declines in Europe (due to increased pricing and portfolio reduction in Russia), North America (due to increased pricing and market contraction) and Greater China (due to portfolio reductions and market contraction). Organic sales increased high single digits driven by more than 20% increases in Latin America and IMEA, high single-digit increases in Asia Pacific and Europe and a low single-digit increase in North America. Global market share of the fabric care category decreased nearly a point.
- Home Care net sales increased mid-single digits. Positive impacts of higher pricing (driven primarily by Europe and North America) and favorable product mix were partially offset by unfavorable foreign exchange and a decrease in unit volume. The volume decrease was driven by declines in Europe (due to market contraction and increased pricing) and North America (due to market contraction). Organic sales increased high single digits driven by a mid-teens growth in Europe and a high single-digit growth in North America. Global market share of the home care category increased more than a point.

Net earnings increased 10% to \$4.8 billion due to the increase in net sales and a **110 20** basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by **increased higher** pricing and **productivity savings**, partially offset by **an increase in commodity** and input material costs, **unfavorable foreign exchange** and **unfavorable product mix**. mix (due to a decline in respiratory products, which have higher than segment-average gross margins). SG&A as a percentage of net sales increased due to **increased marketing spending**, partially offset by the positive scale impacts of the net sales increase.

FABRIC & HOME CARE

(\$ millions)	2024	2023	Change vs. 2023
Volume	N/A	N/A	1%
Net sales	\$29,495	\$28,371	4%
Net earnings	\$5,687	\$4,828	18%
% of net sales	19.3%	17.0%	230 bps

Fabric & Home Care net sales increased 4% to \$29.5 billion driven by higher pricing of 3%, favorable mix of 1% and a 1% increase in unit volume, partially offset by unfavorable foreign exchange of 1%. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 5%. Global market share of the Fabric & Home Care segment was unchanged.

- Fabric Care net sales increased low single digits driven by the positive impacts of higher pricing (driven by Europe, Asia Pacific and Latin America, partially offset by increased trade spending in North America) and favorable geographic mix (due to disproportionate growth in North America, which has higher than category-average selling prices). Unit volume was unchanged as growth in North America (due to increased marketing support and market growth) and Europe (due to innovation and increased marketing support) was offset by declines primarily in Asia Pacific (due to increased pricing) and Greater China (due to market contraction and portfolio rationalization). Organic sales also increased low single digits driven by a high single-digit increase in Europe and a low single-digit increase in North America, partially offset by a mid-teens decline in Greater China. Global market share of the fabric care category decreased 0.5 points.
- Home Care net sales increased high single digits. Positive impacts of higher pricing (driven primarily by Europe and North America), a unit volume increase and favorable premium product mix were partially offset by unfavorable foreign exchange. The unit volume increase was due to growth in North America and Europe (both due to innovation), partially offset by decline in Latin America (due to increased pricing). Organic sales increased high single digits driven by mid-teens growth in Europe and a high single-digit growth in North America. Global market share of the home care category increased 0.8 points.

Net earnings increased 18% to \$5.7 billion due to the increase in net sales and a 230 basis-point improvement in net earnings margin. Net earnings margin increased due to an increase in **media** gross margin, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by **productivity savings**, **lower commodity costs** and **higher pricing**. SG&A as a percentage of net sales increased due primarily to an increase in marketing spending, partially offset by the positive scale effects of the net sales increase.

BABY, FEMININE & FAMILY CARE

(\$ millions)	(\$ millions)	2023	2022	Change vs. 2022	(\$ millions)	2024	2023	Change vs. 2023
Volume	Volume	N/A	N/A	(3)%	Volume	N/A	N/A	(2)%
Net sales	Net sales	\$20,217	\$19,736	2%	Net sales	\$20,277	\$20,217	—%
Net earnings	Net earnings	\$3,545	\$3,266	9%	Net earnings	\$4,020	\$3,545	13%
% of net sales	% of net sales	17.5%	16.5%	100 bps	% of net sales	19.8%	17.5%	230 bps

Baby, Feminine & Family Care net sales increased 2% to \$20.2 billion were unchanged at \$20.3 billion as the positive impacts of higher pricing of 8% 3% and favorable mix of 1% (due to a higher proportion of sales in North America, which has higher than segment-average selling prices) were partially offset by a 2% decrease in unit volume and unfavorable foreign exchange of 4% and a 3% decrease in unit volume. 2%. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 6% 2%. Global market share of the Baby, Feminine & Family Care segment was unchanged, decreased 0.2 points.

- Baby Care net sales decreased low single digits. Negative impacts of a decrease in unit volume and unfavorable foreign exchange were partially offset by higher pricing (across all regions) (driven primarily by Latin America and Europe) and favorable product and geographic mix (due to a higher proportion of premium-priced diapers). Volumes decreased in all regions led by Europe, IMEA and North America, due to increased pricing and competitive activity. Organic sales decreased low single digits driven by a mid-single-digit decline in North America. Europe partially offset by mid-teens growth in Latin America. Global market share of the baby care category decreased 0.3 points.
- Feminine Care net sales increased low single digits. Positive impacts of higher pricing (driven primarily by Europe, Latin America and IMEA) and favorable mix (due to a higher proportion of premium products) were partially offset by a decrease in unit volume and unfavorable foreign exchange. The volume decrease was driven primarily by declines in

24 The Procter & Gamble Company

Europe (due to increased pricing pricing), Latin America (due to increased competitive activity) and portfolio reduction IMEA (due to increased pricing), partially offset by growth in Russia), North America (due to increased pricing) marketing support and Greater China. distribution gains). Organic sales increased mid-single digits driven by a more than 30% growth in Latin America, high single-digit growth in IMEA and mid-single-digit growth in North America and Europe, partially offset by a double-digit decline in Greater China. Global market share of the baby care category was unchanged.

- Feminine Care net sales increased mid-single digits. Positive impacts of higher pricing (driven by all regions) and favorable product and geographic mix (due to a decline in Europe, which has lower than category-average selling prices) were partially offset by unfavorable foreign exchange and a decrease in unit volume. The volume decrease was driven primarily by declines in Europe (due to portfolio reduction in Russia and increased pricing) and IMEA (due to increased pricing). Organic sales increased double digits driven by growth in all regions led by a mid-teens increase increases in Europe and IMEA and a double-digit low single-digit increase in North America. Market share of the feminine care category increased nearly half a point. 0.2 points.
- Net sales in Family Care, which is predominantly a North American business, increased low single digits driven by a unit volume increase (due to market growth and increased marketing support) and higher pricing. Unit volume had a neutral impact on net sales. pricing, partially offset by unfavorable product mix (due to growth of larger pack sizes with lower than category-average selling prices). Organic sales also increased mid-single low single digits. North America's share of the family care category decreased nearly half a point. 0.4 points.

Net earnings increased 9% 13% to \$3.5 billion \$4.0 billion due to the increase in net sales and a 100 230 basis-point increase in net earnings margin. Net earnings margin increased primarily due to an increase in gross margin, and a modest decrease partially offset by an increase in SG&A as a percentage of net sales. Gross margin increased primarily due to lower commodity costs, productivity savings and increased pricing, partially offset by an increase in commodity and input material costs. unfavorable foreign exchange. SG&A as a percentage of net sales decreased increased due to the positive scale effects of the net sales increase partially offset by an increase in other operating expense. marketing and overhead spending.

CORPORATE

(\$ millions)	(\$ millions)	2023	2022	Change vs. 2022	(\$ millions)	2024	2023	Change vs. 2023
Net sales	Net sales	\$765	\$744	3%	Net sales	\$601	\$765	(21)%
Net earnings/(loss)	Net earnings/(loss)	\$(399)	\$485	N/A	Net earnings/(loss)	\$(1,430)	\$(399)	N/A

Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing activities, impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization. Corporate also includes reconciling items to adjust the accounting policies used

within the reportable segments to U.S. GAAP. The most notable ongoing reconciling item is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.

Corporate net sales increased 3% decreased \$164 million to \$765 million \$601 million due to an increase a decrease in net sales of the incidental businesses managed at the corporate level. Corporate net earnings decreased \$884 million \$1.0 billion due to a loss of \$399 million \$1.4 billion due primarily due to higher interest expense, lower excess tax benefits of share-based compensation and higher foreign exchange transactional charges, partially offset by the increase in net sales impairment charge of the incidental businesses Gillette intangible asset and higher interest income. incremental restructuring charges.

Restructuring Program to Deliver Productivity and Cost Savings

The Company has historically had an ongoing restructuring program with annual spending in the range of \$250 to \$500 million. before tax. On December 5, 2023, the Company announced an incremental limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria.

In fiscal 2024, the Company incurred before tax restructuring costs of \$659 million, which include foreign currency translation losses recognized as a non-cash charge of approximately \$216 million due to the substantial liquidation of operations in certain Enterprise Markets, including Nigeria. Restructuring accruals of \$166 million as of June 30, 2024, are classified as current liabilities. Excluding the non-cash charges of foreign currency translation losses for certain Enterprise Markets, including Nigeria, approximately 64% of the restructuring charges incurred in fiscal 2024 either have been or will be settled with cash. Consistent with our policies for restructuring-type activities, the resulting charges are funded by and included within Corporate for segment reporting.

Savings generated from the Company's restructuring program are difficult to estimate, given the nature of the activities, the timing of the execution and the degree of reinvestment. In fiscal 2023, the Company incurred before tax restructuring costs within the range of our historical annual ongoing level of \$250 to \$500 million.

24 The Procter & Gamble Company

Restructuring accruals of \$174 million as of June 30, 2023, are classified as current liabilities. Approximately 87% of the restructuring charges incurred in fiscal 2023 either have been or will be settled with cash. Consistent with our policies for ongoing restructuring-type activities, the resulting charges are funded by and included within Corporate for segment reporting.

In addition to our restructuring programs, we have additional ongoing savings efforts in our supply chain, marketing and overhead areas that yield additional benefits to our operating margins. Refer to Note 3 to the Consolidated Financial Statements for more details on the restructuring program.

CASH FLOW, FINANCIAL CONDITION AND LIQUIDITY

We believe our financial condition continues to be of high quality, as evidenced by our ability to generate substantial cash from operations and to readily access capital markets at competitive rates.

Operating cash flow provides the primary source of cash to fund operating needs and capital expenditures. Excess operating cash is used first to fund shareholder dividends. Other discretionary uses include share repurchases and acquisitions to complement our portfolio of businesses, brands and geographies. As necessary, we may supplement operating cash flow with debt to fund these activities. The overall cash position of the Company reflects our strong business results and a global cash management strategy that takes into account liquidity management, economic factors and tax considerations.

The Procter & Gamble Company 25

Cash Flow Analysis

(\$ millions)	(\$ millions)	2023	2022	(\$ millions)	2024	2023
Net cash provided by operating activities	Net cash provided by operating activities	\$16,848	\$16,723			
Net cash used in investing activities	Net cash used in investing activities	(3,500)	(4,424)			
Net cash used in financing activities	Net cash used in financing activities	(12,146)	(14,876)			
Adjusted Free Cash Flow	Adjusted Free Cash Flow	14,011	13,792			

Acquisitions. Acquisition activity used cash of \$765 million in 2023, primarily related to a Beauty acquisition.investment hedges.

Financing Cash Flow

Net financing activities consumed \$12.1 billion used \$14.9 billion of cash in 2023, 2024, mainly due to dividends to shareholders, and treasury stock purchases partially offset by and a net debt increase and decrease, partially offset by the impact of stock options and other.

Dividend Payments. Our first discretionary use of cash is dividend payments. Dividends per common share increased 4% to \$3.6806 per share in 2023. Total dividend payments to common and preferred shareholders were \$9.0 billion in 2023. In April 2023, the Board of Directors declared a 3% increase in our quarterly dividend from \$0.9133 to \$0.9407 per share on Common Stock and Series A and B Employee Stock Ownership Plan (ESOP) Convertible Class A Preferred Stock. This is the 67th consecutive year that our dividend has increased. We have paid a dividend for 133 consecutive years, every year since our incorporation in 1890.

Long-Term and Short-Term Debt. We maintain debt levels we consider appropriate after evaluating a number of factors, including cash flow expectations, cash requirements for ongoing operations, investment and financing plans (including acquisitions and share repurchase activities) and the overall cost of capital. Total debt was \$34.6 billion as of June 30, 2023. We generated \$2.9 billion from net debt issuances in short-term debt and long-term debt markets.

Treasury Purchases. Total share repurchases were \$7.4 billion in 2023.

Impact of Stock Options and Other. The exercise of stock options and other financing activities generated \$1.3 billion of cash in 2023.

Liquidity

At June 30, 2023 June 30, 2024, our current liabilities exceeded current assets by \$13.1 billion \$8.9 billion, largely due to accounts payable, short-term borrowings under our commercial paper program, and debt due within one year. We anticipate being able to support our short-term liquidity and operating needs largely through cash generated from operations. The Company regularly assesses its cash needs and the available sources to fund these needs. As of June 30, 2023 June 30, 2024, the Company had \$5.1 billion \$6.1 billion of cash and cash equivalents related to foreign subsidiaries, primarily in various European and Asian countries. We did not have material cash and cash equivalents related to any country subject to exchange controls that significantly restrict our ability to access or repatriate the funds. Under current law, we do not expect restrictions or taxes on repatriation of cash held outside of the U.S. to have a material effect on our overall liquidity, financial condition or the results of operations for the foreseeable future.

We utilize short- and long-term debt to fund discretionary items, such as acquisitions and share repurchases. We have strong short- and long-term debt ratings, which have enabled and should continue to enable us to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse group of financial institutions that, if needed, should provide sufficient funding to meet short-term financing requirements.

On June 30, 2023 June 30, 2024, our short-term credit ratings were P-1 (Moody's) and A-1+ (Standard & Poor's), while our long-term credit ratings were Aa3 (Moody's) and AA- (Standard & Poor's), all with a stable outlook.

We maintain bank credit facilities to support our ongoing commercial paper program. The current facility is an \$8.0 billion \$8.0 billion facility split between a \$3.2 billion \$3.2 billion five-year facility and a \$4.8 billion \$4.8 billion 364-day facility, which expire in November 2027 2028 and

26 The Procter & Gamble Company

November 2023, October 2024, respectively. Both facilities can be extended for certain periods of time as specified in the terms of the credit agreement. These facilities are currently undrawn and we anticipate that they will remain undrawn. These credit facilities do not

26 The Procter & Gamble Company

have cross-default or ratings triggers, nor do they have material adverse events clauses, except at the time of signing. In addition to these credit facilities, we have an automatically effective registration statement on Form S-3 filed with the SEC that is available for registered offerings of short- or long-term debt securities. For additional details on debt, see Note 10 to the Consolidated Financial Statements.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, which we believe could have a material impact on our financial condition or liquidity.

Contractual Commitments

The following table provides information on the amount and payable date of our contractual commitments as of June 30, 2023 June 30, 2024.

(\$ millions)	(\$ millions)	Less Than					(\$ millions)	Total	Less Than 1 Year	1-3 Years	3-5 Years	After 5 Years
		Total	1 Year	Years	Years	Years						
RECORDED LIABILITIES	RECORDED LIABILITIES											
Total debt												
Total debt												
Total debt	Total debt	\$35,248	\$10,316	\$5,328	\$5,899	\$13,705						
Leases	Leases	911	222	322	171	196						

U.S. Tax Act transitional charge ⁽¹⁾	U.S. Tax Act transitional charge ⁽¹⁾	1,575	421	1,154	—	—
OTHER	OTHER					
Interest payments relating to long-term debt	Interest payments relating to long-term debt	5,727	713	1,245	946	2,823
Interest payments relating to long-term debt						
Interest payments relating to long-term debt						
Minimum pension funding ⁽²⁾	Minimum pension funding ⁽²⁾	591	192	399	—	—
Purchase obligations ⁽³⁾	Purchase obligations ⁽³⁾	2,989	1,169	976	482	362
TOTAL	TOTAL					
CONTRACTUAL COMMITMENTS	CONTRACTUAL COMMITMENTS	\$47,041	\$13,033	\$9,424	\$7,498	\$17,086

⁽¹⁾ Represents the U.S. federal tax liability associated with the repatriation provisions of the U.S. Tax Act.

⁽²⁾ Represents future pension payments to comply with local funding requirements. These future pension payments assume the Company continues to meet its future statutory funding requirements. Considering the current economic environment in which the Company operates, the Company believes its cash flows are adequate to meet the future statutory funding requirements. The projected payments beyond fiscal year 2026 2027 are not currently determinable.

⁽³⁾ Primarily reflects future contractual payments under various take-or-pay arrangements entered into as part of the normal course of business. Commitments made under take-or-pay obligations represent minimum commitments with suppliers and are in line with expected usage. This includes service contracts for information technology, human resources management and facilities management activities that have been outsourced. While the amounts listed represent contractual obligations, we do not believe it is likely that the full contractual amount would be paid if the underlying contracts were canceled prior to maturity. In such cases, we generally are able to negotiate new contracts or cancellation penalties, resulting in a reduced payment. The amounts do not include other contractual purchase obligations that are not take-or-pay arrangements. Such contractual purchase obligations are primarily purchase orders at fair value that are part of normal operations and are reflected in historical operating cash flow trends. We do not believe such purchase obligations will adversely affect our liquidity position.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In preparing our financial statements in accordance with U.S. GAAP, there are certain accounting policies that may require a choice between acceptable accounting methods or may require substantial judgment or estimation in their application. These include revenue recognition, income taxes, certain employee benefits and goodwill and intangible assets. We believe these accounting policies, and others set forth in Note 1 to the Consolidated Financial Statements, should be reviewed as they are integral to understanding the results of operations and financial condition of the Company.

The Company has discussed the selection of critical accounting policies and the effect of estimates with the Audit Committee of the Company's Board of Directors.

Revenue Recognition

Our revenue is primarily generated from the sale of finished product to customers. Those sales predominantly contain a single performance obligation and revenue is recognized at a single point in time when ownership, risks and rewards transfer, which can be on the date of shipment or the date of receipt by the customer. Trade promotions, consisting primarily of customer pricing allowances, in-store merchandising funds, advertising and other promotional activities and consumer coupons, are offered through various programs to customers and consumers. Sales are recorded net of trade promotion spending, which is recognized as incurred at the time of the sale. Amounts accrued for trade promotions at the end of a period require estimation, based on contractual terms, sales volumes and historical utilization and redemption rates. The actual amounts paid may be different from such estimates. These differences, which have historically not been significant, are recognized as a change in management estimate in a subsequent period.

Income Taxes

Our annual tax rate is determined based on our income, statutory tax rates and the tax impacts of items treated differently for tax purposes than for financial reporting purposes. Also inherent in determining our annual tax rate are judgements judgments and assumptions

The Procter & Gamble Company 27

assumptions regarding the recoverability of certain deferred tax balances, primarily net operating loss and other carryforwards, and our ability to uphold certain tax positions.

Realization of net operating losses and other carryforwards is dependent upon generating sufficient taxable income in the appropriate jurisdiction prior to the expiration of the carryforward periods, which involves business plans, planning opportunities and expectations about future outcomes. Although realization is not assured, management believes it is more likely than not that our deferred tax assets, net of valuation allowances, will be realized.

We operate in multiple jurisdictions with complex tax policy and regulatory environments. In certain of these jurisdictions, we may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority. These interpretational differences with the respective governmental taxing

authorities can be impacted by the local economic and fiscal environment.

A core operating principle is that our tax structure is based on our business operating model, such that profits are earned in line with the business substance and functions of the various legal entities in the jurisdictions where those functions are performed. However, because of the complexity of transfer pricing concepts, we may have income tax uncertainty related to the determination of intercompany transfer prices for our various cross-border transactions. We have obtained and continue to prioritize the strategy of seeking advance rulings with tax authorities to reduce this uncertainty. We estimate that our current portfolio of advance rulings reduces this uncertainty with respect to over 70% of our global earnings. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties considering changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have several audits in process in various jurisdictions. Although the resolution of these tax positions is uncertain, based on currently available information, we believe that the ultimate outcomes will not have a material adverse effect on our financial position, results of operations or cash flows.

Because there are several estimates and assumptions inherent in calculating the various components of our tax provision, certain future events such as changes in tax legislation, geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an impact on those estimates and our effective tax rate. See Note 5 to the Consolidated Financial Statements for additional details on the Company's income taxes.

Employee Benefits

We sponsor various postretirement benefits throughout the world. These include pension plans, both defined contribution plans and defined benefit plans, and other postretirement benefit (OPRB) plans consisting primarily of health care and life insurance for retirees. For accounting purposes, the defined benefit pension and OPRB plans require assumptions to estimate the net projected and accumulated benefit obligations, including the following variables: discount rate; expected salary increases; certain employee-related factors, such as turnover, retirement age and mortality; expected return on assets; and health care cost trend rates. These and other assumptions affect the annual expense and net obligations recognized for the underlying plans. Our assumptions reflect our historical experiences and management's best judgment regarding future expectations. As permitted by U.S. GAAP, the net amount by which actual results differ from our assumptions is deferred. If this net deferred amount exceeds 10% of the greater of plan assets or liabilities, a portion of the deferred amount is included in expense for the following year. The cost or benefit of plan changes, such as increasing or decreasing benefits for prior employee service (prior service cost), is deferred and included in expense on a straight-line basis over the average remaining service period of the employees expected to receive benefits.

The expected return on plan assets assumption impacts our defined benefit expense since many of our defined benefit pension plans and our primary OPRB plan are partially funded. The process for setting the expected rates of return is described in Note 8 to the Consolidated Financial Statements. For 2023, 2024, the average return on assets assumptions for pension plan assets and OPRB assets was 5.9% 6.0% and 8.4% 8.5%, respectively. A change in the rate of return of 100 basis points for both pension and OPRB assets would impact annual after-tax benefit/expense by approximately \$135 million \$145 million.

Since pension and OPRB liabilities are measured on a discounted basis, the discount rate impacts our plan obligations and expenses. Discount rates used for our U.S. defined benefit pension and OPRB plans are based on a yield curve constructed from a portfolio of high-quality bonds for which the timing and amount of cash outflows approximate the estimated payouts of the plan. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA or better. The average discount rate on the defined benefit pension plans of 4.2% represents a weighted average of local rates in countries where such plans exist. A 100 basis-point change in the discount rate would impact annual after-tax benefit expense by approximately \$130 million \$85 million. The average discount rate on the OPRB plan of 5.6% 5.8% reflects the higher interest rates generally applicable in the U.S., which is where most of the plan participants receive benefits. A 100 basis-point change in the discount rate would impact annual after-tax OPRB expense by approximately \$30 million. See Note 8 to the Consolidated Financial Statements for additional details on our defined benefit pension and OPRB plans.

Goodwill and Intangible Assets

Significant judgment is required to estimate the fair value of our goodwill reporting units and intangible assets. Accordingly, we typically obtain the assistance of third-party valuation specialists for significant goodwill reporting units and intangible assets. Determining the useful life of an intangible asset also requires judgment. Certain brand intangible assets are expected to have

28 The Procter & Gamble Company

indefinite lives based on their history and our plans to continue to support and build the acquired brands. Other acquired intangible assets (e.g., certain brands, customer relationships, patents and technologies) are expected to have determinable

28 The Procter & Gamble Company

useful lives. Our assessment as to brands that have an indefinite life and those that have a determinable life is based on a number of factors including competitive environment, market share, brand history, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the brands are sold. Determinable-lived intangible assets are amortized to expense over their estimated lives. An impairment assessment for determinable-lived intangibles is only required when an event or change in circumstances indicates that the carrying amount of the asset may not be recoverable.

Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach, which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets occurs during the three months ended December 31.

Most of Other than our Gillette indefinite-lived intangible asset, our goodwill reporting units and our indefinite-lived intangible assets have fair value cushions values that significantly exceed their underlying carrying values. In connection with

During the Grooming operating segment integration as described further in Note 2, fiscal year ended June 30, 2024, we concluded that determined the Shave Care and Appliances categories now operate as one reporting unit for goodwill impairment testing. Based on our annual impairment testing during the three months ended December 31, 2022, our

Grooming reporting unit goodwill has a fair value cushion of over 30%. As of June 30, 2023, the carrying value of the Grooming reporting unit goodwill was \$12.7 billion. Most of our indefinite-lived intangible assets have fair value cushions that significantly exceed their underlying carrying value. Based on our annual impairment testing during the three months ended December 31, 2022, the Gillette indefinite-lived intangible asset's fair value exceeded asset was less than its carrying value by approximately 5%.value. As a result, we recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) to reduce the carrying amount to be equivalent to the estimated fair value. As of June 30, 2023 June 30, 2024, the carrying value of the Gillette indefinite-lived intangible asset was \$14.1 billion \$12.8 billion. The impairment charge arose due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of a new restructuring program focused primarily in certain Enterprise Markets, including Argentina and Nigeria.

While we have concluded that no triggering event has occurred during the fiscal year quarter ended June 30, 2023 June 30, 2024, the Gillette indefinite-lived intangible asset is most susceptible to future impairment risk. Adverse changes in the business or in the macroeconomic environment including foreign currency devaluation, increasing global inflation, or market contraction from an economic recession, and the Russia-Ukraine War, could reduce the underlying cash flows used to estimate the fair value of the Gillette indefinite-lived intangible asset and trigger a future impairment charge. Further reduction of the Gillette business activities in Russia could reduce the estimated fair value by up to 5%.

The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales growth rates (including residual growth rates), discount rate and royalty rates.

Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors including the Russia-Ukraine War, could result in additional and prolonged devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which the Gillette brand is expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are consistent with the brand operating plans and approximates expected long-term category market growth rates. The residual growth rates depend on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rates could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased competitive environment.

The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.

The royalty rates are rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.

We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended December 31, 2022 December 31, 2023, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rates to demonstrate the potential impacts to the estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate, a 25 basis-point decrease in our shorter-term and residual growth rates, or a 50 basis-point decrease in our royalty rates, which may result in an additional impairment of the Gillette indefinite-lived intangible asset.

	Approximate Percent Change in Estimated Fair Value		
	+25 bps Discount Rate	-25 bps Growth Rate	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset	(6)%	(6)%	(4)%

The Procter & Gamble Company 29

	Approximate Percent Change in Estimated Fair Value		
	+25 bps Discount Rate	-25 bps Growth Rate	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset	(5)%	(5)%	(4)%

See Note 4 to the Consolidated Financial Statements for additional discussion on goodwill and intangible assets.

The Procter & Gamble Company 29

New Accounting Pronouncements

Refer to Note 1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of June 30, 2023 June 30, 2024.

OTHER INFORMATION

Hedging and Derivative Financial Instruments

As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and commodity prices. We evaluate exposures on a centralized basis to take advantage of natural exposure correlation and netting. We leverage the Company's diversified portfolio of exposures as a natural hedge and prioritize operational hedging activities over financial market instruments. To the extent we choose to further manage volatility within our financing operations, as discussed below, we enter into various financial transactions which we account for using the applicable accounting guidance for derivative instruments and hedging activities. These financial transactions are governed by our policies covering acceptable counterparty exposure, instrument types and other hedging practices. See Note 9 to the Consolidated Financial Statements for a discussion of our accounting policies for derivative instruments.

Derivative positions are monitored using techniques including market valuation, sensitivity analysis and value-at-risk modeling. The tests for interest rate, currency rate and commodity derivative positions discussed below are based on the RiskManager™ value-at-risk model using a one-year horizon and a 95% confidence level. The model incorporates the impact of correlation (the degree to which exposures move together over time) and diversification (from holding multiple currency, commodity and interest rate instruments) and assumes that financial returns are normally distributed. Estimates of volatility and correlations of market factors are drawn from the RiskMetrics™ dataset as of June 30, 2023 June 30, 2024. In cases where data is unavailable in RiskMetrics™, a reasonable proxy is included.

Our market risk exposures relative to interest rates, currency rates and commodity prices, as discussed below, have not changed materially versus the previous reporting period. In addition, we are not aware of any facts or circumstances that would significantly impact such exposures in the near term.

Interest Rate Exposure on Financial Instruments. Exposure. We are exposed to interest rate movements due to our long and short-term borrowing program. Interest rate swaps are used to manage exposures to interest rates on underlying debt obligations. Certain interest rate swaps denominated in foreign currencies are designated to hedge exposures to currency exchange rate movements on our investments in foreign operations. These currency interest rate swaps are designated as hedges of the Company's foreign net investments.

Based on our interest rate exposure as of and during the fiscal year ended June 30, 2023 June 30, 2024, including derivative and other instruments sensitive to interest rates, we believe a near-term change in interest rates, at a 95% confidence level based on historical interest rate movements, would not materially affect our financial statements.

Currency Rate Exposure on Financial Instruments. Exposure. Because we manufacture and sell products and finance operations in a number of countries throughout the world, we are exposed to the impact on revenue and expenses of movements in currency exchange rates. We leverage the Company's diversified portfolio of exposures as a natural hedge. Corporate policy prescribes the range of allowable hedging activity. To manage the exchange rate risk associated with the financing of our operations, we primarily use forward contracts and currency swaps with maturities of less than 18 months.

Based on our currency rate exposure on derivative and other instruments as of and during the fiscal year ended June 30, 2023 June 30, 2024, we believe, at a 95% confidence level based on historical currency rate movements, the impact on such instruments of a near-term change in currency rates would not materially affect our financial statements.

Commodity Price Exposure on Financial Instruments. Exposure. We use raw materials that are subject to price volatility caused by weather, supply conditions, political and economic variables and other unpredictable factors. We may use futures, options and swap contracts to manage the volatility related to the above exposures. During the fiscal years ended June 30, 2023 June 30, 2024 and 2022, 2023, we did not have any financial commodity hedging activity.

Measures Not Defined By U.S. GAAP

In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the a reconciliation to the most closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring or unusual items) and results and provide a supplemental measure of year-over-year results. The non-GAAP measures described below are used by management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as they provide supplemental information about business performance and provide investors with a view of our business results through the eyes of management. These measures are also used to evaluate senior management and are a factor in determining their at-risk at-

30 The Procter & Gamble Company

risk compensation. These non-GAAP measures are not intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted. These measures include:

Organic Sales Growth. Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions, divestitures and foreign exchange from year-over-year comparisons. We believe this measure provides investors with a

30 The Procter & Gamble Company

supplemental understanding of underlying sales trends by providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

The following tables provide a numerical reconciliation of organic sales growth to reported net sales growth:

Fiscal year ended June 30, 2023	Acquisition				Organic Sales Growth
	Net Sales Growth	Foreign Exchange Impact	& Divestiture Impact	Other Sales	
	(1)	(1)	(1)	(1)	
Fiscal year ended June 30, 2024	Fiscal year ended June 30, 2024	Net Sales Growth	Foreign Exchange Impact	Acquisition & Divestiture Impact/Other (1)	Organic Sales Growth

Core EPS. Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used in assessing the achievement of management goals for at-risk compensation. For The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:

- Incremental restructuring:** The Company has historically had an ongoing level of restructuring activities of approximately \$250 - \$500 million before tax. On December 5, 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria. The adjustment to Core earnings includes the restructuring charges that exceed the normal, recurring level of restructuring charges.

The Procter & Gamble Company 31

- Intangible asset impairment:** As discussed in Note 4 to the Consolidated Financial Statements, in the fiscal years year ended June 30, 2023 June 30, 2024, the Company recognized a non-cash, after-tax impairment charge of \$1.0 billion (\$1.3 billion before tax) to adjust the carrying value of the Gillette intangible asset acquired as part of the Company's 2005 acquisition of The Gillette Company.

We do not view the above items to be part of our sustainable results, and 2022, there were no adjustments to or reconciling their exclusion from core earnings measures provides a more comparable measure of year-on-year results. These items for diluted EPS, are also excluded when evaluating senior management in determining their at-risk compensation.

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES						
Reconciliation of Non-GAAP Measures						
Amounts in millions except per share amounts	Fiscal Year Ended June 30, 2024				Fiscal Year Ended June 30, 2023	
	As Reported (GAAP)	Incremental		Core (Non-GAAP)	As Reported	
		Restructuring	Intangible Impairment		(GAAP) ⁽¹⁾	
Cost of products sold	\$ 40,848	\$(70)	\$ —	\$ 40,778	\$ 42,760	
Selling, general and administrative expense	23,305	(33)	—	23,273	21,112	
Operating income	18,545	103	1,341	19,988	18,134	
Non-operating income, net	668	248	—	916	668	
Income taxes	3,787	(25)	315	4,077	3,615	
Net earnings attributable to P&G	14,879	376	1,026	16,281	14,653	
				Core EPS		
Diluted net earnings per common share ⁽²⁾	\$ 6.02	\$ 0.15	\$ 0.42	\$ 6.59	\$ 5.90	
⁽¹⁾ For the fiscal year ended June 30, 2023, there were no adjustments to or reconciling items for Core EPS.						
⁽²⁾ Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.						
CHANGE VERSUS YEAR AGO						
Net earnings attributable to P&G	2 %					
Core net earnings attributable to P&G	11 %					
Diluted net earnings per common share	2 %					
Core EPS	12 %					

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
The information required by this item is incorporated by reference to the section entitled Other Information in the MD&A and Note 9 to the Consolidated Financial Statements.

32 The Procter & Gamble Company 31

Item 8. Financial Statements and Supplementary Data.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Management is responsible for establishing and maintaining adequate internal control over financial reporting of The Procter & Gamble Company (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America.

Strong internal controls is an objective that is reinforced through our *Worldwide Business Conduct Manual*, which sets forth our commitment to conduct business with integrity, and within both the letter and the spirit of the law. Our people are deeply committed to our Purpose, Values and Principles, which unite us in doing what's right. Our system of internal controls includes written policies and procedures, segregation of duties and the careful selection and development of employees. Additional key elements of our internal control structure include our Global Leadership Council, which is actively involved in oversight of the business strategies, initiatives, results and controls, our Disclosure Committee, which is responsible for evaluating disclosure implications of significant business activities and events, our Board of Directors, which provides strong and effective corporate governance, and our Audit Committee, which reviews critical accounting policies and estimates, financial reporting and internal control matters.

Global Internal Audit performs audits of internal controls over financial reporting as well as broader financial, operational and compliance audits around the world, provides training and continually improves our internal control processes. The Company's internal control over financial reporting also includes a robust Control Self-Assessment Program that is conducted annually on critical financial reporting areas of the Company. Management takes the appropriate action to correct any identified control deficiencies.

Because of its inherent limitations, any system of internal control over financial reporting, no matter how well designed, may not prevent or detect misstatements due to the possibility that a control can be circumvented or overridden or that misstatements due to error or fraud may occur that are not detected. Also, because of changes in conditions, internal control effectiveness may vary over time.

Management assessed the effectiveness of the Company's internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, using criteria established in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and concluded that the Company maintained effective internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on these criteria.

Deloitte & Touche LLP, an independent registered public accounting firm, has audited the effectiveness of the Company's internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, as stated in their report which is included herein.

/s/ Jon R. Moeller

(Jon R. Moeller)

Chairman of the Board, President and Chief Executive Officer

/s/ Andre Schulten

(Andre Schulten)

Chief Financial Officer

August 4, 2023 **August 5, 2024**

32 The Procter & Gamble Company 33

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of The Procter & Gamble Company

Opinion on the Financial Statements

We have audited the accompanying Consolidated Balance Sheets of The Procter & Gamble Company and subsidiaries (the "Company") as of **June 30, 2023** **June 30, 2024** and **2022, 2023**, the related Consolidated Statements of Earnings, Comprehensive Income, Shareholders' Equity and Cash Flows, for each of the three years in the period ended **June 30, 2023** **June 30, 2024**, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of **June 30, 2023** **June 30, 2024** and **2022, 2023**, and the results of its operations and its cash flows for each of the three years in the period ended **June 30, 2023** **June 30, 2024**, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated **August 4, 2023** **August 5, 2024**, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Intangible Assets — Gillette Indefinite Lived Indefinite-Lived Intangible Asset — Refer to Notes 1 and 4 to the financial statements

Critical Audit Matter Description

The Company's evaluation of the Gillette indefinite lived indefinite-lived intangible asset (the "Gillette Brand" "Gillette Brand") for impairment involves the comparison of the fair value to its carrying value. The Company estimates fair value using the income method, which is based on the present value of estimated future cash flows attributable to the respective asset. This requires management to make significant estimates and assumptions related to forecasts of future net sales and earnings, including growth rates beyond a 10-year time period, royalty rates, rate and discount rate. Changes in the assumptions could have a significant impact on either the fair value, the amount of any impairment charge, or both. The Company performed their annual impairment assessment of the Gillette Brand as of December 31, 2022 October 1, 2023. Because During the fiscal year ended June 30, 2024, the Company determined that the fair value of the Gillette indefinite-lived intangible asset was less than its carrying amount. As a result, the Company recorded an impairment charge of \$1.3 billion (\$1.0 billion after tax) to reduce the carrying amount to be equivalent to the estimated fair value exceeds the carrying value, no impairment was recorded, as of December 31, 2023. As of June 30, 2023 June 30, 2024, the carrying value of the Gillette Brand was \$14.1 billion \$12.8 billion.

We identified the Company's impairment evaluation of the Gillette Brand as a critical audit matter because of the significant judgments made by management to estimate the fair value of the indefinite lived indefinite-lived intangible asset. A high degree of auditor judgment and an increased extent of effort was required when performing audit procedures to evaluate the reasonableness of management's estimates and assumptions related to the forecasts of future net sales and earnings as well as the selection of royalty rates rate and discount rate, including the need to involve our fair value specialists.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to forecasts of future net sales and earnings and the selection of the royalty rates rate and discount rate for the Gillette Brand included the following, among others:

34 The Procter & Gamble Company

- We tested the effectiveness of controls over the Gillette Brand, including those over the determination of fair value, such as controls related to management's development of forecasts of future net sales and earnings, and the selection of royalty rates rate and discount rate.
- We evaluated management's ability to accurately forecast net sales and earnings by comparing actual results to management's historical forecasts.

The Procter & Gamble Company 33

- We evaluated the reasonableness of management's forecast of net sales and earnings by comparing the forecasts to:
 - Historical net sales and earnings.
 - Underlying analysis detailing business strategies and growth plans.
 - Internal communications to management and the Board of Directors.
 - Forecasted information included in analyst and industry reports for the Company and certain of its peer companies.
- With the assistance of our fair value specialists, we evaluated the net sales and earnings growth rates, royalty rates, rate, and discount rate by:
 - Testing the source information underlying the determination of net sales and earnings growth rates, royalty rates, rate, and discount rate and the mathematical accuracy of the calculations.
 - Developing a range of independent estimates for the discount rate and comparing the discount rate selected by management to that range.

/s/ Deloitte & Touche LLP

Cincinnati, Ohio

August 4, 2023 5, 2024

We have served as the Company's auditor since 1890.

34 The Procter & Gamble Company 35

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of The Procter & Gamble Company

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of The Procter & Gamble Company and subsidiaries (the "Company") as of **June 30, 2023** **June 30, 2024**, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended **June 30, 2023** **June 30, 2024**, of the Company and our report dated **August 4, 2023** **August 5, 2024**, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Cincinnati, Ohio

August **4, 2023** **5, 2024**

Consolidated Statements of Earnings

<u>Amounts in</u> <u>millions except per</u> <u>share amounts;</u> <u>fiscal years ended</u> <u>June 30</u>	<u>Amounts in</u> <u>millions except per</u> <u>share amounts;</u> <u>fiscal years ended</u> <u>June 30</u>	2023	2022	2021	<u>Amounts in millions except per share amounts; fiscal years ended June 30</u>	2024	2023	2022
NET SALES	NET SALES	\$82,006	\$80,187	\$76,118				
Cost of products sold	Cost of products sold	42,760	42,157	37,108				
Selling, general and administrative expense	Selling, general and administrative expense	21,112	20,217	21,024				
Indefinite-lived intangible asset impairment charge								
OPERATING INCOME	OPERATING INCOME	18,134	17,813	17,986				

Interest expense	Interest expense	(756)	(439)	(502)
Interest income	Interest income	307	51	45
Other non-operating income, net	Other non-operating income, net	668	570	86
EARNINGS BEFORE INCOME TAXES	EARNINGS BEFORE INCOME TAXES	18,353	17,995	17,615
Income taxes	Income taxes	3,615	3,202	3,263
NET EARNINGS	NET EARNINGS	14,738	14,793	14,352

NET EARNINGS

NET EARNINGS

Less: Net earnings attributable to noncontrolling interests	Less: Net earnings attributable to noncontrolling interests	85	51	46
---	---	----	----	----

NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE	NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE	\$14,653	\$14,742	\$14,306
NET EARNINGS PER COMMON SHARE ⁽¹⁾	NET EARNINGS PER COMMON SHARE ⁽¹⁾			

NET EARNINGS PER COMMON SHARE ⁽¹⁾

NET EARNINGS PER COMMON SHARE ⁽¹⁾

Basic	Basic	\$ 6.07	\$ 6.00	\$ 5.69
Diluted	Diluted	\$ 5.90	\$ 5.81	\$ 5.50

Diluted

Diluted

⁽¹⁾ Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

Consolidated Statements of Comprehensive Income

Amounts in millions; fiscal years ended June 30	2023	2022	2021
NET EARNINGS	\$ 14,738	\$ 14,793	\$ 14,352
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX			
Foreign currency translation (net of tax (benefit)/expense of \$(197), \$515 and \$(266), respectively)	(71)	(1,450)	1,023
Unrealized gains/(losses) on investment securities (net of tax (benefit)/expense of \$(2), \$1 and \$5, respectively)	(7)	5	16
Unrealized gains on defined benefit postretirement plans (net of tax expense of \$9, \$1,022 and \$445, respectively)	40	2,992	1,386
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX	(38)	1,547	2,425
TOTAL COMPREHENSIVE INCOME	14,700	16,340	16,777
Less: Comprehensive income attributable to noncontrolling interests	78	43	50
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE	\$ 14,622	\$ 16,297	\$ 16,727

See accompanying Notes to Consolidated Financial Statements.

Consolidated Balance SheetsAmounts in millions except stated values; as of June 30**Assets****CURRENT ASSETS**

Cash and cash equivalents	\$ 8,246	\$ 7,214
Accounts receivable	5,471	5,143

INVENTORIES

Materials and supplies	1,863	2,168
Work in process	956	856
Finished goods	4,254	3,900
Total inventories	7,073	6,924
Prepaid expenses and other current assets	1,858	2,372

TOTAL CURRENT ASSETS**PROPERTY, PLANT AND EQUIPMENT, NET****GOODWILL****TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET****OTHER NONCURRENT ASSETS****TOTAL ASSETS****Liabilities and Shareholders' Equity****CURRENT LIABILITIES**

Accounts payable	\$ 14,598	\$ 14,882
Accrued and other liabilities	10,929	9,554
Debt due within one year	10,229	8,645

TOTAL CURRENT LIABILITIES**LONG-TERM DEBT****DEFERRED INCOME TAXES****OTHER NONCURRENT LIABILITIES****TOTAL LIABILITIES****SHAREHOLDERS' EQUITY**

Convertible Class A preferred stock, stated value \$1 per share (600 shares authorized)	819	843
Non-Voting Class B preferred stock, stated value \$1 per share (200 shares authorized)	—	—
Common stock, stated value \$1 per share (10,000 shares authorized; shares issued: 2023 - 4,009.2, 2022 - 4,009.2)	4,009	4,009
Additional paid-in capital	66,556	65,795
Reserve for ESOP debt retirement	(821)	(916)
Accumulated other comprehensive loss	(12,220)	(12,189)
Treasury stock (shares held: 2023 - 1,647.1; 2022 - 1,615.4)	(129,736)	(123,382)
Retained earnings	118,170	112,429
Noncontrolling interest	288	265

TOTAL SHAREHOLDERS' EQUITY**TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY**Amounts in millions; fiscal years ended June 30**NET EARNINGS****OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX**

Foreign currency translation (net of tax (benefit)/expense of \$66, \$(197) and \$515, respectively)	(226)	(71)	(1,450)
Unrealized gains/(losses) on investment securities (net of tax (benefit)/expense of \$(1), \$(2) and \$1, respectively)	(3)	(7)	5

Unrealized gains on defined benefit postretirement plans (net of tax expense of \$230, \$9 and \$1,022, respectively)	546	40	2,992
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX	317	(38)	1,547
TOTAL COMPREHENSIVE INCOME	15,291	14,700	16,340
Less: Comprehensive income attributable to noncontrolling interests	92	78	43
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE	\$ 15,199	\$ 14,622	\$ 16,297

See accompanying Notes to Consolidated Financial Statements.

The Procter & Gamble Company 37

Consolidated Statements of Shareholders' Equity Balance Sheets

<u>Dollars in millions except per share amounts:</u> <u>shares in thousands</u>	Common Stock		Preferred	Additional Paid-	Reserve for	Accumulated	Treasury Stock	Retained	Noncontrolling	Total
	Shares	Amount	Stock	In Capital	ESOP Debt Retirement	Other Comprehensive Income/(Loss)		Earnings	Interest	Shareholders' Equity
BALANCE JUNE 30, 2020	2,479,746	\$4,009	\$897	\$64,194	(\$1,080)	(\$16,165)	(\$105,573)	\$100,239	\$357	\$46,878
Net earnings								14,306	46	14,352
Other comprehensive income/(loss)						2,421			4	2,425
Dividends and dividend equivalents (\$3.2419 per share):										
Common								(8,020)		(8,020)
Preferred								(271)		(271)
Treasury stock purchases	(81,343)						(11,009)			(11,009)
Employee stock plans	28,001			650			1,586			2,236
Preferred stock conversions	3,302		(27)	4			23			—
ESOP debt impacts					74			120		194
Noncontrolling interest, net									(131)	(131)
BALANCE JUNE 30, 2021	2,429,706	\$4,009	\$870	\$64,848	(\$1,006)	(\$13,744)	(\$114,973)	\$106,374	\$276	\$46,654
Net earnings								14,742	51	14,793
Other comprehensive income/(loss)						1,555			(8)	1,547
Dividends and dividend equivalents (\$3.5227 per share):										
Common								(8,514)		(8,514)
Preferred								(281)		(281)
Treasury stock purchases	(67,088)						(10,003)			(10,003)
Employee stock plans	28,042			945			1,571			2,516
Preferred stock conversions	3,217		(27)	4			23			—
ESOP debt impacts					90			108		198
Noncontrolling interest, net				(2)					(54)	(56)
BALANCE JUNE 30, 2022	2,393,877	\$4,009	\$843	\$65,795	(\$916)	(\$12,189)	(\$123,382)	\$112,429	\$265	\$46,854
Net earnings								14,653	85	14,738
Other comprehensive income/(loss)						(31)			(7)	(38)
Dividends and dividend equivalents (\$3.6806 per share):										
Common								(8,742)		(8,742)
Preferred								(282)		(282)
Treasury stock purchases	(52,021)						(7,353)			(7,353)
Employee stock plans	17,424			758			978			1,736
Preferred stock conversions	2,840		(24)	3			21			—

ESOP debt impacts					95			112		207
Noncontrolling interest, net				—					(55)	(55)
BALANCE JUNE 30, 2023	2,362,120	\$4,009	\$819	\$66,556	(\$821)	(\$12,220)	(\$129,736)	\$118,170	\$288	\$47,065

Amounts in millions except stated values; as of June 30										
								2024		2023
Assets										
CURRENT ASSETS										
Cash and cash equivalents								\$ 9,482	\$	8,246
Accounts receivable								6,118		5,471
INVENTORIES										
Materials and supplies								1,617		1,863
Work in process								929		956
Finished goods								4,470		4,254
Total inventories								7,016		7,073
Prepaid expenses and other current assets								2,095		1,858
TOTAL CURRENT ASSETS								24,709		22,648
PROPERTY, PLANT AND EQUIPMENT, NET								22,152		21,909
GOODWILL								40,303		40,659
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET								22,047		23,783
OTHER NONCURRENT ASSETS								13,158		11,830
TOTAL ASSETS								\$ 122,370	\$	120,829
Liabilities and Shareholders' Equity										
CURRENT LIABILITIES										
Accounts payable								\$ 15,364	\$	14,598
Accrued and other liabilities								11,073		10,929
Debt due within one year								7,191		10,229
TOTAL CURRENT LIABILITIES								33,627		35,756
LONG-TERM DEBT								25,269		24,378
DEFERRED INCOME TAXES								6,516		6,478
OTHER NONCURRENT LIABILITIES								6,398		7,152
TOTAL LIABILITIES								71,811		73,764
SHAREHOLDERS' EQUITY										
Convertible Class A preferred stock, stated value \$1 per share (600 shares authorized)								798		819
Non-Voting Class B preferred stock, stated value \$1 per share (200 shares authorized)								—		—
Common stock, stated value \$1 per share (10,000 shares authorized; shares issued: 2024 - 4,009.2, 2023 - 4,009.2)								4,009		4,009
Additional paid-in capital								67,684		66,556
Reserve for ESOP debt retirement								(737)		(821)
Accumulated other comprehensive loss								(11,900)		(12,220)
Treasury stock (shares held: 2024 - 1,652.2; 2023 - 1,647.1)								(133,379)		(129,736)
Retained earnings								123,811		118,170
Noncontrolling interest								272		288
TOTAL SHAREHOLDERS' EQUITY								50,559		47,065
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY								\$ 122,370	\$	120,829

See accompanying Notes to Consolidated Financial Statements.

Consolidated Statements of Shareholders' Equity

Dollars in millions except per share amounts: shares in thousands	Accumulated									
	Common Stock		Preferred Stock	Additional Paid-In Capital	Reserve for ESOP Debt Retirement	Other Comprehensive Income/(Loss)	Treasury Stock	Retained Earnings	Noncontrolling Interest	Total Shareholders' Equity
	Shares	Amount								
BALANCE JUNE 30, 2021	2,429,706	\$4,009	\$870	\$64,848	(\$1,006)	(\$13,744)	(\$114,973)	\$106,374	\$276	\$46,654
Net earnings								14,742	51	14,793
Other comprehensive income/(loss)						1,555			(8)	1,547
Dividends and dividend equivalents (\$3.5227 per share):										
Common								(8,514)		(8,514)
Preferred								(281)		(281)
Treasury stock purchases	(67,088)						(10,003)			(10,003)
Employee stock plans	28,042			945			1,571			2,516
Preferred stock conversions	3,217		(27)	4			23			—
ESOP debt impacts					90			108		198
Noncontrolling interest, net				(2)					(54)	(56)
BALANCE JUNE 30, 2022	2,393,877	\$4,009	\$843	\$65,795	(\$916)	(\$12,189)	(\$123,382)	\$112,429	\$265	\$46,854
Net earnings								14,653	85	14,738
Other comprehensive income/(loss)						(31)			(7)	(38)
Dividends and dividend equivalents (\$3.6806 per share):										
Common								(8,742)		(8,742)
Preferred								(282)		(282)
Treasury stock purchases	(52,021)						(7,353)			(7,353)
Employee stock plans	17,424			758			978			1,736
Preferred stock conversions	2,840		(24)	3			21			—
ESOP debt impacts					95			112		207
Noncontrolling interest, net				—					(55)	(55)
BALANCE JUNE 30, 2023	2,362,120	\$4,009	\$819	\$66,556	(\$821)	(\$12,220)	(\$129,736)	\$118,170	\$288	\$47,065
Net earnings								14,879	95	14,974
Other comprehensive income/(loss)						320			(3)	317
Dividends and dividend equivalents (\$3.8286 per share):										
Common								(9,053)		(9,053)
Preferred								(284)		(284)
Treasury stock purchases	(31,877)						(5,014)			(5,014)
Employee stock plans	24,095			1,125			1,353			2,478
Preferred stock conversions	2,713		(21)	3			18			—
ESOP debt impacts					85			99		184
Noncontrolling interest, net				—					(108)	(108)
BALANCE JUNE 30, 2024	2,357,051	\$4,009	\$798	\$67,684	(\$737)	(\$11,900)	(\$133,379)	\$123,811	\$272	\$50,559

See accompanying Notes to Consolidated Financial Statements.

The Procter & Gamble Company 39

Consolidated Statements of Cash Flows

<u>Amounts in millions;</u> <u>fiscal years ended</u> <u>June 30</u>	<u>Amounts in millions;</u> <u>fiscal years ended</u> <u>June 30</u>	2023	2022	2021	<u>Amounts in millions; fiscal years ended June 30</u>	2024	2023	2022
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR	CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF YEAR	\$ 7,214	\$10,288	\$16,181				
OPERATING ACTIVITIES	OPERATING ACTIVITIES							
Net earnings	Net earnings	14,738	14,793	14,352				
Net earnings								
Net earnings								
Depreciation and amortization	Depreciation and amortization	2,714	2,807	2,735				
Loss on early extinguishment of debt		—	—	512				
Share-based compensation expense								
Share-based compensation expense								
Share-based compensation expense	Share-based compensation expense	545	528	540				
Deferred income taxes	Deferred income taxes	(453)	(402)	(258)				
Loss/(gain) on sale of assets	Loss/(gain) on sale of assets	(40)	(85)	(16)				
Indefinite-lived intangible asset impairment charge								
Change in accounts receivable								
Change in accounts receivable								
Change in accounts receivable	Change in accounts receivable	(307)	(694)	(342)				
Change in inventories	Change in inventories	(119)	(1,247)	(309)				
Change in accounts payable and accrued and other liabilities	Change in accounts payable and accrued and other liabilities	313	1,429	1,391				
Change in other operating assets and liabilities	Change in other operating assets and liabilities	(1,107)	(635)	(369)				
Other	Other	564	229	135				
TOTAL OPERATING ACTIVITIES	TOTAL OPERATING ACTIVITIES	16,848	16,723	18,371				
INVESTING ACTIVITIES	INVESTING ACTIVITIES							
Capital expenditures	Capital expenditures	(3,062)	(3,156)	(2,787)				
Capital expenditures								
Capital expenditures								
Proceeds from asset sales	Proceeds from asset sales	46	110	42				
Acquisitions, net of cash acquired	Acquisitions, net of cash acquired	(765)	(1,381)	(34)				
Other investing activity	Other investing activity	281	3	(55)				
TOTAL INVESTING ACTIVITIES	TOTAL INVESTING ACTIVITIES	(3,500)	(4,424)	(2,834)				

FINANCING ACTIVITIES	FINANCING ACTIVITIES			
Dividends to shareholders	Dividends to shareholders	(8,999)	(8,770)	(8,263)
Dividends to shareholders				
Dividends to shareholders				
Additions to short-term debt with original maturities of more than three months	Additions to short-term debt with original maturities of more than three months	17,168	10,411	7,675
Reductions in short-term debt with original maturities of more than three months	Reductions in short-term debt with original maturities of more than three months	(13,031)	(11,478)	(7,577)
Net additions/(reductions) to other short-term debt	Net additions/(reductions) to other short-term debt	(3,319)	917	(3,431)
Additions to long-term debt	Additions to long-term debt	3,997	4,385	4,417
Reductions in long-term debt ⁽¹⁾		(1,878)	(2,343)	(4,987)
Reductions in long-term debt				
Treasury stock purchases	Treasury stock purchases	(7,353)	(10,003)	(11,009)
Impact of stock options and other	Impact of stock options and other	1,269	2,005	1,644
TOTAL FINANCING ACTIVITIES	TOTAL FINANCING ACTIVITIES	(12,146)	(14,876)	(21,531)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH	EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(170)	(497)	101
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	1,032	(3,074)	(5,893)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR	CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF YEAR	\$ 8,246	\$ 7,214	\$10,288
SUPPLEMENTAL DISCLOSURE	SUPPLEMENTAL DISCLOSURE			
SUPPLEMENTAL DISCLOSURE				
SUPPLEMENTAL DISCLOSURE				
Cash payments for interest				
Cash payments for interest				
Cash payments for interest	Cash payments for interest	\$ 721	\$ 451	\$ 531
Cash payments for income taxes	Cash payments for income taxes	4,278	3,818	3,822

⁽¹⁾ Includes early extinguishment of debt costs of \$512 in 2021.

Notes to Consolidated Financial Statements**NOTE 1****SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES****Nature of Operations**

The Procter & Gamble Company's (the "Company," "Procter & Gamble," "we" or "us") business is focused on providing branded consumer packaged goods of superior quality and value. Our products are sold in approximately about 180 countries and territories primarily through mass merchandisers, e-commerce (including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to consumers. We have on-the-ground operations in approximately about 70 countries.

Basis of Presentation

The Consolidated Financial Statements include the Company and its controlled subsidiaries. Intercompany transactions are eliminated.

Because of a lack of control over Venezuelan subsidiaries caused by a number of currency and other operating controls and restrictions, our Venezuelan subsidiaries are not consolidated for any year presented. We account for those subsidiaries at cost, less impairments, plus or minus observable price changes.

Beginning in fiscal year 2022, the Company began to present increases and reductions in short-term debt with maturities of more than three months separately within the Consolidated Statements of Cash Flows. The presentation for the fiscal year ended June 30, 2021, has been revised to align with the current period presentation. This change had no impact on total financing activities, and we have concluded the change is not material.

Use of Estimates

Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying disclosures. These estimates are based on management's best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, consumer and trade promotion accruals, restructuring reserves, pensions, postretirement benefits, stock options, valuation of acquired intangible assets, useful lives for depreciation and amortization of long-lived assets, future cash flows associated with impairment testing for goodwill, indefinite-lived intangible assets and other long-lived assets, deferred tax assets and liabilities, uncertain income tax positions and contingencies. Actual results may ultimately differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any individual year. However, regarding ongoing impairment testing of goodwill and indefinite-lived intangible assets, significant deterioration in future cash flow projections or other assumptions used in estimating fair values versus those anticipated at the time of the initial valuations, could result in impairment charges that materially affect the financial statements in a given year.

Revenue Recognition

Our revenue is primarily generated from the sale of finished product to customers. Those sales predominantly contain a single performance obligation and revenue is recognized at a single point in time when ownership, risks and rewards transfer, which can be on the date of shipment or the date of receipt by the customer. A provision for payment discounts and product return allowances is recorded as a reduction of sales in the same period the revenue is recognized. The revenue recorded is presented net of sales and other taxes we collect on behalf of governmental authorities. The revenue includes shipping and handling costs, which generally are included in the list price to the customer.

Trade promotions, consisting primarily of customer pricing allowances, merchandising funds and consumer coupons, are offered through various programs to customers and consumers. Sales are recorded net of trade promotion spending, which is recognized as incurred at the time of the sale. Most of these arrangements have terms of approximately one year. Accruals for expected payouts under these programs are included as accrued marketing and promotion in the Accrued and other liabilities line item in the Consolidated Balance Sheets.

Cost of Products Sold

Cost of products sold is primarily comprised of direct materials and supplies consumed in the manufacturing of product, as well as manufacturing labor, depreciation expense and direct overhead expenses necessary to acquire and convert the purchased materials and supplies into finished products. Cost of products sold also includes the cost to distribute products to customers, inbound freight costs, internal transfer costs, warehousing costs and other shipping and handling activity.

Selling, General and Administrative Expense

Selling, general and administrative expense (SG&A) is primarily comprised of marketing expenses, selling expenses, research and development costs, administrative and other indirect overhead costs, depreciation and amortization expense on non-manufacturing assets and other miscellaneous operating items. Research and development costs are charged to expense as incurred and were \$2.0 billion in 2024, 2023 and 2022 and \$1.9 billion in 2021. 2022. Advertising costs, charged to expense as incurred, include television, print, radio, digital and in-store advertising expenses and were \$9.6 billion in 2024, \$8.0 billion in 2023 and \$7.9 billion in 2022 and

Amounts in millions of dollars except per share amounts or as otherwise specified.

\$8.2 billion in 2021, 2022. Non-advertising related components of the Company's total marketing spending reported in SG&A include costs associated with consumer promotions, product sampling and sales aids.

Other Non-Operating Income, Net

Other non-operating income, net primarily includes divestiture gains, net non-service impacts related to postretirement benefit plans, investment income, **accumulated foreign currency translation losses** and other non-operating items.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 41

Currency Translation

Financial statements of operating subsidiaries outside the U.S. generally are measured using the local currency as the functional currency. Adjustments to translate those statements into U.S. dollars are recorded in Other comprehensive income (OCI). For subsidiaries operating in highly inflationary economies, the U.S. dollar is the functional currency. Re-measurement adjustments for financial statements in highly inflationary economies and other transactional exchange gains and losses are reflected in earnings.

Cash Flow Presentation

The Consolidated Statements of Cash Flows are prepared using the indirect method, which reconciles net earnings to cash flows from operating activities. Cash flows from foreign currency transactions and operations are translated at monthly exchange rates for each period. Cash flows from hedging activities are included in the same category as the items being hedged. Cash flows from derivative instruments designated as net investment hedges are classified as investing activities. Realized gains and losses from non-qualifying derivative instruments used to hedge currency exposures resulting from intercompany financing transactions are classified as financing activities. Cash flows from other derivative instruments used to manage interest rates, commodity or other currency exposures are classified as operating activities. Cash payments related to income taxes are classified as operating activities.

Investments

The Company holds minor equity investments in certain companies over which we exert significant influence, but do not control the financial and operating decisions. These are accounted for as equity method investments. Other equity investments that are not controlled, and over which we do not have the ability to exercise significant influence, and for which there is a readily determinable market value, are recorded at fair value, with gains and losses recorded through net earnings. Equity investments without readily determinable fair values are measured at cost, less impairments, plus or minus observable price changes. Equity investments are included as Other noncurrent assets in the Consolidated Balance Sheets.

The Company also holds highly liquid investments, primarily money market funds and time deposits. Such investments are considered cash equivalents and are included within Cash and cash equivalents in the Consolidated Balance Sheets.

Inventory Valuation

Inventories are valued at the lower of cost or net realizable value. Product-related inventories are maintained on the first-in, first-out method. The cost of spare part inventories is maintained using the average-cost method.

Property, Plant and Equipment

Property, plant and equipment is recorded at cost reduced by accumulated depreciation. Depreciation expense is recognized over the assets' estimated useful lives using the straight-line method. Machinery and equipment includes office furniture and fixtures (15-year life), computer equipment and capitalized software (3- to 5-year lives) and manufacturing equipment (3- to 20-year lives). Buildings are depreciated over an estimated useful life of 40 years. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts.

Goodwill and Other Intangible Assets

Goodwill and indefinite-lived intangible assets are not amortized but are evaluated for impairment annually or more often if indicators of a potential impairment are present. Our annual impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangible assets.

We have acquired brands that have been determined to have indefinite lives. We evaluate several factors to determine whether an indefinite life is appropriate, including the competitive environment, market share, brand history, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the brands are sold. In addition, when certain events or changes in operating conditions occur, an additional impairment assessment is performed and indefinite-lived assets may be adjusted to a determinable life.

The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, either on a straight-line or accelerated basis over the estimated periods benefited. Patents, technology and other intangible assets with contractual terms are generally amortized over their respective legal or contractual lives. Customer relationships, brands and other non-contractual intangible assets with determinable lives are amortized over periods generally ranging from 5 to 30 years. When certain events or changes in operating conditions occur, an impairment assessment is performed and remaining lives of intangible assets with determinable lives may be adjusted.

For additional details on goodwill and intangible assets see Note 4.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 41

Fair Values of Financial Instruments

Certain financial instruments are required to be recorded at fair value. Changes in assumptions or estimation methods could affect the fair value estimates; however, we do not believe any such changes would have a material impact on our financial condition, results of operations or cash flows. Other financial instruments, including cash equivalents,

Amounts in millions of dollars except per share amounts or as otherwise specified.

REFINITIV 

Fabric Care	Fabric Care	23%	23%	22%	Fabric Care	24%	23%
Home Care	Home Care	12%	12%	12%	Home Care	12%	12%
Baby Care	Baby Care	10%	10%	10%	Baby Care	9%	10%
Family Care	Family Care				Family Care	9%	8%
Hair Care	Hair Care				Hair Care	9%	9%
Skin and Personal Care	Skin and Personal Care	9%	9%	10%	Skin and Personal Care	9%	9%
Hair Care	Hair Care	9%	9%	9%			
Family Care	Family Care	8%	9%	9%			
Grooming (2)	Grooming (2)	8%	6%	7%	Grooming (2)	8%	8%
Oral Care	Oral Care	8%	8%	8%	Oral Care	8%	8%
Feminine Care	Feminine Care	7%	6%	6%	Feminine Care	6%	7%
Personal Health Care	Personal Health Care	6%	6%	5%	Personal Health Care	6%	6%
Other (2)	Other (2)	—%	2%	2%	Other (2)	—%	—%
TOTAL	TOTAL	100%	100%	100%	TOTAL	100%	100%

(1) % of Net sales by operating segment excludes sales recorded in Corporate.

(2) Effective July 1, 2022, the Grooming Sector Business Unit completed the full integration of its Shave Care and Appliances categories to cohesively serve consumers' grooming needs. This transition included the integration of the management team, strategic decision-making, innovation plans, financial targets, budgets and internal management reporting. For the fiscal years year ended June 30, 2022 and 2021, Appliances was presented in Other.

Net sales and long-lived assets in the United States and internationally were as follows (in billions):

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
NET SALES	NET SALES							
United States	United States	\$38.7	\$36.5	\$33.7				
United States	United States							
International	International	\$43.3	\$43.7	\$42.4				
LONG-LIVED ASSETS (1)	LONG-LIVED ASSETS (1)							
United States	United States	\$11.4	\$10.7	\$10.1				
United States	United States							
International	International	\$10.5	\$10.5	\$11.6				

(1) Long-lived assets consists of property, plant and equipment.

No country, other than the United States, exceeds 10% of the Company's consolidated net sales or long-lived assets.

Our largest customer, Walmart Inc. and its affiliates, accounted for consolidated net sales of approximately 16% in 2024 and 15% in 2023 and 2021, 2022. No other customer represents more than 10% of our consolidated net sales.

Amounts in millions of dollars except per share amounts or as otherwise specified.

Global Segment Results	Global Segment Results	Earnings/(Loss)			Depreciation and			Global Segment Results	Earnings/(Loss)			Depreciation and		Total
		Net Sales	Income Taxes	Net Earnings/(Loss)	Amortization	Assets	Capital Expenditures		Net Sales	Before Income Taxes	Net Earnings/(Loss)	Amortization	Assets	
BEAUTY	BEAUTY	2023	\$15,008	\$ 4,009	\$ 3,178	\$ 376	\$ 6,196	\$ 287						
		2022	14,740	3,946	3,160	348	6,055	331						
		2021	14,417	4,018	3,210	333	5,587	386						
		2023												
		2022												
GROOMING	GROOMING	2023	6,419	1,806	1,461	335	20,601	300						
		2022	6,587	1,835	1,490	361	20,482	260						
		2021	6,440	1,728	1,427	378	20,668	291						
		2023												
		2022												
HEALTH CARE	HEALTH CARE	2023	11,226	2,759	2,125	352	8,480	466						
		2022	10,824	2,618	2,006	376	7,888	410						
		2021	9,956	2,398	1,851	372	7,976	364						
		2023												
		2022												
FABRIC & HOME CARE	FABRIC & HOME CARE	2023	28,371	6,303	4,828	675	8,669	979						
		2022	27,556	5,729	4,386	672	8,567	988						
		2021	26,014	5,986	4,622	646	8,334	1,006						
		2023												
		2022												
BABY, FEMININE & FAMILY CARE	BABY, FEMININE & FAMILY CARE	2023	20,217	4,623	3,545	804	8,517	994						
		2022	19,736	4,267	3,266	826	8,443	932						
		2021	18,850	4,723	3,629	846	8,666	814						
		2023												
		2022												
CORPORATE	CORPORATE	2023	765	(1,147)	(399)	172	68,366	36						
		2022	744	(400)	485	224	65,773	235						
		2021	441	(1,238)	(387)	160	68,076	(74)						
		2023												
		2022												
TOTAL COMPANY	TOTAL COMPANY	2023	\$82,006	\$ 18,353	\$ 14,738	\$ 2,714	\$120,829	\$ 3,062						
		2022	80,187	17,995	14,793	2,807	117,208	3,156						
		2021	76,118	17,615	14,352	2,735	119,307	2,787						
		2023												
		2022												

Amounts in millions of dollars except per share amounts or as otherwise specified.

NOTE 3

SUPPLEMENTAL FINANCIAL INFORMATION

The components of property, plant and equipment were as follows:

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
PROPERTY, PLANT AND EQUIPMENT						
Machinery and equipment						
Buildings	Buildings	\$ 8,277	\$ 8,087			
Machinery and equipment		36,521	35,098			
Construction in progress						
Land	Land	867	756			
Construction in progress		2,980	2,756			
TOTAL PROPERTY, PLANT AND EQUIPMENT	TOTAL PROPERTY, PLANT AND EQUIPMENT	48,645	46,697			
Accumulated depreciation	Accumulated depreciation	(26,736)	(25,502)			
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET	\$21,909	\$21,195			

Selected components of current and noncurrent liabilities were as follows:

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
ACCRUED AND OTHER LIABILITIES - CURRENT						
Marketing and promotion		\$ 3,894	\$3,878			
Compensation expenses		2,030	1,797			
Accrued marketing and promotion						
Accrued compensation						
Taxes payable	Taxes payable	828	587			
Accrued interest						
Lease liabilities						
Restructuring reserves						
Derivative liabilities	Derivative liabilities	631	1			
Leases		222	205			
Restructuring reserves		174	147			
Other	Other	3,150	2,939			
TOTAL	TOTAL	\$10,929	\$9,554			
OTHER NONCURRENT LIABILITIES						
Pension benefits		\$ 3,116	\$3,139			
OTHER NONCURRENT LIABILITIES						
OTHER NONCURRENT LIABILITIES						

Pension benefit obligations			
Uncertain tax positions			
Lease liabilities			
Other retiree benefit obligations			
	U.S. Tax Act transitional tax payable		
		1,154	1,661
	Other retiree benefits	690	672
	Uncertain tax positions	622	752
	Long term operating leases	595	595
	Derivative liabilities	445	307
	Other	530	490
TOTAL	TOTAL	\$ 7,152	\$7,616

RESTRUCTURING PROGRAM

The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. Before tax costs incurred under ongoing programs have generally ranged from \$250 to \$500 annually.

Restructuring costs incurred consist In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company expects to record incremental restructuring charges of \$1.0 to \$1.5 billion after tax, consisting primarily of costs foreign currency translation losses to Separate employees, asset-related costs to exit facilities be recognized as non-cash charges upon the substantial liquidation of operations in the affected markets.

The Company incurred total restructuring charges of \$659 and other costs. \$329 for the fiscal years ended June 30, 2024 and 2023. Of the charges incurred for fiscal year 2024, \$248 were recorded in Costs of products sold, \$155 in SG&A and \$255 in Other non-operating income, net. Of the charges incurred in fiscal year 2023, \$160 were recorded in Costs of products sold, \$160 in SG&A and \$9 in Other non-operating income, net.

Amounts in millions of dollars except per share amounts or as otherwise specified.

46 The Procter & Gamble Company

The following table presents restructuring activity for the fiscal years ended June 30, 2024 and 2023:

	Separation Costs	Asset-Related Costs	Other Costs	Total
RESERVE JUNE 30, 2022	\$ 121	\$ —	\$ 26	\$ 147
Cost incurred	175	43	111	329
Cost paid/settled	(141)	(43)	(118)	(302)
RESERVE JUNE 30, 2023	155	—	19	174
Cost incurred	202	101	355	659
Cost paid/settled	(224)	(101)	(342)	(667)
RESERVE JUNE 30, 2024	\$ 133	\$ —	\$ 32	\$ 166

Separation Costs

Employee separation costs relate to severance packages that are primarily voluntary and the amounts calculated are based on salary levels and past service periods. Severance costs related to voluntary separations are generally charged to earnings when the employee accepts the offer.

Asset-Related Costs

Asset-related costs consist of both asset write-downs and accelerated depreciation. depreciation for manufacturing and facilities consolidations. Asset write-downs relate to the establishment of a new fair value basis for assets held-for-sale or for disposal. These assets are written down to the lower of their current carrying basis or amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out of service prior to the end of their normal service period. These assets relate primarily to manufacturing consolidations and technology standardizations. The asset-related charges will not have a significant impact on future depreciation charges.

Other Costs

Other restructuring-type charges primarily are incurred as a direct result of the restructuring plan. Such charges include accumulated foreign currency translation losses, asset removal and termination of contracts related to supply chain Enterprise Market portfolio restructuring. As of June 30, 2024, the Company has substantially liquidated its operations in certain Enterprise Markets, including Nigeria, and overhead optimization. The Company incurred total restructuring charges recorded a non-cash charge of \$329 and \$253 \$216 for the fiscal years ended June 30, 2023 and 2022. Of the charges incurred for fiscal year 2023, \$160 were recorded accumulated foreign currency translation losses previously included in Costs of products sold, \$160 in SG&A and \$9 in Other non-operating income, net. Of the Accumulated other comprehensive income/(loss).

Amounts in millions of dollars except per share amounts or as otherwise specified.

charges incurred in fiscal year 2022, \$182 were recorded in Costs of products sold, \$67 in SG&A, and \$4 in Other non-operating income, net. The following table presents restructuring activity for the fiscal years ended June 30, 2023 and 2022:

	Separations	Asset-Related Costs	Other	Total
RESERVE JUNE 30, 2021	\$ 176	\$ —	\$ 102	\$ 278
Cost incurred and charged to expense	88	87	78	253
Cost paid/settled	(143)	(87)	(154)	(384)
RESERVE JUNE 30, 2022	121	—	26	147
Cost incurred and charged to expense	175	43	111	329
Cost paid/settled	(141)	(43)	(118)	(302)
RESERVE JUNE 30, 2023	\$ 155	\$ —	\$ 19	\$ 174

Consistent with our historical policies for ongoing restructuring-type activities, the restructuring charges are funded by and included within Corporate for management and segment reporting.

reporting. However, for information purposes, the following table summarizes the total restructuring costs related to our reportable segments:

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
Beauty	Beauty	\$ 15	\$ 11	\$ 13				
Grooming	Grooming	17	14	25				
Health Care	Health Care	28	32	51				
Fabric & Home Care	Fabric & Home Care	87	42	22				
Baby, Feminine & Family Care	Baby, Feminine & Family Care	21	83	29				
Corporate	Corporate	161	71	190				
(1)	(1)							
Total Company		\$329	\$253	\$330				
TOTAL								

(1) Corporate includes costs related to allocated overheads, including charges related to our Enterprise Markets, Global Business Services and Corporate Functions activities.

Amounts in millions of dollars except per share amounts or as otherwise specified.

NOTE 4

GOODWILL AND INTANGIBLE ASSETS

The change in the net carrying amount of goodwill by reportable segment was as follows:

		Baby, Fabric & Feminine					
		Beauty	Grooming	Health Care	Home Care	& Family Care	Total Company
Balance at June 30, 2021							
- Net ⁽¹⁾		\$13,257	\$13,095	\$8,046	\$1,873	\$4,653	\$40,924
BALANCE AT JUNE 30, 2022 - NET							
⁽¹⁾							
Acquisitions and divestitures	Acquisitions and divestitures	781	—	1	—	—	782
Translation and other	Translation and other	(742)	(524)	(458)	(65)	(217)	(2,006)
Balance at June 30, 2022							
- Net ⁽¹⁾		13,296	12,571	7,589	1,808	4,436	39,700
BALANCE AT JUNE 30, 2023 - NET							
⁽¹⁾							
Acquisitions and divestitures	Acquisitions and divestitures	405	—	—	—	33	438
Translation and other	Translation and other	187	132	129	13	60	521
Balance at June 30, 2023							
- Net ⁽¹⁾		\$13,888	\$12,703	\$7,718	\$1,821	\$4,529	\$40,659
BALANCE AT JUNE 30, 2024 - NET							
⁽¹⁾							

⁽¹⁾ Grooming goodwill balance is net of \$7.9 billion \$7.9 billion accumulated impairment losses.

Goodwill decreased during fiscal 2024 primarily due to currency translation across all reportable segments and a brand divestiture in the Beauty reportable segment. Goodwill increased during fiscal 2023 primarily due to an acquisition in the Beauty segment, other minor brand acquisitions in the Baby, Feminine & Family Care segment and currency translation across all reportable segments.

Goodwill and indefinite-lived intangibles are tested for impairment at least annually by comparing the estimated fair values of our reporting units and indefinite-lived intangible assets to their respective carrying values. We use the income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach, which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates and profitability). Significant judgement judgment by management is required to estimate the impact of macroeconomic and other factors on future cash flows, including those related to the Russia-Ukraine War flows. Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, a brand's relative market position and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.

Amounts in millions of dollars except per share amounts or as otherwise specified.

We believe the estimates and assumptions utilized in our impairment testing are reasonable and are comparable to those that would be used by other marketplace participants. However, actual events and results could differ substantially from those used in our valuations. To the extent such factors result in a failure to achieve the level of projected cash flows initially used to estimate fair value for purposes of establishing or subsequently impairing the carrying amount of goodwill and related intangible assets, we may need to record additional non-cash impairment charges in the future.

Goodwill increased during During the fiscal 2023 primarily year ended June 30, 2024, we determined that the fair value of the Gillette indefinite-lived intangible asset was less than its carrying amount. As a result, we recorded a non-cash impairment charge of \$1.3 billion (\$1.0 billion after tax) to reduce the carrying amount to be equivalent to the estimated fair value as of December 31, 2023. Following the impairment charge, the carrying value of the Gillette indefinite-lived intangible asset is \$12.8 billion. The impairment charge arose due to an acquisition a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of a new restructuring program focused primarily in the Beauty segment, other minor brand acquisitions certain Enterprise Markets, including Argentina and Nigeria.

Amounts in the Baby, Feminine millions of dollars except per share amounts or as otherwise specified.

48 The Procter & Family Care segment and currency translation across all reportable segments, Gamble Company

Goodwill decreased during fiscal 2022 due to currency translation across all reportable segments, partially offset by three acquisitions (Farmacy Beauty, Ouai and TULA) in the Beauty reportable segment.

Identifiable intangible assets were comprised of:

2023						2022							
2024						2024						2023	
		Gross		Gross			Accumulated			Accumulated			
		Carrying	Accumulated	Carrying	Accumulated								
		Amount	Amortization	Amount	Amortization		Gross Carrying Amount	Amortization	Gross Carrying Amount	Amortization			
As of June 30	As of June 30	Amount	Amortization	Amount	Amortization	As of June 30	Gross Carrying Amount	Amortization	Gross Carrying Amount	Amortization			
INTANGIBLE ASSETS WITH DETERMINABLE LIVES													
Brands	Brands	\$ 4,352	\$ (2,540)	\$ 4,299	\$ (2,628)								
Patents and technology	Patents and technology	2,775	(2,649)	2,769	(2,609)								
Customer relationships	Customer relationships	1,847	(1,039)	1,797	(939)								
Other	Other	73	(28)	147	(97)								
TOTAL	TOTAL	\$ 9,047	\$ (6,256)	\$ 9,012	\$ (6,273)								
INTANGIBLE ASSETS WITH INDEFINITE LIVES													
INTANGIBLE ASSETS WITH INDEFINITE LIVES													
Brands	Brands	20,992	—	20,940	—								
TOTAL	TOTAL												
INTANGIBLE ASSETS	INTANGIBLE ASSETS	\$30,039	\$ (6,256)	\$29,952	\$ (6,273)								
TOTAL INTANGIBLE ASSETS													
TOTAL INTANGIBLE ASSETS													

NOTE 5

INCOME TAXES

Income taxes are recognized for the amount of taxes payable for the current year and for the impact of deferred tax assets and liabilities, which represent future tax consequences of events that have been recognized differently in the financial statements than for tax purposes. Deferred tax assets and liabilities are established using the enacted statutory tax rates and are adjusted for any changes in such rates in the period of change.

We have elected to account for the tax effects of Global Intangible Low-Taxed Income (GILTI) as a current period expense when incurred.

Earnings before income taxes consisted of the following:

<u>Fiscal years</u> <u>ended June 30</u>	<u>Fiscal years</u> <u>ended June 30</u>	2023	2022	2021	<u>Fiscal years ended June 30</u>	2024	2023	2022
United States	United States	\$12,107	\$11,698	\$10,858				
International	International	6,246	6,297	6,757				
TOTAL	TOTAL	\$18,353	\$17,995	\$17,615				

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 47 49

Income taxes consisted of the following:

<u>Fiscal years</u> <u>ended June 30</u>	<u>Fiscal years</u> <u>ended June 30</u>	2023	2022	2021	<u>Fiscal years ended June 30</u>	2024	2023	2022
CURRENT TAX EXPENSE								
U.S. federal	U.S. federal	\$2,303	\$1,916	\$1,663				
International	International	1,412	1,333	1,534				
U.S. state and local	U.S. state and local	353	355	324				
TOTAL	TOTAL	4,068	3,604	3,521				
DEFERRED TAX EXPENSE/(BENEFIT)								
U.S. federal	U.S. federal	(224)	(320)	(65)				
International and other	International and other	(229)	(82)	(193)				
TOTAL	TOTAL	(453)	(402)	(258)				
TOTAL TAX EXPENSE	TOTAL TAX EXPENSE	\$3,615	\$3,202	\$3,263				

A reconciliation of the U.S. federal statutory income tax rate to our actual effective income tax rate is provided below:

<u>Fiscal years</u> <u>ended June 30</u>	<u>Fiscal years</u> <u>ended June 30</u>	2023	2022	2021	<u>Fiscal years ended June 30</u>	2024	2023	2022
U.S. federal statutory income tax rate	U.S. federal statutory income tax rate	21.0 %	21.0 %	21.0 %	U.S. federal statutory income tax rate	21.0 %	21.0 %	21.0 %
Country mix impacts of foreign operations	Country mix impacts of foreign operations	(0.5) %	(0.3) %	(0.5) %	Country mix impacts of foreign operations	0.1 %	(0.5) %	(0.3) %
State income taxes, net of federal benefit	State income taxes, net of federal benefit	1.6 %	1.5 %	1.3 %	State income taxes, net of federal benefit	1.8 %	1.6 %	1.5 %

Excess tax benefits from the exercise of stock options	Excess tax benefits from the exercise of stock options	(1.0)%	(2.0)%	(1.6)%	Excess tax benefits from the exercise of stock options	(1.5) %	(1.0) %	(2.0) %
Foreign derived intangible income deduction (FDII)	Foreign derived intangible income deduction (FDII)	(0.8)%	(1.1)%	(1.0)%	Foreign derived intangible income deduction (FDII)	(1.1) %	(0.8) %	(1.1) %
Changes in uncertain tax positions	Changes in uncertain tax positions	0.1 %	(0.4)%	(0.1)%	Changes in uncertain tax positions	0.1 %	0.1 %	(0.4) %
Other	Other	(0.7)%	(0.9)%	(0.6)%	Other	(0.2) %	(0.7) %	(0.9) %
EFFECTIVE INCOME TAX RATE	EFFECTIVE INCOME TAX RATE	19.7 %	17.8 %	18.5 %	EFFECTIVE INCOME TAX RATE	20.2 %	19.7 %	17.8 %

Country mix impacts of foreign operations includes the effects of foreign subsidiaries' earnings taxed at rates other than the U.S. statutory rate, the U.S. tax impacts of non-U.S. earnings repatriation and any net impacts of intercompany transactions. Changes in uncertain tax positions represent changes in our net liability related to prior year tax positions. Excess tax benefits from the exercise of stock options reflect the excess of actual tax benefits received on employee exercises of stock options and other share-based payments (which generally equals the income taxable to the employee) over the amount of tax benefits that were calculated and recognized based on the grant date fair values of such instruments.

Tax benefits credited Changes in uncertain tax positions represent changes in our net liability related to shareholders' equity totaled \$190 for the fiscal prior year ended June 30, 2023. This primarily relates to the tax effects of net investment hedges. Tax costs charged to shareholders' equity totaled \$1,538 for the fiscal year ended June 30, 2022. This primarily relates to the tax effects of certain adjustments to pension obligations recorded in shareholders' equity and the tax effects of net investment hedges. positions.

Prior to the passage of the U.S. Tax Act, the Company asserted that substantially all of the undistributed earnings of its foreign subsidiaries were considered indefinitely invested and, accordingly, no deferred taxes were provided. Pursuant to the provisions of the U.S. Tax Act, these earnings were subjected to a one-time transition tax. This charge included taxes for all U.S. income taxes and for the related foreign withholding taxes for the portion of those earnings which are no longer considered indefinitely invested. We have not provided deferred taxes on approximately \$24 billion \$22 billion of earnings that are considered indefinitely invested.

A reconciliation of the beginning and ending liability for uncertain tax positions is as follows:

Fiscal years ended June 30	2023	2022	2021
BEGINNING OF YEAR	\$ 583	\$ 627	\$ 485
Increases in tax positions for prior years	113	102	157
Decreases in tax positions for prior years	(119)	(118)	(34)
Increases in tax positions for current year	60	53	60
Settlements with taxing authorities	(108)	(42)	(26)
Lapse in statute of limitations	(7)	(17)	(24)
Currency translation	(7)	(22)	9
END OF YEAR	\$ 515	\$ 583	\$ 627

Amounts in millions of dollars except per share amounts or as otherwise specified.

48 The Procter & Gamble Company

Fiscal years ended June 30	2024	2023	2022
BEGINNING OF YEAR	\$ 515	\$ 583	\$ 627
Increases in tax positions for prior years	157	113	102
Decreases in tax positions for prior years	(133)	(119)	(118)
Increases in tax positions for current year	160	60	53
Settlements with taxing authorities	(100)	(108)	(42)
Lapse in statute of limitations	(9)	(7)	(17)
Currency translation	(8)	(7)	(22)
END OF YEAR	\$ 582	\$ 515	\$ 583

Included in the total liability for uncertain tax positions at **June 30, 2023** **June 30, 2024**, is **\$354** **\$488** that, depending on the ultimate resolution, could impact the effective tax rate in future periods.

The Company is present in **approximately** **about** 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30-40 jurisdictional audits underway at various stages of completion. We evaluate our tax positions and establish liabilities for

Amounts in millions of dollars except per share amounts or as otherwise specified.

50 The Procter & Gamble Company

uncertain tax positions that may be challenged by local authorities and may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and the closing of statutes of limitation. Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably estimate the **timing and** ultimate settlement amounts until the close of **the an** audit. Based on information currently available, we **do not** anticipate **that** over the next 12-month period **any significant** audit activity **could be completed concluding** related to uncertain tax positions **in multiple jurisdictions** for which we have **existing** accrued **existing** liabilities of approximately \$40, including interest and penalties. **liabilities.**

We recognize the additional accrual of any possible related interest and penalties relating to the underlying uncertain tax position in income tax expense. As of **June 30, 2023**, **2022** **June 30, 2024** and **2021, 2023**, we had accrued interest of **\$143, \$179** **\$111** and **\$166** **\$143** and accrued penalties of **\$12, \$12** **\$15** and **\$10, \$12**, respectively, which are not included in the above table. During the fiscal years ended **June 30, 2023** **June 30, 2024**, **2022** **2023** and **2021, 2022**, we recognized **\$18, \$23** **\$21** and **\$38** **\$21** in interest expense and **\$4, \$1** **\$2** and **\$6** **\$2** in penalties expense, respectively.

Deferred income tax assets and liabilities were comprised of the following:

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
DEFERRED TAX ASSETS	DEFERRED TAX ASSETS					
Capitalized research & development						
Capitalized research & development						
Capitalized research & development						
Loss and other carryforwards	Loss and other carryforwards	\$1,014	\$ 914			
Capitalized research & development		930	646			
Pension and other retiree benefits	Pension and other retiree benefits	737	740			
Accrued marketing and promotion	Accrued marketing and promotion	421	420			
Stock-based compensation	Stock-based compensation	412	386			
Unrealized loss on financial and foreign exchange transactions		282	138			
Fixed assets	Fixed assets	223	209			
Lease liabilities	Lease liabilities	197	185			
Unrealized loss on financial and foreign exchange transactions						
Other	Other	874	862			

Valuation allowances	Valuation allowances	(403)	(409)
TOTAL	TOTAL	\$4,687	\$4,091
DEFERRED TAX LIABILITIES	DEFERRED TAX LIABILITIES		

DEFERRED TAX LIABILITIES			
DEFERRED TAX LIABILITIES			
Goodwill and other intangible assets			
Goodwill and other intangible assets			

Goodwill and other intangible assets	Goodwill and other intangible assets	\$5,811	\$5,783
Fixed assets	Fixed assets	1,556	1,542
Other retiree benefits	Other retiree benefits	1,101	1,031
Unrealized gain on financial and foreign exchange transactions	Unrealized gain on financial and foreign exchange transactions	198	439
Lease right-of-use assets	Lease right-of-use assets	191	179
Foreign withholding tax on earnings to be repatriated	Foreign withholding tax on earnings to be repatriated	96	70
Other	Other	381	244
TOTAL	TOTAL	\$9,334	\$9,288

Net operating loss carryforwards were \$2.3 billion at June 30, 2024, and \$2.9 billion at June 30, 2023, and \$2.5 billion at June 30, 2022. If unused, approximately \$300\$100 will expire between 2023 2024 and 2042 2043. The remainder, totaling \$2.6 billion\$2.2 billion at June 30, 2023 June 30, 2024, may be carried forward indefinitely.

NOTE 6

EARNINGS PER SHARE

Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted average number of common shares outstanding during the year. period. Diluted net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble by the diluted weighted average number of common shares outstanding during the year. period. The diluted shares include the dilutive effect of stock options and other share-based awards based on the treasury stock method (see Note 7) and the assumed conversion of preferred stock (see Note 8).

Amounts in millions of dollars except per share amounts or as otherwise specified.

Net earnings per common share were calculated as follows:

Fiscal years ended	Fiscal years ended				Fiscal years ended June 30			
June 30	June 30	2023	2022	2021	2024	2023		2022
CONSOLIDATED AMOUNTS	CONSOLIDATED AMOUNTS							

Net earnings					
Net earnings					
Net earnings	Net earnings	\$14,738	\$14,793	\$14,352	
Less: Net earnings attributable to noncontrolling interests	Less: Net earnings attributable to noncontrolling interests	85	51	46	
Net earnings attributable to P&G	Net earnings attributable to P&G	14,653	14,742	14,306	
Less: Preferred dividends	Less: Preferred dividends	282	281	271	
Net earnings attributable to P&G available to common shareholders (Basic)	Net earnings attributable to P&G available to common shareholders (Basic)	\$14,371	\$14,461	\$14,035	
Net earnings attributable to P&G available to common shareholders (Diluted)	Net earnings attributable to P&G available to common shareholders (Diluted)	\$14,653	\$14,742	\$14,306	
Net earnings attributable to P&G available to common shareholders (Diluted)					
Net earnings attributable to P&G available to common shareholders (Diluted)					
SHARES IN MILLIONS	SHARES IN MILLIONS				
SHARES IN MILLIONS					
SHARES IN MILLIONS					
Basic weighted average common shares outstanding					
Basic weighted average common shares outstanding					
Basic weighted average common shares outstanding	Basic weighted average common shares outstanding	2,368.2	2,410.3	2,465.8	
Add effect of dilutive securities:	Add effect of dilutive securities:				
Stock options and other unvested equity awards ⁽¹⁾					
Stock options and other unvested equity awards ⁽¹⁾					
Stock options and other unvested equity awards ⁽¹⁾	Stock options and other unvested equity awards ⁽¹⁾	39.4	49.5	52.5	
Convertible preferred shares ⁽²⁾	Convertible preferred shares ⁽²⁾	76.3	79.3	82.7	
Convertible preferred shares ⁽²⁾					
Convertible preferred shares ⁽²⁾					

Diluted weighted average common shares outstanding	Diluted weighted average common shares outstanding	2,483.9	2,539.1	2,601.0	Diluted weighted average common shares outstanding	2,471.9	2,483.9	2,539.1
NET EARNINGS PER COMMON SHARE ⁽³⁾								
NET EARNINGS PER COMMON SHARE								
NET EARNINGS PER COMMON SHARE								
NET EARNINGS PER COMMON SHARE								
Basic								
Basic								
Basic	Basic	\$ 6.07	\$ 6.00	\$ 5.69				
Diluted	Diluted	\$ 5.90	\$ 5.81	\$ 5.50				

(1) Excludes 19 million 4 million, 19 million and 11 million in 2024, 2023 and 9 million in 2023, 2022, and 2021, respectively, of weighted average stock options outstanding because the exercise price of these options was greater than the average market value of the Company's stock or their effect was antidilutive.

(2) An overview of preferred shares can be found in Note 8.

(3) Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.

NOTE 7
SHARE-BASED COMPENSATION

The Company has two primary share-based compensation programs under which we annually grant stock option, restricted stock unit (RSU) and performance stock unit (PSU) awards to certain managers and directors.

In our main long-term incentive program, managers can elect to receive stock options or RSUs. All options vest after three years and have a 10-year life. Exercise prices on options are set equal to the market price of the underlying shares on the date of the grant. RSUs vest and settle in shares of common stock three years from the grant date.

Senior-level executives participate in an additional long-term incentive program that awards PSUs, which are paid in shares after the end of a three-year performance period subject to pre-established performance goals. The program includes a Relative Total Shareholder Return (R-TSR) modifier under which the number of shares ultimately granted is also impacted by the Company's actual shareholder return relative to our consumer products competitive peer set.

In addition to these long-term incentive programs, we award RSUs to the Company's non-employee directors and make other minor stock option and RSU grants to employees for which the terms are not substantially different from our long-term incentive awards.

The Company's share-based compensation plan was approved by shareholders in 2019. Under the 2019 plan, a maximum of 150 million shares of common stock was authorized for issuance and a total of 96 million 77 million shares remain available for grant.

The Company recognizes share-based compensation expense based on the fair value of the awards at the date of grant. The expense is recognized on a straight-line basis over the requisite service period. Awards to employees eligible for retirement prior to the award becoming fully vested are recognized as compensation expense ratably from the grant date through the date the employee first becomes eligible to retire and/or is no longer required to provide services to earn the award. Share-based compensation expense is included as part of Cost of products sold and SG&A in the Consolidated Statement Statements of Earnings and includes an estimate of forfeitures, which is based on historical data.

Amounts in millions of dollars except per share amounts or as otherwise specified.

Total expense and related recognized tax benefit were as follows:

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
Stock options	Stock options	\$303	\$271	\$279				
RSUs and PSUs	RSUs and PSUs	242	257	261				

Total share-based expense	Total share-based expense	\$545	\$528	\$540
Income tax benefit	Income tax benefit	\$103	\$ 88	\$102

Income tax benefit

Income tax benefit

We utilize an industry standard lattice-based valuation model to calculate the fair value for stock options granted. Assumptions utilized in the model, which are evaluated and revised to reflect market conditions and experience, were as follows:

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
Interest rate	Interest rate	3.7 - 4.1 %	0.1 - 1.6 %	0.1 - 0.7 %	Interest rate	4.6 - 5.5 %	3.7 - 4.1 %	0.1 - 1.6 %
Weighted average interest rate	Weighted average interest rate	3.7 %	1.5 %	0.6 %	Weighted average interest rate	4.6 %	3.7 %	1.5 %
Dividend yield	Dividend yield	2.6 %	2.4 %	2.4 %	Dividend yield	2.5 %	2.6 %	2.4 %
Expected volatility	Expected volatility	21 %	19 %	20 %	Expected volatility	18 %	21 %	19 %
Expected life in years	Expected life in years	8.8	9.1	9.2	Expected life in years	8.8	8.8	9.1

Lattice-based option valuation models incorporate ranges of assumptions for inputs and those ranges are disclosed in the preceding table. Expected volatilities are based on a combination of historical volatility of our stock and implied volatilities of call options on our stock. We use historical data to estimate option exercise and employee termination patterns within the valuation model. The expected life of options granted is derived from the output of the option valuation model and represents the average period of time that options granted are expected to be outstanding. The interest rate for periods within the contractual life of the options is based on the U.S. Treasury yield curve in effect at the time of grant.

We utilize a Monte-Carlo simulation model to estimate the fair value of performance stock units granted. Assumptions utilized in the model are not substantially different from those used for stock options.

A summary of options outstanding under the plans as of June 30, 2023 June 30, 2024, and activity during the year then ended is presented below:

Options	Options	Options (in thousands)	Weighted Average Exercise Price	Weighted Average Contractual Life in Years	Aggregate Intrinsic Value	Options (in thousands)	Weighted Average Exercise Price	Weighted Average Contractual Life in Years	Aggregate Intrinsic Value
Outstanding at July 1, 2022		126,715	\$ 99.59						
OUTSTANDING AT JULY 1, 2023									
Granted									
Granted									
Granted	Granted	9,672	131.26						
Exercised	Exercised	(14,667)	81.07						
Exercised									
Exercised									
Forfeited/expired	Forfeited/expired	(515)	128.40						
Outstanding at June 30, 2023		121,205	\$104.18	5.1	\$ 5,770				
Forfeited/expired									

Forfeited/expired

OUTSTANDING AT JUNE 30, 2024

OUTSTANDING AT JUNE 30, 2024

OUTSTANDING AT JUNE 30, 2024

Exercisable	Exercisable	86,336	\$ 90.46	3.9	\$ 5,291
-------------	-------------	--------	----------	-----	----------

The following table provides additional information on stock options:

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
Weighted average grant-date fair value of options granted	Weighted average grant-date fair value of options granted	\$29.58	\$21.55	\$20.94				
Intrinsic value of options exercised	Intrinsic value of options exercised	979	1,886	1,401				
Grant-date fair value of options that vested	Grant-date fair value of options that vested	219	177	236				
Cash received from options exercised	Cash received from options exercised	1,189	1,930	1,705				
Actual tax benefit from options exercised	Actual tax benefit from options exercised	207	399	292				

At June 30, 2023 June 30, 2024, \$159 \$171 of compensation cost had not yet been recognized related to stock option grants. That cost is expected to be recognized over a remaining weighted average period of 1.6 years.

Amounts in millions of dollars except per share amounts or as otherwise specified.

A summary of non-vested RSUs and PSUs outstanding under the plans as of June 30, 2023 June 30, 2024, and activity during the year then ended is presented below:

RSUs	PSUs	RSUs	PSUs
RSUs		RSUs	PSUs

RSU and PSU awards	RSU and PSU awards	Units (in thousands)	Weighted Average Grant Date Fair Value	Units (in thousands)	Weighted Average Grant Date Fair Value	RSU and PSU awards	Units (in thousands)	Weighted Average Grant Date Fair Value	Units (in thousands)	Weighted Average Grant Date Fair Value
Non-vested at July 1, 2022		2,832	\$130.37	928	\$152.94					
Non-vested at July 1, 2023										
Granted	Granted	1,727	128.78	569	133.21					
Vested	Vested	(1,286)	116.89	(453)	152.90					
Forfeited	Forfeited	(101)	131.22	(33)	140.68					
Non-vested at June 30, 2023		3,172	\$134.94	1,011	\$142.40					
Non-vested at June 30, 2024										

At June 30, 2023, June 30, 2024, \$218 \$243 of compensation cost had not yet been recognized related to RSUs and PSUs. That cost is expected to be recognized over a remaining weighted average period of 1.7 1.6 years. The total grant date fair value of shares vested was \$256, \$220 and \$248 in 2024, 2023 and 2022, respectively. The Company settles equity issuances with treasury shares. We have no specific policy to repurchase common shares to mitigate the dilutive impact of options, RSUs and PSUs. However, we have historically made adequate discretionary purchases, based on cash availability, market trends and other factors, to offset the impacts of such activity.

NOTE 8

POSTRETIREMENT BENEFITS AND EMPLOYEE STOCK OWNERSHIP PLAN

We offer various postretirement benefits to our employees.

Defined Contribution Retirement Plans

We have defined contribution plans, which cover the majority of our U.S. employees, as well as employees in certain other countries. These plans are fully funded. We generally make contributions to participants' accounts based on individual base salaries and years of service. Total global defined contribution expense was \$425, \$392 and \$366 in 2024, 2023 and 2022, respectively.

The primary U.S. defined contribution plan (the U.S. DC plan) comprises the majority of the expense for the Company's defined contribution plans. For the U.S. DC plan, the contribution rate is set annually. Total contributions for this plan approximated 13% of total participants' annual wages and salaries in 2024 and 2023 and 14% in 2022 and 2021, 2022.

We maintain The Procter & Gamble Profit Sharing Trust (Trust) and Employee Stock Ownership Plan (ESOP) to provide a portion of the funding for the U.S. DC plan and other retiree benefits (described below). Operating details of the ESOP are provided at the end of this Note. The fair value of the ESOP Series A shares allocated to participants reduces our cash contribution required to fund the U.S. DC plan.

Defined Benefit Retirement Plans and Other Retiree Benefits

We offer defined benefit retirement pension plans to certain employees. These benefits relate primarily to plans outside the U.S. and, to a lesser extent, plans assumed in previous acquisitions covering U.S. employees.

We also provide certain other retiree benefits, primarily health care benefits for the majority of our U.S. employees who become eligible for these benefits when they meet minimum age and service requirements. The plans require cost sharing with retirees and the benefits are funded by ESOP Series B shares and certain other assets contributed by the Company.

Amounts in millions of dollars except per share amounts or as otherwise specified.

52 54 The Procter & Gamble Company

Obligation and Funded Status. The following provides a reconciliation of benefit obligations, plan assets and funded status of these defined benefit plans:

Fiscal years ended June 30	Pension Benefits ⁽¹⁾		Other Retiree Benefits ⁽²⁾	
	2023	2022	2023	2022
CHANGE IN BENEFIT OBLIGATION				
Benefit obligation at beginning of year ⁽³⁾	\$ 12,608	\$ 18,469	\$ 3,070	\$ 4,206
Service cost	173	253	71	86
Interest cost	430	253	142	99

Participants' contributions	13	14	50	67
Amendments ⁽⁴⁾	8	5	—	(586)
Net actuarial loss/(gain)	(550)	(4,067)	(208)	(586)
Special termination benefits	5	4	4	1
Currency translation and other	363	(1,720)	31	51
Benefit payments	(551)	(603)	(227)	(268)
BENEFIT OBLIGATION AT END OF YEAR ⁽³⁾	\$ 12,499	\$ 12,608	\$ 2,933	\$ 3,070
CHANGE IN PLAN ASSETS				
Fair value of plan assets at beginning of year	\$ 10,173	\$ 13,041	\$ 6,889	\$ 6,444
Actual return on plan assets	37	(1,233)	482	526
Employer contributions	392	222	42	37
Participants' contributions	13	14	50	67
Currency translation and other	310	(1,268)	1	1
ESOP debt impacts ⁽⁵⁾	—	—	87	82
Benefit payments	(551)	(603)	(227)	(268)
FAIR VALUE OF PLAN ASSETS AT END OF YEAR	\$ 10,374	\$ 10,173	\$ 7,324	\$ 6,889
FUNDED STATUS	\$ (2,125)	\$ (2,435)	\$ 4,391	\$ 3,819

Fiscal years ended June 30	Pension Benefits ⁽¹⁾		Other Retiree Benefits ⁽²⁾	
	2024	2023	2024	2023
CHANGE IN BENEFIT OBLIGATION				
Benefit obligation at beginning of year ⁽³⁾	\$ 12,499	\$ 12,608	\$ 2,933	\$ 3,070
Service cost	164	173	68	71
Interest cost	527	430	157	142
Participants' contributions	14	13	56	50
Amendments	21	8	2	—
Net actuarial loss/(gain)	(11)	(550)	(268)	(208)
Special termination benefits	4	5	3	4
Currency translation and other	(155)	363	(22)	31
Benefit payments	(707)	(551)	(242)	(227)
BENEFIT OBLIGATION AT END OF YEAR ⁽³⁾	\$ 12,355	\$ 12,499	\$ 2,687	\$ 2,933
CHANGE IN PLAN ASSETS				
Fair value of plan assets at beginning of year	\$ 10,374	\$ 10,173	\$ 7,324	\$ 6,889
Actual return on plan assets	1,058	37	784	482
Employer contributions	239	392	44	42
Participants' contributions	14	13	56	50
Currency translation and other	(119)	310	—	1
ESOP debt impacts ⁽⁴⁾	—	—	77	87
Benefit payments	(707)	(551)	(242)	(227)
FAIR VALUE OF PLAN ASSETS AT END OF YEAR	\$ 10,857	\$ 10,374	\$ 8,043	\$ 7,324
FUNDED STATUS	\$ (1,498)	\$ (2,125)	\$ 5,356	\$ 4,391

⁽¹⁾ Primarily non-U.S.-based defined benefit retirement plans.

⁽²⁾ Primarily U.S.-based other postretirement benefit plans.

⁽³⁾ For the pension benefit plans, the benefit obligation is the projected benefit obligation. For other retiree benefit plans, the benefit obligation is the accumulated postretirement benefit obligation.

⁽⁴⁾ For the other retiree benefits, the amendment primarily relates to adjustments in the self-insured U.S. retiree health care program to utilize fully-insured Medicare Advantage Programs impacting fiscal year 2022.

⁽⁵⁾ Represents the net impact of ESOP debt service requirements, which is netted against plan assets for other retiree benefits.

The actuarial gain for pension benefits in 2024 was primarily related to updating of various assumptions in the plan, offset by updates in work experience and decreases in discount rates. The actuarial gain for other retiree benefits in 2024 was primarily related to updating various assumptions in the plan based work experience and an increase in discount

rates. The actuarial gain for pension plans in 2023 was primarily related to increases in discount rates, offset by inflation-related pension benefit increases. The actuarial gain for other retiree benefits in 2023 was primarily related to increases in discount rates and a decrease in assumptions for medical claims costs. The actuarial gain for pension plans in 2022 was primarily related to increases in discount rates. The actuarial gain for other retiree benefits in 2022 was primarily related to increases in discount rates, partially offset by unfavorable medical claim experience.

The underfunding of pension benefits is primarily a function of the different funding incentives that exist outside of the U.S. In certain countries, there are no legal requirements or financial incentives provided to companies to pre-fund pension obligations prior to their due date. In these instances, benefit payments are typically paid directly from the Company's cash as they become due.

		Pension Benefits				Other Retiree Benefits			
		Pension Benefits				Other Retiree Benefits			
As of June 30	As of June 30	2023	2022	2023	2022	As of June 30	2024	2023	2024
CLASSIFICATION	CLASSIFICATION								
OF NET	OF NET								
AMOUNT	AMOUNT								
RECOGNIZED	RECOGNIZED								
Noncurrent assets	Noncurrent assets								
Noncurrent assets	Noncurrent assets								
Noncurrent assets	Noncurrent assets	\$ 1,085	\$ 765	\$ 5,119	\$ 4,525				
Current liabilities	Current liabilities	(94)	(61)	(38)	(34)				
Noncurrent liabilities	Noncurrent liabilities	(3,116)	(3,139)	(690)	(672)				
NET AMOUNT	NET AMOUNT								
RECOGNIZED	RECOGNIZED	\$ (2,125)	\$ (2,435)	\$ 4,391	\$ 3,819				
AMOUNTS	AMOUNTS								
RECOGNIZED IN	RECOGNIZED IN								
ACCUMULATED	ACCUMULATED								
OTHER	OTHER								
COMPREHENSIVE	COMPREHENSIVE								
(INCOME)/LOSS	(INCOME)/LOSS								
(AOCI)	(AOCI)								
Net actuarial	Net actuarial								
loss/(gain)	loss/(gain)	\$ 1,818	\$ 1,906	\$ (1,160)	\$ (1,093)				
Net actuarial loss/(gain)	Net actuarial loss/(gain)								
Net actuarial loss/(gain)	Net actuarial loss/(gain)								
Prior service	Prior service								
cost/(credit)	cost/(credit)	156	170	(787)	(907)				
NET AMOUNTS	NET AMOUNTS								
RECOGNIZED IN	RECOGNIZED IN								
AOCI	IN AOCI	\$ 1,974	\$ 2,076	\$ (1,947)	\$ (2,000)				

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 53 55

The accumulated benefit obligation for all defined benefit pension plans, which differs from the projected obligation in that it excludes the assumption of future salary increases, was \$11.8 billion \$11.6 billion and \$11.9 billion \$11.8 billion as of June 30, 2023 June 30, 2024 and 2022, 2023, respectively. Information related to the funded status of selected pension and other retiree benefits at June 30 is as follows:

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
PENSION PLANS WITH A PROJECTED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS						
Projected benefit obligation	Projected benefit obligation	\$7,967	\$7,989			
Fair value of plan assets	Fair value of plan assets	4,758	4,789			

PENSION PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS

Accumulated benefit obligation	Accumulated benefit obligation	\$7,442	\$7,191
Fair value of plan assets	Fair value of plan assets	4,677	4,433

OTHER RETIREE BENEFIT PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS

Accumulated benefit obligation	Accumulated benefit obligation	\$ 818	\$ 808
Fair value of plan assets	Fair value of plan assets	89	102

Net Periodic Benefit Cost. Components of the net periodic benefit cost were as follows:

Pension Benefits				Other Retiree Benefits							
Pension Benefits								Pension Benefits			
								Other Retiree Benefits			
Fiscal years ended	Fiscal years ended							Fiscal years ended			
June 30	June 30	2023	2022	2021	2023	2022	2021	June 30	2024	2023	2022

AMOUNTS RECOGNIZED IN NET PERIODIC BENEFIT COST/(CREDIT)

Service cost	Service cost	\$173	\$ 253	\$275	\$ 71	\$ 86	\$ 94
Interest cost	Interest cost	430	253	240	142	99	114
Expected return on plan assets	Expected return on plan assets	(591)	(684)	(783)	(611)	(564)	(508)
Amortization of net actuarial loss/(gain)	Amortization of net actuarial loss/(gain)	133	337	423	(7)	11	47
Amortization of prior service cost/(credit)	Amortization of prior service cost/(credit)	26	28	25	(125)	(107)	(60)
Amortization of net actuarial loss/(gain) due to settlements	Amortization of net actuarial loss/(gain) due to settlements	—	(5)	5	—	—	—
Special termination benefits	Special termination benefits	5	4	17	4	1	2
GROSS BENEFIT COST/(CREDIT)		176	186	202	(526)	(474)	(311)
Dividends on ESOP preferred stock		—	—	—	—	—	(8)
NET PERIODIC BENEFIT COST/(CREDIT)	NET PERIODIC BENEFIT COST/(CREDIT)	\$176	\$ 186	\$202	\$(526)	\$ (474)	\$(319)

CHANGE IN PLAN ASSETS AND BENEFIT OBLIGATIONS RECOGNIZED IN AOCI

Net actuarial loss/(gain) - current year	Net actuarial loss/(gain) - current year	\$ 4	\$(2,150)	\$ (79)	\$ (548)
Prior service cost/(credit) - current year	Prior service cost/(credit) - current year	8	5	—	(586)
Amortization of net actuarial loss/(gain)		(133)	(337)	7	(11)

Prior service cost/(credit) - current year

Prior service cost/(credit) - current year

The service cost component of the net periodic benefit cost is included in the Consolidated Statements of Earnings in Cost of products sold and SG&A. All other components are included in the Consolidated Statements of Earnings in Other non-operating income/(expense), income, net, unless otherwise noted.

54 56 The Procter & Gamble Company

Assumptions. We determine our actuarial assumptions on an annual basis. These assumptions are weighted to reflect each country that may have an impact on the cost of providing retirement benefits. The weighted average assumptions used to determine benefit obligations recorded on the Consolidated Balance Sheets as of **June 30, 2023**, **June 30, 2024** and **2022**, **2023**, were as follows: ⁽¹⁾

Pension Benefits						Other Retiree Benefits				
Pension Benefits						Pension Benefits				
As of June 30	As of June 30	2023	2022	2023	2022	As of June 30	2024	2023	2024	2023
Discount rate	Discount rate	4.2 %	3.7 %	5.6 %	5.0 %	Discount rate	4.2 %	4.2 %	5.8 %	5.6 %
Rate of compensation increase	Rate of compensation increase	2.9 %	2.8 %	N/A	N/A	Rate of compensation increase	2.8 %	2.9 %	N/A	N/A
Interest crediting rate for cash balance plans	Interest crediting rate for cash balance plans	4.3 %	4.3 %	N/A	N/A	Interest crediting rate for cash balance plans	4.7 %	4.3 %	N/A	N/A
Health care cost trend rates assumed for next year	Health care cost trend rates assumed for next year	N/A	N/A	6.1 %	6.4 %	Health care cost trend rates assumed for next year	N/A	N/A	6.3 %	6.1 %
Rate to which the health care cost trend rate is assumed to decline (ultimate trend rate)	Rate to which the health care cost trend rate is assumed to decline (ultimate trend rate)	N/A	N/A	4.5 %	4.5 %	Rate to which the health care cost trend rate is assumed to decline (ultimate trend rate)	N/A	N/A	4.9 %	4.5 %
Year that the rate reaches the ultimate trend rate	Year that the rate reaches the ultimate trend rate	N/A	N/A	2028	2028	Year that the rate reaches the ultimate trend rate	N/A	N/A	2029	2028

(1) Determined as of end of fiscal year.

The weighted average assumptions used to determine net benefit cost recorded on the Consolidated Statement of Earnings for the fiscal years ended June 30 were as follows: (1)

Pension Benefits								Other Retiree Benefits							
Pension Benefits								Pension Benefits							
Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022	2024	2023	2022	
Discount rate	Discount rate	3.7 %	1.7 %	1.5 %	5.0 %	3.2 %	3.1 %	Discount rate	4.2 %	3.7 %	1.7 %	5.6 %	5.0 %	3.2 %	
Expected return on plan assets	Expected return on plan assets	5.9 %	5.5 %	6.5 %	8.4 %	8.4 %	8.4 %	Expected return on plan assets	6.0 %	5.9 %	5.5 %	8.5 %	8.4 %	8.4 %	
Rate of compensation increase	Rate of compensation increase	2.8 %	2.7 %	2.5 %	N/A	N/A	N/A	Rate of compensation increase	2.9 %	2.8 %	2.7 %	N/A	N/A	N/A	
Interest crediting rate for cash balance plans	Interest crediting rate for cash balance plans	4.3 %	4.4 %	4.4 %	N/A	N/A	N/A	Interest crediting rate for cash balance plans	4.3 %	4.3 %	4.4 %	N/A	N/A	N/A	

(1) Determined as of beginning of fiscal year.

For plans that make up the majority of our obligation, the Company calculates the benefit obligation and the related impacts on service and interest costs using specific spot rates along the corporate bond yield curve. For the remaining plans, the Company determines these amounts utilizing a single weighted average discount rate derived from the corporate bond yield curve used to measure the plan obligations.

Several factors are considered in developing the estimate for the long-term expected rate of return on plan assets. For the defined benefit retirement plans, these factors include historical rates of return of broad equity and bond indices and projected long-term rates of return obtained from pension investment consultants. The expected long-term rates of return for plan assets are 8 - 9% for equities and 3 - 5% for bonds. For other retiree benefit plans, the expected long-term rate of return reflects that the assets are comprised primarily of Company stock. The expected rate of return on Company stock is based on the long-term projected return of 8.5% and reflects the historical pattern of returns.

Plan Assets. Our investment objective for defined benefit retirement plan assets is to meet the plans' benefit obligations and to improve plan self-sufficiency for future benefit obligations. The investment strategies focus on asset class diversification, liquidity to meet benefit payments and an appropriate balance of long-term investment return and risk. Target ranges for asset allocations are determined by assessing different investment risks and matching the actuarial projections of the plans' future liabilities and benefit payments with current as well as expected long-term rates of return on the assets, taking into account investment return volatility and correlations across asset classes. Plan assets are diversified across several investment managers and are generally invested in liquid funds that are selected to track broad market equity and bond indices. Investment risk is carefully controlled with plan assets rebalanced to target allocations on a periodic basis and with continual monitoring of investment managers' performance relative to the investment guidelines established with each investment manager.

Our target asset allocation for the fiscal year ended June 30, 2023, June 30, 2024, and actual asset allocation by asset category as of June 30, 2023, June 30, 2024 and 2022, 2023, were as follows:

Target Asset Allocation					Actual Asset Allocation at June 30								
				Other	Pension Benefits		Other Retiree Benefits						
Target Asset Allocation				Retiree Benefits	Target Asset Allocation								
Target Asset Allocation				Retiree Benefits	Actual Asset Allocation								
					Pension Benefits								
Asset Category	Pension Benefits	Asset Category		Other Retiree Benefits	2023	2022	2023	2022	Asset Category	Pension Benefits	Other Retiree Benefits	2024	2023
Cash	Cash	Pension Benefits		1 % Benefits	1 %	2 %	2 %	Cash	1 %	2 %	1 %		
Debt securities	Debt securities	59 %		— %	60 %	58 %	1 %	1 %	Debt securities	61 %		61 %	60 %
Equity securities	Equity securities	40 %		98 %	39 %	41 %	97 %	97 %	Equity securities	38 %		37 %	39 %
TOTAL	TOTAL	100 %		100 %	100 %	100 %	100 %	100 %	TOTAL	100 %		100 %	100 %

Company preferred stock ⁽¹⁾	Company preferred stock ⁽¹⁾		—	—	2	6,721	6,340
Fixed income securities ⁽²⁾	Fixed income securities ⁽²⁾	2	1,190	1,545		—	—
Insurance contracts ⁽³⁾	Insurance contracts ⁽³⁾	3	93	94		—	—
TOTAL ASSETS IN THE FAIR VALUE HIERARCHY	TOTAL ASSETS IN THE FAIR VALUE HIERARCHY		1,337	1,717		7,237	6,789
Investments valued at net asset value ⁽⁴⁾	Investments valued at net asset value ⁽⁴⁾		9,037	8,456		87	100
TOTAL ASSETS AT FAIR VALUE	TOTAL ASSETS AT FAIR VALUE		\$10,374	10,173		\$7,324	6,889

⁽¹⁾ Company preferred stock is valued based on the value of Company common stock and is presented net of ESOP debt discussed below.

⁽²⁾ Fixed income securities are estimated by using pricing models or quoted prices of securities with similar characteristics.

⁽³⁾ Fair values of insurance contracts are valued based on either their cash equivalent value or models that project future cash flows and discount the future amounts to a present value using market-based observable inputs, including credit risk and interest rate curves. The activity for Level 3 assets is not significant for all years presented.

⁽⁴⁾ Investments valued using net asset value as a practical expedient are primarily equity and fixed income collective funds.

Cash Flows. Management's best estimate of cash requirements and discretionary contributions for the defined benefit retirement plans and other retiree benefit plans for the fiscal year ending **June 30, 2024** **June 30, 2025**, is **\$206** **\$180** and **\$52**, **\$53**, respectively. Expected contributions are dependent on many variables, including the variability of the market value of the plan assets as compared to the benefit obligation and other market or regulatory conditions. In addition, we take into consideration our business investment opportunities and resulting cash requirements. Accordingly, actual funding may differ significantly from current estimates.

Total benefit payments expected to be paid to participants, which include payments funded from the Company's assets and payments from the plans are as follows:

<u>Fiscal years ending June 30</u>		<u>Pension Benefits</u>		<u>Other Retiree Benefits</u>	
<u>Fiscal years ending June 30</u>	<u>June 30</u>	<u>Pension Benefits</u>	<u>Other Retiree Benefits</u>	<u>Fiscal years ending June 30</u>	<u>Pension Benefits</u>
EXPECTED BENEFIT PAYMENTS	EXPECTED BENEFIT PAYMENTS				
2024		\$ 648	\$ 179		
2025					
2025					
2025	2025	633	186		
2026	2026	632	189		
2027	2027	652	196		
2028	2028	704	202		
2029 - 2033		3,800	1,102		
2029					
2030 - 2034					

Employee Stock Ownership Plan

We maintain the ESOP to provide funding for certain employee benefits discussed in the preceding paragraphs.

The ESOP borrowed \$1.0 billion in 1989, and the proceeds were used to purchase Series A ESOP Convertible Class A Preferred Stock to fund a portion of the U.S. DC plan. Principal and interest requirements of the borrowing were paid by the Trust from dividends on the preferred shares and from advances provided by the Company. The original borrowing of \$1.0 billion has been repaid in **full, and full**. No advances from the Company of **\$8** remain outstanding at **June 30, 2023** **June 30, 2024**. Each share is convertible at the option of the holder into one share of the Company's common stock. The dividend for the current year was equal to the common stock dividend of **\$3.68** **\$3.83** per share. The liquidation value is \$6.82 per share.

In 1991, the ESOP borrowed an additional \$1.0 billion. The proceeds were used to purchase Series B ESOP Convertible Class A Preferred Stock to fund a portion of retiree health care benefits. These shares, net of the ESOP's debt, are considered plan assets of the other retiree benefits plan discussed above. The original borrowings of \$1.0 billion were repaid in 2021. Debt service requirements were funded by preferred stock dividends, cash contributions and advances provided by the Company, of

58 The Procter & Gamble Company

which \$814 \$737 are outstanding at June 30, 2023 June 30, 2024. Each share is convertible at the option of the holder into one share of the Company's common stock. The dividend for the current year was equal to the common stock dividend of \$3.68 \$3.83 per share. The liquidation value is \$12.96 per share.

Amounts in millions of dollars except per share amounts or as otherwise specified.

56 The Procter & Gamble Company

Our ESOP accounting practices are consistent with current ESOP accounting guidance, including the permissible continuation of certain provisions from prior accounting guidance. ESOP debt, which was guaranteed by the Company, was recorded as debt with an offset to the Reserve for ESOP debt retirement, which is presented within Shareholders' equity. Advances to the ESOP by the Company are recorded as an increase in the Reserve for ESOP debt retirement. Interest incurred on the ESOP debt was recorded as Interest expense. Dividends on all preferred shares are charged to Retained earnings.

The series A and B preferred shares of the ESOP are allocated to employees based on debt service requirements. The number of preferred shares outstanding at June 30 was as follows:

Shares in thousands	Shares in thousands	2023	2022	2021	Shares in thousands	2024	2023	2022
Allocated	Allocated	24,449	25,901	27,759				
Unallocated	Unallocated	535	1,123	1,769				
TOTAL	TOTAL							
SERIES A	SERIES A	24,984	27,024	29,528				
Allocated	Allocated	32,172	30,719	29,203				
Allocated								
Allocated								
Unallocated	Unallocated	17,867	20,120	22,349				
TOTAL	TOTAL							
SERIES B	SERIES B	50,039	50,839	51,552				

For purposes of calculating diluted net earnings per common share, the preferred shares held by the ESOP are considered converted from inception.

NOTE 9

RISK MANAGEMENT ACTIVITIES AND FAIR VALUE MEASUREMENTS

As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and commodity prices. We evaluate exposures on a centralized basis to take advantage of natural exposure correlation and netting. To the extent we choose to manage volatility associated with the net exposures, we enter into various financial transactions that we account for using the applicable accounting guidance for derivative instruments and hedging activities. These financial transactions are governed by our policies covering acceptable counterparty exposure, instrument types and other hedging practices.

If the Company elects to do so and if the instrument meets certain specified accounting criteria, management designates derivative instruments as cash flow hedges, fair value hedges or net investment hedges. We record derivative instruments at fair value and the accounting for changes in the fair value depends on the intended use of the derivative, the resulting designation and the effectiveness of the instrument in offsetting the risk exposure it is designed to hedge. We generally have a high degree of effectiveness between the exposure being hedged and the hedging instrument.

Credit Risk Management

We have counterparty credit guidelines and normally enter into transactions with investment grade financial institutions, to the extent commercially viable. Counterparty exposures are monitored daily and downgrades in counterparty credit ratings are reviewed on a timely basis. We have not incurred, and do not expect to incur, material credit losses on our risk management or other financial instruments.

Substantially all of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a net liability position was \$1,088 \$307 and \$219 \$1,088 as of June 30, 2023 June 30, 2024 and 2022, 2023, respectively. The Company has not been required to post collateral as a result of these contractual features.

Interest Rate Risk Management

Our policy is to manage interest cost using a mixture of fixed-rate and variable-rate debt. To manage this risk in a cost-efficient manner, we enter into interest rate swaps whereby we agree to exchange with the counterparty, at specified intervals, the difference between fixed and variable interest amounts calculated by reference to a notional amount.

We designate certain interest rate swaps on fixed rate debt that meet specific accounting criteria as fair value hedges. For fair value hedges, the changes in the fair value of both the hedging instruments and the underlying debt obligations are immediately recognized in earnings.

Amounts in millions of dollars except per share amounts or as otherwise specified.

Foreign Currency Risk Management

We manufacture and sell our products and finance our operations in a number of countries throughout the world. As a result, we are exposed to movements in foreign currency exchange rates. We leverage the Company's diversified portfolio of exposures as a natural hedge. In certain cases, we enter into non-qualifying foreign currency contracts to hedge certain balance sheet items subject to revaluation. The change in fair value of these instruments and the underlying exposure are both immediately recognized in earnings.

Amounts in millions of dollars except per share amounts or as otherwise specified.

To manage exchange rate risk related to our intercompany financing, we primarily use forward contracts and currency swaps. The change in fair value of these non-qualifying instruments is immediately recognized in earnings, substantially offsetting the foreign currency mark-to-market impact of the related exposure.

Net Investment Hedging

We hedge certain net investment positions in foreign subsidiaries. To accomplish this, we either borrow directly in foreign currencies and designate all or a portion of the foreign currency debt as a hedge of the applicable net investment position or we enter into foreign currency swaps that are designated as hedges of net investments. The time value component of the net investment hedge currency swaps is excluded from the assessment of hedge effectiveness. Changes in the fair value of the swap, including changes in the fair value of the excluded time value component, are recognized in OCI and offset the value of the net investment being hedged. The time value component is subsequently reported in income on a systematic basis.

Commodity Risk Management

Certain raw materials used in our products or production processes are subject to price volatility caused by weather, supply conditions, political and economic variables and other unpredictable factors. As of and during the fiscal years ended June 30, 2023, June 30, 2024 and 2022, 2023, we did not have any financial commodity hedging activity.

Insurance

We self-insure for most insurable risks. However, we purchase insurance for Directors and Officers Liability and certain other coverage where it is required by law or by contract.

Fair Value Hierarchy

Accounting guidance on fair value measurements for certain financial assets and liabilities requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following categories:

- Level 1: Quoted market prices in active markets for identical assets or liabilities.
- Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
- Level 3: Unobservable inputs reflecting the reporting entity's own assumptions or external inputs from inactive markets.

The Company had no significant activity with Level 3 assets and liabilities during the periods presented. Except for the impairment of the Gillette indefinite-lived intangible asset discussed in Note 4, there were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis for the periods presented. When applying fair value principles in the valuation of assets and liabilities, we are required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company has not changed its valuation techniques used in measuring the fair value of any financial assets or liabilities during the year.

When active market quotes are not available for financial assets and liabilities, we use industry standard valuation models. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including credit risk, interest rate curves and forward and spot prices for currencies. In circumstances where market-based observable inputs are not available, management judgment is used to develop assumptions to estimate fair value.

Assets and Liabilities Measured at Fair Value

Cash equivalents were \$6.8 billion, \$8.0 billion and \$6.0 billion, \$6.8 billion as of June 30, 2023, June 30, 2024 and 2022, 2023, respectively, and are classified as Level 1 within the fair value hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.

The fair value of long-term debt was \$26.9 billion, \$27.7 billion and \$25.7 billion, \$26.9 billion as of June 30, 2023, June 30, 2024 and 2022, 2023, respectively. This includes the current portion of long-term debt instruments (\$3.9, \$3.8 billion as of June 30, 2023, June 30, 2024, and \$3.6 billion, \$3.9 billion as of June 30, 2022, June 30, 2023). Certain long-term debt (debt designated as a fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.

Amounts in millions of dollars except per share amounts or as otherwise specified.

Disclosures about Financial Instruments

The notional amounts and fair values of financial instruments used in hedging transactions as of June 30, 2023, June 30, 2024 and 2022, 2023, are as follows:

The fair value of the interest rate derivative asset/~~liability~~ (~~liability~~) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair value adjustment, was **\$3.6 billion** **\$2.7 billion** and **\$4.7 billion** **\$3.6 billion** as of **June 30, 2023** **June 30, 2024** and **2022**, **2023**, respectively. In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments, was **\$11.8 billion** **\$11.9 billion** and **\$11.2 billion** **\$11.8 billion** as of **June 30, 2023** **June 30, 2024** and **2022**, **2023**, respectively. The increase in the notional balance of derivative instruments designated as net investment

hedges is primarily driven by the Company's decision to leverage favorable interest rate spreads in the foreign currency swap market. The decrease in the notional balance of foreign currency contracts not designated as hedging instruments reflects changes in the level of intercompany financing activity during the period.

Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value hierarchy.

Before tax gains/(losses) on our financial instruments in hedging relationships are categorized as follows:

		Amount of Gain/(Loss) Recognized in OCI on Derivatives					
		Amount of Gain/(Loss) Recognized in OCI on Derivatives				Amount of Gain/(Loss) Recognized in OCI on Derivatives	
<u>Fiscal</u> <u>years</u> <u>ended</u> <u>June 30</u>	<u>Fiscal</u> <u>years</u> <u>ended</u> <u>June 30</u>	2023	2022	<u>Fiscal years ended June 30</u>	2024	2023	
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS ⁽¹⁾ ⁽²⁾							
Foreign currency interest rate contracts	Foreign currency interest rate contracts	\$(544)	\$1,033				

- (1) For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was \$238 \$229 and \$73 \$238 for the fiscal years ended June 30, 2023 June 30, 2024 and 2022, 2023, respectively.
- (2) In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) recognized in AOCI for such instruments was \$ (315) \$255 and \$1,639, \$ (315), for the fiscal years ended June 30, 2023 June 30, 2024 and 2022, 2023, respectively.

		Amount of Gain/(Loss) Recognized in Earnings					
		Amount of Gain/(Loss) Recognized in Earnings				Amount of Gain/(Loss) Recognized in Earnings	
<u>Fiscal</u> <u>years</u> <u>ended</u> <u>June 30</u>	<u>Fiscal</u> <u>years</u> <u>ended</u> <u>June 30</u>	2023	2022	<u>Fiscal years ended June 30</u>	2024	2023	
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS							
Interest rate contracts	Interest rate contracts	\$(141)	\$(450)				

DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS

Foreign currency contracts	Foreign currency contracts	\$ (97)	\$ (149)
----------------------------	----------------------------	---------	----------

The loss gains/(losses) on the derivatives in fair value hedging relationships is are fully offset by the mark-to-market impact of the related exposure. These are both recognized in the Consolidated Statement of Earnings in Interest Expense. expense. The loss losses on derivatives not designated as hedging instruments is are substantially offset by the currency mark-to-market of the related exposure. These are both recognized in the Consolidated Statements of Earnings in SG&A, Selling, general and administrative expense (SG&A).

Amounts in millions of dollars except per share amounts or as otherwise specified.

SHORT-TERM AND LONG-TERM DEBT

(1) Weighted average interest rate of debt due within one year includes the effects of interest rate swaps discussed in Note 9.

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
LONG-TERM DEBT	LONG-TERM DEBT					
3.10% USD note due August 2023	3.10% USD note due August 2023					
3.10% USD note due August 2023	3.10% USD note due August 2023					
3.10% USD note due August 2023	3.10% USD note due August 2023	\$ 1,000	\$ 1,000	\$	—	\$ 1,000
1.13% EUR note due November 2023	1.13% EUR note due November 2023					
1.13% EUR note due November 2023	1.13% EUR note due November 2023	1,359	1,306	1.13% EUR note due November 2023	—	1,359
0.50% EUR note due October 2024	0.50% EUR note due October 2024					
0.50% EUR note due October 2024	0.50% EUR note due October 2024	544	523	0.50% EUR note due October 2024	534	544
0.63% EUR note due October 2024	0.63% EUR note due October 2024					
0.63% EUR note due October 2024	0.63% EUR note due October 2024	870	836	0.63% EUR note due October 2024	855	870
0.55% USD note due October 2025	0.55% USD note due October 2025					
0.55% USD note due October 2025	0.55% USD note due October 2025	1,000	1,000	0.55% USD note due October 2025	1,000	1,000

4.10%	4.10%						
USD note due	USD note due						
January 2026	January 2026	650	—	4.10% USD note due January 2026	650		650
2.70%	2.70%						
USD note due	USD note due						
February 2026	February 2026	600	600	2.70% USD note due February 2026	600		600
1.00%	1.00%						
USD note due April 2026	USD note due April 2026	1,000	1,000	1.00% USD note due April 2026	1,000		1,000
3.25%	3.25%						
EUR note due	EUR note due						
August 2026	August 2026	707	—	3.25% EUR note due August 2026	695		707
2.45%	2.45%						
USD note due	USD note due						
November 2026	November 2026	875	875	2.45% USD note due November 2026	875		875
1.90%	1.90%						
USD note due	USD note due						
February 2027	February 2027	1,000	1,000	1.90% USD note due February 2027	1,000		1,000
2.80%	2.80%						
USD note due	USD note due						
March 2027	March 2027	500	500	2.80% USD note due March 2027	500		500
4.88%	4.88%						
EUR note due May 2027	EUR note due May 2027	1,087	1,045	4.88% EUR note due May 2027	1,069		1,087
2.85%	2.85%						
USD note due	USD note due						
August 2027	August 2027	750	750	2.85% USD note due August 2027	750		750
3.95%	3.95%						
USD note due	USD note due						
January 2028	January 2028	600	—	3.95% USD note due January 2028	600		600
3.15%							
EUR note due April 2028							
1.20%	1.20%						
EUR note due	EUR note due						
October 2028	October 2028	870	836				

4.35% USD note due January 2029									
1.25% EUR note due October 2029	1.25% EUR note due October 2029	544	523	1.25% EUR note due October 2029		534		544	
3.00% USD note due March 2030	3.00% USD note due March 2030	1,500	1,500	3.00% USD note due March 2030		1,500		1,500	
0.35% EUR note due May 2030	0.35% EUR note due May 2030	544	523	0.35% EUR note due May 2030		534		544	
1.20% USD note due October 2030	1.20% USD note due October 2030	1,250	1,250	1.20% USD note due October 2030		1,250		1,250	
1.95% USD note due April 2031	1.95% USD note due April 2031	1,000	1,000	1.95% USD note due April 2031		1,000		1,000	
3.25% EUR note due August 2031	3.25% EUR note due August 2031	707	—	3.25% EUR note due August 2031		695		707	
2.30% USD note due February 2032	2.30% USD note due February 2032	850	850	2.30% USD note due February 2032		850		850	
4.05% USD note due January 2033	4.05% USD note due January 2033	850	—	4.05% USD note due January 2033		850		850	
4.55% USD note due January 2034									
3.20% EUR note due April 2034									
5.55% USD note due March 2037	5.55% USD note due March 2037	716	716	5.55% USD note due March 2037		716		716	

1.88%	1.88%								
EUR note due	EUR note due								
October 2038	October 2038	544	523	1.88% EUR note due October 2038			534		544
3.55%	3.55%								
USD note due	USD note due								
March 2040	March 2040	516	516	3.55% USD note due March 2040			516		516
0.90%	0.90%								
EUR note due	EUR note due								
November 2041	November 2041	652	627	0.90% EUR note due November 2041			641		652
All other long-term debt	All other long-term debt	5,244	7,196	All other long-term debt			5,550		5,244
Current portion of long-term debt	Current portion of long-term debt	(3,951)	(3,647)	Current portion of long-term debt			(3,838)		(3,951)
TOTAL	TOTAL	\$24,378	\$22,848	TOTAL			\$ 25,269	\$	24,378
Weighted average interest rate of long-term debt ⁽¹⁾	Weighted average interest rate of long-term debt ⁽¹⁾	2.9%	2.2%	Weighted average interest rate of long-term debt ⁽¹⁾			3.2%		2.9%

⁽¹⁾ Weighted average interest rate of long-term debt includes the effects of interest rate swaps discussed in Note 9.

Amounts in millions of dollars except per share amounts or as otherwise specified.

60 62 The Procter & Gamble Company

Long-term debt maturities during the next five fiscal years are as follows:

<u>Fiscal years ending</u>	<u>Fiscal years ending</u>													
<u>June 30</u>	<u>June 30</u>	2024	2025	2026	2027	2028	<u>Fiscal years ending June 30</u>		2025	2026	2027	2028	2029	
Debt maturities	Debt maturities	\$3,951	\$1,954	\$3,364	\$4,368	\$1,380	Debt maturities		\$3,838	\$3,367	\$4,350	\$2,074	\$1,867	

Credit Facilities

We maintain bank credit facilities to support our ongoing commercial paper program. The current facility is an \$8.0 billion facility split between a \$3.2 billion five-year facility and a \$4.8 billion 364-day facility, which expire in November 2028 and October 2024, respectively. Both facilities can be extended for certain periods of time as specified in the terms of the credit agreement. These facilities are currently undrawn and we anticipate that they will remain undrawn. These credit facilities do not have cross-default or ratings triggers, nor do they have material adverse event clauses, except at the time of signing.

NOTE 11

ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)

The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the reclassifications out of AOCI by component:

Changes in Accumulated Other Comprehensive Income/(Loss) by Component

	Investment Securities	Post-retirement Benefit Plans	Foreign Currency Translation	Total AOCI
BALANCE at JUNE 30, 2021	\$ 15	\$ (2,963)	\$ (10,796)	\$ (13,744)
OCI before reclassifications ⁽¹⁾	4	2,797	(1,451)	1,350
Amounts reclassified to the Consolidated Statement of Earnings ⁽²⁾	1	195	1	197
Net current period OCI	5	2,992	(1,450)	1,547
Less: OCI attributable to non-controlling interests	—	2	(10)	(8)
BALANCE at JUNE 30, 2022	20	27	(12,236)	(12,189)
OCI before reclassifications ⁽³⁾	(7)	21	(71)	(57)
Amounts reclassified to the Consolidated Statement of Earnings ⁽⁴⁾	—	19	—	19
Net current period OCI	(7)	40	(71)	(38)
Less: OCI attributable to non-controlling interests	—	—	(7)	(7)
BALANCE at JUNE 30, 2023	\$ 13	\$ 67	\$ (12,300)	\$ (12,220)

⁽¹⁾ Net of tax (benefit)/expense of \$1, \$953 and \$515 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the period ended June 30, 2022. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions.

⁽²⁾ Net of tax (benefit)/expense of \$0, \$69 and \$0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the period ended June 30, 2022.

⁽³⁾ Net of tax (benefit)/expense of \$(2), \$1 and \$(197) for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the period ended June 30, 2023. Income tax effects within foreign currency translation include impacts from items such as net investment hedge transactions.

⁽⁴⁾ Net of tax (benefit)/expense of \$0, \$8 and \$0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively, for the period ended June 30, 2023.

Changes in Accumulated Other Comprehensive Income/(Loss) by Component

	Investment Securities	Post-retirement Benefit Plans	Foreign Currency Translation	Total AOCI
BALANCE AT JUNE 30, 2022, NET OF TAX	\$ 20	\$ 27	\$ (12,236)	\$ (12,189)
Other comprehensive income/(loss), before tax:				
OCI before reclassifications	(9)	22	(268)	(255)
Amounts reclassified to the Consolidated Statement of Earnings	—	27	—	27
Total other comprehensive income/(loss), before tax	(9)	49	(268)	(228)
Tax effect	2	(9)	197	190
Total other comprehensive income/(loss), net of tax	(7)	40	(71)	(38)
Less: OCI attributable to non-controlling interests, net of tax	—	—	(7)	(7)
BALANCE AT JUNE 30, 2023, NET OF TAX	13	67	(12,300)	(12,220)
Other comprehensive income/(loss), before tax:				
OCI before reclassifications	(4)	823	(376)	443
Amounts reclassified to the Consolidated Statement of Earnings	—	(47)	216	169
Total other comprehensive income/(loss), before tax	(4)	776	(160)	612
Tax effect	1	(230)	(66)	(295)
Total other comprehensive income/(loss), net of tax	(3)	546	(226)	317
Less: OCI attributable to non-controlling interests, net of tax	—	—	(3)	(3)
BALANCE AT JUNE 30, 2024, NET OF TAX	\$ 10	\$ 613	\$ (12,522)	\$ (11,900)

The below provides additional details on amounts reclassified from AOCI into the Consolidated Statement of Earnings:

- Investment securities: amounts reclassified from AOCI into Other non-operating income, net.
- Postretirement benefit plans: plan amounts are reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic postretirement costs (see Note 8).
- Foreign currency translation amounts are reclassified from AOCI into Other non-operating income, net. These amounts relate to accumulated foreign currency translation losses recognized due to the substantial liquidation of operations in certain Enterprise Markets, including Nigeria (see Note 3).

NOTE 12

LEASES

The Company determines whether a contract contains a lease at the inception of a contract by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. We lease certain real estate, machinery, equipment, vehicles and office equipment for varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included within the lease term when it has

become reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate our lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing rate. Our operating lease agreements do not contain any material guarantees or restrictive covenants. The Company does not have any material finance leases or sublease activities. Short-term leases, defined

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 63

as leases with initial terms of 12 months or less, are not reflected on the Consolidated Balance Sheets. Lease expense for such short-term leases is not material. The most significant assets in our leasing portfolio relate to real estate and vehicles. For purposes of calculating lease liabilities for such leases, we have combined lease and non-lease components.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 61

The components of the Company's total operating lease cost for the fiscal years ended June 30, 2023, June 30, 2024, 2022, 2023 and 2021, 2022, were as follows:

Fiscal years ended June 30	Fiscal years ended June 30	2023	2022	2021	Fiscal years ended June 30	2024	2023	2022
Operating lease cost	Operating lease cost	\$229	\$220	\$245				
Variable lease cost (1)	Variable lease cost (1)	79	89	75				
Total lease cost	Total lease cost	\$308	\$309	\$320				

(1) Includes primarily costs for utilities, common area maintenance, property taxes and other operating costs associated with operating leases that are not included in the lease liability and are recognized in the period in which they are incurred.

Supplemental balance sheet and other information related to leases is as follows:

As of June 30	As of June 30	2023	2022	As of June 30	2024	2023
Operating leases:	Operating leases:					
Right-of-use assets (Other noncurrent assets)	Right-of-use assets (Other noncurrent assets)	\$ 781	\$ 760			
Right-of-use assets (Other noncurrent assets)	Right-of-use assets (Other noncurrent assets)					
Right-of-use assets (Other noncurrent assets)	Right-of-use assets (Other noncurrent assets)				\$ 875	\$ 781
Current lease liabilities (Accrued and other liabilities)	Current lease liabilities (Accrued and other liabilities)					
Current lease liabilities (Accrued and other liabilities)	Current lease liabilities (Accrued and other liabilities)					

Current lease liabilities (Accrued and other liabilities)	Current lease liabilities (Accrued and other liabilities)	222	205		243	222
Noncurrent lease liabilities (Other noncurrent liabilities)	Noncurrent lease liabilities (Other noncurrent liabilities)	595	595	Noncurrent lease liabilities (Other noncurrent liabilities)	666	595
Total operating lease liabilities	Total operating lease liabilities	\$ 817	\$ 800	Total operating lease liabilities	\$ 909	\$ 817
Weighted average remaining lease term:						
Weighted average remaining lease term:						
Operating leases	Operating leases	6.2 years	6.4 years	Operating leases	6.0 years	6.2 years
Weighted average discount rate:						
Weighted average discount rate:						
Operating leases	Operating leases	3.5 %	3.2 %	Operating leases	4.5 %	3.5 %

At June 30, 2023 June 30, 2024, future payments of operating lease liabilities were as follows:

		Operating Leases	
		June 30, 2023 2024	
1 year		\$	222 244
2 years			185 206
3 years			137 164
4 years			100 122
5 years			71 105
Over 5 years			196 190
Total lease payments			911 1,031
Less: Interest			(94) (122)
Present value of lease liabilities		\$	817 909

Total cash paid for amounts included in the measurement of lease liabilities was \$233 \$255 and \$228 \$233 for the fiscal years ended June 30, 2023 June 30, 2024 and 2022 2023, respectively.

The right-of-use assets obtained in exchange for lease liabilities were \$213 \$357 and \$217 \$213 for the fiscal years ended June 30, 2023 June 30, 2024 and 2022 2023, respectively.

NOTE 13

COMMITMENTS AND CONTINGENCIES

Guarantees

In conjunction with certain transactions, primarily divestitures, we may provide routine indemnifications (e.g., indemnification for representations and warranties and retention of previously existing environmental, tax and employee liabilities) for which terms range in duration and, in some circumstances, are not explicitly defined. The maximum obligation under some

Amounts in millions of dollars except per share amounts or as otherwise specified.

indemnifications is also not explicitly stated and, as a result, the overall amount of these obligations cannot be reasonably estimated. We have not made significant payments for these indemnifications. We believe that if we were to incur a loss on any of these matters, the loss would not have a material effect on our financial position, results of operations or cash flows.

Amounts in millions of dollars except per share amounts or as otherwise specified.

In certain situations, we guarantee loans for suppliers and customers. The total amount of guarantees issued under such arrangements is not material.

Off-Balance Sheet Arrangements

We do not have off-balance sheet financing arrangements, including variable interest entities, that have a material impact on our financial statements.

Purchase Commitments

We have purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. Commitments made under take-or-pay obligations are as follows:

Fiscal years ending June 30	Fiscal years ending June 30								Fiscal years ending June 30							
		2024	2025	2026	2027	2028	Thereafter		2025	2026	2027	2028	2029	Thereafter		
Purchase obligations	Purchase obligations	\$1,169	\$597	\$379	\$314	\$168	\$ 362									

Such amounts represent minimum commitments under take-or-pay agreements with suppliers and are in line with expected usage. These amounts include purchase commitments related to service contracts for information technology, human resources management and facilities management activities that have been outsourced to third-party suppliers. Due to the proprietary nature of many of our materials and processes, certain supply contracts contain penalty provisions for early termination. We do not expect to incur penalty payments under these provisions that would materially affect our financial position, results of operations or cash flows.

Litigation

We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows.

We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of environmental remediation will materially affect our financial position, results of operations or cash flows.

NOTE 14

SUPPLIER FINANCE PROGRAMS

The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a Supply Chain Finance program ("SCF") with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate participating suppliers' ability to sell receivables from the Company to a SCF bank. These participating suppliers negotiate their sales of receivables arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the Company's creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier's decision to sell a receivable. Once a qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company's obligations to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier's decisions to finance amounts under these arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount due to suppliers participating in SCF and included in Accounts payable was approximately \$5.6 billion as of June 30, 2024 and \$5.7 billion as of June 30, 2023.

NOTE 15

SUBSEQUENT EVENT

On July 1, 2024, the Company completed the divestiture of its business in Argentina. The Company expects to record a non-cash charge of approximately \$750 for accumulated foreign currency translation losses in the first quarter of the fiscal year ended June 30, 2025.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

Not applicable.

Amounts in millions of dollars except per share amounts or as otherwise specified.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

The Company's Company's Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company's Company's Chief Financial Officer, Andre Schulten, performed an evaluation of the Company's Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this Annual Report on Form 10-K. report.

Messrs. Moeller and Schulten have concluded that the Company's Company's disclosure controls and procedures were effective to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission SEC rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding required disclosure.

Reports on Internal Control over Financial Reporting.

The information required by this item is incorporated by reference to "Management's Report on Internal Control over Financial Reporting" and "Report of Independent Registered Public Accounting Firm" included in Item 8 of this Form 10-K.

Changes in Internal Control over Financial Reporting.

There were no changes in our internal control over financial reporting that occurred during the Company's fourth fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Item 9B. Other Information.

Not applicable. During the fiscal year ended June 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.

Insider Trading Arrangements and Policies

The Company has insider trading policies and procedures that govern the purchase, sale and other dispositions of its securities by directors, officers and employees, as well as by the Company itself. We believe these policies and procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations and applicable listing standards.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

Amounts in millions of dollars except per share amounts or as otherwise specified.

The Procter & Gamble Company 63

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The Board of Directors has determined that the following members of the Audit Committee are independent and are Audit Committee financial experts as defined by SEC rules: Mr. Brett Biggs, Ms. Patricia A. Woertz Christine McCarthy (Chair) and Ms. Christine M. McCarthy. Patricia Woertz.

The information required by this item is incorporated by reference to the following sections of the 2023 2024 Proxy Statement filed pursuant to Regulation 14A, which will be filed no later than 120 days after June 30, 2023 June 30, 2024: the section entitled Election of Directors; the subsection of the Corporate Governance section entitled Board Meetings and Committees of the Board; the subsection of the Corporate Governance section entitled Code of Ethics; and the subsection of the Other Matters section entitled Shareholder Recommendations or Nominations of Director Candidates. Pursuant to the Instruction to Item 401 of Regulation S-K, Executive Officers of the Registrant are reported in Part I of this report.

Item 11. Executive Compensation.

The information required by this item is incorporated by reference to the following sections of the 2023 2024 Proxy Statement filed pursuant to Regulation 14A, which will be filed no later than 120 days after June 30, 2023 June 30, 2024: the subsections of the Corporate Governance section entitled Board Meetings and Committees of the Board, Compensation Committee Interlocks and Insider Participation, and Risk Oversight - Compensation-Related Risk; and the portion beginning with the section entitled Director Compensation up to but not including the section entitled Pay Versus Performance.

66 The Procter & Gamble Company

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table gives information about the Company's common stock that may be issued upon the exercise of options, warrants and rights under all of the Company's equity compensation plans as of June 30, 2023 June 30, 2024. The table includes the following plans: The Procter & Gamble 1992 Stock Plan; The Procter & Gamble 2001 Stock and Incentive Compensation Plan; The Procter & Gamble 2003 Non-Employee Directors' Stock Plan; The Procter & Gamble 2009 Stock and Incentive Compensation Plan; The Procter & Gamble 2014 Stock and Incentive Compensation Plan; and The Procter & Gamble 2019 Stock and Incentive Compensation Plan.

Plan Category	Plan Category	(a)	(b) Weighted average exercise price of outstanding options, warrants and rights	(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))	Plan Category	(a)	(b) Weighted average exercise price of outstanding options, warrants and rights	(c) Number of remaining a future issu equity compe (excluding reflected in
		Number of securities to be issued upon exercise of outstanding options, warrants and rights				Number of securities to be issued upon exercise of outstanding options, warrants and rights		
Equity compensation plans approved by security holders	Equity compensation plans approved by security holders							
Stock Options/Stock Appreciation Rights	Stock Options/Stock Appreciation Rights	121,226,313	\$104.1900	(1)				
Stock Options/Stock Appreciation Rights	Stock Options/Stock Appreciation Rights							
Stock Options/Stock Appreciation Rights	Stock Options/Stock Appreciation Rights					107,379,563	\$111.5700	(1)
Restricted Stock Units (RSUs)/Performance Stock Units (PSUs)	Restricted Stock Units (RSUs)/Performance Stock Units (PSUs)	6,430,184	N/A	(1)	Restricted Stock Units (RSUs)/Performance Stock Units (PSUs)	6,696,628	N/A	N/A
TOTAL	TOTAL	127,656,497	\$104.1900	(2)				

(1) Of the plans listed above, only The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "2019 Plan") allows for future grants of securities. The maximum number of shares that may be granted under this plan is 187 million shares. Stock options and stock appreciation rights are counted on a one-for-one basis while full value awards (such as RSUs and PSUs) are counted as five shares for each share awarded. Total shares available for future issuance under this plan is 96 million 77 million.

(2) Weighted average exercise price of outstanding options only.

Additional information required by this item is incorporated by reference to the following section of the 2023 2024 Proxy Statement filed pursuant to Regulation 14A, which will be filed no later than 120 days after June 30, 2023 June 30, 2024: the subsection of the Beneficial Ownership section entitled Security Ownership of Management and Certain Beneficial Owners.

Item 13. Certain Relationships and Related Transactions and Director Independence.

The information required by this item is incorporated by reference to the following sections of the 2023 2024 Proxy Statement filed pursuant to Regulation 14A, which will be filed no later than 120 days after June 30, 2023 June 30, 2024: the subsections of the Corporate Governance section entitled Director Independence and Review and Approval of Transactions with Related Persons.

Item 14. Principal Accountant Fees and Services.

The information required by this item is incorporated by reference to the following section of the 2023 2024 Proxy Statement filed pursuant to Regulation 14A, which will be filed no later than 120 days after June 30, 2023 June 30, 2024: Report of the Audit Committee, which ends with the subsection entitled Services Provided by Deloitte.

PART IV

Item 15. Exhibits and Financial Statement Schedules.

1. Financial Statements:

The following Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries, management's report and the reports of the independent registered public accounting firm are incorporated by reference in Part II, Item 8 of this Form 10-K.

- Management's Report on Internal Control over Financial Reporting
- Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting (PCAOB Firm ID is 34)
- Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements
- Consolidated Statements of Earnings - for fiscal years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021 2022
- Consolidated Statements of Comprehensive Income - for fiscal years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021 2022
- Consolidated Balance Sheets - as of June 30, 2023 June 30, 2024 and 2022 2023
- Consolidated Statements of Shareholders' Equity - for fiscal years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021 2022
- Consolidated Statements of Cash Flows - for fiscal years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021 2022
- Notes to Consolidated Financial Statements

2. Financial Statement Schedules:

These schedules are omitted because of the absence of the conditions under which they are required or because the information is set forth in the Consolidated Financial Statements or Notes thereto.

EXHIBITS

- Exhibit (3-1) - [Amended Articles of Incorporation \(as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of Directors on April 8, 2016\) \(Incorporated by reference to Exhibit \(3-1\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016\).](#)
- (3-2) - [Regulations \(as approved by the Board of Directors on December 13, 2022\) pursuant to authority granted by shareholders at the annual meeting on October 13, 2009\) \(Incorporated by reference to Exhibit \(3-2\) of the Company's Current Report on Form 8-K filed December 13, 2022\).](#)
- Exhibit (4-1) - [Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee \(Incorporated by reference to Exhibit \(4-1\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015\).](#)
- (4-2) - The Company agrees to furnish to the Securities and Exchange Commission, upon request, a copy of any other instrument defining the rights of holders of the Company's long-term debt.
- (4-3) - [Description of the Company's Common Stock \(Incorporated by reference to Exhibit \(4-3\) of the Company's Annual report on Form 10-K for the year ended June 30, 2019\).](#)
- (4-4) - [Description of the Company's 0.625% Notes due 2024, 1.200% Notes due 2028, and 1.875% Notes due 2038 \(Incorporated by reference to Exhibit \(4-4\) of the Company's Annual report on Form 10-K for the year ended June 30, 2019\).](#)
- (4-5) - [Description of the Company's 4.875% EUR notes due May 2027, 6.250% GBP notes due January 2030, and 5.250% GBP notes due January 2033 \(Incorporated by reference to Exhibit \(4-5\) of the Company's Annual report on Form 10-K for the year ended June 30, 2021\).](#)
- (4-6) - [Description of the Company's 0.500% Notes due 2024 and 1.250% Notes due 2029 \(Incorporated by reference to Exhibit \(4-6\) of the Company's Annual report on Form 10-K for the year ended June 30, 2019\).](#)
- (4-7) - [Description of the Company's 1.375% Notes due 2025 and 1.800% Notes due 2029 \(Incorporated by reference to Exhibit \(4-7\) of the Company's Annual report on Form 10-K for the year ended June 30, 2019\).](#)
- (4-8) - [Description of the Company's 1.125% Notes due 2023 \(Incorporated by reference to Exhibit \(4-8\) of the Company's Annual report on Form 10-K for the year ended June 30, 2019\).](#)
- (4-9) - [Description of the Company's 0.350% EUR Notes due 2030 and 0.900% EUR Notes due 2041 \(Incorporated by reference to Exhibit \(4-10\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2022\).](#)
- (4-10) - [Description of the Company's 0.110% Yen Notes due 2026 and 0.230% Yen Notes due 2031 \(Incorporated by reference to Exhibit \(4-11\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2022\).](#)
- (4-11) - [Description of the Company's 3.250% Notes due 2026 and 3.250% Notes due 2031 \(Incorporated by reference to Exhibit \(4-11\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2023\).](#)
- (4-12) - [Description of the Company's 3.150% Notes due 2028 and 3.200% Notes due 2034.](#)

- Exhibit (10-1) - [The Procter & Gamble 2001 Stock and Incentive Compensation Plan \(as amended\), which was originally adopted by shareholders at the annual meeting on October 9, 2001 \(Incorporated by reference to Exhibit \(10-1\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2018\).](#)*
- (10-2) - [The Procter & Gamble 2001 Stock and Incentive Compensation Plan related correspondence and terms and conditions \(Incorporated by reference to Exhibit \(10-1\) of the Company's Form 10-Q for the quarter ended December 31, 2013\).](#)*
- (10-3) - [The Procter & Gamble 1992 Stock Plan \(as amended December 11, 2001\), which was originally adopted by the shareholders at the annual meeting on October 12, 1992 \(Incorporated by reference to Exhibit \(10-2\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2018\).](#)*
- (10-4) - [The Procter & Gamble Executive Group Life Insurance Policy \(Incorporated by reference to Exhibit \(10-3\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2018\).](#)*
- (10-5) - [Summary of the Company's Retirement Plan Restoration Program \(Incorporated by reference to Exhibit \(10-5\) of the Company's Form 10-Q for the quarter ended December 31, 2019\).](#)* +
- (10-6) - [Retirement Plan Restoration Program - Related Correspondence and Terms and Conditions.](#)* +
- (10-7) - [Summary of the Company's Long-Term Incentive Program \(Incorporated by reference to Exhibit \(10-3\) of the Company's Form 10-Q for the quarter ended September 30, 2020\).](#)*
- (10-8) - [Long-Term Incentive Program related correspondence and terms and conditions \(Incorporated by reference to Exhibit \(10-3\) \(10-5\) of the Company's Form 10-Q for the quarter ended September 30, 2021 September 30, 2023\).](#)*
- (10-9) - [The Procter & Gamble Company Executive Deferred Compensation Plan \(Incorporated by reference to Exhibit \(10-2\) of the Company's Form 10-Q for the quarter ended March 31, 2020\).](#)*
- (10-10) - [Summary of the Company's Short Term Achievement Reward Program \(Incorporated by reference to Exhibit \(10-1\) of the Company's Form 10-Q for the quarter ended December 31, 2022 September 30, 2023\).](#)*

- (10-11) - [Short Term Achievement Reward Program – related correspondence and terms and conditions \(Incorporated by reference to Exhibit \(10-2\) of the Company's Form 10-Q for the quarter ended September 30, 2021 September 30, 2023\).](#)*⁺
- (10-12) - [Company's Form of Separation Agreement & Release \(Incorporated by reference to Exhibit \(10-12\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2022\).](#)*⁺
- (10-13) - [Company's Form of Separation Letter and Release \(Incorporated by reference to Exhibit \(10-1\) of the Company's Form 10-Q for the quarter ended March 31, 2023\) March 31, 2023\).](#)*
- (10-14) - [Summary of personal benefits available to certain officers and non-employee directors \(Incorporated by reference to Exhibit \(10-5\) \(10-1\) of the Company's Form 10-Q for the quarter ended September 30, 2021 March 31, 2024\).](#)*
- (10-15) - [The Gillette Company Deferred Compensation Plan \(Incorporated by reference to Exhibit \(10-18\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017\).](#)*
- (10-16) - [Senior Executive Officer Recoupment Policy \(Incorporated by reference to Exhibit \(10-19\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2018\).](#)*⁺
- (10-17) - [The Gillette Company Deferred Compensation Plan \(for salary deferrals prior to January 1, 2005\) as amended through August 21, 2006 \(Incorporated by reference to Exhibit \(10-20\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017\).](#)*
- (10-18) - [The Procter & Gamble 2009 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October 13, 2009 \(Incorporated by reference to Exhibit \(10-21\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017\).](#)*
- (10-19) - [Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2009 Stock and Incentive Compensation Plan, The Procter & Gamble 2001 Stock and Incentive Compensation Plan, The Procter & Gamble 1992 Stock Plan, The Procter & Gamble 1992 Stock Plan \(Belgium Version\), The Gillette Company 2004 Long-Term Incentive Plan and the Gillette Company 1971 Stock Option Plan \(Incorporated by reference to Exhibit \(10-21\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2018\).](#)*
- (10-20) - [The Procter & Gamble 2009 Stock and Incentive Compensation Plan - Additional terms and conditions and related correspondence \(Incorporated by reference to Exhibit \(10-2\) of the Company Form 10-Q for the quarter ended December 31, 2013\).](#)*
- (10-21) - [The Procter & Gamble Performance Stock Program Summary \(Incorporated by reference to Exhibit \(10-5\) \(10-3\) of the Company's Form 10-Q for the quarter ended September 30, 2020 September 30, 2023\).](#)*
- (10-22) - [Performance Stock Program related correspondence and terms and conditions \(Incorporated by reference to Exhibit \(10-4\) of the Company's Form 10-Q for the quarter ended September 30, 2021 September 30, 2023\).](#)*
- (10-23) - [The Procter & Gamble 2013 Non-Employee Directors' Stock Plan \(Incorporated by reference to Exhibit \(10-3\) of the Company's Form 10-Q for the quarter ended December 31, 2013\).](#)*

- (10-24) - [The Procter & Gamble 2014 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October 14, 2014 \(Incorporated by reference to Exhibit \(10-25\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2016\).](#) *
- (10-25) - [Regulations of the Compensation and Leadership Development Committee for The Procter & Gamble 2019 Stock and Incentive Compensation Plan and The Procter & Gamble 2014 Stock and Incentive Compensation Plan \(Incorporated by reference to Exhibit \(10-1\) of the Company's Form 10-Q for the quarter ended December 31, 2019\).](#) * +
- (10-26) - [The Procter & Gamble 2014 Stock and Incentive Compensation Plan - Additional terms and conditions \(Incorporated by reference to Exhibit \(10-26\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2017\).](#) *
- (10-27) - [The Procter & Gamble 2019 Stock and Incentive Compensation Plan, which was originally adopted by shareholders at the annual meeting on October 8, 2019 \(Incorporated by reference to Exhibit \(10-1\) of the Company's Current Report on Form 8-K filed October 11, 2019\).](#) *
- (10-28) - [The Procter & Gamble 2019 Stock and Incentive Compensation Plan - Additional terms and conditions \(Incorporated by reference to Exhibit \(10-28\) of the Company's Annual Report on Form 10-K for the year ended June 30, 2021\).](#) * +
- Exhibit (19-1) - [P&G Global Insider Trading Policy.](#) +
- (19-2) - [P&G Share Repurchase Policy.](#) +
- Exhibit (21) - [Subsidiaries of the Registrant.](#) +
- Exhibit (23) - [Consent of Independent Registered Public Accounting Firm.](#) +
- Exhibit (31) - [Rule 13a-14\(a\)/15d-14\(a\) Certifications.](#) +
- Exhibit (32) - [Section 1350 Certifications.](#) +
- Exhibit (97) - [P&G Dodd-Frank Recoupment Policy.](#) +
- Exhibit (99-1) - [Summary of Directors and Officers Insurance Program.](#) +
- 101.INS (1) Inline XBRL Instance Document

The Procter & Gamble Company 69

- 101.SCH (1) Inline XBRL Taxonomy Extension Schema Document
- 101.CAL (1) Inline XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF (1) Inline XBRL Taxonomy Definition Linkbase Document
- 101.LAB (1) Inline XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE (1) Inline XBRL Taxonomy Extension Presentation Linkbase Document
- 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
- (1) Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.
- * Compensatory plan or arrangement.
- + Filed herewith.

Item 16. Form 10-K Summary.

Not applicable.

70 The Procter & Gamble Company 67

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the city of Cincinnati, State of Ohio.

THE PROCTER & GAMBLE COMPANY

By /s/ JON R. MOELLER

(Jon R. Moeller)

Chairman of the Board, President and Chief Executive Officer

August 04, 2023 05, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ JON R. MOELLER</u> (Jon R. Moeller)	Chairman of the Board, President and Chief Executive Officer (Principal Executive Officer)	August 04, 2023 05, 2024
<u>/s/ ANDRE SCHULTEN</u> (Andre Schulten)	Chief Financial Officer (Principal Financial Officer)	August 04, 2023 05, 2024
<u>/s/ MATTHEW W. JANZARUK</u> (Matthew W. Janzaruk)	Senior Vice President - Chief Accounting Officer (Principal Accounting Officer)	August 04, 2023 05, 2024
<u>/s/ B. MARC ALLEN</u> (B. Marc Allen)	Director	August 04, 2023 05, 2024
<u>/s/ BRETT BIGGS</u> (Brett Biggs)	Director	August 05, 2024
<u>/s/ SHEILA BONINI</u> (Sheila Bonini)	Director	August 04, 2023 05, 2024
<u>/s/ ANGELA F. BRALY</u> (Angela F. Braly)	Director	August 04, 2023
<u>/s/ AMY L. CHANG</u> (Amy L. Chang)	Director	August 04, 2023 05, 2024
<u>/s/ JOSEPH JIMENEZ</u> (Joseph Jimenez)	Director	August 04, 2023 05, 2024
<u>/s/ CHRISTOPHER J. KEMPCZINSKI</u> (Christopher J. Kempczinski)	Director	August 04, 2023 05, 2024
<u>/s/ DEBRA L. LEE</u> (Debra L. Lee)	Director	August 04, 2023 05, 2024
<u>/s/ TERRY J. LUNDGREN</u> (Terry J. Lundgren)	Director	August 04, 2023 05, 2024
<u>/s/ CHRISTINE M. MCCARTHY</u> (Christine M. McCarthy)	Director	August 04, 2023 05, 2024
<u>/s/ ASHLEY MCEVOY</u> (Ashley McEvoy)	Director	August 05, 2024
<u>/s/ ROBERT J. PORTMAN</u> (Robert J. Portman)	Director	August 04, 2023 05, 2024
<u>/s/ RAJESH SUBRAMANIAM</u> (Rajesh Subramaniam)	Director	August 04, 2023 05, 2024
<u>/s/ PATRICIA A. WOERTZ</u> (Patricia A. Woertz)	Director	August 04, 2023 05, 2024

Exhibit (4-11) (4-12)

Description of the Company's 3.250% 3.150% EUR Notes due 2026 2028 and 3.250% 3.200% EUR Notes due 2031 2034

Description of the Company's 3.250% 3.150% EUR Notes due 2026 2028 and 3.250% 3.200% EUR Notes due 2031, 2034, Registered Under Section 12 of the Securities Exchange Act of 1934

The following summary of The Procter & Gamble Company's above referenced debt securities is based on and qualified by the Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (the "Indenture") and the 3.250% 3.150% EUR notes due 2026 2028 and 3.250% 3.200% EUR notes due 2031 2034 (collectively, the "notes"). For a complete description of the terms and provisions of the Company's notes, refer to the Indenture and to the forms of notes, which are filed as exhibits to the Form 8-A filed with the Securities and Exchange Commission on May 2, 2023 April 29, 2024.

General

The 2026 2028 notes:

- were issued in an aggregate initial principal amount of €650,000,000, subject to our ability to issue additional 2026 2028 notes which may be of the same series as the 2026 2028 notes as described below under "Further Issues,"
- will mature on August 2, 2026 April 29, 2028,
- bear interest at a rate of 3.250% 3.150% per annum, payable annually in arrears,
- are unsecured,
- are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
- were issued as a separate series under the Indenture, in registered, book-entry form only,
- were issued in euros in denominations of €100,000 and integral multiples of €1,000 in excess thereof,
- will be repaid at par at maturity,
- are redeemable by us at any time prior to maturity as described below under "Optional Redemption" and in connection with certain events involving United States taxation,
- are subject to defeasance and covenant defeasance, and
- are not subject to any sinking fund.

The 2031 2034 notes:

- were issued in an aggregate initial principal amount of €650,000,000 €850,000,000 subject to our ability to issue additional 2031 2034 notes which may be of the same series as the 2031 2034 notes as described below under "Further Issues,"
- will mature on August 2, 2031 April 29, 2034,
- bear interest at a rate of 3.250% 3.200% per annum, payable annually in arrears,
- are unsecured,
- are senior debt, ranking equally with all of our other present and future unsecured and unsubordinated indebtedness,
- were issued as a separate series under the Indenture, in registered, book-entry form only,
- were issued in euros in denominations of €100,000 and integral multiples of €1,000 in excess thereof,

- will be repaid at par at maturity,
- are redeemable by us at any time prior to maturity as described below under "Optional Redemption" and in connection with certain events involving United States taxation,

- are subject to defeasance and covenant defeasance, and
- are not subject to any sinking fund.

The Indenture and the notes do not limit the amount of indebtedness which may be incurred or the amount of securities which may be issued by us or our subsidiaries, and contain no financial or similar restrictions on us or our subsidiaries, except as described **below** under the captions "Restrictions on Secured Debt" and "Restrictions on Sales and Leasebacks."

The notes are listed on the New York Stock Exchange.

Interest

We pay interest on the **2026 2028** notes and the **2031 2034** notes annually on **August 2 April 29** of each year, and on any maturity date (each, an "interest payment date"), commencing **August 2, 2023 April 29, 2025** and ending on any maturity date, to the persons in whose names the **2026 2028** notes and the **2031 2034** notes are registered at the close of business on the Business Day immediately before the next interest payment date; *provided, however*, that interest payable on any maturity date shall be payable to the person to whom the principal of such notes shall be payable.

Interest payable on any interest payment date or maturity date shall be the amount of interest accrued from, and including, the immediately preceding interest payment date in respect of which interest has been paid or duly provided for (or from and including the original issue date, if no interest has been paid or duly provided for with respect to the notes) to, but excluding, such interest payment date or maturity date, as the case may be. If any interest payment date is not a Business Day at the relevant place of payment, we will pay interest on the next day that is a Business Day at such place of payment as if payment were made on the date such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the immediately succeeding Business Day. If the maturity date or redemption date of the notes is not a Business Day at the relevant place of payment, we will pay interest, if any, and principal and premium, if any, on the next day that is a Business Day at such place of payment as if payment were made on the date such payment was due, and no interest will accrue on the amounts so payable for the period from and after such date to the immediately succeeding Business Day.

Where interest is to be calculated in respect of a period which is equal to or shorter than the relevant period for which interest is to be calculated (an "Interest Period"), it will be calculated on the basis of the actual number of days in the relevant period, from and including the date from which interest begins to accrue, to, but excluding, the date on which it falls due, divided by the number of days in the Interest Period in which the relevant period falls (including the first such day but excluding the last).

"Business Day" means any day that is not a Saturday or Sunday and that is not a day on which banking institutions are authorized or obligated by law or executive order to close in the City of New York or London and, for any place of payment outside of the City of New York or London,

in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.

The term “maturity,” when used with respect to a note, means the date on which the principal of such note or an installment of principal becomes due and payable as therein provided or as provided in the Indenture, whether at the stated maturity or by declaration of acceleration, call for redemption, repayment or otherwise.

Optional Redemption

We have the option to redeem the notes of either series, in whole or in part, at our option at any time, at a redemption price equal to the greater of (1) 100% of the principal amount of the notes to be redeemed, plus accrued interest on the notes to be redeemed to, but excluding, the date on which the notes are to be redeemed, or (2) the sum of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed, not including any portion of these payments of interest accrued as of the date of which the notes are to be redeemed, discounted to the date on which the notes are to be redeemed on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 10 basis points with respect to the 2026 2028 notes and at the applicable Comparable Government Bond Rate, plus 15 basis points with respect to the 2031 2034 notes, plus accrued interest on the notes to be redeemed to, but excluding, the date on which the notes are to be redeemed.

“Comparable Government Bond Rate” means the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price on the third Business Day prior to the date fixed for redemption, would be equal to the gross redemption yield on such Business Day of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such Business Day as determined by an independent investment bank selected by us.

“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German government bond whose maturity is closest to the maturity of the notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.

In the case of a partial redemption of any series of notes, the notes to be redeemed will be selected on a pro rata basis or by the trustee by a method the trustee deems to be fair and appropriate or, in case the notes are represented by one or more global notes, beneficial interests therein will be selected for redemption by Clearstream, Luxembourg and Euroclear in accordance with their respective applicable procedures therefor; provided that the unredeemed portion of the note shall be €100,000 in principal amount and €1,000 multiples above that amount. A new note in a principal amount equal to the unredeemed portion of the note will be issued in the name of the holder of the note upon surrender of the original note.

Notice of any redemption will be sent at least 10 days but not more than 60 days before the redemption date to each holder of notes of the applicable series to be redeemed.

The notes of each series are also subject to redemption if certain events occur involving United States taxation. See "Tax Redemption" below.

Additional Amounts

All payments of principal and interest in respect of the notes will be made free and clear of, and without deduction or withholding for or on account of any present or future taxes, duties, assessments or other governmental charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United States or any political subdivision or taxing authority of or in the United States (collectively, "Taxes"), unless such withholding or deduction is required by law.

In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the holder or beneficial owner of any note that is not a United States holder such additional amounts ("Additional Amounts") as may be necessary in order that every net payment by us or any paying agent of principal of or interest on the notes (including upon redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such note to be then due and payable before deduction or withholding for or on account of such Taxes.

However, our obligation to pay Additional Amounts shall not apply to:

(a) any Taxes which would not have been so imposed but for:

(1) the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident of the United States or being or having been engaged in a trade or business in the United States or being or having been present in the United States or having had a permanent establishment in the United States;

(2) the failure of such holder or beneficial owner to comply with any requirement under United States tax laws and regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide Internal Revenue Service Form W-8BEN, Form W-8BEN-E, Form W-8ECI, or any subsequent versions thereof or successor thereto); or

(3) such holder's or beneficial owner's present or former status as a personal holding company or a foreign personal holding company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign investment company

with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a corporation which accumulates earnings to avoid U.S. federal income tax;

(b) any Taxes imposed by reason of the holder or beneficial owner:

(1) owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of our stock,

(2) being a bank receiving interest described in section 881(c)(3)(A) of the Internal Revenue Code of 1986, as amended (the "Code"), or

(3) being a controlled foreign corporation with respect to the United States that is related to us by stock ownership;

(c) any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for payment on a date more than 10 days after the date on which such payment became due and payable or the date on which payment of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or beneficial owner would have been entitled to such additional amounts on presenting such note on any date during such 10-day period;

(d) any estate, inheritance, gift, sales, transfer, personal property, wealth, interest equalization or similar Taxes;

(e) any Taxes which are payable otherwise than by withholding from payment of principal of or interest on such note;

(f) any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary, partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its beneficial or distributive share of the payment;

(g) any Taxes required to be withheld by any paying agent from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent;

(h) any Taxes imposed under Sections 1471 through 1474 of the Code (or any amended or successor provisions that are substantively comparable) and any current or future regulations or official interpretations thereof; or

(i) any combination of items (a), (b), (c), (d), (e), (f), (g) and (h).

For purposes of this section, the acquisition, ownership, enforcement or holding of or the receipt of any payment with respect to a note will not constitute a connection (1) between the holder or beneficial owner and the United States or (2) between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial

owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity and the United States.

Any reference in this exhibit, in the **indenture** or in the notes to principal or interest shall be deemed to refer also to Additional Amounts which may be payable under the provisions of this section.

We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or taxing authority therein with respect to the issuance of the notes.

Except as specifically provided in the notes, we will not be required to make any payment with respect to any tax, duty, assessment or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.

Tax Redemption

The notes of either series may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, together with interest accrued and unpaid to the date fixed for redemption, at any time, on giving not less than 10 nor more than 60 days' notice in accordance with "Notices" below if:

(a) we have or will become obligated to pay Additional Amounts as a result of any change in or amendment to the laws, regulations or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or any change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after **April 24, 2023** **April 24, 2024** or

(b) any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a) above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after **April 24, 2023** **April 24, 2024**, which results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.

However, no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be, in the case of a redemption for the reasons specified in (a) above, or there would be a substantial likelihood that we would be, in the case of a redemption for the reasons specified in (b) above, obligated to pay such Additional Amounts if a payment in respect of the notes were then due and at the time such notification of redemption is given such circumstances remain in effect.

Such notice, once delivered by us to the trustee, will be irrevocable.

Prescription

Under New York's statute of limitations, any legal action to enforce our payment obligations evidenced by the notes or the coupons must be commenced within six years after the payment thereof is due; thereafter our payment obligations will generally become unenforceable.

Further Issues

We may from time to time, without notice to or the consent of the registered holders of notes of any series, create and issue further notes ranking equally with the notes of any series in all respects. Such further notes may be consolidated and form a single series with the notes of any such series and have the same terms as to status, redemption or otherwise as the other notes of such series (other than the issue date of such further notes and first payment of interest following the issue date of such further notes).

Restricted Restrictive Covenants

Restrictions on Secured Debt

If we or any Domestic Subsidiary shall incur, issue, assume or guarantee any Debt secured by a Mortgage on any Principal Domestic Manufacturing Property of ours or any Domestic Subsidiary's or on any shares of stock of any Domestic Subsidiary that owns a Principal Domestic Manufacturing Property, we will secure, or cause such Domestic Subsidiary to secure, the debt securities then outstanding equally and ratably with (or prior to) such Debt. However, we will not be restricted by this covenant if, after giving effect to the particular Debt so secured the total amount of all Debt so secured, together with all Attributable Debt in respect of sale and leaseback transactions involving Principal Domestic Manufacturing Properties, would not exceed 15% of our and our consolidated subsidiaries' Consolidated Net Tangible Assets.

In addition, the restriction will not apply to, and there shall be excluded in computing secured Debt for the purpose of the restriction, Debt secured by

- (1) with respect to any series of debt securities, Mortgages existing on the date of the original issuance of the debt securities of such series;
- (2) Mortgages on property of, or on any shares of stock of, any corporation existing at the time the corporation becomes a Domestic Subsidiary or at the time it is merged into or consolidated with us or a Domestic Subsidiary;
- (3) Mortgages in favor of us or a Domestic Subsidiary;
- (4) Mortgages in favor of U.S., State or foreign governmental bodies to secure progress or advance payments;
- (5) Mortgages on property or shares of stock existing at the time of their acquisition, including acquisition through merger or consolidation, purchase money Mortgages and construction or improvement cost Mortgages; and
- (6) any extension, renewal or refunding of any Mortgage referred to in the immediately preceding clauses (1) through (5), inclusive.

The indenture indenture does not restrict the incurrence of unsecured debt by us or our subsidiaries subsidiaries.

Restrictions on Sales and Leasebacks

Neither we nor any Domestic Subsidiary may enter into any sale and leaseback transaction involving any Principal Domestic Manufacturing Property, the completion of construction and commencement of full operation of which has occurred more than 180 days prior to the transaction, unless

- we or the Domestic Subsidiary could incur a lien on the property under the restrictions described above under "Restrictions on Secured Debt" in an amount equal to the Attributable Debt with respect to the sale and leaseback transaction without equally and ratably securing the debt securities then outstanding, or

- we, within 180 days, apply to either (or a combination of) the investment in one or more other Principal Domestic Manufacturing Properties or the retirement of our Funded Debt an amount not less than the greater of (1) the net proceeds of the sale of the Principal Domestic Manufacturing Property leased pursuant to such arrangement or (2) the fair market value of the Principal Domestic Manufacturing Property so leased, subject to credits for various voluntary retirements of Funded Debt.

This restriction will not apply to any sale and leaseback transaction

- between us and a Domestic Subsidiary,
- between Domestic Subsidiaries, or
- involving the taking back of a lease for a period of less than three years.

Definitions Applicable to Covenants

The term “Attributable Debt” means the lesser of (1) the fair market value of the Principal Domestic Manufacturing Property sold and leased back at the time of entering into a sale and leaseback transaction and (2) the total net amount of rent, discounted at 10% per annum compounded annually, required to be paid during the remaining term of any lease.

The term “Consolidated Net Tangible Assets” means our total assets, less net goodwill and other intangible assets, less total current liabilities, all as described on our and our consolidated subsidiaries’ most recent balance sheet and calculated based on positions as reported in our consolidated financial statements in accordance with generally accepted accounting principles.

The term “Debt” means notes, bonds, debentures or other similar evidences of indebtedness for money borrowed.

The term “Domestic Subsidiary” means any of our subsidiaries except a subsidiary which neither transacts any substantial portion of its business nor regularly maintains any substantial portion of its fixed assets within the United States or which is engaged primarily in financing our and our subsidiaries’ operations outside the United States.

The term “Funded Debt” means Debt having a maturity of more than 12 months from its date of creation.

The term “Mortgage” means pledges, mortgages and other liens.

The term “Principal Domestic Manufacturing Property” means any facility (together with the land on which it is erected and fixtures comprising a part of the land) used primarily for manufacturing or processing, located in the United States, owned or leased by us or one of our subsidiaries and having a gross book value in excess of 1.0% of Consolidated Net Tangible Assets. However, the term “Principal Domestic Manufacturing Property” does not include any

facility or portion of a facility (1) which is financed by obligations the interest on which is exempt from U.S. federal income tax pursuant to Section 103 of the Code (or any predecessor or successor provision thereof), or (2) which, in the opinion of our board of directors, is not of material importance to the total business conducted by us and our subsidiaries as an entirety.

Events of Default

Any one of the following are events of default under the Indenture with respect to debt securities of either series:

- (1) our failure to pay principal of or premium, if any, on any debt security of that series when due;
- (2) our failure to pay any interest on any debt security of that series when due, continued for 30 days;
- (3) our failure to deposit any sinking fund payment, when due, in respect of any debt security of that series;
- (4) our failure to perform any other of our covenants in the Indenture which affects or is applicable to the debt securities of that series, other than a covenant included in the Indenture solely for the benefit of other series of debt securities, continued for 90 days after written notice as provided in the **indenture; Indenture;**
- (5) certain events involving bankruptcy, insolvency or reorganization; and
- (6) any other event of default provided with respect to debt securities of that series.

If an event of default with respect to outstanding debt securities of any series shall occur and be continuing, either the trustee or the holders of at least 25% in principal amount of the outstanding debt securities of that series may declare the principal amount (or, if the debt securities of that series are original issue discount securities, the portion of the principal amount as may be specified in the terms of that series) of all the debt securities of that series to be due and payable immediately. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree based on acceleration has been obtained, the holders of a majority in principal amount of the outstanding debt securities of that series may, under some circumstances, rescind and annul the acceleration. For information as to waiver of defaults, see the section below entitled "Modification and Waiver."

During default, the trustee has a duty to act with the required standard of care. Otherwise, the Indenture provides that the trustee will be under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders, unless the holders shall have offered to the trustee reasonable indemnity. If the provisions for indemnification of the trustee have been satisfied, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series.

We will furnish to the trustee annually a certificate as to our compliance with all conditions and covenants under the Indenture.

Defeasance

Defeasance and Discharge

We will be discharged from any and all obligations in respect of the debt securities of any series if we deposit with the trustee, in trust, money and/or U.S. government securities which through the payment of interest and principal will provide money in an amount sufficient to pay the principal of and premium, if any, and each installment of interest on the debt securities of the series on the dates those payments are due and payable.

If we defease a series of debt securities, the holders of the debt securities of the series will not be entitled to the benefits of the Indenture, except for

- the rights of holders to receive from the trust funds payment of principal, premium and interest on the debt securities,
- our obligation to register the transfer or exchange of debt securities of the series,
- our obligation to replace stolen, lost or mutilated debt securities of the series,
- our obligation to maintain paying agencies,
- our obligation to hold monies for payment in trust, and
- the rights of holders to benefit, as applicable, from the rights, powers, trusts, duties and immunities of the trustee.

We may defease a series of debt securities only if, among other things, we have delivered to the Trustee an opinion of counsel to the effect that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling to the effect that holders and beneficial owners of the debt securities of the series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred.

Defeasance of Covenants and Events of Default

We may omit to comply with the covenants described above under “Restrictions on Secured Debt” and “Restrictions on Sales and Leasebacks”, Leasebacks,” and the failure to comply with these covenants will not be deemed an event of default, if we deposit with the trustee, in trust, money and/or U.S. government securities which through the payment of interest and principal will provide money in an amount sufficient to pay the principal of and premium, if any, and each installment of interest on the debt securities of the series on the dates those payments are due and payable. Our obligations under the Indenture and the debt securities of the series will remain in full force and effect, other than with respect to the defeased covenants and related events of default.

We may defease the covenants and the related events of default described above only if, among other things, we have delivered to the trustee an opinion of counsel, who may be our employee or counsel, to the effect that the holders and beneficial owners of the debt securities of the series

will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and defeasance of the covenants and events of default, and the holders and beneficial owners of the debt securities of the series will be subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if the deposit and defeasance had not occurred.

If we choose covenant defeasance with respect to the debt securities of any series as described above and the debt securities of the series are declared due and payable because of the occurrence of any event of default other than the event of default described in clause (4) under “Events of Default,” the amount of money and U.S. government securities on deposit with the trustee will be sufficient to pay amounts due on the debt securities of the series at the time of their stated maturity. The amount on deposit with the trustee may not be sufficient to pay amounts due on the debt securities of the series at the time of the acceleration resulting from the event of default. However, we will remain liable for these payments.

Modification and Waiver

Procter & Gamble and the trustee may make modifications of and amendments to the Indenture Indenture if the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modification or amendment consent to the modification or

amendment.

However, the consent of the holder of each debt security affected will be required for any modification or amendment that

- changes the stated maturity of the principal of, or any installment of principal of or interest on, any debt security,
- reduces the principal amount of, or the premium, if any, or interest, if any, on, any debt security,
- reduces the amount of principal of an original issue discount security payable upon acceleration of the maturity of the security,
- changes the place or currency of payment of principal of, or premium, if any, or interest, if any, on, any debt security,
- impairs the right to institute suit for the enforcement of any payment on any debt security, or
- reduces the percentage in principal amount of debt securities of any series necessary to modify or amend the Indenture or to waive compliance with various provisions of the Indenture or to waive various defaults.

Without the consent of any holder of debt securities, we and the trustee may make modifications or amendments to the Indenture in order to

- evidence the succession of another person to us and the assumption by that person of the covenants in the Indenture,
- add to the covenants for the benefit of the holders,
- add additional events of default,
- permit or facilitate the issuance of securities in bearer form or uncertificated form,
- add to, change, or eliminate any provision of the Indenture in respect of a series of debt securities to be created in the future,

-
- secure the securities as required by "~~Restrictive~~ Restrictive Covenants-Restrictions on Secured Debt,"
 - establish the form or terms of securities of any series,
 - evidence the appointment of a successor trustee, or
-

- cure any ambiguity, correct or supplement any provision which may be inconsistent with another provision, or make any other provision, provided that any action may not adversely affect the interests of holders of debt securities in any material respect.

The holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive compliance by us with various restrictive provisions of the Indenture.

The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive any past default with respect to that series, except

- a default in the payment of the principal of or premium, if any, or interest on any debt security of that series, or
- a default in respect of a provision which under the Indenture cannot be modified or amended without the consent of the holder of each outstanding debt security of that series that would be affected.

Consolidation, Merger and Sale of Assets

If the conditions below are met, we may, without the consent of any holders of outstanding debt securities:

- consolidate or merge with or into another entity, or
- transfer or lease our assets as an entirety to another entity.

We have agreed that we will engage in a consolidation, merger or transfer or lease of assets as an entirety only if

- either we are the surviving entity or the entity formed by the consolidation or into which we are merged or which acquires or leases our assets is a corporation, partnership, limited liability company or trust organized and existing under the laws of any United States jurisdiction and assumes our obligations on the debt securities and under the **indenture, Indenture,**
- after giving effect to the transaction no event of default would have happened and be continuing, and
- various other conditions are met.

Regarding the Trustee

Deutsche Bank Trust Company Americas is the trustee under the **indenture, Indenture.** In addition, affiliates of Deutsche Bank Trust Company Americas may perform various commercial banking and investment banking services for Procter & Gamble and its subsidiaries from time to time in the ordinary course of business.

Exhibit 10-5

RETIREMENT PLAN RESTORATION PROGRAM SUMMARY

RETIREMENT PLAN RESTORATION PROGRAM SUMMARY

I. OVERVIEW

Each year, the Company grants retirement plan awards intended to supplement or replace awards made under The Procter & Gamble Profit Sharing Trust and Employee Stock Ownership Plan ("PST"). Awards (the "Retirement Awards") are in the form of RSUs under three programs, granted under and subject to The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "2019 Plan").

The PST Restoration program provides an award to eligible U.S. participants already enrolled in the PST. The IRS caps the amount of salary that can be used to calculate individual credits to the PST. This program restores the difference between the allowable PST credit and the amount that would have been credited without the IRS cap by granting PST Restoration Awards to all qualifying participants, including the CEO.

In addition, the International Retirement Plan (IRP) provides awards to foreign-based employees who are placed on U.S. pay programs but work outside the U.S. and are therefore not eligible for the PST. These employees receive a yearly grant of IRP RSUs based on a formula that mirrors the PST contribution formula.

Finally, the Supplemental Retirement Income (SRI) program provides awards to a small number of experienced senior hires. It is intended to supplement the PST based on additional credit service years agreed to at the time of employment.

II. AWARD TERMS

The Retirement Awards earned from the prior fiscal year ended June 30 will be granted on the first Thursday in August (the "Grant Date"). The Retirement Awards vest immediately if the employee has more than 3 years of service. The Retirement Awards are eligible for dividend equivalents. Except as provided in Section III below, the Retirement Awards will have the payment terms and conditions reflected in the applicable attached RSU award agreement (Form RTD for participants other than Principal Officers; Form RTD-C for Principal Officers), as applicable to the participant.

As provided in more detail in the RSU award agreement, vested Retirement Awards will be delivered by default one year post separation and may be further deferred by at least five years in accordance with section 409A of the Internal Revenue Code. In addition, the Restoration Awards and dividend equivalents granted to Principal Officers may be diversified using investment choices available under The Procter & Gamble Company Executive Deferred Compensation Plan once the Principal Officer is age 50. The amount diversified will be determined by multiplying the number of RSUs to be converted by the closing price of the Company's Common Stock on the New York Stock Exchange on the date of conversion.

Award amounts are calculated by the US Retirement Plans Administration Team pursuant to the terms of the PST plan. The Awards will be made in the form of RSUs, with the number of units determined by dividing the amounts of each award by the average of the closing price of the Company's Common Stock on the New York Stock Exchange for last five business days of the fiscal year and including the value of the missed dividend payment. Amounts are rounded up to the next full unit.

If applicable, Participants must accept their awards according to the terms of the Award Letter or the Award will not be granted.

III. AWARD FORM

Awards are made in the form of RSUs, except that if a participant with more than 3 years of service separates before the Grant Date, the award is paid as a lump sum cash payment as soon as practicable following the Grant Date, and in any event no later than 30 days following the Grant Date.

V. AWARD SETTLEMENT

Upon separation from the Company, the Retirement Awards will be settled as shares on the one-year anniversary of the participant's separation, or on the dates designated pursuant to a deferral election or subsequent deferral election under section 409A.

VI. CHANGE IN CONTROL


If there is a Change in Control, the provisions of Article 17 of the 2019 Plan will apply.

VII. GENERAL TERMS AND CONDITIONS

This program document may be amended at any time by the Committee. A participant shall not have a legally binding right to a Retirement Award or a lump sum cash payment unless and until the award is granted or the payment is made.

EXHIBIT (10-6) Retirement Plan Restoration Program - Related

Correspondence and Terms and Conditions



FORM RTD AWARD AGREEMENT

FIRST_NAME_MIDDLE_NAME_LAST_NAME
EMPLOYEE_IDENTIFIER

Subject: Award of Restricted Stock Units

This is to advise you that The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Number of Restricted Stock Units:	TOTAL_SHARES_GRANTED
Grant Date:	OPTION_DATE,'DD-Month-YYYY'-
Vest Date:	Immediately upon Achieving 3 Years of Service
Original Settlement Date:	One Year Following Termination of Employment

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

Voting Rights and Dividend Equivalents

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

Vesting and Payment

If you remain employed through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date (as defined below), whichever is applicable, except in the case of a termination for death or Disability, as described below. If your Termination of Employment occurs for any reason before the Vest Date except for the reasons listed below, the Award will be forfeited. For the purposes of this Award, Termination of Employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

1. Termination on Account of Death or Disability. In the case of death or Disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or Disability, as applicable.

2. Termination pursuant to a Written Separation Agreement. In the event of that your Termination of Employment from the Company or a Subsidiary that occurs before the Vest Date for this Award, this Award is forfeited unless you have executed a written separation agreement with the Company that provides for retention of the Award. If the Award is

retained pursuant to a separation agreement, the Award will be delivered on the Settlement Date as long as you remain in compliance with the terms of the Plan, the Regulations, and the separation agreement.

3. Termination in connection with a divestiture or separation of any of the Company's businesses. In the event of Termination of Employment from the Company in connection with a divestiture or separation of any of the Company's businesses, as determined by the Company's Chief Human Resources Officer, the Award is retained and will become deliverable on the Settlement Date as long as you remain in compliance with the terms of the Plan and the Regulations.

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

Deferral Election

At any time prior to Termination of Employment, you and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance with Internal Revenue Code Section 409A.

This Award Agreement including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award.

Notwithstanding the requirements of confidentiality, U.S. law protects individuals from liability under federal or state trade secret laws for disclosure of trade secrets made by such individual (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; or (iii) to the individual's attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law, provided that any document containing the trade secret is filed under seal and the individual does not otherwise disclose the trade secret, except pursuant to court order.

THE PROCTER & GAMBLE COMPANY

Bala Purushothaman

Chief Human Resources Officer

Attachment A

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my employer and shall not interfere with the ability of my employer to terminate my employment relationship at any time, with or without cause; **and ix) and** no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my employer from any such claim that may arise.

Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

Responsibility for Taxes

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

FORM RTD-C AWARD AGREEMENT

FIRST_NAME_MIDDLE_NAME_LAST_NAME
EMPLOYEE_IDENTIFIER

Subject: Award of Restricted Stock Units

This is to advise you that The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Number of Restricted Stock Units:	TOTAL_SHARES_GRANTED
Grant Date:	OPTION_DATE,'DD-Month-YYYY'
Vest Date:	Immediately upon Achieving 53 Years of Service
Original Settlement Date:	One Year Following Termination of Employment

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

Voting Rights and Dividend Equivalents

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

Vesting and Payment

If you remain employed through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date (as defined below), whichever is applicable, except in the case of a termination for death or Disability, as described below. If your Termination of Employment occurs for any reason before the Vest Date except for the reasons listed below, the Award will be forfeited. For the purposes of this Award, Termination of Employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

1. Termination on Account of Death or Disability. In the case of death or Disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or Disability, as applicable.
2. Termination pursuant to a Written Separation Agreement. In the event that your Termination of Employment from the Company or a subsidiary that Subsidiary occurs before the Vest Date for this Award, this Award is forfeited unless you have executed a written separation agreement with the Company that provides for retention of the Award. If the Award is retained pursuant to a separation agreement, the Award will be delivered on the Settlement Date as long as you remain in compliance with the terms of the Plan, the Regulations, and the separation agreement.
3. Termination in connection with a divestiture or separation of any of the Company's businesses. In the event of Termination of Employment from the Company in connection with a divestiture or separation of any of the Company's businesses, as determined by the Company's Chief Human Resources Officer, the Award is retained and will become deliverable on the Settlement Date as long as you remain in compliance with the terms of the Plan and the Regulations.

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

Deferral Election

At any time prior to Termination of Employment, you and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance with Internal Revenue Code Section 409A.

Conversion to Deferred Compensation Plan

All or a portion of the RSUs and Dividend Equivalent RSUs granted to you pursuant to this Award Agreement may be diversified once the award becomes non-forfeitable on the Vest Date noted above, using investment choices available under The Procter & Gamble Company Executive Deferred Compensation Plan (the "Deferred Compensation Plan") once you reach age 50. Conversions must be completed during one of the Company's open window periods for executives and are subject to the Company's Insider Trading Policy and any other restrictions in place at the time of conversion (claw-back provisions, share ownership requirements, etc.).

The amount diversified shall be determined by multiplying the number of RSUs to be converted by the closing price of the Company's Common Stock on the New York Stock Exchange on the date of conversion.

These contributions to the Deferred Compensation Plan will be placed into a notional account and administered in accordance with the terms and conditions set forth in that plan, as amended, provided, however, that the timing of payment of amounts under such plan will be governed by the payment timing terms of this Award Agreement, including any election to defer the Original Settlement Date.

This Award Agreement including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award.

Notwithstanding the requirements of confidentiality, U.S. law protects individuals from liability under federal or state trade secret laws for disclosure of trade secrets made by such individual (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; or (iii) to the individual's attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law, provided that any document containing the trade secret is filed under seal and the individual does not otherwise disclose the trade secret, except pursuant to court order.

THE PROCTER & GAMBLE COMPANY

Bala Purushothaman

Chief Human Resources Officer

Attachment A

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my employer and shall not interfere with the ability of my employer to terminate my employment relationship at any time, with or without cause; and ix) and no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my employer from any such claim that may arise.

Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

Responsibility for Taxes

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax-Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.

Exhibit 10-12

SEPARATION AGREEMENT & RELEASE



SEPARATION AGREEMENT & RELEASE

To: «Employee_Name»

Date: «Actual_Offer_Date»

«Company» ("P&G") is willing to provide you with certain assistance following your employment separation from the Company. The following, which is subject to your approval, sets forth our proposed agreement to do so. Your receipt of the benefits described below is conditioned upon your accepting, and abiding by, the terms of this Agreement.

Employment Separation Date:

Your Employment Separation Date will be «Exit_Date», referred to as your "Employment Separation Date." You understand and agree that if P&G determines that you engaged in misconduct during your employment, or if you fail to perform your work and responsibilities in a satisfactory manner up to and including your Employment Separation Date, P&G may terminate your employment immediately and will not provide, nor be obligated to provide, the payment(s) and other benefits described in this Agreement. Otherwise, unless noted below, your pay and benefits will cease as of your Employment Separation Date.

Separation Payment:

As soon as administratively practical after your Employment Separation Date, P&G will provide you with a Separation Payment of \$«Total_Amount», less legally required withholdings and deductions. In no event will payment be made before expiration of the seven-day revocation period discussed below or later than the March 15th of the year following the year which includes your Employment Separation Date. The Separation Payment will be the only monetary assistance P&G provides upon your separation. Other resources may be available to you as a participant in general compensation and benefit plans, which it will be your responsibility to identify and make any necessary arrangements upon separation

Amounts you owe to P&G as of your Employment Separation Date, including, but not limited to, wage and/or benefit overpayments and unpaid loans, will also be deducted from the Separation Payment.

Payment for Unvested PST:

If you are not fully-vested in the Procter & Gamble Profit Sharing Trust and Employee Stock Ownership Plan ("PST") as of your Employment Separation Date, as soon as administratively practical after your Employment Separation Date, but no later than the March 15th of the year following the year which includes your Employment Separation Date, you will receive a lump sum payment in an amount substantially equivalent to the non-vested credits in your account in the PST.

STAR Awards:

As of your Employment Separation Date, if you were otherwise eligible for a STAR award and you worked at least 28 days (4 calendar weeks) during that fiscal year, you will receive a pro-rated STAR award for that fiscal year. Your STAR award will be pro-rated by dividing the number of calendar days during the fiscal year from July 1 through your Employment Separation Date by 365. However, if you are on a leave of absence prior to your Employment Separation Date, your first day out of the office will be used to calculate the pro-rated percent.

Your STAR award will be paid in cash in the September (but no later than September 15th) immediately following the end of the fiscal year in which you terminate. Any current election for Stock Options will be reverted to cash.

Equity Awards:

Your separation will be treated as a Special Separation for purposes of any outstanding equity awards granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan or the Gillette Company 2004 Long-Term Incentive Plan and, as a result, you will retain the awards subject to the original terms and conditions of the awards. You will also retain awards granted under the Procter & Gamble 2014 Stock & Incentive Compensation Plan and the Procter & Gamble 2019 Stock & Incentive Compensation Plan subject to the terms and conditions of those Awards. For any award granted under the Long-Term Incentive Program (LTIP) and/or Performance Stock Program (PSP) within one year prior to the separation date, that award will be prorated based on the number of days worked in the 12 months following the October grant date, with a minimum of 28 days worked beyond the October grant date.

This Separation Letter & Release does not alter the rights and obligations that you may have under the Procter & Gamble 2019 Stock & Incentive Compensation Plan, the Procter & Gamble 2014 Stock & Incentive Compensation Plan, the Procter & Gamble 2009 Stock and Incentive Compensation Plan, and the Gillette Company 2004 Long-Term Incentive Plan.

Current Health, Dental, and Life Insurance Benefits: If you are enrolled in P&G's active health (including medical, prescription drug, and EAP coverage), active dental, and company-paid life insurance coverage, that coverage will continue under the same terms until «Benefits End Date».

If you continue to receive P&G active health coverage during the extension of benefits period, that coverage will be impacted if you (or your eligible dependents, including but not limited to your spouse or domestic partner) are or become eligible for Medicare. For more information on this impact, see the Coordination with Medicare section in the Summary Plan Description for your P&G active health coverage.

If you continue to receive P&G active health coverage during the extension of benefits period, you may be entitled to continue your health and dental coverage under COBRA when the extension of benefits period ends. If you are entitled to COBRA continuation coverage, you will receive a notice of your right to elect COBRA.

Retiree Medical and Dental Benefits:

If you were eligible for P&G retiree healthcare coverage on your Employment Separation Date, you will be eligible to enroll in P&G's retiree medical and dental insurance coverage. You are eligible for P&G retiree healthcare coverage if you satisfy the regular retiree eligibility rules (i.e., you are a Regular Retiree) as of your Employment Separation Date. Under the terms of this Agreement, you also are eligible for P&G retiree healthcare coverage as a Special Retiree by satisfying the Rule of 70 as of your Employment Separation Date. You satisfy the Rule of 70 when your full years of age plus your full years of service equal 70.[1] If you are eligible for P&G's retiree healthcare coverage as either a Regular Retiree or a Special Retiree as of your Employment Separation Date, you should contact P&G Benefits Services before your extension of coverage ends to request retiree healthcare enrollment information. For details regarding the terms and conditions of your retiree health coverage, please refer to and review the summary plan descriptions, available at the P&G Benefits website.

Important Note: If you become employed by a direct competitor of P&G (as determined by P&G's Chief Human Resources Officer) in an officer and/or director capacity, you will not be eligible for coverage under P&G's retiree healthcare coverage as long as you remain employed by such competitor. If you have questions, please contact P&G Benefits Services at [phone number]

<u>Outplacement Services:</u>	<p>P&G's preferred third-party provider will provide services to assist you in managing your transition to a new future, based on your interest. Services include pre-decision counseling, career transition programs, and job development opportunities. P&G's preferred third-party provider will also assist you in preparing for your job search, including résumé preparation, cover letters, other written materials and interview and networking training.</p> <p>After accepting this Agreement, and after obtaining your manager's approval, you may begin utilizing outplacement services on a limited basis prior to your Employment Separation Date, consistent with the needs of the business and your responsibilities to complete and/or transition your work. Note that you must begin utilizing outplacement services within 45 days of your Employment Separation Date to be eligible for this benefit</p>
<u>Retraining:</u>	[Not applicable].
<u>No Consideration Without Executing this Agreement:</u>	You affirm that you understand and agree that you would not receive the separation payment and/or benefits specified in this Agreement without executing this Agreement and fulfilling the promises contained in it. Except as provided in this Agreement or under the terms and conditions of an applicable benefit plan or policy sponsored by P&G, you shall not be due any payments or benefits from P&G in connection with your separation from employment.
<u>Continued Employment Through Your Employment Separation Date:</u>	You agree to perform your work and responsibilities as an employee in a satisfactory manner up to and including your Employment Separation Date, including compliance with all provisions of this "Separation Agreement and Release." If P&G determines that you have engaged in misconduct during your employment, you understand and agree that P&G may terminate your employment immediately and will not provide, nor will it be obligated to provide, you with the Separation payment, medical benefits, outplacement, retraining and other benefits described above. If you have already received any such pay or benefits, you agree to repay them to P&G upon demand.
<u>No Admission of Wrongdoing:</u>	You affirm that you understand and agree that neither this Agreement nor the furnishing of the consideration for this Agreement, including the Separation Payment, shall be deemed or construed at any time for any purpose as an admission by P&G of wrongdoing or evidence of any liability or unlawful conduct of any kind.

Release of Claims – Including Age
Discrimination and Employment Claims:

[If the Employee is a resident of: California, Massachusetts, Minnesota, New Jersey, or West Virginia, replace the below language with the State Specific language that can be found here: [State Specific Release Language.docx](#)]

You hereby release P&G from any and all claims or rights you may have against P&G. The term "P&G" includes, «Company», The Procter & Gamble Company and any of its and their present, former and future owners, parents, affiliates and subsidiaries, and its and their directors, officers, shareholders, employees, agents, benefit plans, trustees, fiduciaries, servants, representatives, predecessors, successors and assigns. This release applies to claims about which you now know or may later discover, and includes but is not limited to: (1) claims arising under the **Age Discrimination in Employment Act ("ADEA")**, 29 U.S.C. § 621, et seq.; (2) claims arising under any other federal, state or local law, regulation or ordinance or other order that regulates the employment relationship and/or employee benefits; and (3) claims arising out of or relating in any way to your employment with P&G or the conclusion of that employment. This release does not apply to claims that may arise after the date you sign this letter or that may not be released under applicable law.

Governmental Agencies: Nothing in this Separation Letter & Release prohibits, prevents, or otherwise limits you from filing a charge or complaint with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before any federal, state, or local government agency (e.g., EEOC, NLRB, SEC, OSHA, etc.) or in any legislative or judicial proceeding nor does anything in this Separation Letter & Release preclude, prohibit, or otherwise limit, in any way, your rights and abilities to contact, communicate with, or report unlawful conduct, or provide documents, to federal, state, or local officials for investigation or participate in any whistleblower program administered by any such agencies. In addition, nothing in this Separation Letter & Release, including, but not limited to, the release of claims nor the confidential business information, and return of company property clauses, prohibit you from: (1) reporting possible violations of federal or other law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the Commodity Futures Trading Commission, the U.S. Congress, or any agency Inspector General; (2) making any other disclosures that are protected under the whistleblower provisions of federal or other law or regulations; or (3) filing a charge or complaint or otherwise fully participating in any governmental whistleblower programs, including but not limited to any such programs managed or administered by the U.S. Securities and Exchange Commission, the Commodity Futures Trading Commission or the Occupational Safety and Health Administration. You are not required to notify or obtain permission from P&G when filing a governmental whistleblower charge or complaint or engaging or participating in protected whistleblower activity. Moreover, nothing in this Separation Letter & Release prohibits or prevents you from receiving individual monetary awards or other individual relief by virtue of participating in such governmental whistleblower programs.

Confidential, Proprietary, Trade Secret Information:

Subject to the "Governmental Agencies" portion of the "Release of Claims – Including Age Discrimination and Employment Claims" above, you agree that you will not use or share any confidential, proprietary or trade secret information about any aspect of P&G's business with any non-P&G employee or business entity at any time in the future. You further agree that you will not obtain, transfer or have in your possession any confidential, proprietary or trade secret information on or after your Employment Separation Date, even information you may have created yourself or to which you may have contributed as a P&G employee. Confidential, proprietary or trade secret information includes, but is not limited to, marketing and advertising plans, pricing information, upstream plans, specific areas of research and development, project work, product formulation, processing methods, assignments of individual employees, testing and evaluation procedures, cost figures, construction plans, and special techniques or methods of any kind.

Notwithstanding the requirements of confidentiality contained in this section, the federal Defend Trade Secrets Act of 2016 immunizes you against criminal and civil liability under federal or state trade secret laws for your disclosure of trade secrets that is made i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; or iii) to your attorney for use in a lawsuit alleging retaliation for reporting a suspected violation of law, provided that any document containing the trade secret is filed under seal and you do not otherwise disclose the trade secret, except pursuant to court order.

For the purposes of this section, it shall be conclusively presumed that you have knowledge or information to which you were directly exposed through the actual receipt of memos or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed. The provisions of this section are not in lieu of, but are in addition to, your continuing obligation to not use or disclose P&G's trade secrets and confidential information known to you until any particular trade secret or confidential information becomes generally known (through no fault of yours). Information regarding products in development, in test market or being marketed or promoted in a discrete geographic region, which information P&G is considering for a broader use, shall not be deemed generally known until such broader use is actually commercially implemented. Also, "generally known" means known throughout the domestic United States industry or, if you have job responsibilities outside of the United States, the appropriate foreign country or countries' industry.

If any restriction in this section is found by any court of competent jurisdiction or arbitrator to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it will be modified and interpreted to extend only over the maximum period of time, range of activities or geographic area so that it may be enforceable.

If you are a participant in the Procter & Gamble 2009 Stock and Incentive Compensation Plan you are also bound by the terms of Article F – Restrictions & Covenants of those plans, which are incorporated herein by reference.

If you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the Procter & Gamble 2014 Stock and Incentive Compensation Plan, you are also bound by the terms of Article 6 – Restrictions and Covenants of those plans which are incorporated herein by reference.

Non-Solicitation:

You acknowledge, as a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan, the Procter & Gamble 2014 Stock & Incentive Compensation Plan, the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the Procter & Gamble 2001 Stock and Incentive Plan, the Procter & Gamble 1992 Stock Plan, and/or the Gillette Company 2004 Long-Term Incentive Plan that you are bound to comply with the Plans' non-solicitation obligations. Specifically, you agree that you will not, for 5 years following your Employment Separation Date, attempt to directly or indirectly induce any employee of P&G or its affiliates or subsidiaries to be employed or perform services elsewhere or attempt directly or indirectly to solicit the trade or business of any current or prospective customer, supplier or partner of P&G or its affiliates or subsidiaries.

Acknowledgments and Affirmations:

Subject to the "Governmental Agencies" portion of the "*Release of Claims – Including Age Discrimination and Employment Claims*" above, you affirm that you have not filed, caused to be filed, or presently are a party to any claim against P&G.

You affirm that you have been paid and/or have received all compensation, wages, bonuses, commissions, and/or benefits which are due and payable as of the date you sign this Agreement. To the extent that you are required to report hours worked, you affirm that you have reported all hours worked as of the date you sign this Agreement.

You affirm that you have been granted any leave to which you were entitled under the Family and Medical Leave Act or related state or local leave or disability accommodation laws.

You further affirm that you have no known workplace injuries or occupational diseases that have not been reported.

<u>Assignment of Intellectual Property:</u>	You will promptly and fully disclose, transfer and assign to P&G all inventions and any other intellectual property (collectively "Intellectual Property") made or conceived by you during your employment with P&G. You agree to fully cooperate in executing any papers required for establishing or protecting the Intellectual Property and for establishing P&G's ownership, even if such cooperation is necessary after your Employment Separation Date
<u>Return of P&G Property:</u>	<p>You agree that by your Employment Separation Date, you will return to P&G in good condition all of its equipment, materials and information that were in your possession, custody or control (including, but not limited to, work product, notes, files, memoranda, instructional or personnel manuals, computers, phones, iPads, tablets files, documents, credit cards, keys and identification badges). You further agree that you will provide your manager with all passwords to P&G electronic communication and data systems before your Employment Separation Date</p> <p>You understand and agree that technical, product, business, financial, personnel, and other physical or personal property that you received, prepared, or helped to prepare in connection with your employment with P&G, is P&G property and must be returned to P&G prior to your Employment Separation Date. You further understand and agree that if P&G later discovers that you retained and/or forwarded to yourself P&G property, you will have violated the terms of this Separation Letter & Release, P&G will not be obligated to provide the benefits described in this Letter, and you will be required to return any benefits received under this Separation Letter & Release</p>
<u>Ethics Compliance:</u>	Subject to the "Governmental Agencies" portion of the " <i>Release of Claims – Including Age Discrimination and Employment Claims</i> " above, you agree that you provided P&G all information known to you regarding any violations of the Procter & Gamble Worldwide Business Conduct Manual and/or any other violations of P&G policy or the law.
<u>Severability:</u>	If any court of competent jurisdiction or arbitrator should later find that any portion of this Agreement is invalid, that invalidity will not affect the enforceability of any other portion of this Agreement.
<u>Employment References:</u>	Pursuant to P&G's standard policies, in connection with any and all potential employers seeking references directly from P&G, you agree to refer all such reference inquiries to P&G's employment verification vendor. Information can be found on the GetHelp Portal by searching "Employment and Income Verification".

No Reliance:

This Agreement sets forth the entire agreement between you and P&G and fully supersedes any prior agreements or understanding between the parties except that if you are a participant in the Procter & Gamble 2009 Stock and Incentive Compensation Plan, the terms of Article F – Restrictions & Covenants of those plans remain in full force and effect and are incorporated herein by reference and if you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the Procter & Gamble 2014 Stock and Incentive Compensation Plan, the terms of Article 6 – Restrictions & Covenants of those plans remain in full force and are in effect and are incorporated herein by reference. In deciding to accept this Agreement, you agree that you have not relied upon any statements or promises by P&G, its managers, agents or employees, other than those set forth in this Agreement. No other promises or agreements concerning the matters described in this Agreement shall be binding unless in a subsequent document signed by these parties

Your Attorney:

You acknowledge that you have been and hereby are advised to consult with legal counsel before accepting this Agreement and have either done so or have voluntarily declined to do so.

Timing for Acceptance or Revocation:

You have forty-five (45) calendar days in which to consider this Agreement in which you waive important rights, including those under the Age Discrimination in Employment Act of 1967. If you choose to sign this Agreement, please do so by indicating your acceptance of this Agreement with your electronic signature in P&G's electronic system. We advise you to consult with an attorney of your choosing prior to signing this Agreement. Further, you may within seven (7) calendar days following the date you accept this Agreement, cancel and terminate the Agreement by giving written notice of your intention to revoke the Agreement to your immediate manager, and by returning to P&G any remuneration or benefits that have been advanced to you in anticipation of your not revoking your Agreement and to which you are not entitled. If notice of your revocation is mailed, it must be postmarked within seven (7) calendar days after you sign this Agreement.

You agree that any modifications, material or otherwise, made to this Agreement, do not restart or affect in any manner the original up to forty-five (45) calendar day consideration period.

Applicable Law:

Ohio law will apply in connection with any dispute or proceeding concerning this Agreement without regard to Ohio's conflict of laws provisions.

¹Special rules apply to Gillette Heritage Employees with regard to retiree medical eligibility and the retiree medical cost sharing under the retiree medical plan. If you are a Gillette Heritage Employee, you will receive a separate handout on your retiree medical eligibility.

The benefits described in this Agreement and pursuant to the Summary Plan Description for the Procter & Gamble Basic Separation Program for U.S. Employees (to be obtained from your HR Business Partner), are the special benefits you will receive by signing this Agreement. To the extent this Agreement describes benefits under other benefit plans and policies sponsored by P&G, these special benefits are also described in the summary plan descriptions for those plans. As such, nothing in this Agreement amends or changes the terms of any P&G-sponsored employee benefit plan or policy.

After your Employment Separation Date, you will no longer be an active P&G employee, which may affect your coverage under those plans and policies. For example, plans may require that you enroll in Medicare to be eligible for coverage. For more information on how not being an active P&G employee may affect your coverage, please refer to and review the summary plan descriptions for each plan.

To accept this separation package according to the terms of the above Agreement, go back to the e-mail and electronic link you received and click on the "Accept" button. By clicking "Accept," you acknowledge that you have read the entire Agreement, that you understand it, and that you voluntarily accept its terms. You further agree that you understand that it is a legally binding agreement, that you have been advised to consult with an attorney, that you have been given 45 days to consider the Agreement, and that you can revoke your acceptance within seven days of accepting the Agreement by providing written notification to your immediate manager. If you do not wish to accept the terms of this Agreement, click on the "Decline" button.

EXHIBIT (10-16)
SENIOR EXECUTIVE OFFICER
RECOUPMENT POLICY

SENIOR EXECUTIVE OFFICER
RECOUPMENT POLICY

Effective December 1, 2023

In the event of a significant restatement of financial results, the Compensation and Leadership Development Committee of the Board will review all cash-based and equity-based incentive compensation paid to Executive Officers on the basis of having met or exceeded specific performance targets or goals for performance periods after June 30, 2006 pursuant to the Short Term Achievement Reward (STAR) annual incentive program and/or the Performance Stock Plan (PSP), a long-term incentive program, or any successor programs or plans or other cash-based or equity-based incentive compensation plans approved by the Board or the Compensation and Leadership Development Committee (collectively, "Compensation"). Such Compensation is limited to awards received in the three-year period preceding the date on which the Company is required to prepare the accounting restatement.

If such Compensation would have been lower had it been calculated based on the restated results, the Compensation and Leadership Development Committee will, to the extent permitted by governing law, have the sole and absolute discretion and authority to seek to recoup for the benefit of the Company some or all such Compensation paid to some or all of the Covered Officers, regardless of the fault, misconduct or responsibility of any such covered officer in the restatement. For purposes of this policy, the term "significant restatement" means a restatement triggered by a material accounting error in previously issued financial statements, the term "Covered Officers" means the senior executive officers at Band 7 and above who are not already covered under the SEC and NYSE required executive clawback policy as approved by the Compensation and Leadership Development Committee at its June 13, 2023 meeting to be effective on the effective day of the NYSE listing standard. These covered officers will be subject to recoupment if they were in such positions at the time such Compensation deemed subject to recoupment was paid, and the term "Compensation" includes any amounts deferred under STAR pursuant to the terms of The Procter & Gamble Company Executive Deferred Compensation Plan. In addition, in the event recoupment is required under the Dodd-Frank Recoupment Policy, the Compensation and Leadership Development Committee may apply the same recoupment to the Covered Officers.

This authority is in addition to the Compensation and Leadership Development Committee's authority under any applicable stock and incentive compensation plan to suspend or cancel any outstanding stock option, stock appreciation right, or restricted stock unit issued under the plans, and seek repayment of net proceeds of awards, if the Committee determines that the Participant has acted significantly contrary to the best interests of the Company or its affiliates or subsidiaries.

In addition, this does not affect the Company's ability to pursue any and all available legal rights and remedies under governing law.

Exhibit 10-25
REGULATIONS
OF THE
COMPENSATION AND LEADERSHIP DEVELOPMENT COMMITTEE
FOR
THE PROCTER & GAMBLE 2019 STOCK AND INCENTIVE COMPENSATION PLAN AND THE PROCTER & GAMBLE 2014 STOCK AND INCENTIVE
COMPENSATION PLAN

REGULATIONS
OF THE
COMPENSATION AND LEADERSHIP DEVELOPMENT COMMITTEE
FOR
THE PROCTER & GAMBLE 2019 STOCK AND INCENTIVE COMPENSATION PLAN AND THE PROCTER & GAMBLE 2014 STOCK AND INCENTIVE
COMPENSATION PLAN

I. AUTHORITY FOR REGULATIONS

These regulations (the "Regulations") are adopted pursuant to Article 3.1 of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "2019 Plan") and Article 3.1 of The Procter & Gamble 2014 Stock and Incentive Compensation Plan (together with the 2019 Plan, the "Plans").

II. ADMINISTRATION

- 1 Any capitalized terms used in these Regulations that are not otherwise defined herein are defined in the Plans. In the event the meaning of any defined term used in these Regulations is not clear, the Chief Human Resources Officer ("CHRO") will determine the meaning of the term in his or her sole discretion.
- 2 The Company's Stock Plan Administration group shall be the Plan Administrator for the Plans and is authorized to develop procedures necessary to administer Awards and to engage brokers or other consultants that may be advisable for the administration of the Plans.
- 3 The Chief Executive Officer ("CEO") is authorized to submit recommendations to the Committee for Awards, except for himself.
- 4 The CHRO and the Chief Legal Officer and Secretary ("CLO") are each individually authorized to execute Award Agreements consistent with the 2019 Plan, these Regulations, approved executive compensation programs (e.g., the Performance Stock Program), and/or Committee action through resolution.
- 5 The CHRO is authorized to specify an appropriate time and manner for acceptance of each Award. Any Award not accepted through the specified means within the period specified by the Committee or the CHRO at the time of the grant shall be considered to be canceled.
- 6 The CLO shall maintain the books and records of Awards granted by the Committee and shall report at each meeting of the Committee at which Awards are to be considered the

total number of shares available for Awards under the 2019 Plan. The CLO shall inform the Treasurer and the Plan Administrator of Awards granted on a regular basis.

- 7 The Treasurer is authorized to delegate to an appropriate manager reporting to the Treasurer the authority to acquire, transfer and deliver shares for the purposes of the Plans.
- 8 If the CLO is unavailable, an Assistant Secretary is hereby authorized to perform the duties and have the powers of the CLO outlined in these Regulations. If the Treasurer is unavailable, an Assistant Treasurer is hereby authorized to perform the duties and have the powers of the Treasurer outlined in these Regulations.

III. SUSPENSION, TERMINATION, WITHHOLDING, AND REPAYMENT OF AWARDS

- 1 The CHRO and the CLO are each hereby individually authorized to temporarily withhold payment of an unpaid Award or suspend on a conditional or temporary basis the outstanding Awards of any Participant if the CHRO or CLO believes that such Participant has engaged in action that violates the terms and conditions governing the Award, including, but not limited to, any violation of Article 6 of the Plans. If the Participant is a Principal Officer of the Company, the CEO must concur with the decision.
- 2 In order to permanently terminate, withhold payment, demand repayment of, or otherwise restrict or recoup an Award, within a reasonable time of any such conditional or temporary suspension or withholding of payment, the CHRO and CLO must each concur that the Participant has engaged in action that violates the terms and conditions governing the Award, including, but not limited to, any violation of Article 6 of the Plans. If the Participant is a Principal Officer of the Company, the CEO must concur with the decision. If the applicable parties concur, the proposed action shall be immediately implemented, except in the case of a Section 16 Officer as described below. If they do not concur, the temporary suspension or withholding of payment shall be lifted.
- 3 All alleged violations of the terms and conditions governing an Award held by any Section 16 Officer shall be reviewed by the Committee following the concurrence by the CHRO, CLO and, if applicable, the CEO described in Section III.2 above. If the Committee determines a violation has occurred, the Committee may terminate the Participant's outstanding Awards, withhold payment of an Award, demand repayment of an Award, or otherwise restrict or recoup an Award.
- 4 Actions that significantly contravene the Company's "Statement of Purpose, Values and Principles" will be considered to be actions "significantly contrary to the best interests of the Company" and a violation of Article 6.1(d) of the Plans. This standard also includes any action taken or threatened by the Participant that the Committee determines has, or is reasonably likely to have, a significant adverse impact on the reputation, goodwill, stability, operation, personnel retention and management, or business of the Company or any subsidiary.

IV. TERMS AND CONDITIONS OF AWARDS

-
- 1 The Committee establishes the terms and conditions of Awards by its approval of the program summaries for each compensation program or by approving individual awards. The Award Agreements will include the Grant Date, Vest Date, Expiration Date (for Stock Options and SARs), and Settlement Date (for RSUs) determined by the Committee.
 - 2 A Participant's beneficiary under an Award is the Participant's estate. However, to the extent permitted by the CHRO with respect to Awards under the Plans, and in accordance with rules and procedures established by the CHRO, each Participant may designate a beneficiary or beneficiaries to receive any benefit payable upon death under the terms of the Plans or an Award. In the absence of such designation, the Participant's beneficiary will be the Participant's estate.

V. EXERCISE OR SETTLEMENT OF AWARDS

- 1 Pursuant to Article 6.1 of the Plans, if upon the delivery of notice to exercise, the Participant refuses to certify intent to either remain in the employ of the Company or one of its Subsidiaries for at least one (1) year or otherwise comply with the non-compete provisions of Article 6, a Principal Officer or an employee of the Company or any of its Subsidiaries who has the title of Vice President shall be informed of the Participant's refusal.
 - 2 Notice of exercise of a Stock Option or SAR shall be given prior to the expiration of the Award and shall be given in the form and manner established by the Plan Administrator.
 - 3 The Plan Administrator is authorized from time to time to suspend the exercise of any Stock Option or SAR, the delivery of any Shares or the settlement of any RSUs, where such suspension is deemed necessary or appropriate for corporate purposes. No such suspension shall extend the life of the Stock Option or SAR right beyond its expiration date, and in no event will there be a suspension in the five (5) calendar days immediately preceding the expiration date.
 - 4 The Treasurer or CHRO with Treasurer concurrence, is hereby authorized to establish such terms and conditions regarding exercise or delivery of any Award as is required or advisable to accommodate for differences in local law, tax policy or custom, including but not limited to, requiring that Participants: (i) hold shares acquired upon exercise of any Stock Option for a specified period of time; (ii) hold shares acquired upon exercise of any Stock Option outside of the Participant's jurisdiction of residence; or (iii) immediately repatriate proceeds from the sale of shares or dividends on shares to their local jurisdiction.
 - 5 In the event that the New York Stock Exchange is closed for business on the day upon which shares of the Company's Common Stock are to be valued, the Plan Administrator shall value such shares on the immediately following business day of such Exchange on which day such stock is traded.
 - 6 Awards may be surrendered for cancellation before exercise or settlement in the manner prescribed by the Plan Administrator. Acceptance of such surrender for cancellation before exercise or settlement shall not constitute waiver of the Participant's obligations under Article 6 of the Plans.
-

VI. AWARDS GRANTED TO PARTICIPANTS LOCATED OUTSIDE THE UNITED STATES

- 1 Where local law would prohibit enforcement of provisions 6.1, 6.2 or 6.3 of the Plans, the Committee authorizes the CHRO to waive any or all of those provisions in the Award Agreement.
- 2 Provided Participants located in Belgium pay tax on a Key Manager Stock Option Award at grant, the CHRO is authorized to treat up to thirty-four percent (34%) of Award as non-forfeitable on the Grant Date.
- 3 The CHRO may adjust Award Agreements issued to Participants located in the United Kingdom to shift the employer tax obligations to Participants, if appropriate.
- 4 The CHRO may adjust other Award Agreements as necessary to comply with the terms set out in foreign sub-plans adopted by the Committee.
- 5 The CHRO may amend or create any country specific addenda, appendices, or subplans as may be necessary or advisable to comply with local law.

VIII. MISCELLANEOUS

- 1 Determination by the Committee as to the interpretation of the terms and provisions of the Plans shall be conclusive on all interested parties.
- 2 In the case of a triggering event under Article 4 of the 2019 Plan the appropriate number of such new or additional or different shares or securities will be issued by the Treasurer with the applicable restrictive legend to Participants holding restricted shares, in accordance with each Award Agreement.

3 These Regulations may be amended at any time by action of the Committee.

2019 STOCK & INCENTIVE COMPENSATION PLAN

AUSTRALIA ADDENDUM

1. Purpose

This Addendum (the "Australian Addendum") to The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "U.S. Plan") is hereby adopted to set forth certain rules which, together with the provisions of the U.S. Plan (which are modified by this addendum in certain respects to ensure compliance with the Class Order (see below)), shall govern the operation of the Plan with respect to Australian-resident employees of P&G and its Australian subsidiaries. The Plan is intended to comply with the provisions of the *Corporations Act 2001* (Cth) ASIC Regulatory Guide 49 and ASIC Class Order 14/1000 (the "Class Order").

2. Definitions

Except as set out below, capitalized terms used herein shall have the meaning ascribed to them in the U.S. Plan. In the event of any conflict between these provisions and the U.S. Plan, these provisions shall prevail.

For the purposes of this Australian Addendum:

"ASIC" means the Australian Securities & Investments Commission;

"Associated Body Corporate" means (as determined in accordance with the *Corporations Act 2001*(Cth)):

- (a) a body corporate that is a related body corporate of the Company;
- (b) a body corporate that has voting power in the Company of not less than 20%;
- or
- (c) a body corporate in which the Company has voting power of not less than 20%;

"Australian Subsidiaries" means all subsidiaries of the Company incorporated in Australia;

"Common Stock" means the common stock, without par value, of the Company;

"Company" means The Procter & Gamble Company;

"Option" means an option to acquire, by way of issue, a fully-paid share of Common Stock of the Company in the same class as shares which have been quoted on the New York Stock Exchange for at least 3 months (without suspension for more than a total of 5 trading days during that period) immediately prior to the date of grant, following the lapse of specific restrictions, as determined by the Committee;

"Plan" means the U.S. Plan as modified for implementation in Australia by the Australian Addendum;

"Restricted Stock Units" means a promise by the Company, as of the date of the grant, to deliver fully-paid shares of Common Stock in the same class as shares which have been quoted on the New York Stock Exchange for at least 3 months (without suspension for more than a total of 5 trading days during that period), following the lapse of specific restrictions, as determined by the Committee; and

"U.S. Plan" means The Procter & Gamble 2019 Stock and Incentive Compensation Plan;
and

"P&G" means The Procter & Gamble Company.

3. Forms of Awards

Only shares of Common Stock, Restricted Stock, Options and Restricted Stock Units shall be awarded or offered under the Plan in Australia. Options must be granted at no monetary cost.

Performance awards (including Restricted Stock, Options, and Restricted Stock Units that are subject to performance measures) and other incentive based awards may also be awarded under the Plan in Australia to the extent that these awards fall within the definition of Incentive Right contained in the Class Order.

4. Employees

In Australia, the Plan may only be extended to persons who at the time of the offer are full or part-time employees, non-executive directors, contractors or casual employees (contractors and casual employees who work the pro-rata equivalent of 40% or more of a comparable full-time position) of the Company or an Australian Subsidiary.

5. Form of Offer

5.1 Any offer made in Australia to participate in the Plan must be included in a document ("Offer Document") which sets out the terms of the offer and which must include or be accompanied by a copy of the Plan, or a summary of the Plan. Where a summary only is provided with the offer, the Offer Document must include an undertaking that during the period (the "offer period") during which a Participant may exercise Options acquired under the Plan, the Company or its Australian subsidiary will, within a reasonable period of the Participant so requesting, provide the Participant without charge with a copy of the Plan.

5.2 The Company must take reasonable steps to ensure that any Participant to whom an offer is made is given a copy of the Offer Document.

5.3 Further, the Offer Document must include a statement to the effect that any advice given by the person in connection with the offer is general advice only, and that Participants should consider obtaining their own financial product advice from an independent person who is licensed by ASIC to give such advice.

6. Australian Dollar Equivalent of Option Price at Offer Date

The Offer Document must specify the Australian dollar equivalent of the exercise price of the Options the subject of the Offer Document ("Option Price") as at the date of the offer.

7. Updated Pricing Information

The Offer Document must include an undertaking that, and an explanation of the way in which the Company will, during the offer period and within a reasonable period of a Participant so requesting, make available to the Participant the following information:

- (a) the Australian dollar equivalent of the current market price of a share of Common Stock, as at the date of the Participant's request; and
- (b) the Australian dollar equivalent of the Option Price, as at the date of the Participant's request.

For the purposes of this clause, the current market price of a share of Common Stock shall be taken as the final price published by the New York Stock Exchange for the previous trading day.

8. Exchange Rate for Australia Dollar Equivalent of a Price

For the purposes of clauses 7 and 8, the Australian dollar equivalent of the Option Price and current market price of shares of Common Stock shall be calculated by reference to the Australian/U.S. dollar exchange rate published by an Australian bank (the "Bank") no earlier than the business day before the day to which the price relates.

9. Loan or Financial Assistance

If the Company or any Australian Subsidiary offers a Participant any loan or other financial assistance for the purpose of acquiring the Common Stock to which the offer relates, the Company or any Australian Subsidiary:

- (a) must ensure that the loan is not provided to acquire Options or Incentive Rights; and
- (b) must ensure that under the terms of the loan:
 - (i) no fees or interest is payable; and
 - (ii) either:
 - (A) the lender has no recourse against the Participant in relation to the repayment of the loan; or
 - (B) the recourse of the lender against the Participant in relation to the repayment of the loan is limited to forfeiture of the Common Stock issued or transferred to, or held on behalf of, the Participant in connection with the scheme.

10. Restriction on Capital Raising: 5% limit

In the case of any offer that will involve the issue of shares of Common Stock including as a result of an exercise of an Option, the number of shares of Common Stock that are the subject of the offer under the Plan, or to be received on exercise of an Option when aggregated with:

- (a) the number of shares of Common Stock in the same class which would be issued were each outstanding offer of shares of Common Stock or Option to acquire unissued shares of Common Stock under the Plan or any other employee share scheme of the Company, accepted or exercised (as the case may be); and
 - (b) the number of shares of Common Stock in the same class issued during the previous three years pursuant to the Plan or any other employee share scheme extended only to full or part-time employees or directors of the Company or of any Associated Body Corporate of the Company;
- but disregarding any offer made, or option acquired or shares of Common Stock issued by way or as a result of:
- (c) an offer to a person situated at the time of receipt of the offer outside Australia;

- (d) an offer that was an excluded offer or invitation within the meaning of the Corporations Law as it stood prior to 13 March 2000;
 - (e) an offer that did not require disclosure to investors because of section 708 of the *Corporations Act 2001* (Cth);
 - (f) an offer that did not require the giving of a Product Disclosure Statement because of section 1012D of the *Corporations Act 2001* (Cth); or
 - (g) an offer made under a disclosure document or a Product Disclosure Statement,
- must not exceed 5% of the total number of issued shares in that class of shares of the Company as at the time of the offer or invitation.

11. Lodgment of Offer Document with the ASIC

Within one month of the first offer being made to an Australian Participant under this Australian Addendum, the Company must give ASIC a notice of reliance in accordance with the Class Order.

12. Compliance with Undertakings

The Company or an Australian Subsidiary must comply with any undertaking required to be made in the Offer Document by reason of the Class Order, including the undertaking to provide pricing information upon request.

2019 STOCK AND INCENTIVE COMPENSATION PLAN

FRANCE ADDENDUM

Article A. Introduction

The Board of Directors of The Procter & Gamble Company (the "Company") has established a 2019 Stock and Incentive Compensation Plan (the "U.S. Plan") for the benefit of certain employees of the Company and its subsidiary companies, including its French subsidiaries, (the "Subsidiary") of which the Company holds directly or indirectly at least 10% of the share capital. Article 3 of the U.S. Plan specifically authorizes the Compensation Committee (or other committee) (the "Committee") designated by the Board of Directors (the "Board") to adopt procedures and forms relating to the U.S. Plan as it deems advisable with respect to foreign participants. The Board, therefore, intends to establish a sub-plan for France of the U.S. Plan for the purpose of granting Options which may qualify for the favorable tax and social security treatment in France applicable to Options granted under Sections L. 225-177 to L. 225-186-1 of the French Commercial Code as amended to qualifying employees under the U.S. Plan who are resident in France for French tax purposes (the "Optionees"). The terms of the U.S. Plan, as

subsequently amended and as set out in Appendix 1 hereto, shall, subject to the modifications in the following rules, constitute the Rules of the 2019 Omnibus Incentive Compensation Plan for Employees in France (the "French Plan").

Under the French Plan, the Optionees will be granted only Options as defined under Article B hereunder. In no case will grants under the French Plan include any other substitute awards, e.g., stock appreciation rights and restricted stock.

Article B. Definitions

Capitalized terms used but not defined in the French Plan shall have the same meanings as set forth in the U.S. Plan.

In addition, the term "Option" shall have the following meaning:

A. Purchase Options, that are rights to acquire Common Stock repurchased by the Company prior to the vesting of said Options; or

B. Subscription Options, that are rights to subscribe newly issued Common Stock.

The term "Closed Period" means specific periods as set forth by section L. 225-177 of the French Commercial Code as amended during which French qualifying Options cannot be granted.

Notwithstanding any provisions in the U.S. Plan, the term "Grant Date" shall be the date on which the Board or the Committee both (a) designates the Optionee and (b) specifies the terms and conditions of the Option including the number of shares and the method of determining the Option Price.

The term "Effective Grant Date" shall be the date on which the Option is effectively granted, i.e., the date on which the condition precedent of the expiration of a Closed Period applicable to the Option, if any, is satisfied. Such condition precedent shall be satisfied when the Board, Committee or other authorized body shall determine that the granting of Options is no longer prevented under a Closed Period. If the Grant Date does not occur within a Closed Period, the "Effective Grant Date" shall be the same day as the "Grant Date".

The term "Vesting Date" shall mean the date on which an Optionee's right to all or a portion of an Option granted under the French Plan becomes non-forfeitable.

The term "Disability" is defined in accordance with categories 2 and 3 under Section L. 341-4 of the French Social Security Code, as amended, and subject to the fulfillment of related conditions.

The term "Forced Retirement" shall mean forced retirement as determined under Section L. 1237-5 of the French Labor Code, as amended, and subject to the fulfillment of related conditions.

Article C. Entitlement to Participate

Any individual who at the Effective Grant Date of the Option under the French Plan is either employed under the terms and conditions of an employment contract ("*contrat de travail*") with the Subsidiary or is a corporate officer of the Subsidiary, shall be eligible to receive Options under the French Plan provided that he or she also satisfies the eligibility conditions of the U.S. Plan. Options may not be issued under the French Plan to employees or officers owning more than ten percent (10%) of the Company's share capital or to individuals other than employees and corporate officers of the Subsidiary. Options may not be issued to directors of the Subsidiary, other than managing directors (Président du Conseil d'Administration, Directeur Général, Directeur Général Délégué, Membre du Directoire, Gérant de sociétés par actions), unless the director is an employee of the Subsidiary as defined by French law.

Article D. Conditions of the Option

To ensure the qualified status of Options under the French Plan, the terms and conditions of any Options granted under the French Plan shall not be modified after the Effective Grant Date, unless otherwise authorized by French law.

Notwithstanding any provision in the U.S. Plan to the contrary and since Common Stock of the Company is traded on a regulated securities market, no Option may be granted to eligible Optionees in France during specific Closed Periods as set forth by section L. 225-177 of the French Commercial Code as amended to the extent such Closed Periods are applicable to the Options.

1. Vesting and Exercisability of Options and Holding of Common Stock

The Options will vest and be exercisable pursuant to the terms and conditions set forth in the U.S. Plan and the French Plan and any stock option agreement or notice. As such, no Option can be exercised before the Vesting Date. However, in the case of death of an Optionee, outstanding Options shall be immediately vested and exercisable under the conditions set forth in Article F of the French Plan.

The vesting of Options may be accelerated in accordance with the Change in Control provisions of the U.S. Plan as noted in Article H below.

Specific provisions apply in the event of termination of employment/service and death as provided in Article F below.

2. Option Price

The method of determining the option price payable pursuant to Options issued hereunder shall be fixed by the Committee on the date the Option is granted ("Option Price"). If Options are considered granted on the Effective Grant Date, the Option price will be determined in accordance with the method set forth by the Committee on the Grant Date. In no event shall the Option Price per share be less than the greater of:

- a. with respect to Purchase Options over Common Stock, the higher of either 80% of the average opening price of such Common Stock during the 20 days of quotation immediately preceding the Effective Grant Date or 80% of the average purchase price paid for such Common Stock by the Company;
- b. with respect to Subscription Options over the Common Stock, 80% of the average opening price of such Common Stock during the 20 days of quotation immediately preceding the Effective Grant Date; and
- c. the minimum Option Price permitted under the U.S. Plan.

3. Payment of the Option Price

Notwithstanding any provisions in the U.S. Plan to the contrary, upon exercise of an Option, the full Option Price will be paid either in cash, by check or by credit transfer, exclusive of any other method of payment. Under a cashless exercise program, the Optionee may give irrevocable instructions to a stockbroker to properly deliver the Option Price to the Company. Notwithstanding any provisions in the U.S. Plan to the contrary, no delivery of previously owned shares having a fair market value on the date of delivery equal to the aggregate Option Price of the shares may be used as consideration for exercising the Options.

Furthermore, notwithstanding any provisions in the U.S. Plan to the contrary, shares owed to the Optionee upon exercise may not be withheld in order to meet the tax and/or social security contributions which might be due at the time of exercise or sale of the underlying shares. However, upon sale of the underlying shares, the Company and/or the Subsidiary shall have the right to withhold, or request any third party to withhold, from the proceeds to be paid to the Optionee the sums corresponding to any social security contributions due at exercise or sale by the Optionee. If such amounts are due and are not withheld, the Optionee agrees to submit the amount due to the Subsidiary by means of check, cash or credit transfer.

The shares acquired upon exercise of an Option will be recorded in an account in the name of the shareholder with a broker or in such other manner as the Company may otherwise determine in order to ensure compliance with applicable law.

4. Mandatory Holding Period

To the extent applicable to French-qualified Options granted by the Company, a specific holding period for the Common Stock or a restriction on the exercise of Options may be specified for Optionees in France who serve as managing directors under French law ("mandataires sociaux"). French law defines the following positions as mandataires sociaux: Président du Conseil d'Administration, Directeur Général, Directeur Général Délégué, Membre du Directoire, Gérant de Sociétés par actions.

Article E. Non-transferability of Options

Notwithstanding any provision in the U.S. Plan to the contrary and except in the case of death, Options cannot be transferred to any third party. In addition, the Options are only exercisable by the Optionee during the lifetime of the Optionee.

Article F. Termination of Employment/Service

1. Death

In the event of the death of an Optionee, any outstanding Options on date of death shall become immediately vested and exercisable. The Optionee's heirs may exercise the Option within six months following the death, but any Option which remains unexercised shall expire six months following the date of the Optionee's death.

2. Forced Retirement or Dismissal

In the event of the Forced Retirement (as defined in Article B) or dismissal of a Optionee, as defined by Section 91-ter of Exhibit II to the French Tax Code as construed by the French tax and social security circulars and subject to the fulfilment of related conditions, his or her Option will benefit from the favorable treatment of French qualified Options upon sale of his or her shares of Common Stock, but only if the Option was exercised at least three (3) months prior to the effective date of the retirement or the delivery of the relevant dismissal notice to the Optionee, as defined by French law and as construed by competent French courts.

3. Other Reasons

In the event of a termination of employment for reasons other than death, the Option shall be exercisable as set forth in the stock option Award Agreement entered into with the Optionee.

Article G. Changes In Capitalization

To ensure the qualified status of Options under the French Plan, adjustments to the Option Price and/or the number of shares subject to an Option issued hereunder shall be made to preclude the dilution or enlargement of benefits under the Option only in the event of a transaction involving the Company listed under Section L. 225-181 of the French Commercial Code, as amended, a repurchase of Common Stock by the Company at a price higher than the stock quotation price on the open market, and according to the provisions of Section L. 228-99 of the

French Commercial Code, as amended, as well as according to specific decrees.. Furthermore, even upon occurrence of a transaction involving the Company listed under Section L. 225-181 of the French Commercial Code, as amended, a repurchase of Common Stock by the Company at a price higher than the stock quotation price on the open market, and according to the provisions of Section L. 228-99 of the French Commercial Code, as amended, as well as according to specific

decreases, no adjustment to the kind of shares to be granted shall be made (*i.e.*, only shares of Common Stock shall be granted to Optionees) to preserve the qualified status of the Option. In the event of an adjustment to the Option Price and/or the number of shares of Common Stock subject to an Option issued hereunder, other than as described in this Article G, the Options may not qualify for favorable income tax and social security treatment under French law.

Article H. Change in Control

In the event that a significant decrease in the value of Options granted to the Optionee occurs or is likely to occur as a result of a Change of Control of the Company or a liquidation, reorganization, merger, consolidation or amalgamation with another company in which the Company is not the surviving company, the Committee may, accordingly to the provisions of the U.S. Plan, in its discretion, authorize immediate vesting and exercise of Options before the date on which any Change of Control, liquidation, reorganization, merger, consolidation or amalgamation becomes effective. If this occurs, the Options may not qualify for favorable income tax and social security treatment under French law.

Article I. Disqualification of French-Qualified Options

If the Options are otherwise modified or adjusted in a manner in keeping with the terms of the U.S. Plan or as mandated as a matter of law and the modification or adjustment is contrary to the terms and conditions of this French Plan, the Options may no longer qualify as French-qualified options. The Company does not undertake nor is it required to maintain the French-qualified status of the Options, and the Optionees understand, acknowledge and agree that it will be their responsibility to bear any additional income taxes and/or social security contributions that may be payable as a result of the disqualification of the French-qualified Options.

If the Options no longer qualify as French-qualified options, the Committee may, provided it is authorized to do so under the U.S. Plan, lift, shorten or terminate certain restrictions applicable to the vesting of the Options, the exercisability of the Options, or the sale of the shares of Common Stock which may have been imposed under this French Plan or in the stock option agreement delivered to the Optionees.

Article J. Term of the Option

The term of the Option will be no greater than ten years after the Grant Date. The specific term will be specified in the applicable stock option agreement. This term can be extended only in the event of the death of the Optionee.

Article K. No Surrender of Options

Notwithstanding the provisions of the U.S. Plan, Optionees may not surrender Options in lieu of exercise for cash.

Article L. No Conversion

Notwithstanding the provisions of the U.S. Plan, Optionees may not convert cash compensation into Options.

Article M. Interpretation

In the event of any conflict between the provisions of the present French Plan and the U.S. Plan, the provisions of the French Plan shall control for any grants made thereunder to Optionees.

It is intended that Options granted under the French Plan shall qualify for the favorable tax and social security treatment applicable to stock options granted under Sections L. 225-177 to L. 225-186-1 of the French Commercial Code, as amended, and in accordance with the relevant provisions set forth by French tax and social security laws and the French tax and social security administrations, but there are no undertakings to maintain this status. The terms of the French Plan shall be interpreted accordingly and in accordance with the relevant provisions set forth by French tax and social security laws, the French tax and social security administrations, any relevant Guidelines published by French tax and social security administrations and are subject to the fulfillment of legal, tax and reporting obligations, if any.

Article N. Employment Rights

The adoption of this French Plan shall not confer upon the Optionees any employment rights and shall not be construed as a part of the Optionee's employment contracts. Articles 6.1(a), 6.1(b) and 6.1(c) of the U.S. Plan do not apply to Optionees in France.

Article O. Amendments

Subject to the terms of the U.S. Plan, the Committee reserves the right to amend or terminate the French Plan at any time. Such amendments would only apply to future grants and would not be retroactive.

Article P. Adoption

The French Plan is effective as of October __, 2019.

2019 STOCK AND INCENTIVE COMPENSATION PLAN

RULES OF THE PROCTER & GAMBLE 2019 SCHEDULE 4 CSOP SUB-PLAN FOR THE UNITED KINGDOM

1 General

This schedule to the Procter & Gamble 2019 Stock and Incentive Compensation Plan (the "**Plan**") sets out the rules of the Procter & Gamble 2019 Schedule 4 CSOP Sub-Plan for the United Kingdom (the "**Sub-Plan**").

2 Establishment of Sub-Plan

The Procter & Gamble Company (the "**Company**") has established the Sub-Plan under Section 3.2(f) of the Plan, which authorises the Committee to establish sub-plans to the Plan.

3 Purpose of Sub-Plan

The purpose of the Sub-Plan is to enable the grant to, and subsequent exercise by, employees and directors in the United Kingdom, on a tax advantaged basis, of options to acquire Shares under the Plan within the provisions of Schedule 4.

4 Rules of Sub-Plan

The rules of the Plan, in their present form and as amended from time to time, shall, with the modifications set out in this schedule, form the rules of the Sub-Plan. The provisions on "Vesting and Exercise" in the form of Award Agreement appended to this schedule form part of the Sub-Plan. In the event of any conflict between the rules of the Plan and this Sub-Plan, the Sub-Plan shall prevail.

5 Relationship of Sub-Plan to Plan

The Sub-Plan shall form part of the Plan and not a separate and independent plan.

6 Interpretation

In this Sub-Plan, unless the context otherwise requires, the following words and expressions have the following meanings:

Acquiring Company a company which obtains Control of the Company in the circumstances referred to in rule 25;

Associated Company the meaning given to that expression by paragraph 35(1) of Schedule 4;
Close Company the meaning given to that expression by section 989 of the Income Tax Act 2007, and paragraph 9(4) of Schedule 4;
Committee the Compensation & Leadership Development Committee of the Board or such other committee as may be designated by the Board to administer the Pla
Consortium the meaning given to that word by paragraph 36(2) of Schedule 4;
Constituent Company means the Company or a company which is:

- a. a Subsidiary or
- b. a Jointly Owned Company where neither it nor any company Controlled by it is a constituent company under the provisions of paragraph 34(4) of Schedule 4 in any other CSOP scheme as that term is defined in paragraph 2 of Schedule 4;

Control the meaning given to that word by section 719 of ITEPA 2003 and "Controlled" shall be construed accordingly;

Date of Grant the date on which an Option is granted to an Eligible Employee in accordance with the Articles of the Plan;

Eligible Employee

an individual who falls within the provisions of Article 5 of the Plan and who is:

- a. an employee (other than a director) of a Constituent Company; or
- b. a director of a Constituent Company who is contracted to work at least 25 hours per week for the Company and its subsidiaries or any of them (exclusive of meal breaks)

and who, in either case,:

- i. is not eligible solely by reason that he is a non-executive director of a Constituent Company;
- ii. has earnings in respect of his office or employment which are (or would be if there were any) general earnings to which sections 15, 22 or 26 of ITEPA 2003 applies; and
- iii. does not have at the Date of Grant, and has not had during the preceding twelve months, a Material Interest in a Close Company which is the Company or a company which has Control of the Company or a member of a Consortium which owns the Company;

ITEPA 2003

means the Income Tax (Earnings and Pensions) Act 2003;

Market Value

notwithstanding Section 7.2 of the Plan,

(a) in the case of an Option granted under the Sub-Plan:

(i) if at the relevant time the Shares are listed on the New York Stock Exchange, the average of the highest and lowest sale prices of a Share on the Date of Grant (as quoted in the *Wall Street Journal*) or, if there were no trades on that day, on the dealing day immediately preceding the Date of Grant;

(ii) if paragraph (i) above does not apply, the market value of a Share as determined in accordance with Part VIII of the Taxation of Chargeable Gains Act 1992 and agreed in advance with HM Revenue & Customs Shares and Assets Valuation on the Date of Grant or such earlier date or dates (not being more than thirty days before the Date of Grant) as may be agreed with HM Revenue & Customs;

provided that the Market Value of Shares subject to a Relevant Restriction shall be determined as if they were not subject to a Relevant Restriction;

(b) in the case of an option granted under any other share option scheme, the market value of a Share shall be determined under the rules of such scheme for the purpose of the grant of the option;

Material Interest

the meaning given to that expression by paragraphs 9 to 14 of Schedule 4;

New Option

an option granted by way of exchange under rule 25.1;

New Shares

the shares subject to a New Option as set out in rule 25;

Option

a right to acquire Shares granted under the Sub-Plan;

Option Holder

an individual who holds an Option or, where the context permits, his legal personal representatives;

Relevant Restriction

any provision in any contract, agreement, arrangement or condition to which any of sub-sections (2) to (4) of section 423 of ITEPA 2003 would apply if references in those sub-sections to employment-related securities were references to the Shares;

Schedule 4

means Schedule 4 to ITEPA 2003;

Schedule 4 CSOP

a share plan that meets the requirements of Schedule 4;

Shares

common stock of the Company; and

Subsidiary

means a company which is a subsidiary of the Company within the meaning of section 1159 of the Companies Act 2006 over which the Company has Control.

In this Sub-Plan, unless the context otherwise requires:

- words and expressions not defined above have the same meanings as are given to them in the Plan;
- the contents and rule headings are inserted for ease of reference only and do not affect their interpretation;
- a reference to a rule is a reference to a rule in this Sub-Plan; and

- a reference to a statutory provision is a reference to a United Kingdom statutory provision and includes any statutory modification, amendment or re-enactment thereof.

7 Companies participating in Sub-Plan

Notwithstanding the provisions contained in the definition of "Subsidiary" in Article 2 of the Plan, the companies participating in the Sub-Plan shall be the Company and any Constituent Company which has been nominated by the Company to participate in the Sub-Plan.

8 Shares used in Sub-Plan

The Shares shall form part of the ordinary share capital of the Company and shall at all times comply with the requirements of paragraphs 16 to 20 of Schedule 4.

9 Grant of Options

An Option shall be granted under and subject to the rules of the Plan as modified by this Sub-Plan.

10 Identification of Options

An Award Agreement issued in respect of an Option shall expressly state that it is issued in respect of an Option. An option which is not so identified shall not constitute an Option.

11 Contents of Award Agreement

11.1 An Award Agreement issued in respect of an Option shall state:

- that it is issued in respect of an Option;
- the date of grant of the Option;
- the number of Shares subject to the Option (or how that number may be calculated);
- the exercise price under the Option (or the method by which the exercise price will be determined);
- any performance target or other condition imposed on the exercise of the Option;
- the times at which the Option will ordinarily be exercisable;
- the circumstances in which the Option will lapse;
- details of any Relevant Restriction to which the Shares are subject; and
- any conditions imposed by the Committee under Section 3.2 of the Plan in relation to the Option.

11.2 Notwithstanding the definition of "Award Agreement" in Article 2 of the Plan, an Option granted under this Sub-Plan shall include the terms on vesting and exercise of Options under the heading "Vesting and Exercise" in the form of Award Agreement appended to this schedule, or such other terms as to vesting and exercise at the Vest Date (as defined in the appended form of Award Agreement) or on Termination of Employment as determined by the Committee that comply with the requirements of Schedule 4.

12 Persons to whom Options may be granted

An Option may not be granted to an individual who is not an Eligible Employee at the Date of Grant.

13 Options non transferable

Notwithstanding Article 15 of the Plan, an Option shall be personal to the Eligible Employee to whom it is granted and, subject to rule 23, shall not be capable of being transferred, charged or otherwise alienated and shall lapse immediately if the Option Holder purports to transfer, charge or otherwise alienate the Option.

14 Limit on number of Shares placed under Option under Sub-Plan

For the avoidance of doubt, Shares placed under Option under the Sub-Plan shall be taken into account for the purpose of Section 4.1 of the Plan.

15 HM Revenue & Customs limit (£30,000)

An Option may not be granted to an Eligible Employee if the result of granting the Option would be that the aggregate Market Value of the shares subject to all outstanding options granted to him under the Sub-Plan or any other share option scheme established by the Company or an Associated Company under Schedule 4) would exceed sterling £30,000 or such other limit as may from time to time be specified in paragraph 6 of Schedule 4.

16 Foreign Currency Options

For the purpose of the limit contained in rule 15, the United Kingdom sterling equivalent of the Market Value of a share on any day shall be determined by taking the spot sterling/US dollar exchange rate for that day as shown in the Financial Times.

17 Scaling Down

If the grant of an Option would otherwise cause the limit in rule 15 to be exceeded, it shall take effect as the grant of an Option under the Sub-Plan over the highest number of Shares which does not cause the limit to be exceeded. If more than one Option is granted on the same Date of Grant, the number of Shares which would otherwise be subject to each Option shall be reduced *pro rata*.

18 Exercise price under Options

Notwithstanding Section 7.2 of the Plan, the amount payable per Share on the exercise of an Option shall not be manifestly less than the Market Value of a Share on the Date of Grant.

19 Latest date for exercise of Options

An Option may not be exercised more than ten years after the Date of Grant and to the extent not so exercised by that time the Option shall lapse immediately. This term can be extended only in the event of the death of the Option Holder as required by rule 23.

20 Material Interest

An Option may not be exercised if the Option Holder then has, or has had within the preceding twelve months, a Material Interest in a Close Company which is the Company or which is a company which has Control of the Company or which is a member of a Consortium which owns the Company.

21 Payment for Shares on exercise of Options

The amount due on the exercise of an Option may be paid in cash or by cheque or banker's draft, or by using other arrangements acceptable to the Company to satisfy payment of the

amount due. The payment may not be in the form of relinquishing a portion of the Option or paid by the transfer to the Company of Shares or any other shares or securities, and in any circumstance the Company must not charge an administrative fee for the exercise of an Option or agree any arrangement to satisfy payment of the amount due on exercise which is not consistent with Schedule 4. The date of exercise of an Option shall be the date on which the Company receives the amount due on the exercise of the Option under this rule 21, together with any payment or documentation required under rule 29.

22 Issue or transfer of Shares on exercise of Options

The Company shall, as soon as reasonably practicable and in any event not later than thirty days after the date of exercise of an Option, issue or transfer to the Option Holder, or procure the issue or transfer to the Option Holder of, the number of Shares specified in the notice of exercise, subject only to compliance by the Option Holder with the rules of the Sub-Plan and to any delay necessary to complete or obtain:

22.1 the listing of the Shares on any stock exchange on which Shares are then listed; or

22.2 such registration or other qualification of the Shares under any applicable law, rule or regulation as the Company determines is necessary or desirable.

23 Death of Option Holder

If an Option Holder dies before the tenth anniversary of the Date of Grant, his personal representatives shall be entitled to exercise his Options at any time during the twelve-month period following his death. If not so exercised, the Options shall lapse immediately.

24 Retirement of Option Holder

The definition of the term "Retirement" in Article 2 of the Plan shall not apply to this Sub-Plan and the term "Retirement" in paragraph 2 of the appended form of Award Agreement under the heading "Vesting and Exercise" shall bear its natural meaning in the United Kingdom.

25 Change in Control of Company

25.1 Exchange of Options

Should a Change in Control occur within the terms of Article 17 of the Plan, then only if a company ("Acquiring Company") obtains Control of the Company as a result of making:

25.1.1 a general offer to acquire the whole of the issued ordinary share capital of the Company which is made on a condition such that if it is satisfied the person making the offer will have Control of the Company;

25.1.2 a general offer to acquire all the shares in the Company of the same class as the Shares;

25.1.3 a compromise or arrangement sanctioned by the court under section 899 of the Companies Act 2006; or

25.1.4 a “non-UK company reorganisation arrangement” (within the meaning of paragraph 35ZA of Schedule 4); or

25.1.5 should an Acquiring Company become bound or entitled to acquire Shares under sections 979 to 982 of the Companies Act 2006,

an Option Holder may, at any time during the period set out in rule 25.2, by agreement with the Acquiring Company, release his Option in consideration of the grant to him of a new option (“New Option”) which is equivalent to the Option but which relates to shares (“New Shares”) in:

- the Acquiring Company;
- a company which has Control of the Acquiring Company; or
- a company which either is, or has Control of, a company which is a member of a Consortium which owns either the Acquiring Company or a company having Control of the Acquiring Company.

25.2 Period allowed for exchange of Options

The period referred to in rule 25.1 is:

25.2.1 for events in rules 25.1.1 to 25.1.4 (inclusive), the period of six months beginning with the time when the person making the offer has obtained Control of the Company and any condition subject to which the offer is made has been satisfied; and

25.2.2 for the event in rule 25.1.5, the period during which the Acquiring Company remains bound or entitled to acquire Shares under sections 979 to 982 of the Companies Act 2006.

25.3 Meaning of “equivalent”

The New Option shall not be regarded for the purpose of this rule 25 as equivalent to the Option unless:

25.3.1 the New Shares satisfy the conditions in paragraphs 16 to 20 of Schedule 4;
and

25.3.2 the New Option is exercisable in the same manner as the Option and subject to the provisions of the Sub-Plan as it had effect immediately before the release of the Option; and

25.3.3 the total market value, immediately before the release of the Option, of the Shares which were subject to the Option is substantially the same as the total market value, immediately after the grant of the New Option, of the New

Shares subject to the New Option (market value being determined using a methodology agreed by HM Revenue & Customs);

25.3.4 the total amount payable by the Option Holder for the acquisition of the New Shares under the New Option is substantially the same as the total amount that would have been payable by the Option Holder for the acquisition of the Shares under the Option.

25.4 Date of grant of New Option

The date of grant of the New Option shall be deemed to be the same as the Date of Grant of the Option.

25.5 Application of Sub-Plan to New Option

In the application of the Sub-Plan to the New Option, where appropriate, references to "Company" and "Shares" shall be read as if they were references to the company to whose shares the New Option relates and the New Shares, respectively, (save that in the definition of "Committee", the reference to "Company" shall be read as if it were a reference to The Procter & Gamble Company).

26 Rights attaching to Shares issued on exercise of Options

Notwithstanding the provisions of Article 3 of the Plan, which grant the Committee authority to determine the conditions and restrictions, if any, applying to shares of Common Stock acquired through the exercise of an option, all Shares issued in respect of the exercise of an Option shall, as to any voting, dividend, transfer and other rights, including those arising on a liquidation of the Company, rank equally in all respects and as one class with the shares of the same class in issue at the date of such issue save as regards any rights attaching to such shares by reference to a record date prior to the date of such issue.

27 Amendment of Sub-Plan

Notwithstanding Section 19.1 of the Plan, no amendment may be made to a "key feature" of the Sub-Plan (within the meaning given to that expression in paragraph 30(4) of Schedule 4), whether taking the form of an amendment of the Plan or the Sub-Plan, that would result in the Sub-Plan no longer being a Schedule 4 CSOP.

28 Adjustment of Options

Notwithstanding Section 4.5 of the Plan, to the extent that any adjustment of an Option is permitted under these rules, it shall not be made unless the adjustment is permitted pursuant to, and in compliance with, paragraph 22 of Schedule 4.

29 Tax and social security withholding

An Option may not be exercised unless the Option Holder has beforehand made provision for the payment or withholding of any taxes and social security required to be withheld in

accordance with the applicable law of any jurisdiction in respect of the exercise of the Option, or the receipt of the Shares. Notwithstanding the provisions of Article 20 of the Plan which permit different arrangements to be made to satisfy the payment in respect of any taxes and social security required to be withheld, the payment may not be in the form of relinquishing a portion of the Option or paid by the transfer to the Company of Shares or any other shares or securities, unless this is the Shares by virtue of the exercise of the Option. The Option Holder may, by agreement with the Company, enter into some other arrangement to ensure that such amount is available (whether by authorising the sale of some or all of the Shares subject to his Option and the payment to the Company, or where appropriate the Option Holder's employing company of the requisite amount out of the proceeds of sale or otherwise). Where this is the case, the Option shall not be treated as exercised until the Company determines that such arrangements are satisfactory to it.

30 Transfer of Employer's NIC

The Committee may, at its discretion, impose requirements for the payment by the Option Holder of all or any part of the employer's national insurance contributions ("NIC") which may arise as a result of the exercise of his Option. Such requirements shall be specified on the Date of Grant and shall be a condition of exercise of the Option, provided that the Committee (acting fairly and reasonably) may waive these requirements. They may include in particular, but not by way of limitation, a determination that the Option may not be exercised unless the Option Holder has beforehand paid to the Company (or the company which employs the Option Holder, if different) an amount sufficient to discharge all or any part of the employer's NIC. Alternatively, the Option Holder may, by agreement with the Company or the employing company (as the case may be), enter into some other arrangement to ensure that such amount is available to them or it (whether by authorising the sale of some or all of the Shares subject to his Option and the payment to the Company or the employing company (as the case may be) of the requisite amount out of the proceeds of sale or otherwise). Where this is the case, the Option shall not be treated as exercised until the Company or the employing company (as the case may be) determine that such arrangements are satisfactory to it.

31 Disapplication of certain provisions of Plan

Sections 6.2 and 6.3 of the Plan shall not apply for the purpose of this Sub-Plan. In addition the provisions of the Plan dealing with:

- Incentive Stock Options;
- Stock Appreciation Rights;
- Restricted Stock;
- Restricted Stock Units;
- Performance Stock Units;
- Other Stock-Based Awards; and
- Cash-Based Awards
- the cash cancellation of share options including those contained in Article 17.3(a)(i) of the Plan; and
- the granting of Options in tandem with Stock Appreciation Rights and the subsequent cancellation of Options

shall not form part of, and no such rights may be granted under, this Sub-Plan.

APPENDIX

FORM OF AWARD AGREEMENT

Just scroll and read to the bottom of the grant letter below so you can accept/reject your grant.

AWARD AGREEMENT [●] 20[●]

NAME GLOBAL ID

Subject: UK Tax Advantaged (NON-STATUTORY) STOCK OPTION SERIES [●]-LTIP-F

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you an option to purchase shares of Procter & Gamble Common Stock as follows:

Option Price per Share:	\$
Number of Shares:	
Grant Date:	[•] 20[•]
Expiration Date:	[•] 20[•]
Vest Date:	[•]% on [•] 20[•]
Acceptance Deadline:	[•] 20[•]

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan and the applicable sub-plan, the Schedule 4 CSOP Sub-Plan for the United Kingdom (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and this Award Agreement, including Attachment A and the Exercise Instructions in place as may be revised from time to time, except that the Committee has waived the provisions of Sections 6.1(a) and 6.1(c) of the Plan. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Schedule 4 CSOP Sub-Plan for the United Kingdom and the Regulations of the Committee by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

Vesting and Exercise

If you leave the Company before the Vest Date, the Award will be forfeited unless you meet one of the conditions listed below. If you remain employed through the Vest Date, the Award will become exercisable on the Vest Date. If you terminate employment before the Expiration Date and prior to exercising the Award, except for the reasons listed below, the Award will be forfeited immediately upon your termination of employment. For the purposes of this Award, termination of employment

will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

1. Termination on Account of Death. In the event of death, the Vest Date for this Award becomes your date of death and the Award in its entirety remains exercisable until the Expiration Date.

2. Termination for a Qualified Reason Listed Below. In the event you terminate employment for one of the qualified reasons listed below, after the Grant Date but before October 28, 20[•], the Award will be forfeited. In the event of termination for one of the qualified reasons listed below, on or after October 28, 20[•], but prior to September 30, 20[•], the award will be prorated based on the number of days you remained an employee between the Grant Date and September 30, 20[•]. If the termination for one of the qualified reasons listed below occurs after September 30, 20[•], the entire award will be retained. The portion of the award that is ultimately retained will be exercisable on the Vest Date in this Award Agreement and will expire on the Expiration Date as long as you remain in compliance with the terms of the Plan and the Regulations. Qualified termination reasons are as follows:

- Retirement or Disability;
- Termination pursuant to a written separation agreement from the Company or a subsidiary that provides for equity retention; or
- Termination in connection with a divestiture or separation of any of the Company's businesses.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

THE PROCTER & GAMBLE COMPANY

Chief Human Resources Officer

Attachment(s):

[Attachment A](#)

To Reject Your Award

To Accept Your Award

To Accept Your Award

Read and check the boxes below:

Read and check the box(es) below:


 imagea.jpg

I have read, understand and agree to be bound by each of:

- The Procter & Gamble 2019 Stock and Incentive Compensation Plan
- The Schedule 4 CSOP Sub-Plan for the United Kingdom (applies to series [●]-LTIP-F only)
- Regulations of the Committee
- This Award Agreement, including Attachment A

 imagea.jpg


I accept the stock option award detailed above (Including attachments)

 imagea.jpg

I have read and understand the terms noted above and do not agree to be bound by these terms. I hereby reject the stock option award detailed above.

Exhibit 10-28

The Procter & Gamble 2019 Stock & Incentive Compensation Plan - Additional Terms and Conditions



FORM BOD AWARD AGREEMENT

<Director Name> October __, 20__

Subject: Award of Restricted Stock Units

This is to advise you that The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Number of Restricted Stock Units:	[# SHARES]
Grant Date:	[GRANT DATE]
Vest Date:	[DATE (Day Before Next Annual Meeting Following Grant)]
Original Settlement Date:	[DATE]

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub-plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), and this Award Agreement, including Attachment A-BOD. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan.

Voting Rights and Dividend Equivalents

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share units may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

Vesting and Payment

If you remain a Non-Employee Director through the Vest Date, the Award will be paid on the Original Settlement Date or Agreed Settlement Date, whichever is applicable, except in the case of death or Disability. In the case of death or Disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or Disability, as applicable. If you leave the Board without cause before the Vest Date you will retain a pro-rata portion of your Award based on days of service during the vesting period, subject to the terms and conditions governing the Award.

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

Deferral Election

At any time prior to Termination of Directorship, you and the Company may agree to postpone the Original Settlement Date to such later date ("Agreed Settlement Date") as may be elected by you, which date shall be at least five years later than the Original Settlement Date and in accordance with Internal Revenue Code Section 409A.

This Award Agreement including Attachment A-BOD, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understanding and/or agreements that have been entered by you with the Company regarding this specific Award. Any legal action related to this Award may be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service of process from said courts solely for legal actions related to this Award.

THE PROCTER & GAMBLE COMPANY

Balaji Purushothaman

Chief Human Resources Officer

Attachment A-BOD

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation for any purposes including, but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments; vi) the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with P&G; vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not interfere with the ability of P&G to terminate my directorship at any time, with or without cause; and ix) no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G from any such claim that may arise.

Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G holds certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, , any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of


implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I

may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

Responsibility for Taxes

Regardless of any action P&G takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related withholding ("Tax-Related Items"), I acknowledge that the ultimate liability for all Tax-Related Items is and remains my responsibility and that P&G (1) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) does not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G to satisfy all withholding and payment on account obligations of P&G. In this regard, I authorize P&G to withhold all applicable Tax-Related Items from my wages or other cash compensation paid to me by P&G or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax-Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G any amount of Tax-Related Items that P&G may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax-Related Items as described in this section.



FORM RTN2 AWARD AGREEMENT

FIRST_NAME_MIDDLE_NAME_LAST_NAME
EMPLOYEE_IDENTIFIER

Subject: RESTRICTED STOCK UNIT SERIES RTN2

In recognition of your contributions to the future success of the business, The Procter & Gamble Company ("Company") hereby grants to you Restricted Stock Units ("RSUs") of Procter & Gamble Common Stock as follows:

Grant Date:	OPTION_DATE, 'DD-Month-YYYY'
Grant Date Share Price:	MARKET_VALUE
Number of Restricted Stock Units:	SHARES_PERIOD 1,
Vest Date:	VEST_DATE_PERIOD 1, DD-Month-YYYY'
Settlement Date:	See Payment and Vesting Details Below
Number of Restricted Stock Units:	SHARES_PERIOD2,
Vest Date:	VEST_DATE_PERIOD2, DD-Month-YYYY'
Settlement Date:	See Payment and Vesting Details Below
Total Number of Restricted Stock Units:	TOTAL_SHARES_GRANTED,

This Award is granted in accordance with and subject to the terms of The Procter & Gamble 2019 Stock and Incentive Compensation Plan (including any applicable sub- plan) (the "Plan"), the Regulations of the Compensation and Leadership Development Committee of the Board of Directors ("Committee"), this Award Agreement including Attachments, and the Settlement Instructions in place as may be revised from time to time. Any capitalized terms used in this Agreement that are not otherwise defined herein are defined in the Plan. You may access the Plan by activating this hyperlink: [The Procter & Gamble 2019 Stock and Incentive Compensation Plan](#) and the Regulations and Sub Plans by activating this hyperlink: [Regulations of the Committee](#). If you have difficulty accessing the materials online, please send an email to Execcomp.IM@pg.com for assistance.

Voting Rights and Dividend Equivalents

As a holder of RSUs, during the period from the Grant Date until the date the RSUs are paid, each time a cash dividend or other cash distribution is paid with respect to Common Stock, you will receive additional RSUs ("Dividend Equivalent RSUs"). The number of Dividend Equivalent RSUs will be determined as follows: multiply the number of RSUs and Dividend Equivalent RSUs currently held by the per share amount of the cash dividend or other cash distribution on Common Stock, then divide the result by the price of the Common Stock on the date of the dividend or distribution. These Dividend Equivalent RSUs will be subject to the same terms and conditions as the original RSUs that gave rise to them, including vesting and settlement terms, except that if there is a fractional number of Dividend Equivalent RSUs on the date the RSUs are paid, the resulting fractional share unit may be paid as cash, fractional shares, or rounded up to the nearest full share based on administrative preference of the Company. This Award represents an unfunded, unsecured right to receive payment in the future, and does not entitle you to voting rights or dividend rights as a shareholder.

Payment and Vesting

If you remain employed through the Vest Dates, the Award will be paid on the Vest Date(s) according to the vesting schedule except if you are a Board- Designated Section 16 Officer of the Company on the Vest Date(s) and in the case of death, as described below. If your Termination of Employment occurs for any reason before a Vest Date except for the reasons listed below, the Award will be forfeited. For the purposes of this Award, Termination of Employment will be effective as of the date that you are no longer actively employed and will not be extended by any notice period required under local law.

- 1 **Termination on Account of Death or Disability.** In the case of death or disability, the Award will be fully vested and payment will be made by the later of the end of the calendar year or two and a half months following the date of death or disability.
- 2 **Termination without Cause Pursuant to a Written Separation Agreement.** In the event of your Termination of Employment from the Company or a Subsidiary without Cause, your Award is forfeited unless you have executed a written separation agreement with the Company that provides for retention of outstanding

equity awards. In this case the Award will be delivered on the Vest Date(s) as long as you remain in compliance with the terms of the Plan, the Regulations, and your separation agreement.

- 3 Vesting for Board- Designated Section 16 Officers. Payment will be on the Vest Date(s) except when the Vest Date(s) is outside of an open trading window as designated by the Company in accordance with the Company's Insider Trading Policy and the Section 16 Officer does not have a valid 10b5-1 plan in place instructing the sale of Common Stock to cover taxes and administrative costs, in which case payment will be made on the first day of the first such open trading window following the Vest Date(s).

Notwithstanding the foregoing, in the event of a Change in Control, payment shall be made pursuant to the terms provided in the Plan.

Payment under this Award will be made in the form of Common Stock or such other form of payment as determined by the Committee pursuant to the Plan, subject to applicable tax withholding.

This Award Agreement, including Attachment A, the Plan and Regulations of the Committee together constitute an agreement between the Company and you in accordance with the terms thereof and hereof, and no other understandings and/or agreements have been entered by you with the Company regarding this specific Award. Any legal action related to this Award, including Article 6 of the Plan, must be brought in any federal or state court located in Hamilton County, Ohio, USA, and you hereby agree to accept the jurisdiction of these courts and consent to service

of process from said courts solely for legal actions related to this Award. You have the right to consult with a lawyer before accepting this Award.

THE PROCTER & GAMBLE COMPANY

Bala Purushothaman
Chief Human Resources Officer

IMPORTANT

By accepting this award within your E*TRADE account, you agree to be bound by [The Procter & Gamble 2019 Stock Plan](#) including the non-compete and non-solicitation clauses, the [Stock Plan Regulations of the Committee](#) and this Award Agreement including Attachment A (at end of this document).

Attachment A

Please note that when the issue or transfer of the Common Stock covered by this Award may, in the opinion of the Company, conflict or be inconsistent with any applicable law or regulation of any governmental agency, the Company reserves the right to refuse to issue or transfer said Common Stock and that any outstanding Awards may be suspended or terminated and net proceeds may be recovered by the Company if you fail to comply with the terms and conditions governing this Award.

Nature of the Award

By completing this form and accepting the Award evidenced hereby, I acknowledge that: i) the Plan is established voluntarily by The Procter & Gamble Company ("P&G"), it is discretionary in nature and it may be amended, suspended or terminated at any time; ii) Awards under the Plan are voluntary and occasional and this Award does not create any contractual or other right to receive future Awards, or benefits in lieu of an Award, even if Awards have been granted repeatedly in the past; iii) all decisions with respect to future Awards, if any, will be at the sole discretion of P&G; iv) my participation in the Plan is voluntary; v) this Award is an extraordinary item and not part of normal or expected compensation or salary for any purposes including, but not limited to, calculating any termination, severance,

resignation, redundancy, end of service payments, bonuses, long- service awards, pension or retirement benefits or similar payments; vi) in the event that my employer is not P&G, the Award will not be interpreted to form an employment relationship with P&G; and furthermore, the Award will not be interpreted to form an employment contract with my employer ("Employer"); vii) the future value of the shares purchased under the Plan is unknown and cannot be predicted with certainty, may increase or decrease in value and potentially have no value; viii) my participation in the Plan shall not create a right to further employment with my employer and shall not interfere with the ability of my employer to terminate my employment relationship at any time, with or without cause; and ix) no claim or entitlement to compensation or damages arises from the termination of the Award or the diminution in value of the Award or shares purchased and I irrevocably release P&G and my employer from any such claim that may arise.

Data Privacy

I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this document by and among, as applicable, my Employer and The Procter & Gamble Company and its subsidiaries and affiliates ("P&G") for the exclusive purpose of implementing, administering and managing my participation in the Plan.

I understand that P&G and my Employer hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in P&G, details of all Awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor, for the purpose of implementing, administering and managing the Plan ("Data"). I understand that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in my country or elsewhere (including countries outside the European Economic Area), and that the recipient's country may have different data privacy laws and protections than my country. I understand that I may request a list with the names and addresses of any potential recipients of the Data by contacting my local human resources representative. I authorize the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom I may elect to deposit any shares of stock acquired upon exercise or settlement of the Award. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the Plan. I understand that I may, at any time, view Data, request additional information about the storage and processing of Data, require

any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing my local human resources representative. I understand, however, that refusing or withdrawing my consent may affect my ability to participate in the Plan. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.

Responsibility for Taxes

Regardless of any action P&G or my Employer takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax- related withholding ("Tax- Related Items"), I acknowledge that the ultimate liability for all Tax- Related Items is and remains my responsibility and that P&G and/or my Employer (1) make no representations or undertakings regarding the treatment of any Tax- Related Items in connection with any aspect of this Award, including the issuance, vesting or exercise, settlement, the subsequent sale of shares acquired, the receipt of any dividends or dividend equivalents or the potential impact of current or future tax legislation in any jurisdiction; and (2) do not commit to structure the terms of the Award or any aspect of the Award to reduce or eliminate my liability for Tax-Related Items.

Prior to exercise or settlement of an Award, I shall pay or make adequate arrangements satisfactory to P&G and/or my Employer to satisfy all withholding and payment on account obligations of P&G and/or my employer. In this regard, I authorize P&G and/or my Employer to withhold all applicable Tax- Related Items from my wages or other cash compensation paid to me by P&G and/or my Employer or from proceeds of the sale of the shares. Alternatively, or in addition, if permissible under local law, P&G may (1) sell or arrange for the sale of shares that I acquire to meet the withholding obligation for Tax- Related Items, and/or (2) withhold in shares, provided that P&G only withholds the amount of shares necessary to satisfy the minimum withholding amount. Finally, I shall pay to P&G or my Employer any amount of Tax- Related Items that P&G or my Employer may be required to withhold as a result of my participation in the Plan or my purchase of shares that cannot be satisfied by the means previously described. P&G may refuse to honor the exercise and refuse to deliver the shares if I fail to comply with my obligations in connection with the Tax- Related Items as described in this section.

Exhibit (19-1)
P&G
Global Insider Trading Policy

P&G
Global Insider Trading Policy

As a Company employee or director, you may not use—or help others use—confidential information that you learn through your work to trade in the stock market or make other investment decisions. You could face personal, criminal liability for doing so. This includes profiting or avoiding losses when trading Company stock or other securities like options or bonds, and this restriction applies to information about the Company or about any other publicly traded company.

Under the law, if you have material, non-public information about a company, it is illegal to buy or sell that company's stock or other securities or to share this information with others who engage in such trading (known as "tipping"). As a result, this Global Insider Trading Policy generally restricts certain "Transactions" in "Securities" by employees, directors and their "Related Persons" when they possess "Inside Information." Each of these terms is defined in Section 6 below.

All persons who are subject to the Global Insider Trading Policy are categorized according to their anticipated access to sensitive corporate information. The Corporate Secretary's Office, in consultation with the appropriate business unit or corporate function, determines which employees are subject to more stringent trading restrictions based on this access, as well as applicable law.

Category	Who	Restriction Status
Category 1: Rarely Restricted Employees in positions that only rarely involve Inside Information	<ol style="list-style-type: none">1. All employees, including employees of non-integrated businesses, whenever in possession of Inside Info2. Related Persons of the above employees	<ol style="list-style-type: none">1. Not on Insider Trading List2. Can make Transactions at any time, except when in actual possession of Inside Information
Category 2: More Restricted Employees in roles/groups with frequent access to Information as part of their	<ol style="list-style-type: none">1. All employees determined by the Corporate Secretary's Office, in consultation with the appropriate business unit or corporate function, to have frequent access to Inside I2. Related Persons of the above employees	<ol style="list-style-type: none">1. On Insider Trading List2. Limited to Transactions during four Window periods3. See Section 7 for additional trading restrictions
Category 3: Most Restricted Senior management and members of the Board Directors	<ol style="list-style-type: none">1. Board of Directors2. Section 16 Officers as determined by the Board3. Related Persons to any of the above	<ol style="list-style-type: none">1. On Insider Trading List2. Limited to Transactions during four Window periods3. Must pre-clear all Transactions4. See Sections 7 and 8 for applicable trading restrictions

2.0 COMPANY INTENT

As a Company and as individuals we operate based on the principle of doing the right thing in all that we do. The Global Insider Trading Policy provides guidelines with respect to transactions in the

Securities of, and the handling of confidential information about, the Company and the companies with which the Company does business. The Company has adopted this policy to promote compliance with the securities laws that prohibit persons who are aware of Inside Information about a company from: (i) trading in the securities of that company or (ii) providing material non-public information to other persons who may trade on the basis of that information. However, each individual is ultimately responsible for their own conduct, including their obligation to refrain from trading when they possess material, non-public information.

3.0 SCOPE

This policy applies to: **all employees** of the Company or any of its subsidiaries or affiliates, in all locations, including non-integrated businesses; members of the **Board of Directors**; **third parties** with access to sensitive information about the Company or other publicly traded companies as a result of their engagement with the Company; and **Related Persons** to all of the above.

4.0 WHAT YOU NEED TO DO

ALL EMPLOYEES & DIRECTORS:

1. **Handle confidential information appropriately.** We each have a responsibility to handle P&G's confidential information properly. This includes not only securing our office workspaces and communications but also taking steps to safeguard information outside the office. For example, you should not leave documents unattended or computer screens unlocked while at home, share potentially confidential information with friends or family, or discuss confidential matters in public where you could be overheard. Because this Policy applies to Related Persons, it is especially important that you handle P&G information securely at home. Please refer to the policies, training materials, and related resources available at security.pg.com for additional information.
2. **Operate on a "need-to-know" basis.** P&G employees are committed to the success of the Company and are naturally curious about important business developments. But curiosity about total Company results and overall financial performance that have not yet been disclosed publicly can lead to improper exposure to Inside Information. Unless your core work concerns such matters, do not seek out this kind of information until it is publicly disclosed and do not share this kind of information except with those who need it as part of their work.
3. **Report any potential violations.** If you become aware of any employee or third party obtaining or using Inside Information in an unauthorized manner, immediately report it to the Corporate Secretary's Office via [email address].
4. **Understand how to handle knowledge of significant events.** If you become aware of any event or information that you believe could have a meaningful impact on the Company's financial results or ability to deliver its commitments to consumers, customers, or shareholders, immediately contact the Corporate Secretary's Office via [email address] to see if a restriction is appropriate.

-
5. **Trading restrictions may continue after employment terminates.** For Category 2 and Category 3 insiders who leave the Company, the trading restrictions continue to apply until the first Window after termination of employment or when Inside Information pertaining to the Company, suppliers, or customers becomes publicly known (see Section 7 for a description of the Company's "Window" periods).

MANAGERS OF OTHERS (Band 3 and Up):

6. **Awareness of the policy.** Managers (Band 3 and up) are required to share the policy with any new hire, with all direct reports on a regular basis, and with any team that is assigned to sensitive work involving Inside Information.
7. **Identification of Insiders.** Managers should identify team members and other support staff who belong on the Insider List due to their routine access to sensitive corporate information.

5.0 POLICY EXCEPTIONS

Any exception to this Policy must be approved by the Corporate Secretary's Office. To request an exception, contact the Corporate Secretary's Office at [email address]. No exceptions may be given to the prohibition of Derivative Transactions set out in Section 7.

6.0 DEFINITIONS

Inside Information

Under this Policy, "Inside Information" is defined as "material, non-public information."

Non-Public: Information is non-public unless it is: (1) broadly available to the general marketplace, and (2) the investing public has had sufficient time to digest the information (one business day is a safe guideline for this purpose).

Material: Information is considered material if there is a substantial likelihood that a reasonable investor would consider that information important in making a decision to buy, hold or sell a security. Any information that could be expected to affect a company's stock price, whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all the facts and circumstances and is often evaluated by enforcement authorities with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that could be regarded as material are:

1. Draft earnings reports or reasonably accurate profit/loss forecasts.
2. Pending mergers, or the planned acquisition or disposition of significant assets.
3. Gain or loss of a significant customer or supplier.
4. Gain or loss of a significant contract.
5. Significant disruptions in supply chain, source of supply, or product availability.
6. Significant changes in senior management.
7. Significant legal exposure due to actual or threatened litigation or investigations.

-
8. Significant cybersecurity incidents, such as a hack or data breach.
 9. Significant research and development advancements or product introductions.
 10. Significant product problems or recalls.
 11. Major changes in accounting methods.
 12. Proposed equity or debt offerings.
 13. Major labor disputes, including strikes or lockouts.
 14. Significant changes in debt or credit ratings.

These examples may relate either to the Company's business or the business of a publicly traded supplier, customer, or other third party who does business with the Company.

Because of the complexity in determining materiality for other publicly traded companies, the Company deems all non-public information about other companies to be material under this policy. This helps protect you from an inadvertent violation of the law. A transaction too small to be material for P&G might still be material to another company. For example, a \$5 million acquisition may be material to a company with \$10 million in annual sales, though it would not necessarily be material to P&G due to our larger size.

Even partial knowledge may be material. Partial knowledge about important confidential events can constitute Inside Information. For example, if you learn that a big acquisition or sales contract is being planned, you may have Inside Information, even if you only have an educated guess about the name of the other company involved. Strictly refrain from discussing or speculating about potentially significant, non-public Company events and overall financial results.

Related Person

"Related Person" includes:

1. Family members who reside with you (including a spouse, child, child away at college, stepchild, grandchild, parents, stepparents, grandparents, siblings, and in-laws).
2. Anyone else who lives in your household.
3. Family members whose transactions in P&G securities you influence or control.
4. Partnerships in which you are a general partner; trusts of which you are a trustee; estates of which you are an executor or executrix; entities in which you have a controlling interest.

The Company expects its employees to keep business data confidential but also recognizes that Related Persons may not always be able to avoid general awareness of business activity, especially when a significant project transcends normal working hours or disrupts routines at home. To avoid even the appearance of impropriety, Related Persons are subject to this policy. This protects both you as an employee and your Related Persons. It is your responsibility to ensure that they follow the requirements in this policy when trading in Company securities and the securities of P&G suppliers and customers.

Although this policy does not technically extend to certain family members who do not reside with you, keep in mind that all persons are subject to insider trading laws. Securities regulators may view with greater scrutiny any trades by a family member or close associate of an employee when those trades would otherwise be prohibited by this policy.

Securities

"Securities" include:

1. Common stock, whether held at a brokerage, retirement account, stock plan account, or elsewhere.
2. Stock options.
3. Stock units, such as RSUs, PSUs, and Stock Appreciation Rights (SARs).
4. Derivatives, including put and call options, convertible Preferred stock.
5. Debentures, bonds, and notes.

Transactions

For purposes of this Policy, "Transactions" include:

1. Buying or selling stock or any other Securities, including derivatives transactions.
2. Instructing trustees of a Company benefit plan to convert into or out of investment in Company stock, which includes borrowing, or changing the percentage of contributions allocated to Company stock.
3. Instructing trustees or administrators of a Company savings plan or similar stock ownership plan or program (e.g., SIP, ISOP, DSPP) to increase or decrease your monthly contributions for the purchase of Company stock.
4. Use of share withholding to pay applicable income taxes when exercising stock options.
5. Cashless exercise of a stock option.
6. Exercise of stock appreciation rights, regardless of the form of payment (cash or stock).
7. Trading involving debt securities (debentures, bonds, and notes).
8. Pledging Company Securities as collateral.
9. Gifts of Company stock.

The following are **not** Transactions restricted by the Policy:

1. Exercises of stock options awarded under the Company's stock option plans as long as payment for option costs and applicable income taxes is made only in cash. However, sales of shares acquired from an exercise are subject to the trading restrictions.
2. Purchases of Company stock in the 401(k) plan or other similar dividend reinvestment plan pursuant to a previous payroll deduction election made while not in possession of Inside Information (or, for those individuals in Category 2 or 3, made during a Window – see Sections 7 and 8). Restrictions do apply, however, to changes in the percentage of contributions allocated to Company stock; to any intra-plan transfer into or out of the Company stock fund; and to loans against the plan account that reduce your Company stock fund balance.
3. Purchases of Company stock under the dividend reinvestment plan, as long as you make no additional contributions or voluntary purchases.
4. Periodic, automatic payroll contributions to your Shareholder Investment Program (SIP), International Stock Ownership Plan (ISOP), or similar account according to an election made while not in possession of Inside Information (or, for those individuals in Category 2 or 3,

made during a Window – see Sections 7 and 8). However, any sale of stock held in a SIP, ISOP, or similar account is subject to trading restrictions.

5. The purchase, sale or holding of an interest in a publicly traded mutual fund, even if the fund holds or trades in Company securities.
6. The automatic sale of stock for cash upon settlement of a stock award (e.g., a "Sell All" transaction upon settlement of a grant of RSUs or PSUs) according to an election made while not in possession of Inside Information (or, for those individuals in Category 2 or 3, made during a Window – see Sections 7 and 8). However, any later, employee-initiated sale of shares from a settled stock award (e.g., shares with E*TRADE resulting from a "Sell to Cover" transaction) are subject to trading restrictions.
7. Transactions pursuant to a valid Rule 10b5-1 trading plan. A Rule 10b5-1 trading plan is a personal sales contract with a broker that authorizes purchases and sales of P&G stock according to pre-established criteria, even outside of Windows. The Company requires any employee 10b5-1 trading plans to comply with applicable law, including any mandatory "cooling off" periods, restrictions on overlapping plans, and requirements that these plans be entered, operated, amended, and cancelled in good faith. Category 3 Insiders must contact the Corporate Secretary's Office prior to entering into, modifying, or cancelling any 10b5-1 Trading Plan.
8. Sales of stock initiated and administered by the Company to cover tax withholding obligations arising upon the vest or settlement of an employee equity award are also not restricted Transactions, as long as such sale occurs without regard to any employee instruction.

Transactions involving securities of other publicly traded companies. If in the context of your work, you learn Inside Information about other publicly traded companies or private companies planning to go public, you are prohibited from engaging in transactions in those companies' Securities or "tipping" others who engage in such trading. These other publicly traded companies may include:

1. Suppliers (both services and products).
2. Customers.
3. Parties to acquisitions and divestitures.
4. Licensing partners.
5. Any other company about which you receive non-public information in connection with your role.

7.0 ADDITIONAL GUIDANCE FOR CATEGORY 2 & CATEGORY 3 INSIDERS

Who are Category 2 Insiders? Employees in roles or groups with frequent access to Inside Information as part of their work are deemed Category 2 Insiders. All Category 2 Insiders must:

1. Be listed on the relevant Insider List(s) posted on the Company's Insider Trading Policy at <https://tradingpolicy.pg.com>.

2. Certify via the Company's Governance, Risk, and Compliance platform, upon initial designation as a Category 2 Insider and annually when and if required by the WBCM

Compliance Certification Questionnaire, their agreement to comply with the Company's Insider Trading Policy and the Category 2 restrictions.

3. Complete, upon initial designation as a Category 2 Insider and every three years following, the specific Avoiding Insider Trading course in MyLearning, in addition to the general training on Insider Trading delivered as part of the Company's Worldwide Business Conduct Manual training.

List Contacts. Each group that has Category 2 Insiders has a designated employee (known as a "List Contact") responsible for maintaining and updating the list of Category 2 Insiders for that group. Please work with your List Contact if you believe you were included in a particular list in error or are transitioning to a different assignment. Your current List Contact can be found on the home page of the Insider Trading Policy website at <https://tradingpolicy.pg.com>.

Who are Category 3 Insiders? The Company's Board of Directors and all Section 16 Officers are deemed Category 3 Insiders. The Corporate Secretary's Office maintains the list of Directors and Section 16 Officers. Additional compliance requirements for Category 3 Insiders are listed in Section 8.

Trading Restrictions for Category 2 and Category 3 Insiders.

Category 2 and Category 3 Insiders:

- Are only permitted to engage in Transactions in Company securities during the Company's four annual Window periods. The Windows typically open one business day after the public release of each of the Company's four earnings statements and extend until the last business day of the second month of each quarter. The Window periods for the current fiscal year are posted in the Insider Trading Policy website at <https://tradingpolicy.pg.com>.
 - Even during a Window, employees may not trade when in possession of Inside Information.
 - If an exceptional or significant event occurs when the trading Window is otherwise open, the Corporate Secretary's Office may contact certain employees aware of or likely to be impacted by the event to close the Window for those employees until such information becomes public or is otherwise determined to not be material. Nevertheless, each employee is personally responsible to ensure that they do not trade while in possession of Inside Information, regardless of whether they have been contacted by the Corporate Secretary's Office.
 - Bona fide gifts of stock may be made outside of a Window as long as the Insider does not possess Inside Information at the time of the gift.
- Are prohibited from engaging in pledging, collars, short sales, hedging transactions or other derivative transactions related to Company Securities. (See "Derivative Transactions" below).
- May only engage in limit orders if such orders are placed during a Window (and while not in possession of Inside Information). Limit orders may not be amended or cancelled outside of a Window (or while in possession of Inside Information).
 - A limit order is an order placed with a broker to buy or sell a predetermined amount of stock at a specified price or to exercise and sell a predetermined number of stock options at a specified price.

Additional restrictions apply to Category 3 Insiders (see Section 8).

Derivative Transactions. Category 2 and Category 3 Insiders may not engage in any of the following transactions involving Company Securities:

1. Hedging transactions

2. Short sales
3. Pledging
4. Collars
5. Any other Derivative Transactions.

For purposes of this policy, a “Derivatives Transaction” involves the use of market investments to manage the risk of price movements in stock or, alternatively, to leverage the potential return of a predicted move in stock, up or down. This is accomplished, for example, by entering into forward sale contracts, futures, puts, calls, collars, or other derivatives that are intended to offset, or profit from, potential market fluctuation in stock.

8.0 ADDITIONAL GUIDANCE FOR CATEGORY 3 INSIDERS

Additional restrictions for Category 3 Insiders.

Category 3 Insiders must comply with all restrictions applicable to Section 2 Insiders, as set forth in Section 7 above. In addition, Category 3 Insiders:

- Must pre-clear any proposed Transaction in Company securities with the Corporate Secretary's Office at least one day prior, including any proposed gifts of stock or other transfers.
- May only execute Transactions within the Window or other period indicated by the Corporate Secretary's Office and while not in possession of Inside Information.
- May only make bona fide gifts of stock when not in possession of Inside Information.
- May only engage in limit orders if such orders are placed, executed, or cancelled during a Window and while not in possession of Inside Information. If a limit order is not executed by the last day of the Window, it must be cancelled.
- May not have opposite-way Transactions (i.e., purchase and sale) within a six-month period (the “Short Swing Trading” rule).
- Must (in addition to pre-clearance) report to the Corporate Secretary's Office within one business day the completion of any Transaction or transfer to enable timely reporting on Form 4.
- Must contact the Corporate Secretary's Office prior to entering into, modifying, or cancelling any 10b5-1 Trading Plan or similar written trading arrangement. Any such plan must be approved by the Corporate Secretary's Office in order to exclude the subject Transactions from trading restrictions under this Policy, to enable required reporting in the Company's securities filings, and to ensure the proposed plan or action complies with applicable law, including relevant cooling off periods, restrictions on overlapping plans, and good faith requirements.
- Must initially and thereafter annually certify via the Company's Governance, Risk, and Compliance platform or the Company's D&O Questionnaire platform, their agreement to comply with the Company's Insider Trading Policy. In addition, Category 3 Insiders who are Company employees must also complete initially and every three years thereafter the Avoiding Insider Trading course in MyLearning.

Exhibit (19-2)

P&G Share Repurchase Policy

P&G Share Repurchase Policy

Purpose

This policy sets guidelines for The Procter & Gamble Company (“The Company”) repurchasing shares of The Procter & Gamble Company or any of its affiliates or publicly listed subsidiaries common stock through share repurchase programs. The United States tax and securities laws, as well as the

tax and securities laws of the various countries where we have subsidiaries, place significant restrictions on dealing of any kind in P&G Securities, including any form of stock, debt or other security, issued by The Procter and Gamble Company or any of its affiliates or subsidiaries.

Restriction

In general, the Company and any employee acting on behalf of the Company are not allowed to deal in P&G Securities. For the avoidance of doubt, this restriction does not apply to personal shares owned by Procter & Gamble employees. Personal share transactions by Procter & Gamble employees are subject to the Procter & Gamble Global Insider Trading Policy.

Exceptions to this restriction include any Company Board authorized share repurchase program managed and executed by the Company's Global Treasury Organization, any debt repurchase or tender offer program managed and executed by the Company's Global Treasury Organization and certain Company plans (Profit Sharing Trust). Any use of these exceptions needs to be approved in advance by the Company's Legal Division in Cincinnati.

Share Repurchase Programs

The Company may choose to repurchase shares of P&G common stock as part of a publicly announced share repurchase program authorized by the Company's Board of Directors, including through the use of plans designed to comply with Rules 10b5-1 and 10b-18 of the Securities Exchange Act of 1934.

The Company typically announces its share repurchase program as a range for the next fiscal year in the current fiscal year's fourth quarter Earnings Release. If there are any material updates to the program, including material changes to the range, those updates are typically announced during the next quarterly Earnings Release or are otherwise disclosed publicly. The timing, magnitude and volume of individual share repurchase contracts under the program during the fiscal year, as well as the brokers utilized to execute share repurchase contracts, are at the discretion of management and must be in compliance with all applicable securities laws. It is the Company's practice to have a 30-day cooling off period after entering into a repurchase contract. To the extent possible and subject to the next sentence, contracts or cancellation of existing contracts, if applicable, must be made during open trading windows. In all cases, the Chief Financial Officer must confirm that the Company is not in possession of material non-public information prior to entering into a new contract or cancelling an existing contract. Company employees with direct responsibility for managing any share repurchase program will provide the

Company's Legal Division with any share purchase data necessary for the Company's securities filings.

EXHIBIT (21)

The Procter & Gamble Company and Subsidiaries

Subsidiaries of the Registrant

The Procter & Gamble Company and Subsidiaries

The registrant's subsidiaries are listed below, omitting certain entities that have de minimis activity that, if considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of **June 30, 2023** **June 30, 2024**.

SUBSIDIARIES OF THE PROCTER & GAMBLE COMPANY

1837, LLC
Agile Pursuits Franchising, Inc.
Agile Pursuits, Inc.
Arbora & Ausonia, S.L.U.
Braun (Shanghai) Co., Ltd.
Braun GmbH
Celtic Insurance Company, Inc.
Charlie Banana (USA), LLC
Detergent Products Sarl
Detergenti S.A.
Farmacy Beauty, **Japan Kabushiki Kaisha**
Farmacy Beauty, LLC
Fater Central Europe SRL
Fater Eastern Europe LLC
Fater Portugal Unipessoal Lda
Fater S.p.A.
Fater Temizlik Urunleri Ltd STI
First Aid Beauty Limited
Fountain Square Music Publishing Co., Inc.
FPG Oleochemicals Sdn. Bhd.
Gillette (China) Limited
Gillette (Shanghai) Ltd.
Gillette Australia Pty. Ltd.
Gillette Commercial Operations North America
Gillette Diversified Operations Pvt. Ltd.
Gillette Dominicana, S.A.S.
Gillette Egypt S.A.E.
Gillette Holding Company LLC
Gillette India Limited
Gillette Industries Ltd.
Gillette Latin America Holding B.V.
Gillette Management, LLC
Gillette Pakistan Limited
Gillette Poland International Sp. z o.o.
Gillette U.K. Limited
Grooming Ventures - FL LLC
Grooming Ventures LLC
Hyginett KFT
iMFLUX Inc.
Ismail Abudawood Procter & Gamble - Dammam
Laboratoire Vicks S.A.S.
Laboratorios Vicks, S.L.U.
Lamberts Healthcare Ltd.
Liberty Street Music Publishing Company, Inc.
LLC "Procter & Gamble - Novomoskovsk"
LLC with foreign investments "Procter & Gamble Ukraine"
Mielle Organics, LLC
Mielle, Inc.
Modern Products Company - Jeddah
Nature's Best Health Products Ltd.
New Chapter Canada Inc.

Jurisdiction JURISDICTION

Ohio
Ohio
Ohio
Spain
China
Germany
Vermont
Delaware
Switzerland
Romania
Japan
New Jersey
Romania
Russia
Portugal
Italy
Turkey
Delaware
Ohio
Malaysia
China
China
Australia
Massachusetts
India
Dominican Republic
Egypt
Delaware
India
U.K.
Netherlands
Delaware
Pakistan
Poland
U.K.
Florida
Delaware
Hungary
Delaware
Saudi Arabia
France
Spain
U.K.
Ohio
Russia
Ukraine
Delaware
Delaware
Saudi Arabia
U.K.
Canada

New Chapter Canada Inc.

New Chapter, Inc.
 Oral-B Laboratories
 P&G Consumer Health Germany GmbH
 P&G Distribution East Africa Limited
 P&G Distribution Morocco SAS SA
 P&G Hair Care Holding, Inc.
 P&G Health Austria GmbH & Co. OG
 P&G Health Belgium BV
 P&G Health France S.A.S.
 P&G Health Germany GmbH
 P&G Healthcare (Zhejiang) Company Limited
 P&G Industrial Peru S.R.L.
 P&G Innovation Godo Kaisha
 P&G Investment Management Ltd.
 P&G Israel M.D.O. Ltd.
 P&G Japan G.K.
 P&G K.K.
 P&G Northeast Asia Pte. Ltd.
 P&G Prestige Godo Kaisha
 P&G South African Trading (Pty.) Ltd.
 "Petersburg Products International" LLC

PG13 Launchpad Gamma, Inc.

Phase II Holdings Corporation
 Principle Forsakrings AB
 Procter & Gamble (Chengdu) Ltd.
 Procter & Gamble (China) Ltd.
 Procter & Gamble (China) Sales Co., Ltd.
 Procter & Gamble (Guangzhou) Commerce Co. Ltd.
 Procter & Gamble (Guangzhou) Consumer Products Co., Ltd.
 Procter & Gamble (Guangzhou) Enterprise Management Service Company Limited
 Procter & Gamble (Guangzhou) Ltd.
 Procter & Gamble (Guangzhou) Technology Innovation Co., LTD.
 Procter & Gamble (Health & Beauty Care) Limited
 Procter & Gamble (Jiangsu) Ltd.
 Procter & Gamble (L&CP) Limited
 Procter & Gamble (Malaysia) Sdn Bhd
 Procter & Gamble (Manufacturing) Ireland Limited
 Procter & Gamble (Singapore) Pte. Ltd.
 Procter & Gamble Algeria EURL
 Procter & Gamble Amiens S.A.S.
 Procter & Gamble Arabia L.L.C.
 Procter & Gamble Argentina SRL
 Procter & Gamble Asia Pte. Ltd.
 Procter & Gamble Australia Proprietary Limited
 Procter & Gamble Azerbaijan Services LLC
 Procter & Gamble Bangladesh Private Ltd.
 Procter & Gamble Blois S.A.S.
 Procter & Gamble Brazil Holdings B.V.

Canada

Delaware
 Delaware
 Germany
 Kenya
 Morocco
 Delaware
 Austria
 Belgium
 France
 Germany
 China
 Peru
 Japan
 United Arab Emirates
 Israel
 Japan
 Japan
 Singapore
 Japan
 South Africa
 Russia

Delaware

Philippines
 Sweden
 China
 China
 China
 China
 China
 China
 China
 U.K.
 China
 U.K.
 Malaysia
 Ireland
 Singapore
 Algeria
 France
 United Arab Emirates
 Argentina
 Singapore
 Australia
 Azerbaijan
 Bangladesh
 France
 Netherlands

Procter & Gamble Bulgaria EOOD
Procter & Gamble Business Services Canada Company
Procter & Gamble Canada Holding B.V.
Procter & Gamble Chile Limitada
Procter & Gamble Colombia Ltda.
Procter & Gamble Commercial LLC

Bulgaria
Canada
Netherlands
Chile
Colombia
Puerto Rico

Procter & Gamble Czech Republic s.r.o.
Procter & Gamble d.o.o. za trgovinu
Procter & Gamble Danmark ApS
Procter & Gamble de Venezuela, S.C.A.
Procter & Gamble de Venezuela, S.R.L.
Procter & Gamble Detergent (Beijing) Ltd.
Procter & Gamble Deutschland GmbH
Procter & Gamble Distributing (Philippines) Inc.
Procter & Gamble Distribution Company (Europe) BV
Procter & Gamble Distribution S.R.L.
Procter & Gamble Distributorskaya Compania LLC
Procter & Gamble do Brasil Ltda.
Procter & Gamble do Brazil, LLC
Procter & Gamble do Nordeste S/A
Procter & Gamble doo Beograd
Procter & Gamble DS Polska Sp. z o.o.
Procter & Gamble Eastern Europe, LLC
Procter & Gamble Ecuador Cia. Ltda.
Procter & Gamble Egypt
Procter & Gamble Egypt Distribution
Procter & Gamble Egypt Holding
Procter & Gamble Egypt Supplies
Procter & Gamble Energy Company LLC
Procter & Gamble España, S.A.U.
Procter & Gamble Far East, Inc.
Procter & Gamble Finance Holding Ltd.
Procter & Gamble Finance Management S.a.r.l.
Procter & Gamble Financial Investments LLP
Procter & Gamble Financial Services Ltd.
Procter & Gamble Finland OY
Procter & Gamble France S.A.S.
Procter & Gamble Germany GmbH
Procter & Gamble Germany GmbH & Co. Operations oHG
Procter & Gamble Germany Holding GmbH
Procter & Gamble Ghana Trading Limited
Procter & Gamble GmbH
Procter & Gamble Grundstücks-und Vermögensverwaltungs GmbH & Co. KG
Procter & Gamble Gulf FZE
Procter & Gamble Hair Care, LLC
Procter & Gamble Health Limited
Procter & Gamble Health Ltd.
Procter & Gamble Health Poland Sp. z o.o.
Procter & Gamble Hellas Single Member Ltd.

Czech Republic
Croatia
Denmark
Venezuela
Venezuela
China
Germany
Philippines
Belgium
Romania
Russia
Brazil
Delaware
Brazil
Serbia and Montenegro
Poland
Ohio
Ecuador
Egypt
Egypt
Egypt
Egypt
Ohio
Spain
Ohio
U.K.
Luxembourg
U.K.
U.K.
Finland
France
Germany
Germany
Ghana
Germany
Germany
United Arab Emirates
Delaware
India
U.K.
Poland
Greece

Procter & Gamble Holding (Thailand) Limited	Thailand
Procter & Gamble Holding France S.A.S.	France
Procter & Gamble Holding GmbH	Germany
Procter & Gamble Holding LLC	Delaware
Procter & Gamble Holding S.r.l.	Italy
Procter & Gamble Home Products Private Limited	India
Procter & Gamble Honduras S de RL	Honduras
Procter & Gamble Hong Kong Limited	Hong Kong
Procter & Gamble Hungary Wholesale Trading Partnership (KKT)	Hungary
Procter & Gamble Hygiene & Health Care Limited	India
Procter & Gamble Inc.	Canada
Procter & Gamble India Holdings, Inc.	Ohio

Procter & Gamble Indochina Company Limited	Vietnam
Procter & Gamble Industrial - 2012 C.A.	Venezuela
Procter & Gamble Industrial e Comercial Ltda.	Brazil
Procter & Gamble Industrial S.C.A.	Venezuela
Procter & Gamble Interamericas de Costa Rica, Limitada	Costa Rica
Procter & Gamble Interamericas de El Salvador, Limitada de Capital Variable	El Salvador
Procter & Gamble Interamericas de Guatemala, Limitada	Guatemala
Procter & Gamble Interamericas de Panama, S. de R.L.	Panama
Procter & Gamble International Operations SA	Switzerland
Procter & Gamble International Operations SA-ROHQ	Philippines
Procter & Gamble International Sarl	Switzerland
Procter & Gamble Italia, S.p.A.	Italy
Procter & Gamble Kazakhstan Distribution LLP	Kazakhstan
Procter & Gamble Kazakhstan Operations LLP	Kazakhstan
Procter & Gamble Korea S&D Co.	Korea
Procter & Gamble Korea, Inc.	Korea
Procter & Gamble Leasing LLC	Ohio
Procter & Gamble Levant S.A.L.	Lebanon
Procter & Gamble Limited	U.K.
Procter & Gamble LLC	Russia
Procter & Gamble Manufacturing (Thailand) Limited	Thailand
Procter & Gamble Manufacturing (Tianjin) Co. Ltd.	China
Procter & Gamble Manufacturing Belgium N.V.	Belgium
Procter & Gamble Manufacturing Berlin GmbH	Germany
Procter & Gamble Manufacturing GmbH	Germany
Procter & Gamble Manufacturing Mexico S. de R.L. de C.V.	Mexico
Procter & Gamble Manufacturing SA (Pty) Ltd	South Africa
Procter & Gamble Marketing Romania SRL	Romania
Procter & Gamble Mataro, S.L.U.	Spain
Procter & Gamble Mexico (US) LLC	Delaware
Procter & Gamble Mexico S. de R.L. de C.V.	Mexico
Procter & Gamble Middle East FZE	United Arab Emirates
Procter & Gamble Nederland B.V.	Netherlands
Procter & Gamble Nigeria Limited	Nigeria
Procter & Gamble Norge AS	Norway
Procter & Gamble Operations Polska Sp. z o.o.	Poland
Procter & Gamble Overseas India B.V.	Netherlands

Procter & Gamble Pakistan (Private) Limited	Pakistan
Procter & Gamble Peru S.R.L.	Peru
Procter & Gamble Philippines Business Services Inc.	Philippines
Procter & Gamble Philippines, Inc.	Philippines
Procter & Gamble Polska Sp. z o.o	Poland
Procter & Gamble Portugal - Produtos De Consumo, Higiene e Saúde S.A.	Portugal
Procter & Gamble Product Supply (U.K.) Limited	U.K.
Procter & Gamble Productions, Inc.	Ohio
Procter & Gamble Retail Services Sarl	Switzerland
Procter & Gamble RHD, Inc.	Ohio
Procter & Gamble RSC Regional Service Company Ltd.	Hungary
Procter & Gamble S.r.l.	Italy
Procter & Gamble Service, GmbH	Germany
Procter & Gamble Services (Switzerland) Sarl	Switzerland
Procter & Gamble Services Company N.V.	Belgium
Procter & Gamble South Central Asia Sarl	Switzerland
Procter & Gamble Sverige AB	Sweden
Procter & Gamble Taiwan Limited	Taiwan

Procter & Gamble Taiwan Sales Company Limited	Taiwan
Procter & Gamble Technical Centres Limited	U.K.
Procter & Gamble Technology (Beijing) Co., Ltd.	China
Procter & Gamble Trading (Thailand) Limited	Thailand
"Procter & Gamble Trading Ukraine", LLC	Ukraine
Procter & Gamble Tuketim Mallari Sanayii A.S.	Turkey
Procter & Gamble UK	U.K.
Procter & Gamble UK Group Holdings Ltd	U.K.
Procter & Gamble Vietnam Company Limited	Vietnam
Procter & Gamble West Africa Sarl	Switzerland
Procter & Gamble, Spol. s.r.o. (Ltd.)	Slovak Republic
Procter & Gamble-Rakona s.r.o.	Czech Republic
Procter and Gamble Lanka (Private) Limited	Sri Lanka
Progam Realty & Development Corporation	Philippines
Proof Company, LLC	California
PT Procter & Gamble Home Products Indonesia	Indonesia
PT Procter & Gamble Operations Indonesia	Indonesia
Redmond Products, Inc.	Minnesota
Richardson-Vicks Real Estate Inc.	Ohio
Riverfront Music Publishing Co., Inc.	Ohio
Rosemount LLC	Delaware
Series Acquisition B.V.	Netherlands
Seven Seas Limited	U.K.
Shanghai Farmacy Beauty Co., Ltd.	China
Shulton, Inc.	New Jersey
Snowberry New Zealand Limited	New Zealand
SPD Development Company Limited	U.K.
SPD Swiss Precision Diagnostics GmbH	Switzerland
Sunflower Distributing LLC	Delaware
Tambrands Inc.	Delaware
TAOS - FL, LLC	Florida
Temple Trees Impex & Investment Private Limited	India
The Caden Companies, LLC	California
The Dover Wipes Company	Ohio
The Gillette Company LLC	Delaware

The Procter & Gamble Distributing LLC	Delaware
The Procter & Gamble Global Finance Company, LLC	Ohio
The Procter & Gamble Manufacturing Company	Ohio
The Procter & Gamble Paper Products Company	Ohio
The Procter & Gamble U.S. Business Services Company	Ohio
This is L. Inc.	Delaware
TULA Life, Inc.	Delaware
United Beauty Brands, LLC	California
US CD LLC	Delaware
VitaminHaus Pty Ltd	Australia
VitaminHaus Pty Ltd	U.K.
Walker & Co. Brands, Inc.	Delaware
Winc Design Limited	Hong Kong
Zenlen, Inc.	Delaware
ZeroBrush, Inc.	Delaware

EXHIBIT (23)

Consent of Independent Registered Public Accounting Firm

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following registration statements of our reports dated August 4, 2023 August 5, 2024, relating to the consolidated financial statements of The Procter & Gamble Company and the effectiveness of The Procter & Gamble Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended June 30, 2023 June 30, 2024:

Form S-8

No. 33-49289
No. 33-47656
No. 33-50273
No. 33-51469
No. 333-14381
No. 333-21783
No. 333-37905
No. 333-51213
No. 333-51219
No. 333-51221
No. 333-34606
No. 333-44034
No. 333-47132
No. 333-75030
No. 333-100561
No. 333-108991
No. 333-108993
No. 333-108994
No. 333-108995
No. 333-108997
No. 333-108998

Form S-8

No. 333-108997 333-108999
No. 333-108998 333-111304
No. 333-108999 333-128859
No. 333-111304 333-143801
No. 333-128859 333-155046
No. 333-143801 333-161725
No. 333-155046 333-164612
No. 333-161725 333-192841
No. 333-164612 333-208407
No. 333-192841 333-208408
No. 333-208407 333-208409
No. 333-208408 333-208410
No. 333-208409 333-208411
No. 333-208410 333-208412
No. 333-208411 333-234131
No. 333-208412 333-199592
No. 333-234131 333-270100
No. 333-199592 333-278655
No. 333-270100 333-278656
No. 333-280237
No. 333-280851

Form S-3

No. 333-249543 333-275068
No. 333-249545 333-275069
No. 333-249546 333-275071

/s/ Deloitte & Touche LLP

Cincinnati, Ohio

August 4, 2023 5, 2024

EXHIBIT (31)

Rule 13a-14(a)/15d-14(a) Certifications

I, Jon R. Moeller, certify that:

- (1) I have reviewed this Form 10-K of The Procter & Gamble Company;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 - iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ JON R. MOELLER

(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer

August 4, 2023 5, 2024
Date

EXHIBIT (31)

Rule 13a-14(a)/15d-14(a) Certifications

I, Andre Schulten, certify that:

- (1) I have reviewed this Form 10-K of The Procter & Gamble Company;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- (4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and

have:

- i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - iii) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 - iv) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- (5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ ANDRE SCHULTEN

(Andre Schulten)
Chief Financial Officer

August 4, 2023 5, 2024
Date

EXHIBIT (32)

Section 1350 Certifications

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble Company (the "Company") certifies to his knowledge that:

- (1) Form 10-K of the Company for the year ended June 30, 2023 June 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ JON R. MOELLER

(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer

August 4, 2023 5, 2024
Date

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to The Procter & Gamble Company and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

EXHIBIT (32)

Section 1350 Certifications

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble Company (the "Company") certifies to his knowledge that:

- (1) Form 10-K of the Company for the year ended **June 30, 2023** **June 30, 2024** fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in that Form 10-K fairly presents, in all material respects, the financial conditions and results of operations of the Company.

/s/ ANDRE SCHULTEN

(Andre Schulten)
Chief Financial Officer

August 4, 2023 5, 2024
Date

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to The Procter & Gamble Company and will be retained by The Procter & Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 97

DODD-FRANK RECOUPMENT POLICY

DODD-FRANK RECOUPMENT POLICY

The Compensation & Leadership Development Committee of the Board of Directors of The Procter & Gamble Company has adopted this Dodd-Frank Compensation Recoupment Policy as of the Effective Date (as defined below). It is the intention of the Committee that this Policy be interpreted and administered in a manner consistent with applicable laws and regulations and Securities Exchange listing requirements, including without limitation Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, Rule 10D-1 of the Securities Exchange Act of 1934, and Section 303A.14 of the New York Stock Exchange Listed Company Manual. In the event of a conflict between this Policy and such laws, regulations, and listing requirements, the applicable laws, regulations, and listing requirements shall govern.

This Policy applies to awards of Incentive-Based Compensation received on or after the Effective Date by Executive Officers of the Company. With respect to Executive Officers, the existing Senior Executive Recoupment Policy shall apply to awards of Incentive-Based Compensation received before the Effective Date. The Senior Executive Recoupment Policy shall continue to apply to non-Executive Officers as set forth therein.

Definitions

“Board” means the Board of Directors of the Company.

“Committee” means the Compensation and Leadership Development Committee of the Board of Directors of the Company.

“Company” means The Procter & Gamble Company.

“Effective Date” means the effective date of the NYSE listing standard.

“Executive Officer” means, for purposes of this Policy and in compliance with 10D-1 of the Securities Exchange Act of 1934, the Company’s Section 16 Officers.

“Excess Incentive-Based Compensation” means the amount of Incentive-Based Compensation received by a current or former Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had the amount of such Incentive-Based Compensation been determined based on the accounting restatement, computed without regard to taxes paid by the Executive Officer. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Excess Incentive-Based Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, Excess Incentive-Based Compensation means a reasonable estimate of the effect of the accounting restatement on the applicable Financial Reporting Measure.

“Financial Reporting Measure” means any measure that is determined and presented in accordance with the accounting principles used to preparing the Company’s financial

statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return metrics are also Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission.

“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure, [and as such term may be interpreted by the guidance issued by the SEC and the Securities Exchange].

“Listing Standard” means Section 303A.14 of the New York Stock Exchange Listed Company Manual.

“Lookback Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement. For purposes of this definition, the date on which the Company is required to prepare an accounting restatement shall be deemed to be the earlier of (i) the date the Company’s Board, a committee of the Board, or the officer(s) of the Company authorized to take such action (if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement; and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an accounting restatement.

“Policy” means this Dodd-Frank Compensation Recoupment Policy.

“Securities Exchange” means the securities exchange upon which the Company’s Common Stock trades.

Recoupment for an Accounting Restatement

The Company shall recover reasonably promptly any Excess Incentive-Based Compensation in the event that the Company is required to restate its financial statements due to the material noncompliance of the Company with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error (i) in previously issued financial statements that is material to the previously issued financial statements or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. The preceding sentence shall apply to Excess Incentive-Based Compensation received by any current or former Executive Officer: (a) after beginning service as an Executive Officer; (b) who served as an Executive Officer at any time during the performance period for the applicable

Incentive-Based Compensation; (c) while the Company has a class of securities listed on a national securities exchange or a national securities association; and (d) during the Lookback Period. For purposes of this paragraph, Incentive-Based Compensation is deemed “received” in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.

Notwithstanding the foregoing, if the Committee makes a determination that recovery would be impracticable, and one of the following enumerated conditions is satisfied, the Company need not recover such Excess Incentive-Based Compensation.

- a Expenses Exceed Recovery Amount: If the direct expense to be paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered; provided, however, that the Company must make a reasonable attempt to recover the Excess Incentive-Based Compensation and document such attempt(s) prior to the Committee’s determination that recovery would be impracticable. The Company must provide the documentation evidencing the attempt(s) to the Securities Exchange consistent with the listing standards of the Securities Exchange.
- b Recovery Would Violate Home Country Law: If recovery would violate home country law where that law was adopted prior to November 28, 2022; provided, however, that the Company must obtain an opinion of home country counsel, in a form acceptable to the Securities Exchange, that recovery would result in such violation. The Company must provide the opinion to the Securities Exchange consistent with the listing standards of the Securities Exchange.
- c Recovery Would Violate ERISA Anti-Alienation Provisions: If recovery would likely cause an otherwise tax-qualified plan, under which benefits are broadly available to employees of the Company, to fail to meet the anti-alienation provisions of the Employee Retirement Income Security Act of 1974, as amended, contained in 26 U.S.C. § 401(a)(13) or 26 U.S.C. § 411(a), and regulations promulgated thereunder.

Method of Recoupment

Subject to the Listing Standard and Section 409A of the Internal Revenue Code, the Committee shall have the sole discretion and authority to determine the means, timing (which shall in all circumstances be reasonably prompt) and any other terms by which any recoupment required by this Policy shall occur, including but not limited to deductions from future payments including stock option exercises and RSU/PSP settlements, forfeitures, and/or award cancellations, and impose any other terms, conditions or procedures (e.g., the imposition of interest charges on un-repaid amounts and payment of the Company’s legal expenses) to govern the current or former Executive Officer’s repayment of Excess Incentive-Based Compensation. The Chair of the Committee may approve any of the items set forth above and will report such approval to the Committee at its next meeting.

Other Policy Terms

Any applicable award agreement, plan or other document setting forth the terms and conditions of any Incentive-Based Compensation covered by this Policy shall be deemed to (i) incorporate this Policy by reference; and (ii) be governed by the terms of this Policy in the event of any inconsistency with the terms of the Incentive-Based Compensation. Acceptance of any Incentive-Based Compensation by an Executive Officer shall be deemed to include acceptance of this Policy.

Any recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights that may be available to the Company or its affiliates under applicable law, including, without limitation: (i) terminating the employment of the Executive Officer; (ii) adjusting the future compensation of the Executive Officer; and/or (iii) authorizing legal action or

taking such other action to enforce the Executive Officer's obligations to the Company or its affiliates as it may deem appropriate in view of all of the facts and circumstances surrounding the particular case.

Incentive-Based Compensation and other compensation paid to employees of the Company and its affiliates may also be subject to other recoupment or similar policies, and this Policy does not supersede any such other policies. However, in the event of any conflict or duplication between any such policy and this Policy, this Policy shall govern and take precedence.

Current or former Executive Officers shall not be entitled to any indemnification by or from the Company or its affiliates with respect to any amounts subject to recoupment pursuant to this Policy.

This Policy and all rights and obligations hereunder are governed by and construed in accordance with the laws of the State of Ohio, excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction. All actions arising out of or relating to this Policy shall be heard and determined exclusively in the any federal or state court located in Hamilton County, Ohio, USA.

Administration

The Committee is responsible for monitoring the application of this Policy with respect to all Executive Officers. The Committee shall have the sole authority to review, interpret, construe, and implement the provisions of this Policy and to delegate to one or more executive officers and/or employees certain administrative and record-keeping responsibilities, as appropriate, with respect to the implementation of this Policy; provided, however, that no such action shall contravene the federal securities laws or Securities Exchange rules. Any determinations of the Board or Committee under this Policy shall be binding on the applicable individual.

The Committee may amend, modify, or change this Policy, as well as any related rules and procedures, at any time and from time to time as it may determine, in its sole discretion, is necessary or appropriate.

The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings.

EXHIBIT (99-1)

Summary of Directors and Officers Insurance Program

The Procter & Gamble Company purchases Directors and Officers Liability insurance from various insurance carriers. The policy limits for the period from June 30, 2022 to June 30, 2023 to June 30, 2023 June 30, 2024 were \$300 million.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.